NCT01975389,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,AL,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,AL,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT02164513,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT02182830,Boehringer Ingelheim,False,AL,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,AL,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02528253,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,AL,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,AL,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,AL,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01663402,Sanofi,False,AL,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01652872,Amgen,False,AL,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,AL,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT02573311,Boehringer Ingelheim,False,AL,https://ClinicalTrials.gov/show/NCT02573311,True,Actual Use Study of Tamsulosin in Men,Urological Manifestations,Drug:tamsulosin hydrochloride,[],"January 25, 2016",18,9223372036854775807,Male,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02487446,Novartis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT02487446,True,Efficacy and Safety Study of QVA149 in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02465567,"Pearl Therapeutics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,AL,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02336685,"Janssen Research & Development, LLC",False,AL,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT01968967,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,AL,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01272037,National Cancer Institute (NCI),False,AL,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02590432,Forest Laboratories,False,AL,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02388165,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02367456,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02367456,True,"A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients",Myelodysplastic Syndrome,Drug:PF-04449913; Drug:Azacitidine; Drug:PF-04449913 Placebo,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT02343458,"Pearl Therapeutics, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT02343458,True,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",COPD,Drug:GFF MDI (PT003); Drug:FF MDI (PT005); Drug:GP MDI (PT001); Drug:Placebo MDI,[],"September 28, 2015",40,80,Both,False
NCT02258542,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02258542,True,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Asthma,Biological:Benralizumab; Biological:Benralizumab,[],"January 12, 2016",12,75,Both,False
NCT02194699,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT02194699,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Experimental: Tralokinumab; Other:Placebo,[],"January 29, 2016",12,75,Both,False
NCT02092467,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT01997333,Celldex Therapeutics,False,AL,https://ClinicalTrials.gov/show/NCT01997333,True,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,AL,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01751906,Abbott Vascular,False,AL,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,AL,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,AL,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01546038,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01546038,True,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,Acute Myeloid Leukemia,Drug:PF-04449913; Drug:Low dose ARA-C (LDAC); Drug:PF-04449913; Drug:Decitabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Daunorubicin; Drug:Cytarabine; Drug:PF-04449913; Drug:Low dose ARA-C (LDAC),[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,AL,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00547469,Dynogen Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT00547469,True,A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females,Irritable Bowel Syndrome,Drug:DDP733,[],"April 7, 2008",18,65,Female,False
NCT02674386,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02640612,Boehringer Ingelheim,False,AL,https://ClinicalTrials.gov/show/NCT02640612,True,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:BI 695501,[],"February 2, 2016",18,80,Both,False
NCT02488967,NRG Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02375204,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02375204,True,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],"December 8, 2015",14,9223372036854775807,Male,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02003222,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT01272037,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01856192,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02059265,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT01013649,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01620190,University of Washington,False,AK,https://ClinicalTrials.gov/show/NCT01620190,True,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation,"[u'Anchorage Oncology Centre', u'Katmai Oncology Group', u'Providence Alaska Medical Center', u'Bozeman Deaconess Hospital', u'Kadlec Clinic Hematology and Oncology', u'Skagit Valley Hospital', u'Olympic Medical Center', u'Group Health Cooperative', u'Fred Hutch/University of Washington Cancer Consortium', u'Spokane Valley Cancer Center-Mission', u'Multicare Health System', u'Wenatchee Valley Hospital and Clinics']","January 29, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02152982,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01908101,University of Washington,False,AK,https://ClinicalTrials.gov/show/NCT01908101,True,Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer,Recurrent Breast Carcinoma; Stage IV Breast Cancer,Drug:Eribulin Mesylate; Other:Laboratory Biomarker Analysis,"[u'Katmai Oncology Group', u'Providence Alaska Medical Center', u'The University of Arizona Medical Center-University Campus', u'Bozeman Deaconess Hospital', u'Bend Memorial Clinic', u'Kadlec Clinic Hematology and Oncology', u'Skagit Valley Hospital', u'Olympic Medical Center', u'Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium', u'Group Health Cooperative-Seattle', u'Multicare Health System', u'Wenatchee Valley Hospital and Clinics']","November 12, 2015",18,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT02663908,Ferring Pharmaceuticals,False,AK,https://ClinicalTrials.gov/show/NCT02663908,True,A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,Prostate Cancer,Drug:Degarelix; Drug:Leuprolide,[],"January 22, 2016",0,9223372036854775807,Male,False
NCT02614183,Eli Lilly and Company,False,AK,https://ClinicalTrials.gov/show/NCT02614183,True,Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Migraine,Drug:LY2951742; Drug:Placebo,[],"January 28, 2016",18,65,Both,False
NCT02589236,"Nivalis Therapeutics, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT02589236,True,Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation,Cystic Fibrosis,Drug:N91115; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02477020,Takeda,False,AK,https://ClinicalTrials.gov/show/NCT02477020,True,A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia,Schizophrenia,Drug:TAK-063 20 mg; Drug:Placebo,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","January 18, 2016",18,65,Both,False
NCT02470585,AbbVie,False,AK,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02451137,Sanofi,False,AK,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02443688,"Celtaxsys, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT02443688,True,"EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult CF Patients",Cystic Fibrosis,Drug:CTX-4430; Drug:Placebo,"[u'University of Alabama', u'Providence Health and Services', u'Banner University of Arizona Medical Center', u'Pediatric Pulmonary and Cystic Fibrosis Clinic, Stanford University', u'University of California Davis Medical Center', u'National Jewish Health', u'University of Florida', u'Central Florida Pulmonary Group', u'Emory University', u'University of Chicago', u'Massachusetts General Hospital', u'University of Michigan', u'Spectrum Health Butterworth Campus', u'University of New Mexico', u'Hershey Medical Center', u""Children's Hospital of Pittsburgh of UPMC"", u'Universiy of Tennessee Medical Center UHS']","February 1, 2016",18,30,Both,False
NCT02431611,Mayo Clinic,False,AK,https://ClinicalTrials.gov/show/NCT02431611,True,Biomarker Feedback to Motivate Cessation in Pregnancy,Nicotine Dependence; Pregnancy,Behavioral:Biomarker feedback (phone based smoking cessation counseling); Behavioral:Control condition (phone based smoking cessation counseling),[u'Alaska Native Tribal Health Consortium'],"January 12, 2016",18,45,Female,True
NCT02406677,AstraZeneca,False,AK,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02365818,"Cold Genesys, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT02365818,True,Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,Bladder Cancer,Drug:CG0070,"[u'Alaska Clinical Research Center', u'BCG Oncology', u'Tower Urology', u'Institute of Urologic Oncology at UCLA', u'UC Irvine Medical Center', u'UF Health Cancer Center', u'University of Chicago', u'Michigan Institute of Urology, P.C.', u'Adult Pediatric Urology and Urogynecology, PC', u'Premier Urology Group, LLC.', u'Premier Medical Group of the Hudson Valley', u'Wake Forest University School of Medicine', u'The Urology Group', u'Erlanger Institute for Clinical Research', u'Vanderbilt University Medical Center, Dept. of Urologic Surgery']","February 1, 2016",18,9223372036854775807,Both,False
NCT02326454,Light Sciences Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02326454,True,A Placebo Controlled Study of MR901 for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Drug:talaporfin sodium; Drug:Saline; Device:Drug Activator 100 J/cm; Device:Drug Activator 200 J/cm,[],"February 1, 2016",40,9223372036854775807,Male,False
NCT02319837,"Medivation, Inc.",False,AK,https://ClinicalTrials.gov/show/NCT02319837,True,Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate,Drug:Enzalutamide; Drug:Placebo; Drug:Leuprolide,[],"December 1, 2015",18,9223372036854775807,Male,False
NCT02315469,NRG Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02439320,CoLucid Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT02439320,True,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,AZ,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT01966107,AstraZeneca,False,AZ,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01594333,Brigham and Women's Hospital,False,AZ,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,AZ,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT01975376,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01845025,Novartis Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,AZ,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01968967,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02638129,Takeda,False,AZ,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02301234,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02301234,True,"Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg; Drug:Celecoxib 100 mg; Drug:Celecoxib 100 mg Matching Placebo,[],"January 20, 2016",18,99,Both,False
NCT02019264,Eisai Inc.,False,AZ,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02674386,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02590432,Forest Laboratories,False,AZ,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02336698,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02336698,True,"Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,AZ,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01652872,Amgen,False,AZ,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02673190,Radiation Therapy Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02504268,Bristol-Myers Squibb,False,AZ,https://ClinicalTrials.gov/show/NCT02504268,True,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Methotrexate; Other:Abatacept Placebo; Other:Methotrexate Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,AZ,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02465515,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02451137,Sanofi,False,AZ,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02412917,"ContraVir Pharmaceuticals, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02412917,True,A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia,Shingles; Herpes Zoster; Postherpetic Neuralgia,Drug:FV-100; Drug:valacyclovir,[],"September 1, 2015",50,9223372036854775807,Both,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02164864,Boehringer Ingelheim,False,AZ,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02047097,Biogen,False,AZ,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01997333,Celldex Therapeutics,False,AZ,https://ClinicalTrials.gov/show/NCT01997333,True,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT01953601,Merck Sharp & Dohme Corp.,False,AZ,https://ClinicalTrials.gov/show/NCT01953601,True,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),Amnestic Mild Cognitive Impairment; Alzheimer's Disease; Prodromal Alzheimer's Disease,Drug:Verubecestat (Part I and Part II); Drug:Verubecestat (Part I and Part II); Drug:Placebo (Part I); Drug:Verubecestat (Part II),[],"December 31, 2015",50,85,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,AZ,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01901900,Novartis Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT01901900,True,Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.,Rheumatoid Arthritis,Biological:Secukinumab (AIN457),[],"January 12, 2015",18,9223372036854775807,Both,False
NCT01885078,Eli Lilly and Company,False,AZ,https://ClinicalTrials.gov/show/NCT01885078,True,An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Baricitinib; Drug:Placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,AZ,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01729455,"Human Genome Sciences Inc., a GSK Company",False,AZ,https://ClinicalTrials.gov/show/NCT01729455,True,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01633112,Novartis Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,AZ,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,AZ,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02640612,Boehringer Ingelheim,False,AZ,https://ClinicalTrials.gov/show/NCT02640612,True,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:BI 695501,[],"February 2, 2016",18,80,Both,False
NCT02629159,AbbVie,False,AZ,https://ClinicalTrials.gov/show/NCT02629159,True,A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE),Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo for ABT-494; Drug:Adalimumab; Drug:Placebo for Adalimumab,[],"December 10, 2015",18,99,Both,False
NCT00351611,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT00351611,True,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],"January 19, 2016",18,65,Both,False
NCT02150577,University of Arkansas,True,AR,https://ClinicalTrials.gov/show/NCT02150577,True,Implementation Trial of Evidence Based Practices for Mood Disorders,Bipolar Disorder; Treatment Resistant Depression,Behavioral:Evidence Based Quality Improvement,"[u'Mainline Health Systems Inc.', u'Boston Mountain Rural Health Center', u'Lee County Cooperative Clinic', u'ARcare', u'Jefferson Comprehensive Care System', u'East Arkansas Family Health Center']","October 14, 2015",18,100,Both,False
NCT01274338,National Cancer Institute (NCI),False,AR,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT00858364,Amgen,False,AR,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02674386,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,AR,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02427802,Innocoll,False,AR,https://ClinicalTrials.gov/show/NCT02427802,True,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],"January 4, 2016",18,85,Both,False
NCT02406677,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02164864,Boehringer Ingelheim,False,AR,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,AR,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01888120,Jazz Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT01888120,True,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],"June 18, 2015",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,AR,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02528253,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02431806,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT02431806,True,Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder,Major Depressive Disorder (MDD),Drug:Placebo; Drug:Levomilnacipran ER; Drug:Fluoxetine,[],"December 23, 2015",12,17,Both,False
NCT02357420,"Rhythm Pharmaceuticals, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02357420,True,A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis,Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis,Drug:RM-131; Drug:Placebo,[],"December 2, 2015",18,75,Both,False
NCT02240121,"Valeant Pharmaceuticals International, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT02240121,True,One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02182830,Boehringer Ingelheim,False,AR,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,AR,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02075047,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02075047,True,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Drug:placebo oral capsules; Drug:ziprasidone oral capsules,[],"January 16, 2016",10,17,Both,False
NCT02048813,National Cancer Institute (NCI),False,AR,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01970865,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT01970865,True,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Drug:PF-06463922; Drug:Crizotinib,[],"January 20, 2016",18,9223372036854775807,Both,False
NCT01968876,University of Arkansas,False,AR,https://ClinicalTrials.gov/show/NCT01968876,True,Is a Smartphone Application Effective as an Oral Medication Adherence Aid,Hypertension; Diabetes; Dyslipidemia,Other:Medication Adherence Smartphone App,"[u'Internal Medicine Clinic North; University of Arkansas for Medical Sciences', u'Remedy Drug', u'Internal Medicine Clinic West; University of Arkansas for Medical Sciences']","November 12, 2015",18,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,AR,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01828112,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT01828112,True,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,Non-Small Cell Lung Cancer,Drug:LDK378; Drug:pemetrexed; Drug:docetaxel,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,AR,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01546571,Polynoma LLC,False,AR,https://ClinicalTrials.gov/show/NCT01546571,True,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients",Melanoma,Biological:POL-103A; Biological:POL-103A without API,[],"December 8, 2015",18,80,Both,False
NCT01120249,Southwest Oncology Group,False,AR,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01101035,Takeda,True,AR,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT02638129,Takeda,False,AR,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02592434,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02592434,True,Efficacy Study Of Tofacitinib In Pediatric JIA Population,Juvenile Idiopathic Arthritis,"Drug:CP-690,550 (tofacitinib); Other:placebo","[u""Arkansas Children's Hospital - Attention: Billy Furgerson (IP Shipment Address)"", u""Arkansas Children's Hospital"", u'Tufts Medical Center, Inc.', u'Tufts Medical Center', u'Montefiore Medical Center (Drug Shipment)', u'Montefiore Medical Center', u""Cohen Children's Medical Center of NY"", u""Cohen Children's Medical Center of New York (Drug Shipment Address)"", u""Randall Children's Hospital at Legacy Emanuel""]","January 11, 2016",2,17,Both,False
NCT02590432,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02580305,Suven Life Sciences Limited,False,AR,https://ClinicalTrials.gov/show/NCT02580305,True,SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study,Alzheimer's Disease,Drug:SUVN-502; Drug:Placebo,"[u'Woodland International Research Group, LLC', u'Woodland Research Northwest', u'ATP Clinical Research, Inc.', u'Neuro-Pain Medical Center Inc', u'Senior Clinical Trials, Inc.', u'Jacksonville Center for Clinical Research', u'Premier Clinical Research Institute Inc', u'Miami Research Associates, LLC', u'The Roskamp Institute, Inc.', u'Neurology Clinical Research, Inc.', u'Axiom Clinical Research of Florida', u'Stedman Clinical Trials', u'Radiant Research', u'Sheppard Pratt Health System', u'AdvanceMed Research', u'Biobehavioral Health', u'Advanced Memory Research Institute', u'Integrative Clinical Trials, LLC', u'Eastside Comprehensive Medical Center, LLC', u'Valley Medical Research', u'IPS Research Company', u'Tulsa Clinical Research, LLC', u'Radiant Research, Inc.', u'Universal Research Group, LLC']","January 18, 2016",50,85,Both,False
NCT02580058,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT02580058,True,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),Ovarian Cancer,Biological:avelumab; Drug:PLD,"[u'Highlands Oncology Group', u'Highlands Oncology Group', u'Cabrini Health Limited', u'Cabrini Health Limited']","January 13, 2016",18,9223372036854775807,Female,False
NCT02544152,Sucampo AG,False,AR,https://ClinicalTrials.gov/show/NCT02544152,True,Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome,Irritable Bowel Syndrome,Drug:Lubiprostone; Drug:Placebo,"[u'Gastroenterology Associates,P.A.', u'Arkansas Gastroenterology', u'GW Research Inc.', u'Therapeutic Research Institute of Orange County', u'The Regents of the University of California / Los Angeles Campus', u'Advanced Gastroenterology Associates, LLC', u'Digestive Care Physicians', u'Meritus Center for Clinical Research', u'Mayo Clinic', u'Cumberland Research Associates, LLC', u'Wake Research Associates, LLC', u'Clinical Research Solutions', u'Nashville Medical Research Institute', u'Houston Endoscopy Research Center']","January 4, 2016",18,9223372036854775807,Both,False
NCT02504268,Bristol-Myers Squibb,False,AR,https://ClinicalTrials.gov/show/NCT02504268,True,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Methotrexate; Other:Abatacept Placebo; Other:Methotrexate Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,AR,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,AR,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02486718,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT02486718,True,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Other:Best Supportive Care (BSC),[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02674386,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02601209,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02540993,Bayer,False,CA,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02506153,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,CA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,CA,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,CA,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02315469,NRG Oncology,False,CA,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,CA,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02135042,NRG Oncology,False,CA,https://ClinicalTrials.gov/show/NCT02135042,True,Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA,Epstein-Barr Virus Infection; Stage II Nasopharyngeal Carcinoma; Stage III Nasopharyngeal Carcinoma; Stage IVA Nasopharyngeal Carcinoma; Stage IVB Nasopharyngeal Carcinoma,Drug:Cisplatin; Other:Clinical Observation; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,CA,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02092467,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,CA,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02059265,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02019264,Eisai Inc.,False,CA,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01991795,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,CA,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01903811,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,CA,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01872975,NSABP Foundation Inc,False,CA,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01870778,Novartis Pharmaceuticals,False,CA,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,CA,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,CA,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01856192,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,CA,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01808573,"Puma Biotechnology, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,CO,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,CO,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01674140,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01216683,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01079780,Pam Cogliano,False,CO,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02085408,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00074282,Eastern Cooperative Oncology Group,True,CO,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,CO,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,CT,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01668719,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01349881,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,CT,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01470612,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,CT,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00807768,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01274338,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,CT,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01975389,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01458574,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01458574,True,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Ulcerative Colitis,"Drug:Placebo; Drug:CP690,550; Drug:CP-690,550",[],"January 15, 2016",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00565851,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02406677,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT01991795,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,CT,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT00351611,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT00351611,True,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],"January 19, 2016",18,65,Both,False
NCT02459925,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT02459925,True,MOMS Hubs- CT Dept of Social Services Block Grant,Depression,Behavioral:CBT- Mental Health Program; Behavioral:MOMS GROW,"[u'Boys & Girls Club of New Haven', u'Center for Wellbeing of Women and Mothers, Dept. of Psychiatry, Yale University', u'Stop & Shop', u""West Rock Author's Academy""]","February 1, 2016",18,9223372036854775807,Female,False
NCT02358031,Merck Sharp & Dohme Corp.,False,CT,https://ClinicalTrials.gov/show/NCT02358031,True,A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer,Biological:Pembrolizumab; Drug:Cisplatin; Drug:Carboplatin; Drug:5-FU; Biological:Cetuximab,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02352883,ECOG-ACRIN Cancer Research Group,False,CT,https://ClinicalTrials.gov/show/NCT02352883,True,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],"September 22, 2015",18,9223372036854775807,Female,False
NCT02271217,Acorda Therapeutics,False,CT,https://ClinicalTrials.gov/show/NCT02271217,True,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke,Post-Ischemic Stroke,Drug:Placebo; Drug:dalfampridine-ER 7.5mg; Drug:dalfampridine-ER 10mg,[],"November 18, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01920711,Novartis Pharmaceuticals,False,CT,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,CT,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01771809,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT01771809,True,Long-Term Safety Of PF-00547659 In Ulcerative Colitis,Ulcerative Colitis,Drug:PF-00547659; Drug:PF-00547659; Drug:PF-00547659,[],"January 16, 2016",18,65,Both,False
NCT01414608,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01107626,Eastern Cooperative Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,CT,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02601209,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,DE,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02412670,ECOG-ACRIN Cancer Research Group,False,DE,https://ClinicalTrials.gov/show/NCT02412670,True,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],"August 19, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,DE,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01622868,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01595061,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01595061,True,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01575548,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01415752,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01013649,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02152137,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT02152137,True,Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer,Drug:efatutazone; Drug:paclitaxel,[],"August 12, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01236547,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01236547,True,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,DE,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT02474160,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02474160,True,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT01439711,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01439711,True,Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ,Breast Cancer,Drug:letrozole; Procedure:MRI; Procedure:conventional surgery,[],"September 18, 2015",18,9223372036854775807,Female,False
NCT02352883,ECOG-ACRIN Cancer Research Group,False,DE,https://ClinicalTrials.gov/show/NCT02352883,True,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],"September 22, 2015",18,9223372036854775807,Female,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,DE,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01959581,University of Delaware,False,DE,https://ClinicalTrials.gov/show/NCT01959581,True,Movement Enhancing Device for Children,Upper Extremity Dysfunction,Device:Movement Enhancing Device,"[u'Christiana Care Health Services', u'University of Delaware', u'Nemours Foundation']","December 11, 2014",1,6,Both,True
NCT01809691,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT02673190,Radiation Therapy Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02336685,"Janssen Research & Development, LLC",False,DE,https://ClinicalTrials.gov/show/NCT02336685,True,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02674386,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02545049,Bayer,False,FL,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,FL,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,FL,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02427802,Innocoll,False,FL,https://ClinicalTrials.gov/show/NCT02427802,True,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"Foot Ulcer, Diabetic; Infection",Drug:Gentamicin collagen sponge; Other:Placebo,[],"January 4, 2016",18,85,Both,False
NCT02406677,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,FL,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02336698,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02336698,True,"Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",Osteoarthritis; Pain,Drug:Placebo; Drug:Fulranumab 1 mg; Drug:Fulranumab 3 mg,[],"January 20, 2016",18,99,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02291679,"Ironwood Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02291679,True,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug:Linaclotide; Drug:Matching Placebo,[],"March 24, 2015",18,9223372036854775807,Both,False
NCT02234583,Daiichi Sankyo Inc.,False,FL,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,FL,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02155660,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT02138916,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02138916,True,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],"January 29, 2016",40,85,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02100514,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02100514,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02092467,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02049515,"Infinity Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02049515,True,A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Drug:IPI-145 (duvelisib); Drug:Ofatumumab,[],"November 16, 2015",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,FL,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01968967,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,FL,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01897532,Boehringer Ingelheim,False,FL,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,FL,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01858532,AbbVie,False,FL,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01674140,Southwest Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01663402,Sanofi,False,FL,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01652872,Amgen,False,FL,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,FL,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,FL,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,FL,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,FL,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00867815,Bayer,False,FL,https://ClinicalTrials.gov/show/NCT00867815,True,PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION),Anterior Ischemic Optic Neuropathy,Drug:Diagnostic procedures,[],"January 25, 2016",40,9223372036854775807,Male,False
NCT00858364,Amgen,False,FL,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02465567,"Pearl Therapeutics, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT01767311,Eisai Inc.,False,FL,https://ClinicalTrials.gov/show/NCT01767311,True,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",Alzheimer's Disease,Drug:BAN2401 2.5 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg; Drug:BAN2401 5.0 mg/kg; Drug:BAN2401 10 mg/kg,[],"November 29, 2015",50,90,Both,False
NCT01406756,Children's Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01190930,Children's Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT02601703,Glenmark Pharmaceuticals Ltd. India,False,FL,https://ClinicalTrials.gov/show/NCT02601703,True,"To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)",Atopic Dermatitis,"Drug:Tacrolimus Ointment 0.1%; Drug:Protopic ointment, 0.1%; Drug:Placebo of Tacrolimus Ointment",[],"December 11, 2015",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,GA,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01966107,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT02194738,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01975389,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT01975376,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,GA,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,GA,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT01359592,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT02182830,Boehringer Ingelheim,False,GA,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,GA,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01274338,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02003209,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02674386,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02528188,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02187003,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02187003,True,Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease,"Anemia, Sickle Cell",Drug:Rivipansel; Other:Placebo,[],"January 8, 2016",6,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,GA,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,GA,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,GA,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,GA,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01535053,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02528253,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,GA,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01845025,Novartis Pharmaceuticals,False,GA,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,GA,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02465567,"Pearl Therapeutics, Inc.",False,GA,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT02138916,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT02138916,True,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Placebo,[],"January 29, 2016",40,85,Both,False
NCT02066636,Bristol-Myers Squibb,False,GA,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01897532,Boehringer Ingelheim,False,GA,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01870778,Novartis Pharmaceuticals,False,GA,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,GA,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01674140,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01632241,"Human Genome Sciences Inc., a GSK Company",False,GA,https://ClinicalTrials.gov/show/NCT01632241,True,Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Drug:Standard therapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,GA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02194738,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02177695,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02177695,True,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02059265,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT02152137,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02152137,True,Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer,Drug:efatutazone; Drug:paclitaxel,[],"August 12, 2015",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,HI,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,HI,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00700882,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01286272,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01286272,True,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01595061,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01595061,True,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01013649,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,HI,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01414608,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02186847,NRG Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02186847,True,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,HI,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01272037,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02488967,NRG Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02003222,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01674140,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01966107,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02375204,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02375204,True,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],"December 8, 2015",14,9223372036854775807,Male,False
NCT02003209,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01853748,Dana-Farber Cancer Institute,False,ID,https://ClinicalTrials.gov/show/NCT01853748,True,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01516216,Dana-Farber Cancer Institute,False,ID,https://ClinicalTrials.gov/show/NCT01516216,True,Study of Vitamin D in Untreated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug:FOLFOX + bevacizumab; Dietary Supplement:Vitamin D; Dietary Supplement:Vitamin D,"[u""Mountain States Tumor Institute at St. Luke's Regional Medical Center"", u'Mountain States Tumor Institute- Fruitland', u'Mountain States Tumor Institute - Meridian', u'Mountain States Tumor Institute- Nampa', u'Mountain States Tumor Institute- Twin Falls', u'The Robert H. Lurie Comprehensive Cancer Center of Northwestern University', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Lowell General Hospital', u""Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center"", u'Newton-Wellesley Hospital', u""Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital"", u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'Dana-Farber/New Hampshire Oncology-Hematology', u'Vanderbilt-Ingram Cancer Center']","January 10, 2016",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02134912,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02134912,True,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,ID,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,ID,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02601209,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02388165,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02315469,NRG Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT01968967,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01839864,Family Medicine Residency of Idaho,False,ID,https://ClinicalTrials.gov/show/NCT01839864,True,Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial,Metabolic Syndrome,"Behavioral:Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count","[u'Saint Alphonsus Medical Group Caldwell Clinic', u'Saint Lukes Clinic Jerome', u'St Alphonsus Medical Group Nampa Clinic']","April 22, 2013",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02474160,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02474160,True,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02412670,ECOG-ACRIN Cancer Research Group,False,IL,https://ClinicalTrials.gov/show/NCT02412670,True,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],"August 19, 2015",18,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02249949,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02249949,True,"Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients With Previously Treated, Unresectable Myxoid Liposarcoma",Liposarcoma,Drug:efatutazone; Drug:placebo,[],"June 12, 2015",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02143414,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02143414,True,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 15, 2016",65,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02059265,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,IL,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003222,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,IL,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01575548,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01416688,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01416688,True,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"October 15, 2015",18,120,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01164228,Eastern Cooperative Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01164228,True,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug:gemcitabine hydrochloride; Drug:sunitinib malate,[],"July 24, 2014",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00565851,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT00843882,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01535053,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02115282,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,IN,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01622868,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02164916,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT00892866,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00892866,True,"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells",Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Human Papillomavirus Infection; Stage 0 Cervical Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02406677,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02065687,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01991795,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02451137,Sanofi,False,IN,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,IN,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,IN,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT01810913,Radiation Therapy Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT00978458,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,IN,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,IN,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT01872975,NSABP Foundation Inc,False,IN,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,IN,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,IA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,IA,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01950390,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01013649,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02154490,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,IA,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00492778,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02003209,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02032823,AstraZeneca,False,IA,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01415752,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01242800,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01835145,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT00828009,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00828009,True,BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,Lung Cancer,Biological:bevacizumab; Biological:emepepimut-S; Drug:carboplatin; Drug:cyclophosphamide; Drug:paclitaxel; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00897442,Gynecologic Oncology Group,True,IA,https://ClinicalTrials.gov/show/NCT00897442,True,Collecting Tumor Samples From Patients With Gynecological Tumors,Cancer,Other:biologic sample preservation procedure,[],"August 30, 2012",0,9223372036854775807,Female,False
NCT00807768,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT02488967,NRG Oncology,False,KS,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,KS,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003222,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01903811,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,KS,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01674140,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01649089,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01649089,True,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01575548,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01416688,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01416688,True,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"October 15, 2015",18,120,Both,False
NCT01372787,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01372787,True,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"May 8, 2013",18,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01164228,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01164228,True,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug:gemcitabine hydrochloride; Drug:sunitinib malate,[],"July 24, 2014",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,KS,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00700882,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02143414,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02143414,True,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 15, 2016",65,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT00840177,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00840177,True,"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia",Leukemia,Drug:cytarabine; Drug:idarubicin; Drug:pravastatin sodium,[],"September 25, 2015",18,9223372036854775807,Both,False
NCT00316888,Eastern Cooperative Oncology Group,True,KS,https://ClinicalTrials.gov/show/NCT00316888,True,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",Anal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:fluorouracil; Radiation:radiation therapy,[],"August 22, 2012",18,9223372036854775807,Both,False
NCT00074282,Eastern Cooperative Oncology Group,True,KS,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT01272037,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02488967,NRG Oncology,False,KY,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT02315469,NRG Oncology,False,KY,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02154490,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02451137,Sanofi,False,KY,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02164916,Southwest Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,KY,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT02601209,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01872975,NSABP Foundation Inc,False,KY,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01808573,"Puma Biotechnology, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,KY,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,KY,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02048917,University of Kentucky,False,KY,https://ClinicalTrials.gov/show/NCT02048917,True,Smoking Cessation Strategies in Community Cancer Programs for Lung and Head and Neck Cancer Patients,Lung Cancer; Head and Neck Cancer,Drug:High Intensity Counseling + Long Acting NRT + PRN NRT; Drug:High Intensity Counseling + bupropion + PRN NRT; Drug:High Intensity Counseling + varenicline + PRN NRT; Drug:High Intensity Counseling + Long Acting NRT; Drug:High Intensity Counseling + bupropion; Drug:High Intensity Counseling + varenicline; Drug:Low Intensity Counseling + Long Acting NRT + PRN NRT; Drug:Low Intensity Counseling + bupropion + PRN NRT; Drug:Low Intensity Counseling + varenicline + PRN NRT; Drug:Low Intensity Counseling + Long Acting NRT; Drug:Low Intensity Counseling + bupropion; Drug:Low Intensity Counseling + varenicline,"[u""King's Daughters Medical Center"", u'Hardin Memorial Health Cancer Care Center', u'ARH Cancer Center', u'Kentucky Cancer Clinic', u'University Of Kentucky, Markey Cancer Center', u'University of Louisville, James Graham Brown Cancer Center', u'St. Claire Regional Medical Center']","January 6, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01845025,Novartis Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01389596,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01389596,True,A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years,"Epilepsy, Partial Seizures",Drug:Pregabalin add-on therapy; Drug:Pregabalin add-on therapy; Drug:Pregabalin add-on therapy,[],"January 8, 2016",4,16,Both,False
NCT02072226,"Genentech, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT02072226,True,A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS),Brain Ischemia,Drug:alteplase [Activase]; Drug:alteplase placebo; Drug:aspirin; Drug:aspirin placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,KY,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01663402,Sanofi,False,KY,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01649089,Gynecologic Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT01649089,True,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01594333,Brigham and Women's Hospital,False,KY,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01463306,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01463306,True,A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures,"Epilepsy, Partial Seizures; Epilepsy, Primary Generalized Tonic-Clonic Seizures",Drug:Pregabalin,[],"January 20, 2016",1,65,Both,False
NCT01312909,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT01312909,True,Smoking Cessation Study In Healthy Adolescent Smokers,Smoking Cessation,Drug:Varenicline 1mg BID; Drug:Varenicline 0.5mg BID; Drug:Placebo,[],"February 3, 2016",12,19,Both,False
NCT01274338,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02671981,Radiation Therapy Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,LA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,LA,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01966107,AstraZeneca,False,LA,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,LA,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01975389,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01594333,Brigham and Women's Hospital,False,LA,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,LA,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,LA,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02164513,GlaxoSmithKline,False,LA,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,LA,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,LA,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01845025,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01652872,Amgen,False,LA,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,LA,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,LA,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02164916,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01950390,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,LA,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01663402,Sanofi,False,LA,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,LA,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,LA,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02528188,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02182830,Boehringer Ingelheim,False,LA,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01877915,"Janssen Research & Development, LLC",False,LA,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01870778,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,LA,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,LA,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02155296,RAND,False,ME,https://ClinicalTrials.gov/show/NCT02155296,True,RCT of the Restorative Practices Intervention,Intervention Schools (Schools Receiving RPI); Control Schools (Schools Not Receiving RPI),Behavioral:Restorative Practices Intervention,"[u'Bath Middle School', u'Boothbay school', u'Bucksport school', u'Bonny Eagle school', u'Ridge View school', u'Hall-Dale school', u'Molly Ockett', u'Gorham school', u'Hope school', u'Jefferson Village school', u'Mt. Jefferson school', u'Libby school', u'Maranacook school', u'Oak Hill school', u'Skowhegan school', u'Windham school']","October 27, 2015",12,9223372036854775807,Both,True
NCT02194738,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,ME,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02115282,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,ME,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01663402,Sanofi,False,ME,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,ME,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02488967,NRG Oncology,False,ME,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01950390,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT02562716,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02438722,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02164916,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,ME,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,ME,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01903811,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01772472,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT01772472,True,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),Breast Cancer,Drug:trastuzumab; Drug:trastuzumab emtansine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01311336,University of Vermont,False,ME,https://ClinicalTrials.gov/show/NCT01311336,True,Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain,Pegfilgrastim-induced Back and Leg Pain,Drug:Loratadine; Drug:placebo,"[u'Cancer Care of Maine', u'Maine Center for Cancer Medicine', u'York Hospital', u'CR Wood Cancer Center', u'Mountainview Medical Center', u'Vermont Cancer Center', u'Vermont Center for Cancer Medicine']","January 23, 2013",18,9223372036854775807,Both,False
NCT01286272,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01286272,True,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,Grade 3a Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Drug:Bendamustine Hydrochloride; Drug:Bortezomib; Radiation:Fludeoxyglucose F-18; Other:Laboratory Biomarker Analysis; Biological:Ofatumumab; Procedure:Positron Emission Tomography with Radiolabeled Targeting Agent,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT00048958,Alliance for Clinical Trials in Oncology,True,ME,https://ClinicalTrials.gov/show/NCT00048958,True,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],"August 6, 2015",18,9223372036854775807,Both,False
NCT02670083,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT02670083,True,"CREAD Study"" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",Alzheimer's Disease,Drug:Crenezumab; Drug:Placebo,[],"February 3, 2016",50,85,Both,False
NCT02406677,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02180867,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02173379,Abbott Vascular,False,ME,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,ME,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02027428,Celgene Corporation,False,ME,https://ClinicalTrials.gov/show/NCT02027428,True,Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer,"Squamous Cell Carcinoma, Non-Small-Cell Lung",Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Drug:Abraxane (Maintenance); Other:Best Supportive Care (Maintenance); Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Other:Best Supportive Care (Maintenance),[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01966107,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,ME,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01858532,AbbVie,False,ME,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01674140,Southwest Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,MD,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,MD,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,MD,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT01991795,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,MD,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02115282,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MD,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02364999,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02364999,True,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Non-small Cell Lung Cancer (NSCLC),Drug:Bevacizumab-Pfizer; Drug:Bevacizumab-EU; Drug:Paclitaxel; Drug:Carboplatin,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT02254577,Shady Grove Fertility Reproductive Science Center,True,MD,https://ClinicalTrials.gov/show/NCT02254577,True,Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer,Infertility,Drug:Endometrin Only; Drug:Endometrin plus Progesterone in Oil (PIO); Drug:Progesterone in Oil (PIO) Only,"[u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center', u'Shady Grove Fertility Center']","November 17, 2015",18,48,Female,False
NCT02032823,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,MD,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01872975,NSABP Foundation Inc,False,MD,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02111564,"Janssen Research & Development, LLC",False,MD,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02075047,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02075047,True,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Drug:placebo oral capsules; Drug:ziprasidone oral capsules,[],"January 16, 2016",10,17,Both,False
NCT01663402,Sanofi,False,MD,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01101035,Takeda,True,MD,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00351611,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT00351611,True,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug:Lyrica (pregabalin); Drug:placebo,[],"January 19, 2016",18,65,Both,False
NCT02251366,Johns Hopkins University,False,MD,https://ClinicalTrials.gov/show/NCT02251366,True,NVAMD Satellite Study,Neovascular Age Related Macular Degeneration,Procedure:Physician-guided diagnostic,"[u'Wilmer Eye Institute', u'Wilmer Eye Institute', u'Wilmer Eye Institute', u'Wilmer Eye Institute', u'Wilmer Eye Institute']","September 7, 2015",18,9223372036854775807,Both,True
NCT02187003,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02187003,True,Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease,"Anemia, Sickle Cell",Drug:Rivipansel; Other:Placebo,[],"January 8, 2016",6,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02125461,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT02125461,True,A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Drug:MEDI4736; Other:PLACEBO,[],"January 11, 2016",18,130,Both,False
NCT02114203,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT02114203,True,"Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease",Phase 1 Sickle Cell,Drug:PDE9i; Drug:PDE9i; Drug:placebo for PDE9i; Drug:PDE9i,[],"February 1, 2016",18,65,Both,False
NCT02066636,Bristol-Myers Squibb,False,MD,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02047097,Biogen,False,MD,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01997333,Celldex Therapeutics,False,MD,https://ClinicalTrials.gov/show/NCT01997333,True,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.,Drug:CDX-011; Drug:Capecitabine,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,MD,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01855750,"Janssen Research & Development, LLC",False,MD,https://ClinicalTrials.gov/show/NCT01855750,True,"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",Lymphoma,Drug:Ibrutinib; Drug:Placebo; Drug:Rituximab; Drug:Cyclophosphamide; Drug:Doxorubicin; Drug:Vincristine; Drug:Prednisone (or equivalent),[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,MA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02154490,Southwest Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01238588,Brigham and Women's Hospital,False,MA,https://ClinicalTrials.gov/show/NCT01238588,True,The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan,Dialysis; Cardiovascular Disease; Atherosclerosis; Inflammation; Hyperphosphatemia,Drug:Sevelamer Carbonate (Renvela),"[u""Brigham and Women's Hospital"", u'BWH/FH/DCI Outpatient Dialysis Unit', u'Fresenius Boston-TKC', u'Fresenius Framingham (#1109)', u'Fresenius Marlborough (#3448)', u'Fresenius Medford Dialysis (#1246)', u'Fresenius Quincy (#1610)', u'Fresenius Roxbury (#1630)', u'DCI Dialysis Unit-Somerville', u'Fresenius QCDC-Weymouth (#9144)']","October 5, 2015",50,9223372036854775807,Both,False
NCT00251875,Agency for Healthcare Research and Quality (AHRQ),False,MA,https://ClinicalTrials.gov/show/NCT00251875,True,Shared Online Health Records for Patient Safety and Care,Diabetes,Device:online health information journal,"[u'Beacon Hill/Downtown Primary Care', u'Bulfinch Medical Group', u""Massachusetts General Hospital Women's Health Associates"", u'Charlestown Health Center', u""Brigham & Women's Physicians Group"", u""Brigham & Women's Hospital Women's Health Center"", u'Brigham Primary Physicians at Faulkner', u'Southern Jamaica Plain Health Center', u""Brigham & Women's Hospital at Norwood"", u'Revere Health Center']","November 9, 2005",18,9223372036854775807,Both,True
NCT02060630,New England Research Institutes,False,MA,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01817660,Boston University,False,MA,https://ClinicalTrials.gov/show/NCT01817660,True,Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial,Popliteal Artery Aneurysm.,Procedure:Open repair of popliteal artery; Procedure:Endovascular repair of popliteal artery,"[u'Danbury Hospital', u'Hartford Hospital', u'Yale-New Haven Hospital', u'Indiana University Medical Center', u'LSU Medical Center', u'Maine Medical Center', u""Brigham and Women's Hospital"", u'BI-Deaconess Hospital', u'Boston Medical Center', u'Massachusetts General Hospital', u'Tufts Medical Center', u'St. Elizabeth Hospital', u'Charlton Memorial Hospital/St. Anne', u'Bay State Medical Center', u'Henry Ford Hospital', u'Dartmouth Medical Center', u'Cardiothoracic Surgical Associates, PA', u'Albany Medical Center', u'Rhode Island Hospital', u'Fletcher Allen Healthcare', u'University of Virginia Health Center']","March 28, 2013",35,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02359084,Boston University,False,MA,https://ClinicalTrials.gov/show/NCT02359084,True,"Project EARLY: Engagement, Assessment, Referral, & Linkage for Young Children",Autism; Developmental Delay Disorders,Behavioral:Family Navigation; Behavioral:Conventional Care Management,"[u'Yale University School of Medicine', u'Boston University School of Public Health', u'South End Community Health Center', u'Dorchester House Multi-Service Center', u'Codman Square Health Center', u'East Boston Neighborhood Health Center', u'Boston Medical Center', u'MGH Chelsea', u""Children's Hospital of Philadelphia""]","July 28, 2015",15,27,Both,False
NCT02019264,Eisai Inc.,False,MA,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01947283,Cambridge Health Alliance,False,MA,https://ClinicalTrials.gov/show/NCT01947283,True,"Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation",Mental Disorders,Behavioral:DECIDE-PA; Behavioral:DECIDE-PC,"[u'South Cove Community Health Center', u""Children's Hospital Boston (Martha Elliot Health Center)"", u'Beth Israel Deaconess Medical Center (Ambulatory Psychiatry Unit)', u'Beth Israel Deaconess Medical Center (Latino Mental Health)', u'Cambridge Health Alliance (Windsor Clinic, Macht Building, Central Street, Malden Primary Care Mental Health)', u'Harbor Health Services, Inc. (Geiger Gibson Community Health Center and Neponset Health Center)', u'Edward M Kennedy Health Center (Great Brook Valley Health Center)']","May 4, 2015",18,80,Both,False
NCT01853748,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01853748,True,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01672892,Radiation Therapy Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01516216,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01516216,True,Study of Vitamin D in Untreated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug:FOLFOX + bevacizumab; Dietary Supplement:Vitamin D; Dietary Supplement:Vitamin D,"[u""Mountain States Tumor Institute at St. Luke's Regional Medical Center"", u'Mountain States Tumor Institute- Fruitland', u'Mountain States Tumor Institute - Meridian', u'Mountain States Tumor Institute- Nampa', u'Mountain States Tumor Institute- Twin Falls', u'The Robert H. Lurie Comprehensive Cancer Center of Northwestern University', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Lowell General Hospital', u""Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center"", u'Newton-Wellesley Hospital', u""Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital"", u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'Dana-Farber/New Hampshire Oncology-Hematology', u'Vanderbilt-Ingram Cancer Center']","January 10, 2016",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02509078,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02509078,True,Reevaluation Of Systemic Early Neuromuscular Blockade,Acute Respiratory Distress Syndrome,Drug:cisastracurium besylate,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,MA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,MA,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,MA,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01858532,AbbVie,False,MA,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT00858364,Amgen,False,MA,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00042289,National Institute of Allergy and Infectious Diseases (NIAID),True,MA,https://ClinicalTrials.gov/show/NCT00042289,True,Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy,HIV Infections,Drug:Current ARV medications; Drug:Current TB medications; Drug:Current hormonal contraceptive medications,[],"September 2, 2015",0,9223372036854775807,Female,False
NCT02673190,Radiation Therapy Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02477618,Sage Therapeutics,False,MA,https://ClinicalTrials.gov/show/NCT02477618,True,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Super-Refractory Status Epilepticus,Drug:SAGE-547; Drug:Placebo,[],"January 28, 2016",2,9223372036854775807,Both,False
NCT02239120,Boehringer Ingelheim,False,MA,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02233946,Children's Hospital Boston,True,MA,https://ClinicalTrials.gov/show/NCT02233946,True,Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care,Prevention Harmful Effects,Behavioral:computer-facilitated brief intervention,"[u'Tufts Medical Center', u'Boston Childrens Primary Care Center', u'Longwood Pediatrics', u'East Boston Neighborhood Health Center', u'Lexington Pediatrics']","February 5, 2015",9,18,Both,True
NCT02065687,Gynecologic Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02047097,Biogen,False,MA,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01950390,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01870778,Novartis Pharmaceuticals,False,MA,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01827787,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01827787,True,Eribulin in HER2 Negative Metastatic BrCa,Breast Cancer,Drug:Eribulin,"[u'Eastern Maine Medical Center', u'Dana-Farber Cancer Institute at Faulkner Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'DF/BWCC at Milford Regional Cancer Center', u'South Shore Hospital', u'Dana-Farber/New Hampshire Oncology-Hematology']","January 26, 2016",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,MA,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01674842,Dana-Farber Cancer Institute,False,MA,https://ClinicalTrials.gov/show/NCT01674842,True,Cisplatin + RT for Triple Negative Breast Cancer,Breast Cancer,Radiation:Radiation Therapy; Drug:Cisplatin,"[u'Massachusetts General Hospital', u""Brigham and Women's Hospital"", u'Dana-Farber Cancer Institute', u'Dana-Farber at Milford', u'Dana Farber at South Shore Hospital']","January 19, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02488967,NRG Oncology,False,MI,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02085408,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,MI,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003222,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,MI,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01674140,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01622868,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00843882,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT01101451,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01079780,Pam Cogliano,False,MI,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,MI,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02488967,NRG Oncology,False,MN,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,MN,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02059265,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,MN,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003209,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01903811,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,MN,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01649089,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01649089,True,Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Lymphedema; Sexual Dysfunction and Infertility; Stage IA Cervical Cancer; Stage IB Cervical Cancer,Procedure:Conization; Procedure:Loop Electrosurgical Excision; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01535053,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01372787,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01372787,True,"Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:assessment of therapy complications; Procedure:cognitive assessment; Procedure:fatigue assessment and management; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"May 8, 2013",18,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01079780,Pam Cogliano,False,MN,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00978458,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT00897767,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00719303,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00700882,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT01991795,AstraZeneca,False,MS,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,MS,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT02142868,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT02142868,True,"Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",Advanced Breast Cancer (Female),Drug:Palbociclib; Drug:Letrozole,[],"January 20, 2016",18,9223372036854775807,Female,False
NCT01594333,Brigham and Women's Hospital,False,MS,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,MS,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02273726,FibroGen,False,MS,https://ClinicalTrials.gov/show/NCT02273726,True,Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects,CKD Anemia in Stable Dialysis Patients,Drug:Epoetin Alfa; Drug:FG-4592,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT02052310,FibroGen,False,MS,https://ClinicalTrials.gov/show/NCT02052310,True,Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients,Anemia in Incident Dialysis Patients,Drug:FG-4592 (roxadustat); Drug:Epoetin Alfa,[],"March 24, 2015",18,9223372036854775807,Both,False
NCT01920711,Novartis Pharmaceuticals,False,MS,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT00858364,Amgen,False,MS,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02528253,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,MS,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02066636,Bristol-Myers Squibb,False,MS,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,MS,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01975389,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01845025,Novartis Pharmaceuticals,False,MS,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,MS,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MS,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,MS,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,MS,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02674386,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02615002,Neurim Pharmaceuticals Ltd.,False,MS,https://ClinicalTrials.gov/show/NCT02615002,True,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),Alzheimer's Disease,Drug:Piromelatine; Drug:Placebo,[],"January 26, 2016",60,85,Both,False
NCT02574078,Bristol-Myers Squibb,False,MS,https://ClinicalTrials.gov/show/NCT02574078,True,A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),Non-Small Cell Lung Cancer,Drug:Nivolumab; Drug:Bevacizumab; Drug:Pemetrexed; Other:Palliative radiation; Drug:nab-Paclitaxel; Drug:Paclitaxel; Drug:Docetaxel; Drug:Gemcitabine; Drug:Erlotinib; Drug:Crizotinib; Drug:Carboplatin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02542384,"Cara Therapeutics, Inc.",False,MS,https://ClinicalTrials.gov/show/NCT02542384,True,A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery,Post Abdominal Surgery Pain,Drug:CR845 IV 1 mcg/kg; Drug:CR845 IV 2 mcg/kg; Drug:CR845 IV 5 mcg/kg; Drug:Placebo IV,[],"February 3, 2016",21,9223372036854775807,Both,False
NCT02504294,"Hospira, Inc.",False,MS,https://ClinicalTrials.gov/show/NCT02504294,True,A Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease (CKD),Drug:Epoetin Hospira Arm; Other:Standard of Care Arm,"[u'CA Institute of Renal Research', u'CA Institute of Renal Research', u'Genesis Clinical Research, Inc', u'Boise Kidney and Hypertension Institute', u'Nephrology Center, PC', u'South Mississippi Medical Research, LLC', u'Southern Renal Research Group, LLC', u'Metrolina Nephrology Associates, PA', u'Durham Nephrology Associates', u'Delaware Valley Nephrology and Hypertension Associates, PC', u'Rhode Island Hospital', u'Knoxville Kidney Center, PLLC', u'Nephrology Associates, PC', u'Research Management Inc', u'Gamma Medical Research, Inc', u'Southwest Houston Research, Ltd', u'Eugenia M. Galindo-Ramos', u'Jose L. Cangiano-Rivera']","November 25, 2015",18,9223372036854775807,Both,False
NCT02422615,Novartis Pharmaceuticals,False,MS,https://ClinicalTrials.gov/show/NCT02422615,True,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,"Breast Neoplasms; Breast Diseases; Neoplasms; Neoplasms by Site; Fulvestrant; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Estrogen Receptor Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Therapeutic Use",Drug:Ribociclib; Drug:fulvestrant; Drug:Ribociclib placebo,[],"September 14, 2015",18,9223372036854775807,Female,False
NCT02415400,Bristol-Myers Squibb,False,MS,https://ClinicalTrials.gov/show/NCT02415400,True,Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention,Acute Coronary Syndromes,Drug:Apixaban; Drug:vitamin K antagonist; Drug:Acetylsalicylic acid; Other:Acetylsalicylic acid placebo,[],"January 11, 2016",18,95,Both,False
NCT02406677,AstraZeneca,False,MS,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02367794,Hoffmann-La Roche,False,MS,https://ClinicalTrials.gov/show/NCT02367794,True,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131],Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Nab-paclitaxel; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,MS,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02240108,"Valeant Pharmaceuticals International, Inc.",False,MS,https://ClinicalTrials.gov/show/NCT02240108,True,One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease,Crohn's Disease,Drug:Rifaximin DR; Drug:Placebo,[],"June 11, 2015",18,9223372036854775807,Both,False
NCT02235545,St. Jude Medical,False,MS,https://ClinicalTrials.gov/show/NCT02235545,True,Optisure Lead Post Approval Study,"Heart Failure; Tachycardia, Ventricular",Device:St. Jude Medical Optisure Lead,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT02228681,Gynecologic Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT02228681,True,Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,"Advanced, Persistent, or Recurrent Endometrial Cancer",Drug:Everolimus; Drug:Tamoxifen; Drug:Letrozole; Drug:Medroxyprogesterone Acetate,[],"November 18, 2015",18,9223372036854775807,Female,False
NCT02155660,AstraZeneca,False,MS,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT02065687,Gynecologic Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01946204,"Aragon Pharmaceuticals, Inc.",False,MS,https://ClinicalTrials.gov/show/NCT01946204,True,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,Prostatic Neoplasms,Drug:ARN-509; Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Male,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,MS,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01870778,Novartis Pharmaceuticals,False,MS,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT01729455,"Human Genome Sciences Inc., a GSK Company",False,MS,https://ClinicalTrials.gov/show/NCT01729455,True,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01705977,"Human Genome Sciences Inc., a GSK Company",False,MS,https://ClinicalTrials.gov/show/NCT01705977,True,Belimumab Assessment of Safety in SLE,Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Other:Standard therapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01652872,Amgen,False,MS,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02488967,NRG Oncology,False,MO,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,MO,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,MO,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003222,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,MO,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01622868,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,MO,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01169337,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MO,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01013649,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02474160,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02474160,True,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,MO,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00892866,Gynecologic Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00892866,True,"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells",Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Human Papillomavirus Infection; Stage 0 Cervical Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02438722,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02412670,ECOG-ACRIN Cancer Research Group,False,MO,https://ClinicalTrials.gov/show/NCT02412670,True,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,Localized Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter,Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin Hydrochloride; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Drug:Carboplatin; Procedure:Therapeutic Conventional Surgery; Other:Laboratory Biomarker Analysis,[],"August 19, 2015",18,9223372036854775807,Both,False
NCT02143414,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02143414,True,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 15, 2016",65,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,MO,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01903811,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01950390,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,MO,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,MO,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00807768,Gynecologic Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02059265,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT01810913,Radiation Therapy Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT00843882,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01169337,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01359592,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00700882,Eastern Cooperative Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT00840177,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00840177,True,"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia",Leukemia,Drug:cytarabine; Drug:idarubicin; Drug:pravastatin sodium,[],"September 25, 2015",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT02601209,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01535053,Gynecologic Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02134912,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT02134912,True,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT02003222,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,MT,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02562716,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02488967,NRG Oncology,False,MT,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,MT,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02177695,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT02177695,True,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT02115282,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,NE,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02488967,NRG Oncology,False,NE,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01950390,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT02315469,NRG Oncology,False,NE,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02101788,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02601209,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01013649,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT01966107,AstraZeneca,False,NE,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01169337,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00666731,University of Nebraska,False,NE,https://ClinicalTrials.gov/show/NCT00666731,True,A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer,Breast Cancer; Precancerous Condition,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:Excess human biological tissue; Procedure:quality-of-life assessment,[],"November 30, 2015",19,120,Both,False
NCT02134912,Southwest Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT02134912,True,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT02106546,AbbVie,False,NE,https://ClinicalTrials.gov/show/NCT02106546,True,"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",Squamous Non-Small Cell Lung Cancer,Drug:veliparib; Drug:carboplatin; Drug:paclitaxel; Drug:placebo,[],"January 13, 2016",18,99,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,NE,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,NE,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00828009,Eastern Cooperative Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT00828009,True,BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,Lung Cancer,Biological:bevacizumab; Biological:emepepimut-S; Drug:carboplatin; Drug:cyclophosphamide; Drug:paclitaxel; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00316888,Eastern Cooperative Oncology Group,True,NE,https://ClinicalTrials.gov/show/NCT00316888,True,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",Anal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:fluorouracil; Radiation:radiation therapy,[],"August 22, 2012",18,9223372036854775807,Both,False
NCT02524275,University of Nebraska,False,NE,https://ClinicalTrials.gov/show/NCT02524275,True,Docetaxel and Capecitabine in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,Head and Neck Squamous Cell Carcinoma,Drug:Capecitabine; Drug:Docetaxel; Other:Quality-of-Life Assessment,"[u'Saint Francis Medical Center', u'Faith Regional Medical Offices West', u'Great Plains Regional Medical Center', u'Omaha Veterans Administration Medical Center', u'University of Nebraska Medical Center', u'Bellevue Hospital Center', u'Avera Cancer Institute', u'Veterans Affairs Medical Center - Memphis']","August 12, 2015",18,9223372036854775807,Both,False
NCT02601209,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,NV,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,NV,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02177695,Southwest Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT02177695,True,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02003222,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,NV,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01575548,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,NV,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,NV,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01169337,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01013649,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,NV,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00492778,Gynecologic Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,NV,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02474160,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02474160,True,Collection and Storage of Tissue and Blood Samples From Patients With Cancer,Malignant Neoplasm,Other:Cytology Specimen Collection Procedure,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,NV,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,NV,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02439320,CoLucid Pharmaceuticals,False,NV,https://ClinicalTrials.gov/show/NCT02439320,True,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,NV,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,NV,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,NV,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,NV,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01406756,Children's Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01190930,Children's Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT02674386,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02059265,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT01966107,AstraZeneca,False,NV,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01272037,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT02194738,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02390401,Dartmouth-Hitchcock Medical Center,False,NH,https://ClinicalTrials.gov/show/NCT02390401,True,Vacuum Assisted Closure for Cesarean Section,Surgical Wound Infection,Device:Vacuum-assisted closure; Device:Standard sterile dressing,"[u'Dartmouth-Hitchcock Medical Center', u""Women's Care of Nashua"", u'Dartmouth-Hitchcock Nashua', u'Southern New Hampshire Medical Center']","January 20, 2016",18,9223372036854775807,Female,True
NCT02154490,Southwest Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01853748,Dana-Farber Cancer Institute,False,NH,https://ClinicalTrials.gov/show/NCT01853748,True,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01516216,Dana-Farber Cancer Institute,False,NH,https://ClinicalTrials.gov/show/NCT01516216,True,Study of Vitamin D in Untreated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug:FOLFOX + bevacizumab; Dietary Supplement:Vitamin D; Dietary Supplement:Vitamin D,"[u""Mountain States Tumor Institute at St. Luke's Regional Medical Center"", u'Mountain States Tumor Institute- Fruitland', u'Mountain States Tumor Institute - Meridian', u'Mountain States Tumor Institute- Nampa', u'Mountain States Tumor Institute- Twin Falls', u'The Robert H. Lurie Comprehensive Cancer Center of Northwestern University', u'Massachusetts General Hospital', u'Beth Israel Deaconess Medical Center', u'Dana-Farber Cancer Institute', u'Lowell General Hospital', u""Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center"", u'Newton-Wellesley Hospital', u""Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital"", u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'New Hampshire Oncology Hematology-P.A.', u'Dana-Farber/New Hampshire Oncology-Hematology', u'Vanderbilt-Ingram Cancer Center']","January 10, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02164916,Southwest Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02032277,AbbVie,False,NH,https://ClinicalTrials.gov/show/NCT02032277,True,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],"October 9, 2015",18,99,Female,False
NCT01950390,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,NH,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01809691,Southwest Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01349881,Southwest Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01208662,"Paul G. Richardson, MD",False,NH,https://ClinicalTrials.gov/show/NCT01208662,True,"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65",Multiple Myeloma,Drug:Lenalidomide; Drug:Bortezomib; Drug:Dexamethasone; Procedure:Autologous Stem Cell Transplant,[],"January 21, 2016",18,65,Both,False
NCT00922974,Radiation Therapy Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT00922974,True,Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis,Metastatic Cancer; Pain,Radiation:external beam radiation therapy; Radiation:image-guided radiation therapy; Radiation:radiosurgery; Radiation:stereotactic body radiation therapy,[],"November 19, 2015",18,120,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT02673190,Radiation Therapy Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02513394,"Alliance Foundation Trials, LLC.",False,NH,https://ClinicalTrials.gov/show/NCT02513394,True,PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer,Breast Cancer,Drug:Palbociclib; Drug:Standard Adjuvant Endocrine Therapy,"[u'', u'', u'']","December 10, 2015",18,9223372036854775807,Both,False
NCT02360319,Vanguard Research Group,False,NH,https://ClinicalTrials.gov/show/NCT02360319,True,Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics,Schizophrenia,Drug:Any FDA approved antipsychotic agent; Drug:aripiprazole long acting injectable formulation,[],"December 7, 2015",18,35,Both,False
NCT02315469,NRG Oncology,False,NH,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02277665,Dartmouth-Hitchcock Medical Center,False,NH,https://ClinicalTrials.gov/show/NCT02277665,True,Clinical Trial Tobacco Marijuana,Cannabis Use Disorder; Tobacco Use Disorder,Behavioral:CUD Treatment; Behavioral:Tobacco Treatment,"[u'Geisel School of Medicine at Dartmouth; State Building Site', u'Geisel School of Medicine at Dartmouth; Rivermill Complex Site', u'University of Washington School of Social Work']","August 3, 2015",18,9223372036854775807,Both,True
NCT02254278,NRG Oncology,False,NH,https://ClinicalTrials.gov/show/NCT02254278,True,Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer,Stage III Oropharyngeal Squamous Cell Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma,Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02188745,Dartmouth-Hitchcock Medical Center,False,NH,https://ClinicalTrials.gov/show/NCT02188745,True,ER Reactivation Therapy for Breast Cancer,Metastatic Breast Cancer,Drug:17B-estradiol; Drug:Letrozole; Drug:Anastrozole; Drug:Exemestane,"[u'Dartmouth Hitchcock Medical Center', u'Dartmouth Hitchcock Medical Center']","December 7, 2015",18,90,Female,False
NCT02178956,"Boston Biomedical, Inc",False,NH,https://ClinicalTrials.gov/show/NCT02178956,True,A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer,Gastric Cancer; Gastroesophageal Junction Cancer,Drug:BBI608; Drug:Paclitaxel; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02161718,"Alkermes, Inc.",False,NH,https://ClinicalTrials.gov/show/NCT02161718,True,A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder,Schizophrenia; Alcohol Use Disorder,Drug:Samidorphan + olanzapine (ALKS 3831); Drug:Placebo,[],"February 3, 2016",18,65,Both,False
NCT02065687,Gynecologic Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02037529,Academic and Community Cancer Research United,False,NH,https://ClinicalTrials.gov/show/NCT02037529,True,A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer,Metastatic Breast Cancer; Locally Recurrent Breast Cancer,Drug:Eribulin; Drug:Paclitaxel,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01984268,Dartmouth-Hitchcock Medical Center,False,NH,https://ClinicalTrials.gov/show/NCT01984268,True,ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate,Rheumatoid Arthritis,Drug:ACTHAR; Drug:NSAID,"[u'Dartmouth-Hitchcock Medical Center', u'Dartmouth-Hitchcock Medical Center']","November 13, 2013",18,70,Both,True
NCT01822496,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT01822496,True,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Drug:Cisplatin; Drug:Crizotinib; Drug:Erlotinib Hydrochloride; Drug:Etoposide; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01817660,Boston University,False,NH,https://ClinicalTrials.gov/show/NCT01817660,True,Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial,Popliteal Artery Aneurysm.,Procedure:Open repair of popliteal artery; Procedure:Endovascular repair of popliteal artery,"[u'Danbury Hospital', u'Hartford Hospital', u'Yale-New Haven Hospital', u'Indiana University Medical Center', u'LSU Medical Center', u'Maine Medical Center', u'BI-Deaconess Hospital', u""Brigham and Women's Hospital"", u'Boston Medical Center', u'Massachusetts General Hospital', u'Tufts Medical Center', u'St. Elizabeth Hospital', u'Charlton Memorial Hospital/St. Anne', u'Bay State Medical Center', u'Henry Ford Hospital', u'Dartmouth Medical Center', u'Cardiothoracic Surgical Associates, PA', u'Albany Medical Center', u'Rhode Island Hospital', u'Fletcher Allen Healthcare', u'University of Virginia Health Center']","March 28, 2013",35,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00492778,Gynecologic Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02675244,Icahn School of Medicine at Mount Sinai,False,NH,https://ClinicalTrials.gov/show/NCT02675244,True,Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery,Mild Tricuspid Regurgitation; Moderate Tricuspid Regurgitation; Tricuspid Regurgitation,Procedure:TV Annuloplasty; Procedure:MVS Alone,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02666664,Esperion Therapeutics,True,NH,https://ClinicalTrials.gov/show/NCT02666664,True,Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk,Hypercholesterolemia; Atherosclerotic Cardiovascular Diseases,Drug:ETC-1002; Drug:Placebo,"[u'', u'', u'', u'', u'', u'']","January 25, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02193282,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02406677,AstraZeneca,False,NJ,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT01975389,Pfizer,False,NJ,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,NJ,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,NJ,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01872975,NSABP Foundation Inc,False,NJ,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01594333,Brigham and Women's Hospital,False,NJ,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01013649,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,NJ,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,NJ,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01663402,Sanofi,False,NJ,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,NJ,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,NJ,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,NJ,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT02301156,"TG Therapeutics, Inc.",False,NJ,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,NJ,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,NJ,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02003209,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01877915,"Janssen Research & Development, LLC",False,NJ,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT01856192,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,NJ,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,NJ,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01951534,"Rutgers, The State University of New Jersey",False,NJ,https://ClinicalTrials.gov/show/NCT01951534,True,Decisional Aid Intervention for Women Considering Breast Reconstruction,Breast Cancer,Behavioral:Breast Reconstruction Decisional Aid (BRDA); Behavioral:Usual Care,"[u'Ocean Medical Center', u'Cooper Hospital/University Medical Center', u'Bayshore Community Hospital', u'Southern Ocean Medical Center', u'Jersey Shore University Medical Center', u'Rutgers Cancer Institute of New Jersey', u'Riverview Medical Center', u'Somerset Medical Center', u'Fox Chase Cancer Center']","June 10, 2015",18,9223372036854775807,Female,False
NCT01406756,Children's Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01307579,Children's Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT01307579,True,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Fungal Infection; Neutropenia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug:caspofungin acetate; Drug:fluconazole; Other:laboratory biomarker analysis,[],"August 18, 2015",3,30,Both,False
NCT01190930,Children's Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT00807768,Gynecologic Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00936390,Radiation Therapy Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02003209,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,NM,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01079780,Pam Cogliano,False,NM,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02629159,AbbVie,False,NM,https://ClinicalTrials.gov/show/NCT02629159,True,A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE),Rheumatoid Arthritis,Drug:ABT-494; Drug:Placebo for ABT-494; Drug:Adalimumab; Drug:Placebo for Adalimumab,[],"December 10, 2015",18,99,Both,False
NCT02163694,AbbVie,False,NM,https://ClinicalTrials.gov/show/NCT02163694,True,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",Metastatic Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Other:Placebo,[],"January 26, 2016",18,99,Both,False
NCT02101788,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,NM,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,NM,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01856192,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01850524,"Millennium Pharmaceuticals, Inc.",False,NM,https://ClinicalTrials.gov/show/NCT01850524,True,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug:IXAZOMIB + Lenalidomide + Dexamethasone; Drug:Placebo + Lenalidomide + Dexamethasone,[],"February 23, 2015",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01607554,New Mexico Cancer Care Alliance,False,NM,https://ClinicalTrials.gov/show/NCT01607554,True,"Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer",Non-small Cell Lung Cancer,Drug:Irinotecan,"[u'Hematology Oncology Associates', u'University of New Mexico Cancer Center', u'New Mexico Cancer Care Associates']","January 6, 2016",18,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01042522,Gynecologic Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT01042522,True,"Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",Malignant Ovarian Surface Epithelial-Stromal Tumor,Drug:Paclitaxel; Drug:Carboplatin; Biological:Bleomycin Sulfate; Drug:Etoposide Phosphate; Drug:Cisplatin,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00807768,Gynecologic Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00492778,Gynecologic Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,NM,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT02674386,Pfizer,False,NM,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02590432,Forest Laboratories,False,NM,https://ClinicalTrials.gov/show/NCT02590432,True,"An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation",Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Linaclotide 72 micrograms,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT02573311,Boehringer Ingelheim,False,NM,https://ClinicalTrials.gov/show/NCT02573311,True,Actual Use Study of Tamsulosin in Men,Urological Manifestations,Drug:tamsulosin hydrochloride,[],"January 25, 2016",18,9223372036854775807,Male,False
NCT02551822,University of New Mexico,False,NM,https://ClinicalTrials.gov/show/NCT02551822,True,Cycling Versus Continuous Mode in Neuromodulator Programming,"Urinary Incontinence, Urge",Device:sacral neuromodulator,"[u'University of New Mexico Hospital', u'University of New Mexico Health Science Center']","September 15, 2015",21,9223372036854775807,Female,False
NCT02548858,University of New Mexico,False,NM,https://ClinicalTrials.gov/show/NCT02548858,True,Perineorrhaphy Outcomes Related to Body Imagery,Pelvic Organ Prolapse,Procedure:Perineorrhaphy; Procedure:No Perineorrhaphy,"[u'University of New Mexico', u'Sandoval Regional Medical Center']","September 10, 2015",18,9223372036854775807,Female,True
NCT02528253,Pfizer,False,NM,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02528188,Pfizer,False,NM,https://ClinicalTrials.gov/show/NCT02528188,True,Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee,"Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee",Drug:NSAID; Biological:Tanezumab 2.5 mg; Biological:Tanezumab 5 mg,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,NM,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02504268,Bristol-Myers Squibb,False,NM,https://ClinicalTrials.gov/show/NCT02504268,True,Effects of Abatacept in Patients With Early Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Abatacept; Drug:Methotrexate; Other:Abatacept Placebo; Other:Methotrexate Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02470585,AbbVie,False,NM,https://ClinicalTrials.gov/show/NCT02470585,True,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Ovarian Cancer; Ovarian Neoplasm,Other:Placebo; Drug:Veliparib; Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel,[],"January 13, 2016",18,99,Female,False
NCT02365636,"Teva Branded Pharmaceutical Products, R&D Inc.",False,NM,https://ClinicalTrials.gov/show/NCT02365636,True,A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN),Postherpetic Neuralgia,Drug:TV-45070; Drug:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02297698,"Cancer Insight, LLC",False,NM,https://ClinicalTrials.gov/show/NCT02297698,True,Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,Breast Cancer,Biological:NeuVax vaccine; Drug:Trastuzumab; Drug:GM-CSF,"[u'Alliance Research Centers', u'Sarcoma Oncology Research Center, LLC', u'St Joseph Heritage Healthcare', u'North Colorado Medical Center Cancer Institute', u'Sibley Memorial Hospital', u'Memorial Breast Cancer Center', u'Florida Cancer Research Institute', u'Loyola University Medical Center', u'Memorial Hospital of South Bend', u'Medstar Health (Union Memorial Hospital)', u'New Mexico Cancer Care Alliance/Presbyterian Cancer Center', u'New Mexico Care Alliance/University of New Mexico Cancer Center', u'Eastchester Center for Cancer Care', u'Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai', u'MD Anderson Cancer Center', u'Cancer Care Centers of South Texas', u'University of Virginia Human Immune Therapy Center', u'Providence Regional Medical Center', u""Columbia St. Mary's""]","December 21, 2015",18,9223372036854775807,Both,False
NCT02273726,FibroGen,False,NM,https://ClinicalTrials.gov/show/NCT02273726,True,Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects,CKD Anemia in Stable Dialysis Patients,Drug:Epoetin Alfa; Drug:FG-4592,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT02257567,Hoffmann-La Roche,False,NM,https://ClinicalTrials.gov/show/NCT02257567,True,A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,"Diffuse Large B-Cell Lymphoma, Lymphoma, Non Hodgkin, Lymphoma, Follicular",Drug:bendamustine; Drug:obinutuzumab; Drug:polatuzumab vedotin; Drug:rituximab,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02228681,Gynecologic Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT02228681,True,Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,"Advanced, Persistent, or Recurrent Endometrial Cancer",Drug:Everolimus; Drug:Tamoxifen; Drug:Letrozole; Drug:Medroxyprogesterone Acetate,[],"November 18, 2015",18,9223372036854775807,Female,False
NCT02187783,Novartis Pharmaceuticals,False,NM,https://ClinicalTrials.gov/show/NCT02187783,True,LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),Tumors With CDK4/6 Pathway Activation,Drug:LEE011,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT02186821,Novartis Pharmaceuticals,False,NM,https://ClinicalTrials.gov/show/NCT02186821,True,Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE),Tumors With Aberrations in ALK or ROS1,Drug:Ceritinib (LDK378),[],"January 20, 2016",18,9223372036854775807,Both,False
NCT02160041,Novartis Pharmaceuticals,False,NM,https://ClinicalTrials.gov/show/NCT02160041,True,BGJ398 for Patients With Tumors With FGFR Genetic Alterations,Solid Tumor; Hematologic Malignancies,Drug:BGJ398,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,NM,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02032823,AstraZeneca,False,NM,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02028871,Ajna Hamidovic,False,NM,https://ClinicalTrials.gov/show/NCT02028871,True,Intranasal Insulin for Weight Management During Smoking Cessation,Tobacco Abstinence Syndrome,Drug:Intranasal Insulin; Drug:Placebo,"[u'UNM College of Pharmacy', u'UNM College of Pharmacy']","May 11, 2015",18,65,Both,True
NCT02019264,Eisai Inc.,False,NM,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,NY,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,NY,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,NY,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,NY,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,NY,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01674140,Southwest Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,NY,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,NY,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01471522,New York University School of Medicine,True,NY,https://ClinicalTrials.gov/show/NCT01471522,True,International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA),Cardiovascular Diseases; Coronary Disease; Coronary Artery Disease; Heart Diseases; Myocardial Ischemia,Procedure:cardiac catheterization; Procedure:coronary artery bypass graft surgery; Procedure:percutaneous coronary intervention; Behavioral:Lifestyle; Drug:Medication,[],"January 29, 2016",21,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00936390,Radiation Therapy Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00273403,The New York Academy of Medicine,False,NY,https://ClinicalTrials.gov/show/NCT00273403,True,Outcome Evaluation of Minority AIDS Initiative Programs in the New York EMA,HIV Infections,Behavioral:Maintenance in Care Services; Behavioral:Access to Care Services,"[u'Health Center at Tremont, North Bronx Healthcare Network', u'Urban Horizons, The Institute for Urban Family Health', u'Health People', u'Planned Parenthood of New York City, Project Street Beat', u'Bronx Lebanon Hospital Center', u'SUNY Downstate Medical Center', u'HHC Cumberland Diagnostic and Treatment Center', u'Interfaith Medical Center', u'Mount Vernon Hospital', u'Betances Health Center', u'Harlem Hospital Center', u'Saint Vincents Hospital and Medical Center', u'Bellevue Hospital Center', u'William F. Ryan Community Health Center', u'African Services Committee', u'The Bridge, Inc.', u'Partnership Homeless Services Corp.', u'New York Presbyterian Hospital', u'New York Harm Reducation Educators, Inc.', u'Settlement Health', u'Greyston Health Services, Inc.', u'Saint Johns Riverside Hospital, Park Care Pavilion (ATC program)', u'Saint Johns Riverside Hospital, Park Care Pavilion (MIC Program)']","September 21, 2006",0,9223372036854775807,Both,False
NCT02451137,Sanofi,False,NY,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,NY,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02115282,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01470612,Pfizer,False,NY,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01414608,Gynecologic Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT02111564,"Janssen Research & Development, LLC",False,NY,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,NY,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01858532,AbbVie,False,NY,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01190930,Children's Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT00565851,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02065687,Gynecologic Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01751906,Abbott Vascular,False,NY,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00858364,Amgen,False,NY,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02344290,National Institute of Allergy and Infectious Diseases (NIAID),False,NY,https://ClinicalTrials.gov/show/NCT02344290,True,Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults,HIV Infections; Cardiovascular Diseases,Drug:Pitavastatin; Drug:Placebo,[],"February 1, 2016",40,75,Both,False
NCT02180867,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02048813,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01872975,NSABP Foundation Inc,False,NY,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01870778,Novartis Pharmaceuticals,False,NY,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,NC,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,NC,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,NC,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,NC,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02019264,Eisai Inc.,False,NC,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01966107,AstraZeneca,False,NC,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,NC,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,NC,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,NC,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,NC,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,NC,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01991795,AstraZeneca,False,NC,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT02488967,NRG Oncology,False,NC,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01975376,Pfizer,False,NC,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00888615,Gynecologic Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT00888615,True,"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Drug:Elesclomol Sodium; Drug:Paclitaxel,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01903811,Southwest Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01416688,Southwest Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT01416688,True,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity,Procedure:assessment of therapy complications; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"October 15, 2015",18,120,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,NC,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,NC,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT00858364,Amgen,False,NC,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01975389,Pfizer,False,NC,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,NC,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01856192,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01652872,Amgen,False,NC,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,NC,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,NC,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02104817,AstraZeneca,False,NC,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT01897532,Boehringer Ingelheim,False,NC,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,NC,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01298570,UNC Lineberger Comprehensive Cancer Center,False,NC,https://ClinicalTrials.gov/show/NCT01298570,True,Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,Colorectal Cancer Metastatic,Drug:Regorafenib (BAY 73-4506); Drug:FOLFIRI; Drug:Placebo; Drug:FOLFIRI,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00719303,Gynecologic Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01107626,Eastern Cooperative Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02003209,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00632853,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT00632853,True,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,Lung Cancer,Radiation:Standard Radiation Dose Therapy; Drug:cisplatin; Drug:etoposide; Radiation:High Radiation Dose Therapy; Drug:carboplatin,[],"August 10, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,ND,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01950390,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,ND,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02506153,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02375204,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT02375204,True,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],"December 8, 2015",14,9223372036854775807,Male,False
NCT02339571,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02339571,True,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma of the Skin; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Biological:Sargramostim,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02143414,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02143414,True,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 15, 2016",65,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02065687,Gynecologic Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01903811,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01668719,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01595061,Gynecologic Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01595061,True,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01216683,Eastern Cooperative Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02085408,Eastern Cooperative Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,ND,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01663402,Sanofi,False,ND,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01652872,Amgen,False,ND,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT02673190,Radiation Therapy Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02562716,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02516423,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT02516423,True,"Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone",Solitary Osseous Plasmacytoma,Drug:ixazomib; Drug:lenalidomide; Drug:dexamethasone; Drug:zoledronic acid,"[u'Strecker Cancer Center-Belpre', u'Adena Regional Medical Center', u'Mount Carmel Health Center West', u'Columbus Oncology and Hematology Associates Inc', u'Riverside Methodist Hospital', u'Columbus NCI Community Oncology Research Program', u'Grant Medical Center', u'The Mark H Zangmeister Center', u'Mount Carmel East Hospital', u'Doctors Hospital', u'Delaware Health Center-Grady Cancer Center', u'Delaware Radiation Oncology', u'Grady Memorial Hospital', u'Fairfield Medical Center', u'OhioHealth MedCentral Hospital', u'Marietta Memorial Hospital', u'OhioHealth Marion General Hospital', u'Knox Community Hospital', u'Newark Radiation Oncology', u'Licking Memorial Hospital', u'Southern Ohio Medical Center', u""Saint Ann's Hospital"", u'Genesis Healthcare System Cancer Care Center']","January 21, 2016",18,9223372036854775807,Both,False
NCT02506153,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,OH,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,OH,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,OH,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02143414,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02143414,True,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Blinatumomab; Drug:Dasatinib; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 15, 2016",65,9223372036854775807,Both,False
NCT02134912,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT02134912,True,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02085408,Eastern Cooperative Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02059265,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,OH,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003222,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01903811,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,OH,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,OH,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01850654,Ohio State University Comprehensive Cancer Center,True,OH,https://ClinicalTrials.gov/show/NCT01850654,True,Ohio Colorectal Cancer Prevention Initiative,Lynch Syndrome; Colorectal Cancer,Genetic:LS tumor screening; Genetic:Genetic testing; Behavioral:Genetic Counseling; Other:Biorepository; Behavioral:Questionnaire,[],"December 1, 2015",18,9223372036854775807,Both,False
NCT01824875,Eastern Cooperative Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01824875,True,Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors,Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma,Drug:temozolomide; Drug:capecitabine; Other:laboratory biomarker analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01674140,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01622868,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01535053,Gynecologic Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01272037,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01575548,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01975376,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT01975389,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,OK,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01903811,Southwest Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01877915,"Janssen Research & Development, LLC",False,OK,https://ClinicalTrials.gov/show/NCT01877915,True,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Heart Failure; Coronary Artery Disease,Drug:Rivaroxaban; Drug:Placebo; Other:Standard of care for heart failure and coronary artery disease,[],"January 26, 2016",18,95,Both,False
NCT02488967,NRG Oncology,False,OK,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02431806,Forest Laboratories,False,OK,https://ClinicalTrials.gov/show/NCT02431806,True,Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder,Major Depressive Disorder (MDD),Drug:Placebo; Drug:Levomilnacipran ER; Drug:Fluoxetine,[],"December 23, 2015",12,17,Both,False
NCT02194738,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02092467,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,OK,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01872975,NSABP Foundation Inc,False,OK,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,OK,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02670083,Hoffmann-La Roche,False,OK,https://ClinicalTrials.gov/show/NCT02670083,True,"CREAD Study"" A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",Alzheimer's Disease,Drug:Crenezumab; Drug:Placebo,[],"February 3, 2016",50,85,Both,False
NCT02528253,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT02528253,True,A Phase 3 Study of Tanezumab for Chronic Low Back Pain,Low Back Pain,"Biological:Placebo to Week 16; tanezumab 5mg SC; Biological:Placebo to Week 16, tanezumab 10 mg SC; Biological:Tanezumab 5 mg SC; Biological:Tanezumab 10 mg SC; Biological:Tramadol PR oral",[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,OK,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02451137,Sanofi,False,OK,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02439320,CoLucid Pharmaceuticals,False,OK,https://ClinicalTrials.gov/show/NCT02439320,True,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,Acute Migraine,Drug:Lasmiditan 100 mg; Drug:Lasmiditan 200 mg; Drug:Placebo (matches lasmiditan doses),[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02412917,"ContraVir Pharmaceuticals, Inc.",False,OK,https://ClinicalTrials.gov/show/NCT02412917,True,A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia,Shingles; Herpes Zoster; Postherpetic Neuralgia,Drug:FV-100; Drug:valacyclovir,[],"September 1, 2015",50,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02153502,Avanir Pharmaceuticals,False,OK,https://ClinicalTrials.gov/show/NCT02153502,True,"Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","Depressive Disorder, Treatment-Resistant",Drug:AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination); Drug:Placebo,[],"January 28, 2015",18,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,OK,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02075047,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT02075047,True,Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder,Bipolar Disorder,Drug:placebo oral capsules; Drug:ziprasidone oral capsules,[],"January 16, 2016",10,17,Both,False
NCT02060630,New England Research Institutes,False,OK,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT02047097,Biogen,False,OK,https://ClinicalTrials.gov/show/NCT02047097,True,Dimethyl Fumarate (DMF) Observational Study,Multiple Sclerosis,Drug:dimethyl fumarate,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,OK,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01950390,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,OK,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01878292,Forest Laboratories,False,OK,https://ClinicalTrials.gov/show/NCT01878292,True,Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder,Major Depressive Disorder,Drug:Placebo; Drug:Vilazodone; Drug:Vilazodone,[],"December 17, 2015",12,17,Both,False
NCT01751906,Abbott Vascular,False,OK,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01729455,"Human Genome Sciences Inc., a GSK Company",False,OK,https://ClinicalTrials.gov/show/NCT01729455,True,Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry,Systemic Lupus Erythematosus,Biological:BENLYSTA; Other:SLE treatment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01715805,Forest Laboratories,False,OK,https://ClinicalTrials.gov/show/NCT01715805,True,"An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)",Major Depressive Disorder,Drug:Cariprazine; Drug:Placebo,[],"December 23, 2015",18,65,Both,False
NCT01663402,Sanofi,False,OK,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01633112,Novartis Pharmaceuticals,False,OK,https://ClinicalTrials.gov/show/NCT01633112,True,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Relapsing-remitting Multiple Sclerosis (RRMS),Drug:fingolimod; Drug:copaxone,[],"December 9, 2015",18,65,Both,False
NCT01622868,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,OK,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,OK,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01471340,Merck Sharp & Dohme Corp.,False,OK,https://ClinicalTrials.gov/show/NCT01471340,True,A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3),Asthma,Drug:Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug:Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug:Mometasone Furoate MDI 100 mcg; Drug:Mometasone Furoate MDI 200 mcg; Drug:Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug:Prednisone/prednisolone,[],"October 30, 2015",12,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT02674386,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT02674386,True,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug:Investigational Medical Product (IMP) administered in parent study,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,OR,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00565851,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01013649,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT02375204,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT02375204,True,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],"December 8, 2015",14,9223372036854775807,Male,False
NCT02311933,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02003222,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01169337,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01064648,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01742065,Kaiser Permanente,True,OR,https://ClinicalTrials.gov/show/NCT01742065,True,Strategies and Opportunities to Stop Colon Cancer in Priority Populations,Colorectal Cancer,Other:Auto Plus,"[u'Open Door Health Center', u'Mosaic Medical', u'Benton and Linn County Health Centers', u'Virginia Garcia Memorial Health Center', u'La Clinica Health Care', u'Community Health Center', u'Multnomah County Health Department', u'Oregon Health and Science University']","November 12, 2015",50,74,Both,True
NCT01511562,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT01511562,True,Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma,Lymphoma,Drug:carmustine; Drug:cytarabine; Drug:etoposide; Drug:thiotepa; Procedure:stem cell transplant; Drug:G-CSF,[],"October 20, 2015",18,75,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01085630,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT01085630,True,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,Malignant Mesothelioma,Drug:pemetrexed disodium; Other:clinical observation,[],"August 3, 2015",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02301156,"TG Therapeutics, Inc.",False,OR,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01809691,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,OR,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT01368588,Radiation Therapy Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01368588,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:radiation therapy; Radiation:Whole-pelvic radiotherapy (WPRT),[],"October 13, 2015",18,9223372036854775807,Male,False
NCT00499330,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT00499330,True,Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer,Lung Cancer,Procedure:lobectomy; Procedure:segmentectomy or wedge resection,[],"August 28, 2015",18,9223372036854775807,Both,False
NCT02671981,Radiation Therapy Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02234583,Daiichi Sankyo Inc.,False,OR,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,OR,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT02060630,New England Research Institutes,False,OR,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,OR,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01888120,Jazz Pharmaceuticals,False,OR,https://ClinicalTrials.gov/show/NCT01888120,True,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],"June 18, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,PA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,PA,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02376296,"Saladax Biomedical, Inc.",False,PA,https://ClinicalTrials.gov/show/NCT02376296,True,Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients,Prostate Cancer,Drug:docetaxel; Other:Blood draws,"[u'UPMC CancerCenter - Beaver', u'UPMC CancerCenter - Upper St. Clair', u'UPMC CancerCenter - Horizon', u'Arnold Palmer Cancer Center - Oakbrook', u'Arnold Palmer Cancer Center', u'UPMC CancerCenter - Greenville', u'UPMC CancerCenter - Indiana', u'UPMC CancerCenter at John P. Murtha Regional Cancer Center', u'UPMC CancerCenter - Mckeesport', u'UPMC CancerCenter - Monroeville', u'Arnold Palmer Medical Oncology - Mount Pleasant', u'UPMC CancerCenter - New Castle', u'UPMC CancerCenter - St. Margaret', u'UPMC CancerCenter - Hillman Cancer Center', u'UPMC CancerCenter - Passavant HOA', u'UPMC CancerCenter - Passavant OHA', u'UPMC CancerCenter - Northwest', u'UPMC CancerCenter - Uniontown', u'UPMC CancerCenter - Washington', u'UPMC CancerCenter - Jefferson']","December 2, 2015",18,9223372036854775807,Male,False
NCT02194738,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02111564,"Janssen Research & Development, LLC",False,PA,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,PA,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02019264,Eisai Inc.,False,PA,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01975389,Pfizer,False,PA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,PA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,PA,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,PA,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,PA,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,PA,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,PA,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01535053,Gynecologic Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,PA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,PA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,PA,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00843882,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02671981,Radiation Therapy Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01853748,Dana-Farber Cancer Institute,False,PA,https://ClinicalTrials.gov/show/NCT01853748,True,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),Breast Cancer,Drug:Trastuzumab; Drug:Paclitaxel; Drug:Trastuzumab emtansine,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,PA,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,PA,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01236547,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01236547,True,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01903811,Southwest Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01751906,Abbott Vascular,False,PA,https://ClinicalTrials.gov/show/NCT01751906,True,ABSORB III Randomized Controlled Trial (RCT),Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"October 11, 2015",18,9223372036854775807,Both,False
NCT01242800,Eastern Cooperative Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,PA,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT01272037,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02161757,AstraZeneca,False,RI,https://ClinicalTrials.gov/show/NCT02161757,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Tralokinumab; Other:Placebo,[],"January 5, 2016",12,75,Both,False
NCT01557244,Pfizer,False,RI,https://ClinicalTrials.gov/show/NCT01557244,True,A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition,"Urinary Bladder, Neurogenic",Drug:Fesoterodine PR 4 mg; Drug:Fesoterodine PR 8 mg; Drug:Fesoterodine PR 8 mg; Drug:Oxybutynin; Drug:Fesoterodine PR; Drug:Fesoterodine BIC 2 mg; Drug:Fesoterodine BIC 4 mg,[],"February 1, 2016",6,17,Both,False
NCT02412228,"Eric Winer, MD",False,RI,https://ClinicalTrials.gov/show/NCT02412228,True,"BrUOG 299 :Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.",Multiple Myeloma,Drug:Ixazomib; Drug:Cyclophosphamide; Drug:Dexamethasone,"[u'Memorial Hospital of Rhode Island', u'Rhode Island Hospital', u'The Miriam Hospital']","January 28, 2016",18,9223372036854775807,Both,False
NCT02213822,Rhode Island Hospital,False,RI,https://ClinicalTrials.gov/show/NCT02213822,True,"Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis",Solid Tumors; Hematological Malignancies,Other:Molecular Analysis of Cancer,"[u'Rhode Island Comprehensive Cancer Center at East Greenwich', u'Rhode Island Hospital', u'The Miriam Hospital']","August 26, 2014",18,9223372036854775807,Both,False
NCT02032277,AbbVie,False,RI,https://ClinicalTrials.gov/show/NCT02032277,True,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Placebo; Drug:Placebo,[],"October 9, 2015",18,99,Female,False
NCT02022033,howard safran,False,RI,https://ClinicalTrials.gov/show/NCT02022033,True,BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial,Pancreatic Cancer,Drug:FOLFOXA,"[u'Memorial Hospital', u'Rhode Island Hospital (East Greenwich and Newport Hospital)', u'The Miriam Hospital']","January 11, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,RI,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,RI,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01887912,"Sanofi Pasteur, a Sanofi Company",False,RI,https://ClinicalTrials.gov/show/NCT01887912,True,Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection,Clostridium Difficile Infection,Biological:C. difficile Toxoid Vaccine; Biological:Placebo: 0.9% normal saline,[],"December 11, 2015",50,9223372036854775807,Both,True
NCT01885988,"Martin M. Miner, MD",False,RI,https://ClinicalTrials.gov/show/NCT01885988,True,Nebivolol Effects on Endothelial Function and Erectile Function,Erectile Dysfunction,Drug:Nebivolol; Drug:Sugar Pill,"[u'University Medicine', u'Miriam Cardiology', u""The Miriam Hospital / The Men's Health Center""]","June 21, 2013",25,65,Male,False
NCT01845025,Novartis Pharmaceuticals,False,RI,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,RI,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,RI,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,RI,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00858364,Amgen,False,RI,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02506153,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02477800,Biogen,False,RI,https://ClinicalTrials.gov/show/NCT02477800,True,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02469701,howard safran,False,RI,https://ClinicalTrials.gov/show/NCT02469701,True,BrUOG 317:Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease,Non-small Cell Lung Cancer; Lung Cancer; Metastatic Lung Cancer; NSCLC,Drug:nivolumab and ablation,"[u'Rhode Island Hospital', u'The Miriam Hospital']","December 17, 2015",18,9223372036854775807,Both,False
NCT02452190,"Teva Branded Pharmaceutical Products, R&D Inc.",False,RI,https://ClinicalTrials.gov/show/NCT02452190,True,Study of Reslizumab in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils,Asthma,Drug:Reslizumab; Drug:Placebo,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT02412371,AbbVie,False,RI,https://ClinicalTrials.gov/show/NCT02412371,True,A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer Stage III,Drug:Veliparib; Drug:Paclitaxel; Drug:Carboplatin; Radiation:Radiotherapy; Other:Placebo for Veliparib,"[u'Site Reference ID/Investigator# 133037', u'Site Reference ID/Investigator# 133486', u'Site Reference ID/Investigator# 133828', u'Site Reference ID/Investigator# 132944', u'Site Reference ID/Investigator# 133494', u'Site Reference ID/Investigator# 133492', u'Site Reference ID/Investigator# 134438', u'Site Reference ID/Investigator# 133496', u'Site Reference ID/Investigator# 133497', u'Site Reference ID/Investigator# 134608', u'Site Reference ID/Investigator# 133493', u'Site Reference ID/Investigator# 133910', u'Site Reference ID/Investigator# 141321', u'Site Reference ID/Investigator# 133495']","January 18, 2016",18,99,Both,False
NCT02406677,AstraZeneca,False,RI,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02395549,Mimetica Pty Limited,False,RI,https://ClinicalTrials.gov/show/NCT02395549,True,A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris,Acne Vulgaris,Drug:0.375% (w/w) MTC896 Gel; Drug:0.75% (w/w) MTC896 Gel; Drug:1.5% (w/w) MTC896 Gel; Drug:Vehicle Control Gel,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","January 21, 2016",16,65,Both,False
NCT02386072,"Astellas Scientific & Medical Affairs, Inc.",False,RI,https://ClinicalTrials.gov/show/NCT02386072,True,"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",Overactive Bladder; Urinary Bladder Overactive; Urinary Bladder Diseases; Urologic Diseases,Drug:mirabegron; Drug:antimuscarinic medication,[],"December 16, 2015",18,9223372036854775807,Both,False
NCT02352883,ECOG-ACRIN Cancer Research Group,False,RI,https://ClinicalTrials.gov/show/NCT02352883,True,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,Ductal Breast Carcinoma In Situ,Procedure:Magnetic Resonance Imaging; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Surgical Procedure; Radiation:Radiation Therapy; Drug:Endocrine Therapy; Other:Quality-of-Life Assessment; Other:Laboratory Biomarker Analysis; Other:Cytology Specimen Collection Procedure,[],"September 22, 2015",18,9223372036854775807,Female,False
NCT02322814,Hoffmann-La Roche,False,RI,https://ClinicalTrials.gov/show/NCT02322814,True,A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer,Breast Cancer,Drug:cobimetinib; Drug:paclitaxel; Drug:placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02316184,Butler Hospital,False,RI,https://ClinicalTrials.gov/show/NCT02316184,True,Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons,HIV; Hepatitis C,Behavioral:Motivational Interviewing; Behavioral:Brief Advice,"[u'Butler Hospital', u'Miriam Hospital']","August 19, 2015",18,9223372036854775807,Both,False
NCT02273063,Butler Hospital,False,RI,https://ClinicalTrials.gov/show/NCT02273063,True,rTMS for PTSD Comorbid With Major Depressive Disorder,"Posttraumatic Stress Disorder; Major Depressive Disorder; Transcranial Magnetic Stimulation, Repetitive",Device:Transcranial Magnetic Stimulation,"[u'Butler Hospital', u'Providence VA Medical Center']","November 18, 2015",18,70,Both,False
NCT02244606,"Scynexis, Inc.",False,RI,https://ClinicalTrials.gov/show/NCT02244606,True,Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis,"Mycoses; Candidiasis, Invasive; Candidemia",Drug:SCY-078; Drug:Fluconazole; Drug:Micafungin,[],"January 10, 2016",18,80,Both,False
NCT02243293,AbbVie,False,RI,https://ClinicalTrials.gov/show/NCT02243293,True,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection",Chronic Hepatitis C; Hepatitis C Virus,Drug:ABT-493; Drug:ABT-530; Drug:Ribavirin (RBV); Drug:ABT-493/ABT-530,[],"February 4, 2016",18,100,Both,False
NCT02239120,Boehringer Ingelheim,False,RI,https://ClinicalTrials.gov/show/NCT02239120,True,Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS),Stroke; Secondary Prevention,Drug:optional ASA as comedication; Drug:placebo to ASA; Drug:placebo to optional ASA as comedication; Drug:placebo to dabigatran etexilate; Drug:ASA 100 mg; Drug:dabigatran etexilate,[],"January 26, 2016",18,150,Both,False
NCT02173379,Abbott Vascular,False,RI,https://ClinicalTrials.gov/show/NCT02173379,True,Absorb IV Randomized Controlled Trial,Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis,Device:Absorb BVS; Device:XIENCE,[],"July 17, 2015",18,9223372036854775807,Both,False
NCT02164864,Boehringer Ingelheim,False,RI,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,RI,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02104583,Gilead Sciences,False,RI,https://ClinicalTrials.gov/show/NCT02104583,True,Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator,Ventricular Arrhythmia,Drug:Eleclazine; Drug:Placebo to match eleclazine,[],"January 8, 2016",18,80,Both,False
NCT02080364,vTv Therapeutics,False,RI,https://ClinicalTrials.gov/show/NCT02080364,True,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,Alzheimer's Disease,Drug:Azeliragon; Drug:Placebo,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02080221,howard safran,False,RI,https://ClinicalTrials.gov/show/NCT02080221,True,BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial,Metastatic Pancreatic Cancer,Drug:FOLFOXA,"[u'Southcoast centers for cancer care', u'Memorial Hospital of Rhode Island', u'Lifespan Hospitals (The Miriam and RI Hospital, East Greenwich, Newport)']","December 18, 2015",18,9223372036854775807,Both,False
NCT02060630,New England Research Institutes,False,RI,https://ClinicalTrials.gov/show/NCT02060630,True,Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia,Critical Limb Ischemia,Procedure:Open surgical revascularization; Device:Endovascular revascularization,[],"December 7, 2015",18,9223372036854775807,Both,False
NCT02008357,Eli Lilly and Company,False,RI,https://ClinicalTrials.gov/show/NCT02008357,True,Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss,Cognition Disorders,Drug:Solanezumab; Drug:Placebo,[],"January 12, 2016",65,85,Both,True
NCT02003209,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01983683,Actelion,False,RI,https://ClinicalTrials.gov/show/NCT01983683,True,Phase 3 Study With Cadazolid in Clostridium Difficile-associated Diarrhea (CDAD),Clostridium Difficile Infection,Drug:Cadazolid; Drug:vancomycin,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT01960075,University of Virginia,False,RI,https://ClinicalTrials.gov/show/NCT01960075,True,Established Status Epilepticus Treatment Trial,Benzodiazepine Refractory Status Epilepticus,Drug:Fosphenytoin; Drug:Levetiracetam; Drug:Valproic acid,[],"October 30, 2015",2,9223372036854775807,Both,False
NCT01953601,Merck Sharp & Dohme Corp.,False,RI,https://ClinicalTrials.gov/show/NCT01953601,True,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),Amnestic Mild Cognitive Impairment; Alzheimer's Disease; Prodromal Alzheimer's Disease,Drug:Verubecestat (Part I and Part II); Drug:Verubecestat (Part I and Part II); Drug:Placebo (Part I); Drug:Verubecestat (Part II),[],"December 31, 2015",50,85,Both,False
NCT01870778,Novartis Pharmaceuticals,False,RI,https://ClinicalTrials.gov/show/NCT01870778,True,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Acute Heart Failure,Drug:RLX030; Drug:Placebo,[],"September 16, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,SC,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01674140,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01809691,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT02164916,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02003222,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02488967,NRG Oncology,False,SC,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,SC,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,SC,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,SC,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,SC,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,SC,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT01595061,Gynecologic Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT01595061,True,"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva",Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVA Vulvar Cancer; Vulvar Squamous Cell Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Gemcitabine Hydrochloride; Drug:Cisplatin; Procedure:Therapeutic Conventional Surgery,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,SC,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02487498,Novartis Pharmaceuticals,False,SC,https://ClinicalTrials.gov/show/NCT02487498,True,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in COPD Patients,Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:Umeclidinium/vilanterol; Drug:Placebo (umeclidinium/vilanterol ); Drug:Placebo (QVA149),[],"June 29, 2015",40,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,SC,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,SC,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT02562716,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,SC,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02536508,"Pearl Therapeutics, Inc.",False,SC,https://ClinicalTrials.gov/show/NCT02536508,True,"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",COPD,Drug:BGF MDI (PT010) 320/14.4/9.6 g; Drug:GFF MDI (PT003) 14.4/9.6 g; Drug:BFF MDI (PT009) 320/9.6 g,[],"January 6, 2016",40,80,Both,False
NCT02465567,"Pearl Therapeutics, Inc.",False,SC,https://ClinicalTrials.gov/show/NCT02465567,True,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug:BGF MDI 320/14.4/9.6 g; Drug:GFF MDI 14.4/9.6 g; Drug:BGF MDI 160/14.4/9.6 g; Drug:BFF MDI 320/9.6 g,[],"December 22, 2015",40,80,Both,False
NCT02115282,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,SC,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,SC,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT00978458,Eastern Cooperative Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT00978458,True,Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma,Brain and Central Nervous System Tumors; Neurotoxicity,Drug:temozolomide; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"December 4, 2012",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02315469,NRG Oncology,False,SC,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02104817,AstraZeneca,False,SC,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT01950390,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01064648,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02154490,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01674140,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,SD,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,SD,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01950390,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,SD,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01856192,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT00666731,University of Nebraska,False,SD,https://ClinicalTrials.gov/show/NCT00666731,True,A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer,Breast Cancer; Precancerous Condition,Other:medical chart review; Other:questionnaire administration; Other:study of socioeconomic and demographic variables; Procedure:Excess human biological tissue; Procedure:quality-of-life assessment,[],"November 30, 2015",19,120,Both,False
NCT02488967,NRG Oncology,False,SD,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02085408,Eastern Cooperative Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,SD,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,SD,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01349881,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01345019,Amgen,False,SD,https://ClinicalTrials.gov/show/NCT01345019,True,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions,Drug:Denosumab; Drug:Zoledronic acid,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01042522,Gynecologic Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT01042522,True,"Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",Malignant Ovarian Surface Epithelial-Stromal Tumor,Drug:Paclitaxel; Drug:Carboplatin; Biological:Bleomycin Sulfate; Drug:Etoposide Phosphate; Drug:Cisplatin,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00897442,Gynecologic Oncology Group,True,SD,https://ClinicalTrials.gov/show/NCT00897442,True,Collecting Tumor Samples From Patients With Gynecological Tumors,Cancer,Other:biologic sample preservation procedure,[],"August 30, 2012",0,9223372036854775807,Female,False
NCT00888615,Gynecologic Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT00888615,True,"Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma,Drug:Elesclomol Sodium; Drug:Paclitaxel,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00858364,Amgen,False,SD,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02671981,Radiation Therapy Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02506153,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02480153,Pfizer,False,SD,https://ClinicalTrials.gov/show/NCT02480153,True,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Rheumatoid Arthritis,Biological:PF-06410293; Biological:Adalimumab,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02465515,GlaxoSmithKline,False,SD,https://ClinicalTrials.gov/show/NCT02465515,True,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Diabetes Mellitus,Biological:Albiglutide 30 mg; Biological:Albiglutide 50 mg; Biological:Albiglutide matching placebo,[],"February 4, 2016",40,9223372036854775807,Both,False
NCT02438722,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT02438722,True,"Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Afatinib Dimaleate; Biological:Cetuximab; Other:Laboratory Biomarker Analysis,[],"September 1, 2015",0,9223372036854775807,Both,False
NCT02367820,Nektar Therapeutics,False,SD,https://ClinicalTrials.gov/show/NCT02367820,True,Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain,Low Back Pain; Chronic Pain,Drug:NKTR-181,[],"December 21, 2015",18,75,Both,False
NCT02339571,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02339571,True,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma of the Skin; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Biological:Sargramostim,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02311933,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02301156,"TG Therapeutics, Inc.",False,SD,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02243592,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02243592,True,Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment,Malignant Neoplasm,Other:Laboratory Biomarker Analysis,[],"January 22, 2016",0,9223372036854775807,Both,False
NCT02234583,Daiichi Sankyo Inc.,False,SD,https://ClinicalTrials.gov/show/NCT02234583,True,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,Pain Associated With Fibromyalgia,Drug:15mg DS-5565,[],"November 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02343406,AbbVie,False,TN,https://ClinicalTrials.gov/show/NCT02343406,True,ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,Glioblastoma Multiforme,Drug:ABT-414; Drug:Lomustine; Drug:Temozolomide,[],"January 7, 2016",18,99,Both,False
NCT01975389,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,TN,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,TN,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT02301156,"TG Therapeutics, Inc.",False,TN,https://ClinicalTrials.gov/show/NCT02301156,True,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug:Ublituximab; Drug:ibrutinib,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,TN,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,TN,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,TN,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01845025,Novartis Pharmaceuticals,False,TN,https://ClinicalTrials.gov/show/NCT01845025,True,Study of Safety of Foradil in Patients With Persistent Asthma,Persistent Asthma,Drug:Formoterol; Drug:Fluticasone propionate 100 mcg; Drug:Fluticasone propionate 250 mcg; Drug:Fluticasone propionate 500 mcg; Drug:Placebo,[],"February 3, 2016",12,9223372036854775807,Both,False
NCT00761267,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00761267,True,"Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis",Candidemia,Drug:Anidulafungin; Drug:Fluconazole,[],"January 25, 2016",1,17,Both,False
NCT02451137,Sanofi,False,TN,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,TN,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01575548,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01991795,AstraZeneca,False,TN,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01966107,AstraZeneca,False,TN,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01652872,Amgen,False,TN,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02562716,Southwest Oncology Group,False,TN,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02429349,University of Tennessee,True,TN,https://ClinicalTrials.gov/show/NCT02429349,True,Preservation of Ovarian Tissue and Chemo-Radiotherapy,Endocrine Disorders of Female Reproductive System; Secondary Infertility; Infertility Involuntary,Procedure:surgery,"[u'Methodist/LeBonheur Hospital', u""LeBonheur Children's Hospital"", u'Regional One Health Ob-Gyn Clinic', u'Regional One Health, Regional Medical Center, Operating Room', u'Methodist University Hospital', u""St. Jude Children's Research Hospital"", u'Baptist Memorial Hospital']","July 28, 2015",8,40,Female,False
NCT02111564,"Janssen Research & Development, LLC",False,TN,https://ClinicalTrials.gov/show/NCT02111564,True,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,Heart Failure; Respiratory Insufficiency; Stroke Acute; Infectious Diseases; Rheumatic Diseases,"Drug:Rivaroxaban, 10 mg; Drug:Rivaroxaban, 7.5 mg; Drug:Placebo",[],"January 26, 2016",40,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,TN,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01663402,Sanofi,False,TN,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,TN,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,TN,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02216214,"Astellas Pharma Global Development, Inc.",False,TN,https://ClinicalTrials.gov/show/NCT02216214,True,"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",Overactive Bladder (OAB),Drug:Mirabegron; Drug:Placebo,[],"November 18, 2015",65,9223372036854775807,Both,False
NCT02182830,Boehringer Ingelheim,False,TN,https://ClinicalTrials.gov/show/NCT02182830,True,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,"Diabetes Mellitus, Type 2; Hypertension",Drug:Empagliflizon low dose; Drug:placebo; Drug:Empagliflizon high dose,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,TN,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,TN,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT01920711,Novartis Pharmaceuticals,False,TN,https://ClinicalTrials.gov/show/NCT01920711,True,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug:LCZ696; Drug:Valsartan,[],"October 14, 2015",50,9223372036854775807,Both,False
NCT01771809,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT01771809,True,Long-Term Safety Of PF-00547659 In Ulcerative Colitis,Ulcerative Colitis,Drug:PF-00547659; Drug:PF-00547659; Drug:PF-00547659,[],"January 16, 2016",18,65,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,TN,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,TN,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT01470612,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT01470612,True,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug:CP-690,550; Drug:CP-690,550",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,TN,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01227967,National Institute of Allergy and Infectious Diseases (NIAID),True,TN,https://ClinicalTrials.gov/show/NCT01227967,True,"Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications",Influenza,"Drug:Amantadine, Ribavirin, Oseltamivir; Drug:Oseltamivir",[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02409355,Hoffmann-La Roche,False,TN,https://ClinicalTrials.gov/show/NCT02409355,True,A Study of Atezolizumab (MPDL3280A) Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer [IMpower111],Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab (MPDL3280A); Drug:Carboplatin; Drug:Cisplatin; Drug:Gemcitabine,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,TN,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02352948,AstraZeneca,False,TN,https://ClinicalTrials.gov/show/NCT02352948,True,"A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",Non-Small Cell Lung Cancer (NSCLC),Drug:MEDI4736; Drug:Vinorelbine; Drug:Gemcitabine; Drug:Erlotinib; Drug:MEDI4736 in combination with tremelimumab (anti-CTLA4); Drug:tremelimumab (anti-CTLA4),[],"January 11, 2016",18,130,Both,False
NCT02164916,Southwest Oncology Group,False,TN,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02066636,Bristol-Myers Squibb,False,TN,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02574078,Bristol-Myers Squibb,False,TX,https://ClinicalTrials.gov/show/NCT02574078,True,A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),Non-Small Cell Lung Cancer,Drug:Nivolumab; Drug:Bevacizumab; Drug:Pemetrexed; Other:Palliative radiation; Drug:nab-Paclitaxel; Drug:Paclitaxel; Drug:Docetaxel; Drug:Gemcitabine; Drug:Erlotinib; Drug:Crizotinib; Drug:Carboplatin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02545049,Bayer,False,TX,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,TX,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02504216,Bayer,False,TX,https://ClinicalTrials.gov/show/NCT02504216,True,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Rivaroxaban-Placebo",[],"February 1, 2016",50,9223372036854775807,Both,False
NCT02451137,Sanofi,False,TX,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,TX,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01991795,AstraZeneca,False,TX,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01975389,Pfizer,False,TX,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,TX,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,TX,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01897532,Boehringer Ingelheim,False,TX,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,TX,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01652872,Amgen,False,TX,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT01594333,Brigham and Women's Hospital,False,TX,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,TX,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,TX,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,TX,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,TX,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00858364,Amgen,False,TX,https://ClinicalTrials.gov/show/NCT00858364,True,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer,Drug:darbepoetin alfa 500 mcg Q3W; Drug:placebo,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,TX,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02164513,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,TX,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01663402,Sanofi,False,TX,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,TX,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02092467,Pfizer,False,TX,https://ClinicalTrials.gov/show/NCT02092467,True,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug:tofacitinib; Drug:tofacitinib; Biological:adalimumab; Biological:etanercept,[],"January 15, 2016",50,9223372036854775807,Both,False
NCT02066636,Bristol-Myers Squibb,False,TX,https://ClinicalTrials.gov/show/NCT02066636,True,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),Non Small Cell Lung Cancer (NSCLC),Drug:Nivolumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01492361,Amarin Pharma Inc.,False,TX,https://ClinicalTrials.gov/show/NCT01492361,True,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Cardiovascular Diseases,Drug:AMR101; Drug:Placebo,[],"July 14, 2015",45,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,TX,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,TX,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,TX,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,TX,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT02106546,AbbVie,False,TX,https://ClinicalTrials.gov/show/NCT02106546,True,"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",Squamous Non-Small Cell Lung Cancer,Drug:veliparib; Drug:carboplatin; Drug:paclitaxel; Drug:placebo,[],"January 13, 2016",18,99,Both,False
NCT01190930,Children's Oncology Group,False,TX,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT02526524,"Elcelyx Therapeutics, Inc.",False,TX,https://ClinicalTrials.gov/show/NCT02526524,True,"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",Type 2 Diabetes Mellitus,Drug:Met DR; Drug:Met IR; Drug:Placebo,[],"January 7, 2016",25,9223372036854775807,Both,False
NCT02164864,Boehringer Ingelheim,False,TX,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02161757,AstraZeneca,False,TX,https://ClinicalTrials.gov/show/NCT02161757,True,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Uncontrolled Asthma,Biological:Tralokinumab; Other:Placebo,[],"January 5, 2016",12,75,Both,False
NCT02155660,AstraZeneca,False,TX,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT01968967,Pfizer,False,TX,https://ClinicalTrials.gov/show/NCT01968967,True,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Hyperlipidemia,Drug:Bococizumab (PF-04950615; RN316); Other:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01406756,Children's Oncology Group,False,TX,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT00807768,Gynecologic Oncology Group,False,TX,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02461589,Novo Nordisk A/S,False,TX,https://ClinicalTrials.gov/show/NCT02461589,True,Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:semaglutide; Drug:liraglutide; Drug:placebo,[],"October 29, 2015",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02488967,NRG Oncology,False,UT,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02003222,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01674140,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01101451,Gynecologic Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01013649,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01975389,Pfizer,False,UT,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,UT,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,UT,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01236547,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01236547,True,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Radiation:Intensity-Modulated Radiation Therapy; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,UT,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,UT,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01991795,AstraZeneca,False,UT,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01808573,"Puma Biotechnology, Inc.",False,UT,https://ClinicalTrials.gov/show/NCT01808573,True,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,HER2+ Metastatic Breast Cancer (MBC),Drug:neratinib; Drug:capecitabine; Drug:lapatinib; Drug:capecitabine,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00807768,Gynecologic Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT02673190,Radiation Therapy Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT01966107,AstraZeneca,False,UT,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT00565851,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02638129,Takeda,False,UT,https://ClinicalTrials.gov/show/NCT02638129,True,Naltrexone/Bupropion Cardiovascular Outcomes Study,Obesity; Cardiovascular Diseases,Drug:Naltrexone HCl/Bupropion HCl ER; Drug:Placebo,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT02583256,Novartis Vaccines,False,UT,https://ClinicalTrials.gov/show/NCT02583256,True,"Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)",Influenza,Biological:aQIV-aQIV; Biological:aQIV-QIV; Biological:QIV-aQIV; Biological:QIV-QIV,[],"January 15, 2016",18,85,Both,True
NCT02509078,Massachusetts General Hospital,False,UT,https://ClinicalTrials.gov/show/NCT02509078,True,Reevaluation Of Systemic Early Neuromuscular Blockade,Acute Respiratory Distress Syndrome,Drug:cisastracurium besylate,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,UT,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02342249,Vertex Pharmaceuticals Incorporated,False,UT,https://ClinicalTrials.gov/show/NCT02342249,True,Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects,Influenza A,Drug:VX-787 and oseltamivir,[],"July 28, 2015",18,64,Both,False
NCT02310763,Pfizer,False,UT,https://ClinicalTrials.gov/show/NCT02310763,True,"A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy",Duchenne Muscular Dystrophy,Biological:PF-06252616; Drug:Placebo,[],"January 19, 2016",6,9,Male,False
NCT02299414,University of Alabama at Birmingham,False,UT,https://ClinicalTrials.gov/show/NCT02299414,True,Chronic Hypertension and Pregnancy (CHAP) Project,Hypertension,Other:Anti-hypertensive therapy; Other:No anti-hypertensive therapy (unless BP is severe),[],"November 5, 2015",12,9223372036854775807,Female,False
NCT02179086,NRG Oncology,False,UT,https://ClinicalTrials.gov/show/NCT02179086,True,Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy; Radiation:photon beam radiation therapy; Radiation:intensity-modulated radiation therapy; Radiation:proton beam radiation therapy; Drug:temozolomide; Other:laboratory biomarker analysis,[],"August 25, 2015",18,9223372036854775807,Both,False
NCT02132247,IBSA Institut Biochimique SA,False,UT,https://ClinicalTrials.gov/show/NCT02132247,True,Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries,Athletic Injuries,Drug:Diclofenac hydroxyethylpyrrolidine,"[u'Applied Research Center of Arkansas', u'SCORE Physician Alliance', u'Pediatrics and Adolescent Medicine P.A.', u'Arlington Family Research Center Inc.', u'Utah Valley Pediatrics', u'J. Lewis Research Inc./Foothill Family Clininc', u'J. Lewis Research Inc./FirstMed East', u'J. Lewis Research Inc./Foothill Family Clinic South', u'Legacy Point Family Medicine', u'Pediatric Research of Charlottesville']","August 7, 2015",6,16,Both,False
NCT02019264,Eisai Inc.,False,UT,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01672892,Radiation Therapy Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT01672892,True,Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer,Cervical Cancer; Endometrial Cancer; Gastrointestinal Complications; Perioperative/Postoperative Complications; Radiation Toxicity; Urinary Complications; Urinary Tract Toxicity,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01543087,Pfizer,False,UT,https://ClinicalTrials.gov/show/NCT01543087,True,Duration of Immunity Study,Meningococcal Infection,Procedure:blood sampling; Drug:bivalent rLP2086,[],"January 25, 2016",10,18,Both,True
NCT01414608,Gynecologic Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01101035,Takeda,True,UT,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT02573311,Boehringer Ingelheim,False,UT,https://ClinicalTrials.gov/show/NCT02573311,True,Actual Use Study of Tamsulosin in Men,Urological Manifestations,Drug:tamsulosin hydrochloride,[],"January 25, 2016",18,9223372036854775807,Male,False
NCT02407236,"Janssen Research & Development, LLC",False,UT,https://ClinicalTrials.gov/show/NCT02407236,True,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative; Inflammatory Bowel Diseases",Drug:Placebo IV; Drug:Placebo SC; Drug:Ustekinumab IV; Drug:Ustekinumab SC,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,UT,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02160041,Novartis Pharmaceuticals,False,UT,https://ClinicalTrials.gov/show/NCT02160041,True,BGJ398 for Patients With Tumors With FGFR Genetic Alterations,Solid Tumor; Hematologic Malignancies,Drug:BGJ398,[],"January 24, 2016",18,9223372036854775807,Both,False
NCT02104817,AstraZeneca,False,UT,https://ClinicalTrials.gov/show/NCT02104817,True,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug:Epanova (omega-3 carboxylic acids); Drug:corn oil control,[],"December 21, 2015",18,99,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,UT,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01897532,Boehringer Ingelheim,False,UT,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT02673190,Radiation Therapy Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02194738,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02003209,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01622868,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT01622868,True,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2/Neu Positive; Male Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Radiation:Whole-Brain Radiotherapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01311336,University of Vermont,False,VT,https://ClinicalTrials.gov/show/NCT01311336,True,Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain,Pegfilgrastim-induced Back and Leg Pain,Drug:Loratadine; Drug:placebo,"[u'Cancer Care of Maine', u'Maine Center for Cancer Medicine', u'York Hospital', u'CR Wood Cancer Center', u'Mountainview Medical Center', u'Vermont Cancer Center', u'Vermont Center for Cancer Medicine']","January 23, 2013",18,9223372036854775807,Both,False
NCT00982436,University of Vermont,False,VT,https://ClinicalTrials.gov/show/NCT00982436,True,Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer,Head and Neck Neoplasms,Drug:Docetaxel/cisplatin; Radiation:Radiotherapy; Drug:Carboplatin,"[u'Mountainview Medical Center', u'Fletcher Allen Health Care', u'Vermont Center for Cancer Medicine']","March 21, 2012",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02671981,Radiation Therapy Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT02671981,True,Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Proton Beam Radiation Therapy,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02402543,University of Vermont,True,VT,https://ClinicalTrials.gov/show/NCT02402543,True,Pre-Emptive Analgesia in Ano-Rectal Surgery,Hemorrhoids; Fissure in Ano; Rectal Fistula; Anal Condyloma,Drug:Gabapentin; Drug:Ketamine; Drug:Acetaminophen; Drug:Dexamethasone; Drug:Placebo,"[u'University of Vermont Medical Center', u'University of Vermont Medical Center Fanny Allen Campus']","April 6, 2015",18,9223372036854775807,Both,False
NCT02186847,NRG Oncology,False,VT,https://ClinicalTrials.gov/show/NCT02186847,True,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Carboplatin; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Radiation:Volume Modulated Arc Therapy,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02065791,"Janssen Research & Development, LLC",False,VT,https://ClinicalTrials.gov/show/NCT02065791,True,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,"Diabetes Mellitus, Type 2; Diabetic Nephropathy",Drug:Canagliflozin; Drug:Placebo,[],"January 5, 2016",30,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,VT,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01966107,AstraZeneca,False,VT,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01921751,Radiation Therapy Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT01921751,True,High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation,[],"January 29, 2016",18,9223372036854775807,Both,False
NCT01858532,AbbVie,False,VT,https://ClinicalTrials.gov/show/NCT01858532,True,Study Of Diabetic Nephropathy With Atrasentan,Diabetic Nephropathy,Drug:Atrasentan; Drug:Placebo,[],"January 20, 2016",18,85,Both,False
NCT01274338,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT00492778,Gynecologic Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT00048958,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00048958,True,Cytogenetic Studies in Acute Leukemia and Multiple Myeloma,Acute Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Genetic:cytogenetic analysis,[],"August 6, 2015",18,9223372036854775807,Both,False
NCT02659748,University of Vermont Medical Center,False,VT,https://ClinicalTrials.gov/show/NCT02659748,True,Milk Fat Intake and Metabolic Health Markers,Insulin Sensitivity; Type 2 Diabetes,Dietary Supplement:Milk Fat; Dietary Supplement:Control Fat,"[u'Clinical Research Center, University of Vermont Medical Center']","January 15, 2016",18,40,Both,True
NCT02655354,University of Washington,False,VT,https://ClinicalTrials.gov/show/NCT02655354,True,A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity,Posttraumatic Stress Disorder; Depression; Alcohol-Related Disorders; Suicidal Ideation; Substance-Related Disorders; Mild Cognitive Impairment; Quality of Life; Pain; Wounds and Injury; Brain Injuries; Chronic Disease,Behavioral:Motivational Interviewing; Behavioral:Cognitive Behavioral Therapy Elements; Behavioral:Care Management; Drug:Fluoxetine; Drug:Fluvoxamine; Drug:Paroxetine; Drug:Setraline; Drug:Citalopram; Drug:Venlafaxine; Drug:Duloxetine; Drug:Mirtazapine; Drug:Diphenhydramine; Drug:Trazodone; Drug:Prazosin,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02618031,Akron General Medical Center,True,VT,https://ClinicalTrials.gov/show/NCT02618031,True,The Capillary Index Score Trial,Acute Stroke; Brain Ischemia; Ischemic Stroke,Procedure:Endovascular Treatment (EVT),"[u'New York University Langone Medical Center', u'Rochester General Hospital', u'University of North Carolina Hospital', u'Akron General Medical Center', u'Thomas Jefferson University Hospital', u'University of Vermont Medical Center']","January 13, 2016",18,9223372036854775807,Both,False
NCT02596893,Celgene Corporation,False,VT,https://ClinicalTrials.gov/show/NCT02596893,True,Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease,Crohn Disease,Drug:GED-0301; Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02556203,Bayer,False,VT,https://ClinicalTrials.gov/show/NCT02556203,True,Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes,Transcatheter Aortic Valve Replacement,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Acetylsalicylic acid; Drug:Clopidogrel",[],"January 20, 2016",18,9223372036854775807,Both,False
NCT02545049,Bayer,False,VT,https://ClinicalTrials.gov/show/NCT02545049,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02540993,Bayer,False,VT,https://ClinicalTrials.gov/show/NCT02540993,True,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Diabetic Kidney Disease,Drug:Finerenone (BAY94-8862); Drug:Placebo,[],"January 21, 2016",18,9223372036854775807,Both,False
NCT02514473,Vertex Pharmaceuticals Incorporated,False,VT,https://ClinicalTrials.gov/show/NCT02514473,True,"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Drug:VX-809; Drug:Placebo; Drug:VX-770,[],"September 1, 2015",6,11,Both,False
NCT02489396,University of Vermont,False,VT,https://ClinicalTrials.gov/show/NCT02489396,True,Promoting Healthier Food Purchases By Leveraging the Online-Grocery Environment,Obesity,Behavioral:Nutrition facts automatically or not automatically displayed; Behavioral:Nutrition facts in color; Behavioral:Nutrition Facts Label in Larger Font; Behavioral:Healthier Items First,[u'University of Vermont'],"June 30, 2015",0,9223372036854775807,Both,True
NCT02484690,Hoffmann-La Roche,False,VT,https://ClinicalTrials.gov/show/NCT02484690,True,AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD),"Macular Degeneration, Choroidal Neovascularization",Drug:RG7716; Drug:Ranibizumab,[],"September 9, 2015",50,9223372036854775807,Both,False
NCT02484547,Biogen,False,VT,https://ClinicalTrials.gov/show/NCT02484547,True,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,Alzheimer's Disease,Drug:Aducanumab (BIIB037); Drug:Aducanumab (BIIB037); Drug:Placebo,[],"January 14, 2016",50,85,Both,False
NCT02481674,Vaccinex Inc.,True,VT,https://ClinicalTrials.gov/show/NCT02481674,True,VX15/2503 Treatment for Huntington's Disease,Huntington's Disease,Drug:VX15/2503; Drug:Placebo,"[u'University of Alabama at Birmingham', u'University of California, San Diego', u'University of Colorado - Denver', u'Georgetown University', u'Emory University School of Medicine', u'University of Iowa', u'University of Louisville', u'Massachusetts General Hospital', u'University of Michigan', u'Washington University', u'Columbia University', u'University of Rochester', u'Duke University Health Center', u'Wake Forest University', u'University of Cincinnati', u'Ohio State University', u'University of Toledo', u'Vanderbilt University', u'University of Vermont']","January 26, 2016",21,9223372036854775807,Both,False
NCT02477891,"Janssen Research & Development, LLC",False,VT,https://ClinicalTrials.gov/show/NCT02477891,True,Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma,Multiple Myeloma,Drug:Daratumumab,[],"January 27, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02451137,Sanofi,False,VA,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02019264,Eisai Inc.,False,VA,https://ClinicalTrials.gov/show/NCT02019264,True,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes,Drug:APD356-Lorcaserin hydrochloride; Drug:Placebo,[],"November 5, 2015",40,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01966107,AstraZeneca,False,VA,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT02003209,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,VA,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01652872,Amgen,False,VA,https://ClinicalTrials.gov/show/NCT01652872,True,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.,Biological:Darbepoetin alfa,[],"December 9, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01663402,Sanofi,False,VA,https://ClinicalTrials.gov/show/NCT01663402,True,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Acute Coronary Syndrome,Drug:alirocumab; Drug:placebo,[],"February 3, 2016",40,9223372036854775807,Both,False
NCT01975389,Pfizer,False,VA,https://ClinicalTrials.gov/show/NCT01975389,True,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01975376,Pfizer,False,VA,https://ClinicalTrials.gov/show/NCT01975376,True,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,Cardiovascular Disease,Drug:bococizumab (PF-04950615); Drug:Placebo,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,VA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,VA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,VA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02673190,Radiation Therapy Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT01872975,NSABP Foundation Inc,False,VA,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01594333,Brigham and Women's Hospital,False,VA,https://ClinicalTrials.gov/show/NCT01594333,True,Cardiovascular Inflammation Reduction Trial,Cardiovascular Disease,Drug:Methotrexate; Drug:Placebo,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01101035,Takeda,True,VA,https://ClinicalTrials.gov/show/NCT01101035,True,Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities,Cardiovascular Disease,Drug:Febuxostat; Drug:Allopurinol,[],"August 11, 2015",50,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,VA,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01991795,AstraZeneca,False,VA,https://ClinicalTrials.gov/show/NCT01991795,True,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Ticagrelor 60 mg; Drug:Ticagrelor placebo,[],"January 11, 2016",50,130,Both,False
NCT01274338,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT02406677,AstraZeneca,False,VA,https://ClinicalTrials.gov/show/NCT02406677,True,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome,",Other:Study voucher card,[],"January 29, 2016",18,130,Both,False
NCT02112916,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT01406756,Children's Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01190930,Children's Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02164513,GlaxoSmithKline,False,VA,https://ClinicalTrials.gov/show/NCT02164513,True,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate (FF); Drug:vilanterol (VI); Drug:umeclidinium bromide (UMEC),[],"February 4, 2016",40,9223372036854775807,Both,False
NCT01919697,Synergy Pharmaceuticals Inc.,False,VA,https://ClinicalTrials.gov/show/NCT01919697,True,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Chronic Idiopathic Constipation,Drug:Plecanatide,[],"December 10, 2015",18,81,Both,False
NCT01897532,Boehringer Ingelheim,False,VA,https://ClinicalTrials.gov/show/NCT01897532,True,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"Diabetes Mellitus, Type 2",Drug:Placebo; Drug:Linagliptin,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02164864,Boehringer Ingelheim,False,VA,https://ClinicalTrials.gov/show/NCT02164864,True,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Atrial Fibrillation; Percutaneous Coronary Intervention,Drug:Dabigatran Etexilate 110mg; Drug:Warfarin 3mg; Drug:Aspirin; Drug:Dabigatran Etexilate 150mg; Drug:Clopidogrel or Ticagrelor; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 5mg; Drug:Clopidogrel or Ticagrelor; Drug:Warfarin 1mg,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,VA,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01701817,"Janssen Scientific Affairs, LLC",False,VA,https://ClinicalTrials.gov/show/NCT01701817,True,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II),Atrial Fibrillation,Other:Patients with Atrial Fibrillation,[],"January 7, 2016",21,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02388165,Pfizer,False,VA,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02488967,NRG Oncology,False,WA,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02375204,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT02375204,True,Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors,Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma,Drug:paclitaxel; Drug:ifosfamide; Drug:cisplatin; Drug:pegylated G-CSF; Drug:G-CSF; Drug:carboplatin; Drug:etoposide phosphate; Procedure:stem cell reinfusion,[],"December 8, 2015",14,9223372036854775807,Male,False
NCT02315469,NRG Oncology,False,WA,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02003222,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01901094,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT01901094,True,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,Stage II Breast Cancer; Stage IIIA Breast Cancer,Procedure:Axillary Lymph Node Dissection (ALND); Radiation:Nodal Radiation Therapy; Radiation:Axillary Radiation Therapy,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01101451,Gynecologic Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01101451,True,Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage IIA Cervical Cancer,Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01064648,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT00807768,Gynecologic Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00807768,True,"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",Endometrial Cancer; Fatigue; Neurotoxicity,Drug:carboplatin; Drug:paclitaxel; Radiation:brachytherapy; Radiation:intensity-modulated radiation therapy; Radiation:radiation therapy,[],"February 3, 2012",18,9223372036854775807,Female,False
NCT00565851,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT01124695,Eastern Cooperative Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT00840177,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00840177,True,"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia",Leukemia,Drug:cytarabine; Drug:idarubicin; Drug:pravastatin sodium,[],"September 25, 2015",18,9223372036854775807,Both,False
NCT01781468,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT01781468,True,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug:armodafinil 150 mg; Other:Placebo; Drug:armodafinil 250 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01359592,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,WA,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT00843882,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT00936390,Radiation Therapy Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT02115282,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02032823,AstraZeneca,False,WA,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT02163694,AbbVie,False,WA,https://ClinicalTrials.gov/show/NCT02163694,True,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",Metastatic Breast Cancer,Drug:Veliparib; Drug:Carboplatin; Drug:Paclitaxel; Other:Placebo,[],"January 26, 2016",18,99,Both,False
NCT02152982,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT01533207,Gynecologic Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00956007,Radiation Therapy Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02003209,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02194738,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01966107,AstraZeneca,False,WV,https://ClinicalTrials.gov/show/NCT01966107,True,Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.,COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD,Drug:Aclidinium Bromide; Drug:Placebo,[],"January 14, 2016",40,130,Both,False
NCT01274338,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT00843882,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02155660,AstraZeneca,False,WV,https://ClinicalTrials.gov/show/NCT02155660,True,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug:Benralizumab Arm A; Drug:Benralizumab Arm B; Drug:Benralizumab Arm C; Drug:Placebo,[],"January 7, 2016",40,85,Both,False
NCT02027428,Celgene Corporation,False,WV,https://ClinicalTrials.gov/show/NCT02027428,True,Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer,"Squamous Cell Carcinoma, Non-Small-Cell Lung",Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Drug:Abraxane (Maintenance); Other:Best Supportive Care (Maintenance); Drug:Abraxane (Induction); Drug:Carboplatin (Induction); Other:Best Supportive Care (Maintenance),[],"December 8, 2015",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01013649,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02506153,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02506153,True,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Melanoma of the Skin; Recurrent Non-Cutaneous Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck,Other:Laboratory Biomarker Analysis; Biological:Pembrolizumab; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02496884,Daiichi Sankyo Inc.,False,WV,https://ClinicalTrials.gov/show/NCT02496884,True,Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease,Fibromyalgia,Drug:DS-5565; Drug:placebo,"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u'']","January 15, 2016",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,WV,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02451137,Sanofi,False,WV,https://ClinicalTrials.gov/show/NCT02451137,True,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","Diabetes Mellitus, Type 2",Drug:INSULIN GLARGINE (U300); Drug:INSULIN GLARGINE (U100); Drug:Insulin detemir (Levemir),[],"February 3, 2016",18,9223372036854775807,Both,False
NCT02388165,Pfizer,False,WV,https://ClinicalTrials.gov/show/NCT02388165,True,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Posterior Instrumented Lumbar Spinal Fusion Procedure,Staphylococcal Vaccine,Biological:Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine; Other:Placebo,[],"January 25, 2016",18,85,Both,False
NCT02387359,Synergy Pharmaceuticals Inc.,False,WV,https://ClinicalTrials.gov/show/NCT02387359,True,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Irritable Bowel Syndrome Characterized by Constipation,Drug:Plecanatide; Drug:Placebo,[],"December 10, 2015",18,85,Both,False
NCT02180867,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02166463,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02166463,True,Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma,Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Biological:Bleomycin Sulfate; Drug:Brentuximab Vedotin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Vincristine Sulfate,[],"December 1, 2015",2,18,Both,False
NCT02115282,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02112916,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02112916,True,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,Adult T Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Stage II Childhood Lymphoblastic Lymphoma; Stage II Contiguous Adult Lymphoblastic Lymphoma; Stage II Non-Contiguous Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Bortezomib; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"January 28, 2016",2,30,Both,False
NCT02101853,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02101853,True,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Asparaginase; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Mitoxantrone Hydrochloride; Drug:Pegaspargase; Other:Pharmacological Study; Drug:Therapeutic Hydrocortisone; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 1, 2016",1,30,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT02065687,Gynecologic Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT02065687,True,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Metformin Hydrochloride; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01888120,Jazz Pharmaceuticals,False,WV,https://ClinicalTrials.gov/show/NCT01888120,True,Patient Registry of Intrathecal Ziconotide Management(PRIZM),Patients With Severe Chronic Pain,Drug:Ziconotide,[],"June 18, 2015",18,9223372036854775807,Both,False
NCT01810913,Radiation Therapy Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT01810913,True,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:cisplatin; Drug:docetaxel; Biological:cetuximab; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Radiation:intensity-modulated radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT01705977,"Human Genome Sciences Inc., a GSK Company",False,WV,https://ClinicalTrials.gov/show/NCT01705977,True,Belimumab Assessment of Safety in SLE,Systemic Lupus Erythematosus,Biological:Placebo plus standard therapy; Biological:Belimumab 10 mg/kg plus standard therapy; Other:Standard therapy,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01406756,Children's Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT01406756,True,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Clofarabine; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Drug:Hydrocortisone Sodium Succinate; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Radiation:Radiation Therapy; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"February 3, 2016",1,30,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01190930,Children's Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT01190930,True,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Adult B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Stage I B Lymphoblastic Lymphoma; Stage II B Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia,Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Thioguanine; Drug:Vincristine Sulfate,[],"August 6, 2015",1,30,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,WV,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01041703,Eastern Cooperative Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT01041703,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Leukemia,Drug:clofarabine; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:decitabine,[],"July 24, 2014",60,9223372036854775807,Both,False
NCT00956007,Radiation Therapy Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT00956007,True,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,WV,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT02673190,Radiation Therapy Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02673190,Radiation Therapy Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT02673190,True,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Radiation:Selective External Radiation Therapy,[],"January 29, 2016",18,9223372036854775807,Male,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02488967,NRG Oncology,False,WI,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02229539,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02180867,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02180867,True,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Adult Fibrosarcoma; Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Glomus Tumor of the Skin; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Stage IB Soft Tissue Sarcoma; Stage IIB Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma; Synovial Sarcoma; Undifferentiated (Embryonal) Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug:Doxorubicin Hydrochloride; Drug:Ifosfamide; Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery,[],"February 1, 2016",2,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02152982,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02152982,True,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Glioblastoma; Gliosarcoma,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Temozolomide; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT02059265,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02059265,True,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",Endometrial Clear Cell Adenocarcinoma; Estrogen Receptor Negative; Ovarian Clear Cell Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Dasatinib; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Female,False
NCT02048813,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02032823,AstraZeneca,False,WI,https://ClinicalTrials.gov/show/NCT02032823,True,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,Breast Cancer,Drug:Olaparib; Drug:Placebo,[],"January 27, 2016",18,130,Both,False
NCT02003209,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01949337,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT01949337,True,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:enzalutamide; Drug:abiraterone; Drug:prednisone,[],"September 18, 2015",18,9223372036854775807,Male,False
NCT01903811,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01872975,NSABP Foundation Inc,False,WI,https://ClinicalTrials.gov/show/NCT01872975,True,Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery,Stage IB Breast Cancer; Stage II Breast Cancer,Radiation:regional nodal XRT; Radiation:chestwall XRT; Radiation:WBI,[],"January 4, 2016",18,9223372036854775807,Female,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,WI,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01856192,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01856192,True,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01809691,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01809691,True,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",Prostate Cancer,Drug:TAK-700; Drug:Bicalutamide,[],"December 8, 2015",18,9223372036854775807,Male,False
NCT01674140,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01668719,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01668719,True,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",Multiple Myeloma; Plasma Cell Myeloma,Biological:elotuzumab; Drug:bortezomib; Drug:dexamethasone; Drug:lenalidomide,[],"September 28, 2015",18,120,Both,False
NCT01575548,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01535053,Gynecologic Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01349881,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01274338,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01242800,Eastern Cooperative Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01242800,True,Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer,Breast Cancer,Procedure:palliative surgery; Procedure:therapeutic conventional surgery; Radiation:palliative radiation therapy; Radiation:radiation therapy,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT01216683,Eastern Cooperative Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01216683,True,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",18,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT01120249,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT01107626,Eastern Cooperative Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01107626,True,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"December 5, 2012",18,9223372036854775807,Both,False
NCT01079780,Pam Cogliano,False,WI,https://ClinicalTrials.gov/show/NCT01079780,True,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological:cetuximab; Biological:ramucirumab; Drug:irinotecan hydrochloride,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00936390,Radiation Therapy Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT00936390,True,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:triptorelin; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"November 11, 2015",18,9223372036854775807,Male,False
NCT00897767,Eastern Cooperative Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT00897767,True,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,Leukemia; Lymphoma,Other:biologic sample preservation procedure,[],"December 5, 2012",0,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00719303,Gynecologic Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00700882,Eastern Cooperative Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT00700882,True,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",Melanoma (Skin),Drug:dasatinib; Other:laboratory biomarker analysis,[],"September 16, 2014",18,9223372036854775807,Both,False
NCT00565851,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00565851,True,"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Malignant Ovarian Mixed Epithelial Tumor; Mucinous Adenocarcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02164916,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT00897442,Gynecologic Oncology Group,True,WI,https://ClinicalTrials.gov/show/NCT00897442,True,Collecting Tumor Samples From Patients With Gynecological Tumors,Cancer,Other:biologic sample preservation procedure,[],"August 30, 2012",0,9223372036854775807,Female,False
NCT00074282,Eastern Cooperative Oncology Group,True,WI,https://ClinicalTrials.gov/show/NCT00074282,True,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Leukemia,Biological:filgrastim; Biological:pegfilgrastim; Biological:rituximab; Drug:cyclophosphamide; Drug:lenalidomide; Drug:pentostatin,[],"November 9, 2012",18,9223372036854775807,Both,False
NCT02048813,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02048813,True,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Anemia; Fever, Sweat, and Hot Flashes; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; Weight Change",Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",18,70,Both,False
NCT02003209,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02003209,True,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Positive; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Aromatase Inhibition Therapy; Drug:Carboplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Biological:Pertuzumab; Other:Quality-of-Life Assessment; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01349881,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01349881,True,"S0820, Adenoma and Second Primary Prevention Trial",Colorectal Neoplasms,Drug:Eflornithine placebo & sulindac placebo; Drug:eflornithine & sulindac placebo; Drug:Eflornithine placebo & sulindac; Drug:Eflornithine plus sulindac,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01272037,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01272037,True,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",Ductal Breast Carcinoma In Situ; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Drug:Systemic Chemotherapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01120249,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01120249,True,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",Kidney Cancer,Drug:everolimus; Other:placebo,[],"December 8, 2015",18,120,Both,False
NCT00719303,Gynecologic Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT00719303,True,"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Brenner Tumor; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Behavioral:Behavioral Dietary Intervention; Behavioral:Compliance Monitoring; Other:Counseling; Other:Educational Intervention; Behavioral:Exercise Intervention; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT02488967,NRG Oncology,False,WY,https://ClinicalTrials.gov/show/NCT02488967,True,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma,Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT02194738,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02194738,True,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adenosquamous Lung Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Other:Cytology Specimen Collection Procedure; Other:Laboratory Biomarker Analysis,[],"January 22, 2016",18,9223372036854775807,Both,False
NCT02193282,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02193282,True,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT02003222,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02003222,True,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Biological:Blinatumomab; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Drug:Mercaptopurine; Drug:Methotrexate; Drug:Pegaspargase; Drug:Prednisone; Drug:Vincristine Sulfate,[],"January 28, 2016",30,70,Both,False
NCT01903811,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01903811,True,Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Drug:Carfilzomib; Drug:Dexamethasone; Other:Laboratory Biomarker Analysis,[],"August 18, 2015",18,9223372036854775807,Both,False
NCT01863550,ECOG-ACRIN Cancer Research Group,False,WY,https://ClinicalTrials.gov/show/NCT01863550,True,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:bortezomib; Drug:lenalidomide; Drug:dexamethasone; Drug:carfilzomib; Procedure:quality-of-life assessment; Other:laboratory biomarker analysis,[],"December 29, 2015",18,9223372036854775807,Both,False
NCT01835145,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01835145,True,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,Recurrent Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma,Drug:Cabozantinib S-malate; Drug:Dacarbazine; Other:Laboratory Biomarker Analysis; Drug:Temozolomide,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01575548,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01575548,True,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Renal Cell Cancer,Drug:Pazopanib Hydrochloride; Other:Pharmacological Study; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01573442,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01573442,True,Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment,Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction,Drug:testosterone; Other:placebo; Drug:anastrozole,[],"November 3, 2015",18,9223372036854775807,Female,False
NCT01535053,Gynecologic Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01535053,True,Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole,Biological:Dactinomycin; Drug:Leucovorin Calcium; Drug:Methotrexate; Other:Quality-of-Life Assessment,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT01515787,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01515787,True,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,Colorectal Cancer,Drug:FOLFOX (chemotherapy); Other:5 FUCMT (chemoradiation); Procedure:surgery; Procedure:magnetic resonance imaging or endorectal ultrasound,[],"June 25, 2015",18,9223372036854775807,Both,False
NCT01415752,Eastern Cooperative Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01415752,True,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",Lymphoma; Neurotoxicity; Therapy-related Toxicity,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:bortezomib; Drug:lenalidomide,[],"March 13, 2015",60,9223372036854775807,Both,False
NCT01064648,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01064648,True,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,Advanced Malignant Mesothelioma; Epithelioid Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma,Drug:Cediranib Maleate; Drug:Cisplatin; Drug:Pemetrexed Disodium; Other:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT02601209,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02601209,True,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Uterine Corpus Leiomyosarcoma,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Drug:Sapanisertib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02562716,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT02562716,True,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer,Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Drug:Irinotecan Hydrochloride; Drug:Oxaliplatin; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure:Pancreatectomy,[],"January 26, 2016",18,75,Both,False
NCT02523014,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT02523014,True,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,Intracranial Meningioma; Recurrent Meningioma,Drug:vismodegib; Drug:GSK2256098,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02315469,NRG Oncology,False,WY,https://ClinicalTrials.gov/show/NCT02315469,True,Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery,Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Other:Comprehensive Geriatric Assessment; Other:Questionnaire Administration,[],"July 13, 2015",70,9223372036854775807,Female,False
NCT02311933,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02311933,True,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Tamoxifen Citrate; Drug:Z-Endoxifen Hydrochloride,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02134912,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT02134912,True,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Drug:crizotinib; Drug:pemetrexed disodium; Other:laboratory biomarker analysis; Other:pharmacological study,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT01953588,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01953588,True,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:fulvestrant; Drug:anastrozole,[],"September 9, 2015",18,9223372036854775807,Female,False
NCT01950390,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01950390,True,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Bevacizumab; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01814813,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01814813,True,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,Recurrent Glioblastoma; Recurrent Adult Brain Tumor; Gliosarcoma,Biological:HSPPC-96; Drug:bevacizumab,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01674140,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01674140,True,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:everolimus; Drug:exemestane; Drug:goserelin acetate; Drug:letrozole; Drug:leuprolide acetate; Drug:tamoxifen citrate; Other:placebo,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT01556243,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01556243,True,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,Breast Cancer,Procedure:therapeutic conventional surgery; Radiation:whole breast irradiation,[],"December 11, 2015",40,9223372036854775807,Female,False
NCT00887146,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT00887146,True,Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma,Brain and Central Nervous System Tumors,Drug:concomitant temozolomide (TMZ); Radiation:radiotherapy; Drug:procarbazine; Drug:adjuvant temozolomide (TMZ); Drug:CCNU; Drug:vincristine,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT02154490,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT02154490,True,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:anti-B7H1 monoclonal antibody MEDI4736; Drug:PI3 kinase inhibitor GDC-0032; Drug:palbociclib isethionate; Drug:FGFR inhibitor AZD4547; Biological:rilotumumab; Drug:docetaxel; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT02085408,Eastern Cooperative Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT02085408,True,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:clofarabine; Drug:daunorubicin hydrochloride; Other:clinical observation; Drug:cytarabine; Drug:decitabine; Other:laboratory biomarker analysis; Procedure:quality-of-life assessment; Other:questionnaire administration,[],"September 16, 2014",60,9223372036854775807,Both,False
NCT01533207,Gynecologic Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01533207,True,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,Stage I Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Drug:Doxorubicin Hydrochloride; Drug:Gemcitabine Hydrochloride; Drug:Docetaxel; Biological:Filgrastim; Biological:Pegfilgrastim; Other:Clinical Observation,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01414608,Gynecologic Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01414608,True,Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Chemotherapeutic Agent Toxicity; Cognitive Side Effects of Cancer Therapy; Psychological Impact of Cancer; Radiation Toxicity; Sexual Dysfunction and Infertility; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer,Drug:Carboplatin; Drug:Cisplatin; Radiation:External Beam Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"July 16, 2015",18,9223372036854775807,Female,False
NCT01274338,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01274338,True,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Quality-of-Life Assessment; Biological:Recombinant Interferon Alfa-2b,[],"February 4, 2016",12,9223372036854775807,Both,False
NCT01169337,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01169337,True,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma,Other:Clinical Observation; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01150045,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01150045,True,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery",Colorectal Cancer,Drug:celecoxib; Drug:5-fluorouracil; Other:placebo; Drug:oxaliplatin; Drug:leucovorin,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT01013649,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01013649,True,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer,Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Capecitabine; Drug:Erlotinib Hydrochloride; Drug:Fluorouracil; Drug:Gemcitabine Hydrochloride; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00843882,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT00843882,True,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome,Biological:Epoetin Alfa; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00492778,Gynecologic Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT00492778,True,Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer,"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma",Radiation:3-Dimensional Conformal Radiation Therapy; Drug:Cisplatin; Radiation:Intensity-Modulated Radiation Therapy; Radiation:Internal Radiation Therapy,[],"July 13, 2015",0,9223372036854775807,Female,False
NCT00430183,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT00430183,True,Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer,Prostate Cancer,Drug:docetaxel; Drug:LHRH agonist; Procedure:surgery,[],"March 13, 2015",18,9223372036854775807,Male,False
NCT02672748,University of Wyoming,False,WY,https://ClinicalTrials.gov/show/NCT02672748,True,Growing Resilience in Wind River Indian Reservation,Obesity; Overweight; Diabetes,Other:Garden,[u'University of Wyoming'],"February 2, 2016",5,80,Both,True
NCT02229539,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT02229539,True,Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,Acute Oral Mucositis Pain,"Drug:doxepin hydrochloride oral solution; Drug:DLA (diphenhydramine, lidocaine and antacids) rinse; Other:Placebo",[],"August 4, 2015",18,9223372036854775807,Both,False
NCT02177695,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT02177695,True,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug:Gemcitabine; Drug:Cisplatin; Drug:Methotrexate; Drug:Vinblastine; Drug:Doxorubicin; Drug:Filgrastim,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02164916,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT02164916,True,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Biological:cetuximab; Drug:irinotecan hydrochloride; Drug:vemurafenib,[],"January 26, 2016",18,9223372036854775807,Both,False
NCT02115282,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02115282,True,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Entinostat; Drug:Exemestane; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02101788,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02101788,True,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Letrozole; Drug:Paclitaxel; Drug:Pegylated Liposomal Doxorubicin Hydrochloride; Other:Pharmacological Study; Other:Quality-of-Life Assessment; Drug:Tamoxifen Citrate; Drug:Topotecan Hydrochloride; Drug:Trametinib,[],"January 27, 2016",19,9223372036854775807,Female,False
NCT01359592,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01359592,True,S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Other:R-CHOP regimen; Other:laboratory biomarker analysis; Radiation:fludeoxyglucose F 18; Radiation:selective external radiation therapy; Radiation:yttrium Y 90 ibritumomab tiuxetan,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01124695,Eastern Cooperative Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01124695,True,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,Breast Cancer,Drug:tamoxifen citrate; Other:laboratory biomarker analysis,[],"December 6, 2012",18,9223372036854775807,Both,False
NCT00373685,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,AL,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00346216,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00347620,University of Alabama at Birmingham,False,AL,https://ClinicalTrials.gov/show/NCT00347620,False,Improving Vision and Quality of Life in the Nursing Home,Refractive Error; Cataract,Device:spectacles; Procedure:Cataract Surgery,"[u'Integrated Health Services at Briarcliff', u'Shelby Ridge Nursing Home', u'Beverly Healthcare Meadowood', u'Southgate Village', u'Livingston Health Care Center', u'Beverly Healthcare Riverchase', u'Fair Haven Retirement Center', u'Beverly Healthcare Center Forestdale', u'Beverly Healthcare East', u'South Haven', u'Estes Nursing Facility Civic Center', u'Estes Nursing Facility Northway', u'Fairview Health & Rehabilitation Center', u'Beverly Health Care Center West', u'The Self Nursing Home, Inc', u'Beverly Healthcare Pleasant Grove', u'Consult America Cottage Hills']","March 12, 2010",60,9223372036854775807,Both,True
NCT01313676,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT00239681,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT00239681,False,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],"February 6, 2014",50,9223372036854775807,Both,False
NCT01475721,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT01475721,False,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],"December 10, 2015",12,9223372036854775807,Both,False
NCT01543178,"Valeant Pharmaceuticals International, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT01543178,False,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01126437,Boehringer Ingelheim,False,AL,https://ClinicalTrials.gov/show/NCT01126437,False,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],"May 20, 2014",40,9223372036854775807,Both,False
NCT00643409,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT00643409,False,"A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults",Maxillary Sinusitis,"Drug:azithromycin SR (Zithromax; compound: CP-62,993); Other:placebo; Drug:levofloxacin; Other:placebo",[],"May 10, 2011",18,9223372036854775807,Both,False
NCT01510158,"Ardea Biosciences, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT01510158,False,Combining Lesinurad With Allopurinol in Inadequate Responders,Gout,Drug:Lesinurad; Drug:Lesinurad; Drug:Placebo; Drug:Allopurinol,[],"May 18, 2015",18,85,Both,False
NCT01508026,Forest Laboratories,False,AL,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01437397,Forest Laboratories,False,AL,https://ClinicalTrials.gov/show/NCT01437397,False,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:placebo,[],"April 5, 2013",40,9223372036854775807,Both,False
NCT01327846,Novartis Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT01327846,False,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],"May 19, 2015",18,9223372036854775807,Both,False
NCT01130272,"Furiex Pharmaceuticals, Inc",False,AL,https://ClinicalTrials.gov/show/NCT01130272,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"June 11, 2012",18,65,Both,False
NCT00649389,Daiichi Sankyo Inc.,False,AL,https://ClinicalTrials.gov/show/NCT00649389,False,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Hypertension,Drug:Olmesartan medoxomil; Drug:Amlodipine; Drug:Hydrochlorothiazide,[],"August 31, 2010",18,80,Both,False
NCT00430248,Takeda,True,AL,https://ClinicalTrials.gov/show/NCT00430248,False,Efficacy and Safety of Oral Febuxostat in Participants With Gout,Gout,Drug:Febuxostat; Drug:Febuxostat; Drug:Allopurinol,[],"January 31, 2012",18,85,Both,False
NCT00373256,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT00373256,False,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Drug:Sunitinib; Drug:paclitaxel; Drug:bevacizumab; Drug:paclitaxel,[],"September 5, 2012",18,9223372036854775807,Both,False
NCT01789957,AstraZeneca,False,AL,https://ClinicalTrials.gov/show/NCT01789957,False,Extension Study for 2993-112,Type 2 Diabetes Mellitus,Drug:AC2993,[],"February 23, 2015",16,75,Both,False
NCT01572792,Forest Laboratories,False,AL,https://ClinicalTrials.gov/show/NCT01572792,False,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:Placebo,[],"February 27, 2015",40,9223372036854775807,Both,False
NCT01553747,"Furiex Pharmaceuticals, Inc",False,AL,https://ClinicalTrials.gov/show/NCT01553747,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Other:Placebo Comparator,[],"April 26, 2015",18,80,Both,False
NCT00849056,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT00849056,False,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00643760,"XenoPort, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT00643760,False,A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN),"Neuropathy, Diabetic",Drug:Placebo; Drug:GEn 1200mg/day; Drug:GEn 2400mg/day; Drug:GEn 3600mg/day; Drug:Pregabalin,[],"July 15, 2013",18,9223372036854775807,Both,False
NCT00571649,Bayer,True,AL,https://ClinicalTrials.gov/show/NCT00571649,False,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Venous Thromboembolism,"Drug:Rivaroxaban (Xarelto, BAY59-7939); Drug:Enoxaparin; Drug:Rivaroxaban placebo; Drug:Enoxaparin placebo",[],"November 28, 2014",40,9223372036854775807,Both,False
NCT00557921,Cogentus Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT00557921,False,Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1),Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease; Percutaneous Coronary Intervention,Drug:CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Drug:Plavix (clopidogrel 75 mg) and aspirin,[],"January 27, 2009",21,9223372036854775807,Both,False
NCT00347360,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT00347360,False,The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial,Hypertension,Drug:lisinopril; Drug:carvedilol controlled release formulation,[],"April 20, 2015",18,9223372036854775807,Both,False
NCT00255190,Takeda,True,AL,https://ClinicalTrials.gov/show/NCT00255190,False,Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn,Gastroesophageal Reflux Disease,Drug:Dexlansoprazole MR; Drug:Dexlansoprazole MR,[],"April 25, 2011",18,9223372036854775807,Both,False
NCT00168779,Boehringer Ingelheim,False,AL,https://ClinicalTrials.gov/show/NCT00168779,False,"Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension",Hypertension,Drug:telmisartan 80 mg / hydrochlorothiazide 25 mg; Drug:valsartan 160 mg / hydrochlorothiazide 25 mg; Drug:placebo,[],"October 31, 2013",18,9223372036854775807,Both,False
NCT00088179,Alexion Pharmaceuticals,False,AL,https://ClinicalTrials.gov/show/NCT00088179,False,Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II),Coronary Artery Disease,Drug:pexelizumab in conjunction with CABG,[],"August 28, 2005",18,9223372036854775807,Both,False
NCT00067938,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT00067938,False,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],"October 11, 2012",18,9223372036854775807,Both,False
NCT00039026,AstraZeneca,True,AL,https://ClinicalTrials.gov/show/NCT00039026,False,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea,"Diabetes Mellitus, Non-Insulin-Dependent",Drug:AC2993; Drug:AC2993; Drug:Placebo; Drug:Placebo,[],"February 23, 2015",16,75,Both,False
NCT00039013,AstraZeneca,True,AL,https://ClinicalTrials.gov/show/NCT00039013,False,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin,"Diabetes Mellitus, Type 2",Drug:AC2993; Drug:AC2993; Drug:Placebo; Drug:Placebo,[],"February 23, 2015",16,75,Both,False
NCT00005088,Radiation Therapy Oncology Group,True,AL,https://ClinicalTrials.gov/show/NCT00005088,False,Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer,Head and Neck Cancer,Drug:cisplatin; Radiation:radiation therapy,[],"November 18, 2013",0,9223372036854775807,Both,False
NCT00003825,Radiation Therapy Oncology Group,True,AL,https://ClinicalTrials.gov/show/NCT00003825,False,Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy,Diarrhea; Radiation Enteritis,Drug:pentosan polysulfate sodium; Procedure:quality-of-life assessment,[],"August 9, 2013",0,9223372036854775807,Both,False
NCT00002708,Radiation Therapy Oncology Group,True,AL,https://ClinicalTrials.gov/show/NCT00002708,False,Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases,Metastatic Cancer,Procedure:surgical procedure; Radiation:radiation therapy; Radiation:stereotactic radiosurgery,[],"November 18, 2013",18,9223372036854775807,Both,False
NCT01942135,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01942135,False,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Drug:Palbociclib; Drug:Fulvestrant; Drug:Placebo; Drug:Fulvestrant,[],"November 16, 2015",18,9223372036854775807,Female,False
NCT01462344,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT01462344,False,6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg,[],"October 1, 2015",4,11,Both,False
NCT01360554,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01360554,False,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer (NSCLC),Drug:Dacomitinib (PF-00299804); Drug:Active Comparator (erlotinib); Drug:Placebo erlotinib; Drug:Placebo PF00299804,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT01302067,Pfizer,False,AL,https://ClinicalTrials.gov/show/NCT01302067,False,A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine,Overactive Bladder,Drug:Fesoterodine 8mg; Drug:Fesoterodine 4mg; Drug:Placebo,[],"February 25, 2014",18,9223372036854775807,Both,False
NCT01298219,"Sucampo Pharmaceuticals, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT01298219,False,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL),Opioid-induced Bowel Dysfunction,Drug:Lubiprostone; Drug:Placebo,[],"February 1, 2013",18,9223372036854775807,Both,False
NCT01165710,"Janssen Scientific Affairs, LLC",False,AL,https://ClinicalTrials.gov/show/NCT01165710,False,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF),Atrial Fibrillation,Other:Patients with Atrial Fibrillation (AF),[],"January 9, 2015",18,9223372036854775807,Both,False
NCT01147250,Sanofi,False,AL,https://ClinicalTrials.gov/show/NCT01147250,False,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),Acute Coronary Syndrome,Drug:lixisenatide (AVE0010); Drug:placebo,[],"November 12, 2015",30,9223372036854775807,Both,False
NCT00891020,Hoffmann-La Roche,False,AL,https://ClinicalTrials.gov/show/NCT00891020,False,A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs),Rheumatoid Arthritis,Drug:tocilizumab [RoActemra/Actemra]; Drug:tocilizumab [RoActemra/Actemra]; Drug:Nonbiologic DMARDs of investigator's choice,[],"October 19, 2012",18,9223372036854775807,Both,False
NCT00887536,NSABP Foundation Inc,False,AL,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00878709,"Puma Biotechnology, Inc.",False,AL,https://ClinicalTrials.gov/show/NCT00878709,False,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],"August 20, 2015",18,9223372036854775807,Female,False
NCT00839527,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT00839527,False,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00838916,GlaxoSmithKline,False,AL,https://ClinicalTrials.gov/show/NCT00838916,False,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:insulin glargine,[],"May 22, 2014",18,9223372036854775807,Both,False
NCT00743652,Pfizer,False,AK,https://ClinicalTrials.gov/show/NCT00743652,False,Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.,Pneumococcal Disease; 13-valent Pneumococcal Vaccine,Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:13-valent Pneumococcal Conjugate Vaccine,"[u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site']","March 13, 2012",42,5,Both,True
NCT02465060,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02196181,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02116530,Alliance for Clinical Trials in Oncology,False,AK,https://ClinicalTrials.gov/show/NCT02116530,False,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02257528,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02257528,False,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT01886872,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT00946712,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00769379,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02137837,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT02137837,False,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],"May 20, 2015",18,9223372036854775807,Female,False
NCT02042443,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01609790,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01609790,False,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00775645,Southwest Oncology Group,True,AK,https://ClinicalTrials.gov/show/NCT00775645,False,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy",Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity,Dietary Supplement:acetyl-L-carnitine hydrochloride; Other:placebo,[],"January 13, 2014",18,9223372036854775807,Female,False
NCT00733408,University of Washington,False,AK,https://ClinicalTrials.gov/show/NCT00733408,False,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer,Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer,Drug:paclitaxel albumin-stabilized nanoparticle formulation; Biological:bevacizumab; Drug:erlotinib hydrochloride; Other:laboratory biomarker analysis,"[u'Anchorage Oncology Centre', u'Katmai Oncology Group', u'Providence Alaska Medical Center', u'Yuma Cancer Center', u'Saint Joseph Regional Medical Center', u'Bozeman Deaconess Hospital', u'Kalispell Regional Medical Center', u'Bend Memorial Clinic', u'Kadlec Clinic Hematology and Oncology', u'Evergreen Hospital Medical Center', u'Skagit Valley Hospital Regional Cancer Care Center', u'Group Health Cooperative, Redmond', u'Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium', u'Olympic Medical Cancer Care Center', u'Spokane Valley Cancer Center-Mayfair', u'Multicare Medical Oncology Hematology', u'Wenatchee Valley Medical Center']","January 5, 2016",0,9223372036854775807,Female,False
NCT00310180,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT01385137,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01385137,False,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],"October 15, 2015",18,120,Female,False
NCT01243424,Boehringer Ingelheim,False,AK,https://ClinicalTrials.gov/show/NCT01243424,False,CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:linagliptin; Drug:glimepiride; Drug:linagliptin placebo; Drug:glimepride placebo,[],"January 12, 2016",40,85,Both,False
NCT01194830,Boehringer Ingelheim,False,AK,https://ClinicalTrials.gov/show/NCT01194830,False,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,"Diabetes Mellitus, Type 2",Drug:Linagliptin; Drug:Placebo,[],"December 12, 2013",18,80,Both,False
NCT01101438,NCIC Clinical Trials Group,True,AK,https://ClinicalTrials.gov/show/NCT01101438,False,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],"May 5, 2015",18,74,Both,False
NCT01097278,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT01088503,Eli Lilly and Company,False,AK,https://ClinicalTrials.gov/show/NCT01088503,False,Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome,Acute Coronary Syndrome,Drug:ADP receptor inhibitors,[],"December 22, 2015",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00920010,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00920010,False,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],"February 5, 2015",0,9223372036854775807,Both,False
NCT00874211,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00874211,False,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],"March 4, 2015",0,9223372036854775807,Both,False
NCT00746967,Pfizer,False,AK,https://ClinicalTrials.gov/show/NCT00746967,False,"An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder","Sexual Dysfunctions, Psychological; Sexual Arousal Disorder",Drug:sildenafil,[],"September 3, 2008",18,9223372036854775807,Female,False
NCT00513695,University of Washington,False,AK,https://ClinicalTrials.gov/show/NCT00513695,False,"Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer",Inflammatory Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:sunitinib malate; Drug:paclitaxel; Drug:doxorubicin hydrochloride; Drug:cyclophosphamide; Biological:filgrastim; Procedure:therapeutic conventional surgery; Other:laboratory biomarker analysis; Other:flow cytometry,"[u'Anchorage Oncology Centre', u'Katmai Oncology Group', u'Arizona Cancer Center', u""Saint Luke's Mountain States Tumor Institute"", u'Skagit Valley Hospital', u'Olympic Medical Center', u'Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium']","January 5, 2016",0,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,AK,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00410813,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00410813,False,"S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone",Breast Cancer; Metastatic Cancer,Drug:dasatinib,[],"May 22, 2013",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,AK,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00382018,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00382018,False,S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy,Breast Cancer,Drug:chemotherapy,[],"September 15, 2015",18,9223372036854775807,Female,False
NCT00376961,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00376961,False,"S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",Lymphoma,Biological:rituximab; Drug:bortezomib; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate,[],"May 8, 2015",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,AK,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00309985,Eastern Cooperative Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00309985,False,Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer,Prostate Cancer,Drug:antiandrogen therapy; Drug:docetaxel,[],"May 15, 2015",18,9223372036854775807,Male,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,AK,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00134056,Southwest Oncology Group,True,AK,https://ClinicalTrials.gov/show/NCT00134056,False,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],"May 6, 2015",18,9223372036854775807,Male,False
NCT00107276,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00107276,False,S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer,Breast Cancer,Drug:capecitabine; Drug:cyclophosphamide,[],"July 3, 2013",18,9223372036854775807,Female,False
NCT00075764,Southwest Oncology Group,False,AK,https://ClinicalTrials.gov/show/NCT00075764,False,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],"May 8, 2014",18,9223372036854775807,Female,False
NCT00075686,Southwest Oncology Group,True,AK,https://ClinicalTrials.gov/show/NCT00075686,False,S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer,Pancreatic Cancer,Biological:cetuximab; Drug:gemcitabine hydrochloride,[],"November 16, 2015",18,9223372036854775807,Both,False
NCT00070018,Southwest Oncology Group,True,AK,https://ClinicalTrials.gov/show/NCT00070018,False,"S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",Lymphoma,Biological:rituximab; Drug:Cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Radiation:radiation therapy; Biological:Yttrium-90 ibritumomab tiuxetan; Biological:Indium-111 ibritumomab tiuxetan,[],"January 17, 2014",18,9223372036854775807,Both,False
NCT00346216,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,AZ,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00373685,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT01942135,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT01942135,False,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Drug:Palbociclib; Drug:Fulvestrant; Drug:Placebo; Drug:Fulvestrant,[],"November 16, 2015",18,9223372036854775807,Female,False
NCT01508026,Forest Laboratories,False,AZ,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT02565186,CoLucid Pharmaceuticals,False,AZ,https://ClinicalTrials.gov/show/NCT02565186,False,"An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine",Acute Treatment of Migraine in Adults,Drug:lasmiditan 100 mg; Drug:lasmiditan 200 mg,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01475721,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT01475721,False,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],"December 10, 2015",12,9223372036854775807,Both,False
NCT00887536,NSABP Foundation Inc,False,AZ,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00809354,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00809354,False,Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip,Osteoarthritis; Arthritis,Drug:NSAID; Biological:tanezumab; Biological:tanezumab; Biological:tanezumab; Drug:NSAID; Biological:tanezumab; Drug:NSAID,[],"March 4, 2015",18,9223372036854775807,Both,False
NCT00347360,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT00347360,False,The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial,Hypertension,Drug:lisinopril; Drug:carvedilol controlled release formulation,[],"April 20, 2015",18,9223372036854775807,Both,False
NCT02117479,Incyte Corporation,False,AZ,https://ClinicalTrials.gov/show/NCT02117479,False,Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),Metastatic Pancreatic Adenocarcinoma,Drug:Ruxolitinib; Drug:Placebo; Drug:Capecitabine,[],"January 13, 2016",18,9223372036854775807,Both,False
NCT00205777,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00205777,False,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Osteoporosis,Drug:Bazedoxifene Acetate; Other:Placebo,[],"February 28, 2013",55,80,Female,False
NCT00036270,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00036270,False,Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane,Breast Neoplasms,Drug:exemestane (Aromasin); Drug:tamoxifen + exemestane,[],"October 6, 2015",50,9223372036854775807,Female,False
NCT01306890,Dendreon,False,AZ,https://ClinicalTrials.gov/show/NCT01306890,False,A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer,Advanced Prostate Cancer; Prostatic Neoplasms,Biological:sipuleucel-T,[],"October 5, 2015",18,9223372036854775807,Male,False
NCT01130272,"Furiex Pharmaceuticals, Inc",False,AZ,https://ClinicalTrials.gov/show/NCT01130272,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"June 11, 2012",18,65,Both,False
NCT01126437,Boehringer Ingelheim,False,AZ,https://ClinicalTrials.gov/show/NCT01126437,False,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],"May 20, 2014",40,9223372036854775807,Both,False
NCT00839527,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT00839527,False,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00683137,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00683137,False,Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery,Pain; Hallux Valgus,Drug:valdecoxib; Drug:valdecoxib; Drug:valdecoxib/placebo,[],"May 22, 2008",18,9223372036854775807,Both,False
NCT00241722,Cubist Pharmaceuticals LLC,False,AZ,https://ClinicalTrials.gov/show/NCT00241722,False,Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain,Bowel Dysfunction; Constipation,Drug:Alvimopan; Drug:Placebo,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT01701362,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT01701362,False,Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain,Neuropathic Pain,Drug:pregabalin; Drug:placebo,[],"September 30, 2015",18,9223372036854775807,Both,False
NCT01642914,Forest Laboratories,False,AZ,https://ClinicalTrials.gov/show/NCT01642914,False,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Matching placebo,[],"September 30, 2013",18,9223372036854775807,Both,True
NCT01070836,Biogen,False,AZ,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT00999518,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00999518,False,A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome,"Cystitis, Interstitial",Biological:Tanezumab; Biological:Tanezumab; Biological:Tanezumab; Biological:Tanezumab; Other:Placebo,[],"August 23, 2012",18,9223372036854775807,Both,False
NCT00808132,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00808132,False,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Menopause; Osteoporosis,Drug:bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; Drug:bazedoxifene 20 mg/ conjugated estrogens 0.625 mg; Drug:bazedoxifene 20 mg; Drug:conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg; Drug:Placebo,[],"March 10, 2014",40,64,Female,False
NCT00661635,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00661635,False,"A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain",Laparoscopic Cholecystectomy; Pain,Drug:placebo; Drug:valdecoxib; Drug:valdecoxib,[],"April 21, 2008",18,75,Both,False
NCT00658515,Hoffmann-La Roche,False,AZ,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00649389,Daiichi Sankyo Inc.,False,AZ,https://ClinicalTrials.gov/show/NCT00649389,False,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Hypertension,Drug:Olmesartan medoxomil; Drug:Amlodipine; Drug:Hydrochlorothiazide,[],"August 31, 2010",18,80,Both,False
NCT01543178,"Valeant Pharmaceuticals International, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT01543178,False,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01510158,"Ardea Biosciences, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT01510158,False,Combining Lesinurad With Allopurinol in Inadequate Responders,Gout,Drug:Lesinurad; Drug:Lesinurad; Drug:Placebo; Drug:Allopurinol,[],"May 18, 2015",18,85,Both,False
NCT01415505,Forest Laboratories,False,AZ,https://ClinicalTrials.gov/show/NCT01415505,False,Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension,Hypertension,"Drug:Nebivolol, Valsartan and Hydrochlorothiazide",[],"May 31, 2013",18,9223372036854775807,Both,False
NCT01313676,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01227564,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT01227564,False,Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease,Alzheimer's Disease,Biological:ACC-001 3 g/ QS-21 50 g; Biological:ACC-001 10 g/ QS-21 50 g; Other:Placebo- Phosphate buffered saline (PBS),[],"June 13, 2014",50,80,Both,False
NCT01089790,Forest Laboratories,False,AZ,https://ClinicalTrials.gov/show/NCT01089790,False,Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone,"Diabetes Mellitus, Type 2",Drug:Dutogliptin; Drug:Sitagliptin,[],"September 14, 2011",18,86,Both,False
NCT01073878,"Athena Feminine Technologies, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT01073878,False,Athena Pelvic Muscle Trainer - DUETS Trial,Urinary Incontinence,Device:Athena Pelvic Muscle Trainer,[],"July 13, 2011",30,70,Female,False
NCT00948818,Forest Laboratories,False,AZ,https://ClinicalTrials.gov/show/NCT00948818,False,Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation,Irritable Bowel Syndrome Characterized by Constipation,Drug:Linaclotide 290 micrograms; Drug:Matching placebo,[],"December 19, 2012",18,9223372036854775807,Both,False
NCT00878709,"Puma Biotechnology, Inc.",False,AZ,https://ClinicalTrials.gov/show/NCT00878709,False,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],"August 20, 2015",18,9223372036854775807,Female,False
NCT00876187,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00876187,False,A Study of Tanezumab in Adults With Chronic Low Back Pain,Low Back Pain,Biological:Tanezumab 20 mg IV; Drug:Placebo for naproxen; Biological:Tanezumab 10 mg IV; Drug:Placebo for naproxen; Biological:Tanezumab 5 mg IV; Drug:Placebo for naproxen; Biological:Placebo for tanezumab; Drug:Naproxen; Biological:Placebo for tanezumab; Drug:Placebo for naproxen,[],"July 19, 2011",18,9223372036854775807,Both,False
NCT00849056,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT00849056,False,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00838903,GlaxoSmithKline,False,AZ,https://ClinicalTrials.gov/show/NCT00838903,False,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],"August 11, 2014",18,9223372036854775807,Both,False
NCT00830063,Pfizer,False,AZ,https://ClinicalTrials.gov/show/NCT00830063,False,Tanezumab In Osteoarthritis Of The Knee (2),Arthritis; Osteoarthritis,Biological:tanezumab 10 mg; Biological:tanezumab 5 mg; Drug:naproxen; Other:placebo,[],"June 7, 2011",18,9223372036854775807,Both,False
NCT00821977,Novartis,False,AZ,https://ClinicalTrials.gov/show/NCT00821977,False,Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:Vildagliptin; Drug:Vildagliptin; Drug:Placebo,[],"January 2, 2013",18,9223372036854775807,Both,False
NCT00804141,"Valeant Pharmaceuticals International, Inc.",True,AZ,https://ClinicalTrials.gov/show/NCT00804141,False,Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation,Constipation,Drug:N-methylnaltrexone bromide (MOA-728),[],"August 29, 2014",18,9223372036854775807,Both,False
NCT00765999,Forest Laboratories,False,AZ,https://ClinicalTrials.gov/show/NCT00765999,False,"An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",Chronic Constipation; Irritable Bowel Syndrome With Constipation,Drug:Linaclotide 300 micrograms,[],"January 11, 2013",18,9223372036854775807,Both,False
NCT00616772,"AbbVie (prior sponsor, Abbott)",False,AZ,https://ClinicalTrials.gov/show/NCT00616772,False,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia,Drug:ABT-335; Drug:Placebo; Other:Atorvastatin,[],"December 3, 2013",45,9223372036854775807,Both,False
NCT00467259,Warner Chilcott,False,AZ,https://ClinicalTrials.gov/show/NCT00467259,False,Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women,Hypoactive Sexual Desire Disorder,Drug:Testosterone Transdermal System; Drug:Placebo patch,[],"November 10, 2011",45,70,Female,False
NCT00430248,Takeda,True,AZ,https://ClinicalTrials.gov/show/NCT00430248,False,Efficacy and Safety of Oral Febuxostat in Participants With Gout,Gout,Drug:Febuxostat; Drug:Febuxostat; Drug:Allopurinol,[],"January 31, 2012",18,85,Both,False
NCT00079274,National Cancer Institute (NCI),False,AZ,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,AR,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT02604836,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT02604836,False,A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia,Postmenopausal Osteoporosis,Drug:Ibandronate,[],"February 1, 2016",0,9223372036854775807,Female,False
NCT00262600,Boehringer Ingelheim,False,AR,https://ClinicalTrials.gov/show/NCT00262600,False,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],"November 5, 2014",18,9223372036854775807,Both,False
NCT01543178,"Valeant Pharmaceuticals International, Inc.",False,AR,https://ClinicalTrials.gov/show/NCT01543178,False,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT00849056,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT00849056,False,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00838916,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT00838916,False,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:insulin glargine,[],"May 22, 2014",18,9223372036854775807,Both,False
NCT00806195,Novartis,False,AR,https://ClinicalTrials.gov/show/NCT00806195,False,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis; Meningococcal Infection,"Biological:MenACWY-CRM197; Biological:DTaP (Diptheria, Tetanus, Pertussis) Vaccine; Biological:Hib (Haemophilus influenza b) Vaccine; Biological:IPV (Inactivated Polio Vaccine) Vaccine; Biological:Pneumococcal conjugate Vaccine; Biological:MMR (Measles, Mumps, and Rubella) Vaccine; Biological:Varicella Vaccine; Biological:Hepatitis A Virus",[],"May 13, 2013",55,89,Both,True
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT00444457,False,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,"Vaccines, Pneumococcal",Biological:13-valent Pneumococcal Conjugate Vaccine; Biological:7vPnC,[],"October 10, 2012",42,98,Both,True
NCT00345579,GlaxoSmithKline,True,AR,https://ClinicalTrials.gov/show/NCT00345579,False,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age",Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine; Haemophilus Influenza Infections,Biological:GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014; Biological:ActHIB; Biological:Pediarix/Infanrix Penta,[],"February 7, 2013",6,12,Both,True
NCT00324805,National Cancer Institute (NCI),False,AR,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,AR,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00080340,Telik,False,AR,https://ClinicalTrials.gov/show/NCT00080340,False,Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Non Small Cell Lung Carcinoma,Drug:TLK286 (Telcyta) HCl for Injection; Drug:gefitinib (Iressa),[],"January 10, 2008",18,9223372036854775807,Both,False
NCT01499095,Sanofi,True,AR,https://ClinicalTrials.gov/show/NCT01499095,False,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy,Type 2 Diabetes Mellitus,Drug:Lantus (Insulin glargine); Drug:HOE901-U300 (new formulation of insulin glargine),[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01302067,Pfizer,False,AR,https://ClinicalTrials.gov/show/NCT01302067,False,A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine,Overactive Bladder,Drug:Fesoterodine 8mg; Drug:Fesoterodine 4mg; Drug:Placebo,[],"February 25, 2014",18,9223372036854775807,Both,False
NCT01091246,MedImmune LLC,False,AR,https://ClinicalTrials.gov/show/NCT01091246,False,A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children,Healthy or Stable Chronic Illness,Biological:Q/LAIV (MEDI3250); Biological:FluMist/B/Yamagata; Biological:FluMist/B/Victoria,[],"September 22, 2011",2,17,Both,True
NCT00853658,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT00853658,False,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure,Chronic Heart Failure,Drug:Enalapril monotherapy; Drug:Aliskiren monotherapy; Drug:Aliskiren / Enalapril combination therapy,[],"June 23, 2014",18,9223372036854775807,Both,False
NCT00849017,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT00849017,False,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Biological:albiglutide uptitration; Biological:placebo,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00839527,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT00839527,False,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00838903,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT00838903,False,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],"August 11, 2014",18,9223372036854775807,Both,False
NCT00764790,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT00764790,False,Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children,Influenza,Biological:Fluarix; Biological:Fluzone,[],"October 11, 2012",6,35,Both,True
NCT00658515,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00649389,Daiichi Sankyo Inc.,False,AR,https://ClinicalTrials.gov/show/NCT00649389,False,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Hypertension,Drug:Olmesartan medoxomil; Drug:Amlodipine; Drug:Hydrochlorothiazide,[],"August 31, 2010",18,80,Both,False
NCT00639418,MedImmune LLC,True,AR,https://ClinicalTrials.gov/show/NCT00639418,False,A Study to Describe Pediatric Influenza Vaccine Coverage,Healthy,Biological:Influenza vaccination,[],"September 12, 2014",6,9223372036854775807,Both,True
NCT00518115,GlaxoSmithKline,True,AR,https://ClinicalTrials.gov/show/NCT00518115,False,Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only,"Diabetes Mellitus, Type 2",Drug:Albiglutide (GSK716155) or exenatide,[],"June 19, 2014",18,75,Both,False
NCT00503698,Novo Nordisk A/S,False,AR,https://ClinicalTrials.gov/show/NCT00503698,False,The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis,Chronic Kidney Disease; End-Stage Renal Disease,Drug:somatropin; Drug:placebo,[],"October 28, 2014",18,9223372036854775807,Both,False
NCT00334607,GlaxoSmithKline,True,AR,https://ClinicalTrials.gov/show/NCT00334607,False,Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA,Rotavirus Gastroenteritis,Biological:2-dose oral live attenuated G1P[8] human rotavirus vaccine,[],"February 2, 2012",6,16,Both,True
NCT00240370,Bristol-Myers Squibb,False,AR,https://ClinicalTrials.gov/show/NCT00240370,False,A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics,Type 2 Diabetes,Drug:Muraglitazar,[],"September 10, 2010",18,70,Both,False
NCT00143520,Daiichi Sankyo Inc.,False,AR,https://ClinicalTrials.gov/show/NCT00143520,False,Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes,Type 2 Diabetes,Drug:Rivoglitazone; Drug:Pioglitazone; Drug:Placebo,[],"April 8, 2011",18,75,Both,False
NCT00111020,Bayer,False,AR,https://ClinicalTrials.gov/show/NCT00111020,False,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell","Drug:Sorafenib (Nexavar, BAY43-9006)",[],"August 5, 2014",15,9223372036854775807,Both,False
NCT00102973,Telik,False,AR,https://ClinicalTrials.gov/show/NCT00102973,False,TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer,Ovarian Neoplasms,Drug:TLK286 in Combination with Carboplatin; Drug:Doxorubicin HCl Liposome Injection,[],"May 30, 2012",18,9223372036854775807,Female,False
NCT01855789,Hoffmann-La Roche,False,AR,https://ClinicalTrials.gov/show/NCT01855789,False,A Study on the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous RoActemra/Actemra (Tocilizumab) With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:methotrexate; Drug:placebo; Drug:tocilizumab [RoActemra/Actemra],[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01508026,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01499082,Sanofi,True,AR,https://ClinicalTrials.gov/show/NCT01499082,False,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin,Type 2 Diabetes Mellitus,Drug:HOE901-U300 (new formulation of insulin glargine); Drug:Lantus (insulin glargine),[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01462344,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT01462344,False,6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg,[],"October 1, 2015",4,11,Both,False
NCT01372423,"Anchen Pharmaceuticals, Inc",False,AR,https://ClinicalTrials.gov/show/NCT01372423,False,Evaluation of Clinical Equivalence Between Two Lubiprostone Products,Chronic Idiopathic Constipation,Drug:Lubiprostone; Drug:Placebo,[],"July 10, 2012",18,9223372036854775807,Both,False
NCT01336205,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT01336205,False,Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Drug:NKTR-118; Drug:Usual care,[],"October 13, 2014",18,84,Both,False
NCT01327846,Novartis Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT01327846,False,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],"May 19, 2015",18,9223372036854775807,Both,False
NCT01323790,AstraZeneca,False,AR,https://ClinicalTrials.gov/show/NCT01323790,False,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Drug:NKTR-118; Drug:NKTR-118; Drug:Placebo,[],"June 1, 2015",18,84,Both,False
NCT01224795,BioCryst Pharmaceuticals,False,AR,https://ClinicalTrials.gov/show/NCT01224795,False,A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.,Influenza,Drug:Peramivir; Drug:Placebo Comparator,[],"December 15, 2014",12,9223372036854775807,Both,False
NCT01179477,St. Jude Medical,False,AR,https://ClinicalTrials.gov/show/NCT01179477,False,QuickFlex Micro Post Approval Study,Heart Failure,Device:Implantation of a QuickFlex  Model 1258T LV Lead,[],"December 9, 2014",18,9223372036854775807,Both,False
NCT01147250,Sanofi,False,AR,https://ClinicalTrials.gov/show/NCT01147250,False,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),Acute Coronary Syndrome,Drug:lixisenatide (AVE0010); Drug:placebo,[],"November 12, 2015",30,9223372036854775807,Both,False
NCT01130272,"Furiex Pharmaceuticals, Inc",False,AR,https://ClinicalTrials.gov/show/NCT01130272,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"June 11, 2012",18,65,Both,False
NCT01104792,Forest Laboratories,False,AR,https://ClinicalTrials.gov/show/NCT01104792,False,Long-term Study of Cariprazine in Patients With Schizophrenia,Schizophrenia,Drug:Cariprazine,[],"March 28, 2014",18,60,Both,False
NCT01000974,GlaxoSmithKline,False,AR,https://ClinicalTrials.gov/show/NCT01000974,False,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Haemophilus Influenzae Type b,Biological:GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108); Biological:ActHIB; Biological:Pentacel; Biological:Pediarix; Biological:Prevnar 13; Biological:Rotarix; Biological:Engerix-B; Biological:Infanrix,[],"October 30, 2014",6,12,Both,True
NCT00968708,Takeda,False,AR,https://ClinicalTrials.gov/show/NCT00968708,False,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"Diabetes Mellitus, Type 2; Acute Coronary Syndrome",Drug:Alogliptin; Drug:Placebo,[],"April 15, 2014",18,9223372036854775807,Both,False
NCT00959049,CSL Limited,False,AR,https://ClinicalTrials.gov/show/NCT00959049,False,A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population,Influenza,Biological:CSL's Influenza Virus Vaccine (Afluria); Biological:Influenza Virus Vaccine (Fluzone),"[u'', u'', u'', u'', u'', u'', u'', u'', u'', u'', u""Cincinnati Children's Hospital Medical Center- Division of Infectious Disease"", u'', u'UPMC / Community Medicine Inc', u'Pediatric Associates of Latrobe', u'Pediatric Alliance Greentree Division', u'South Hills Pediatrics', u'', u'', u'', u'', u'', u'', u'']","July 14, 2015",6,17,Both,True
NCT02649478,Roxane Laboratories,False,CA,https://ClinicalTrials.gov/show/NCT02649478,False,Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate,Asthma,Drug:Fluticasone / Salmeterol; Drug:Placebo; Drug:Advair Diskus 100/50,[],"January 13, 2016",12,9223372036854775807,Both,False
NCT02500797,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02467816,"University of California, Berkeley",False,CA,https://ClinicalTrials.gov/show/NCT02467816,False,Technology and Design Innovation for School Lunch,Childhood Obesity,Behavioral:SmartMeal application; Behavioral:Distributed points of sale; Behavioral:Staff wellness curriculum,"[u""John O'Connell High School"", u'AP Giannini Middle School', u'Aptos Middle School', u'Balboa High School', u'Burton High School', u'Everett Middle School', u'Francisco Middle School', u'Galileo High School', u'Herbert Hoover Middle School', u'James Denman Middle School', u'James Lick Middle School', u'Washington High School', u'June Jordan High School', u'Lincoln High School', u'Lowell High School', u'Marina Middle School', u'Marshall High School', u'Martin Luther King Middle School', u'Mission High School', u'Presidio Middle School', u'Roosevelt Middle School', u'Visitacion Valley Middle School', u'Wallenberg High School', u'Academy High School and Ruth Asawa School of the Arts']","June 8, 2015",0,9223372036854775807,Both,True
NCT02465060,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02257528,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02257528,False,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02245672,Mylan Inc.,False,CA,https://ClinicalTrials.gov/show/NCT02245672,False,MGR001 / Advair Diskus Local Equivalence Study in Asthma,Asthma,Drug:MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate); Drug:Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate); Drug:Placebo,[],"October 14, 2015",18,9223372036854775807,Both,False
NCT02224781,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02224781,False,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02196181,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02139046,Takeda,False,CA,https://ClinicalTrials.gov/show/NCT02139046,False,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Drug:Febuxostat IR; Drug:Febuxostat XR; Drug:Febuxostat placebo; Drug:Colchicine; Drug:Naproxen; Drug:Lansoprazole,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02122471,Synergy Pharmaceuticals Inc.,False,CA,https://ClinicalTrials.gov/show/NCT02122471,False,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 29, 2015",18,80,Both,False
NCT02117479,Incyte Corporation,False,CA,https://ClinicalTrials.gov/show/NCT02117479,False,Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),Metastatic Pancreatic Adenocarcinoma,Drug:Ruxolitinib; Drug:Placebo; Drug:Capecitabine,[],"January 13, 2016",18,9223372036854775807,Both,False
NCT02058147,Sanofi,False,CA,https://ClinicalTrials.gov/show/NCT02058147,False,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,Type 2 Diabetes,Drug:Insulin glargine/lixisenatide HOE901/AVE0010; Drug:Insulin glargine HOE901; Drug:Lixisenatide AVE0010; Drug:Metformin,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02042443,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT02008344,"MDVI, LLC",False,CA,https://ClinicalTrials.gov/show/NCT02008344,False,Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults,Influenza,Drug:favipiravir; Drug:placebo,[],"October 20, 2015",18,80,Both,False
NCT02008227,Hoffmann-La Roche,False,CA,https://ClinicalTrials.gov/show/NCT02008227,False,"A Randomized Phase 3 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - ""OAK""",Non-Squamous Non-Small Cell Lung Cancer,Drug:Atezolizumab; Drug:docetaxel,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01982240,Synergy Pharmaceuticals Inc.,False,CA,https://ClinicalTrials.gov/show/NCT01982240,False,12-Week Study of Plecanatide for CIC (The CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],"February 17, 2015",18,80,Both,False
NCT01959529,Novo Nordisk A/S,False,CA,https://ClinicalTrials.gov/show/NCT01959529,False,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],"January 8, 2016",50,9223372036854775807,Both,False
NCT01942135,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01942135,False,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Drug:Palbociclib; Drug:Fulvestrant; Drug:Placebo; Drug:Fulvestrant,[],"November 16, 2015",18,9223372036854775807,Female,False
NCT01937715,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01937715,False,A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,Metastatic Colorectal Carcinoma,Drug:PF-05212384; Drug:FOLFIRI regimen; Biological:Bevacizumab; Drug:FOLFIRI,[],"December 15, 2015",18,9223372036854775807,Both,False
NCT01900665,Eli Lilly and Company,False,CA,https://ClinicalTrials.gov/show/NCT01900665,False,Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo,Alzheimer's Disease,Drug:Solanezumab; Drug:Placebo,[],"April 29, 2015",55,90,Both,False
NCT01886872,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01789957,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT01789957,False,Extension Study for 2993-112,Type 2 Diabetes Mellitus,Drug:AC2993,[],"February 23, 2015",16,75,Both,False
NCT01764633,Amgen,False,CA,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT01740427,Pfizer,False,CA,https://ClinicalTrials.gov/show/NCT01740427,False,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),Breast Neoplasms,Drug:PD-0332991; Drug:Letrozole; Drug:Placebo; Drug:Letrozole,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01732822,AstraZeneca,False,CA,https://ClinicalTrials.gov/show/NCT01732822,False,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Peripheral Artery Disease,Drug:Ticagrelor; Drug:Clopidogrel,[],"December 21, 2015",50,130,Both,False
NCT01715818,Hoffmann-La Roche,False,CA,https://ClinicalTrials.gov/show/NCT01715818,False,A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities,"Cardiovascular Disease, Diabetes Mellitus, Type 2",Drug:Placebo; Drug:aleglitazar,[],"February 1, 2016",40,9223372036854775807,Both,False
NCT01714713,FORUM Pharmaceuticals Inc,False,CA,https://ClinicalTrials.gov/show/NCT01714713,False,A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy,Schizophrenia; Impaired Cognition,Drug:EVP-6124,[],"September 14, 2015",18,50,Both,False
NCT01696643,Cubist Pharmaceuticals LLC,False,CA,https://ClinicalTrials.gov/show/NCT01696643,False,Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation,Opioid-Induced Constipation,Drug:CB-5945; Drug:Placebo,[],"January 5, 2016",18,80,Both,False
NCT01693029,Sandoz,False,CA,https://ClinicalTrials.gov/show/NCT01693029,False,Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa,Anemia; Chronic Kidney Disease (CKD),Drug:HX575 epoetin alfa; Drug:US-licensed epoetin alfa,[],"May 20, 2015",18,9223372036854775807,Both,False
NCT01688973,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01688973,False,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery,Childhood Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Tivantinib,[],"January 11, 2016",0,9223372036854775807,Both,False
NCT01664923,"Medivation, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT01664923,False,Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer,Prostate Cancer,Drug:Enzalutamide; Drug:Bicalutamide,[],"May 26, 2015",18,9223372036854775807,Male,False
NCT01658943,National Cancer Institute (NCI),False,CA,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01655680,"AbbVie (prior sponsor, Abbott)",False,CA,https://ClinicalTrials.gov/show/NCT01655680,False,A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia,Schizophrenia,Drug:ABT-126; Drug:ABT-126; Drug:ABT-126; Drug:Placebo,[],"April 28, 2015",20,65,Both,False
NCT01609582,Takeda,False,CA,https://ClinicalTrials.gov/show/NCT01609582,False,Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease,Type 2 Diabetes; Cardiovascular Disease,Drug:TAK-875; Drug:TAK-875 Placebo,[],"October 15, 2015",18,9223372036854775807,Both,False
NCT01576718,Teva Pharmaceutical Industries,False,CA,https://ClinicalTrials.gov/show/NCT01576718,False,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications,Asthma,Drug:Fluticasone propionate DPI Dose 1; Drug:Fluticasone propionate DPI Dose 2; Drug:Fluticasone propionate DPI Dose 3; Drug:Fluticasone propionate DPI Dose 4; Other:Placebo DPI; Drug:Flovent Diskus 250 mcg,[],"March 19, 2015",12,9223372036854775807,Both,False
NCT01553747,"Furiex Pharmaceuticals, Inc",False,CA,https://ClinicalTrials.gov/show/NCT01553747,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Other:Placebo Comparator,[],"April 26, 2015",18,80,Both,False
NCT01553591,"Furiex Pharmaceuticals, Inc",False,CA,https://ClinicalTrials.gov/show/NCT01553591,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"April 26, 2015",18,80,Both,False
NCT01547741,NSABP Foundation Inc,False,CA,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01543178,"Valeant Pharmaceuticals International, Inc.",False,CA,https://ClinicalTrials.gov/show/NCT01543178,False,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01515800,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01515800,False,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],"October 23, 2015",18,120,Female,False
NCT01508026,Forest Laboratories,False,CA,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,CA,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01479621,Teva Pharmaceutical Industries,False,CA,https://ClinicalTrials.gov/show/NCT01479621,False,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids,Asthma,Drug:Placebo; Drug:Flovent Diskus; Drug:Fluticasone propionate DPI Dose 1; Drug:Fluticasone propionate DPI Dose 2; Drug:Fluticasone propionate DPI Dose 3; Drug:Fluticasone propionate DPI Dose 4,[],"March 19, 2015",12,9223372036854775807,Both,False
NCT02500797,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02311907,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02116530,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT02116530,False,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01708954,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01708941,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01708941,False,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01653028,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01653028,False,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01642251,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,CO,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01522976,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01522976,False,Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Adult Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts,Drug:Azacitidine; Drug:Lenalidomide; Drug:Vorinostat,[],"June 24, 2015",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01403649,"University of Colorado, Denver",False,CO,https://ClinicalTrials.gov/show/NCT01403649,False,Collaborative Efforts to Increase Flu Vaccination,Influenza; Collaboration,Behavioral:Private/public collaboration to increase flu vaccination; Other:Usual care,"[u'Tri County Health dept', u'Aurora Family Medicine', u'Forum Family Medicine', u'Premier Pediatrics', u'Indian Crest Pediatrics', u'Centennial Pediatrics', u'Advanced Pediatrics', u'Greenwood Pediatrics', u'Pediatric Pathways', u'Pediatrics 5280', u'CIIS', u'Hampden Medical Group', u'Ft. Morgan Medical Group', u'Family Practice Clinic', u'Haxtun Family Medicine', u'Valley Medical Center', u'Denver West Pediatrics', u'Kids First', u'Jefferson County Health dept', u'Focus on Kids', u'Lone Tree Family Medicine', u'Crown Point Pediatrics', u'Northeast County Health Dept', u'Mountain Land Pediatrics', u'Pediatrics West', u'Wray Clinic', u'Yuma Clinic']","May 29, 2015",6,18,Both,True
NCT01376349,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01376349,False,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],"September 24, 2015",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01256398,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01256398,False,Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Alemtuzumab; Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Procedure:Autologous Hematopoietic Stem Cell Transplantation; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dasatinib; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide Phosphate; Biological:Filgrastim; Drug:Fludarabine Phosphate; Procedure:In Vitro-Treated Peripheral Blood Stem Cell Transplantation; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Melphalan; Drug:Mercaptopurine; Drug:Methotrexate; Biological:Pegfilgrastim; Other:Pharmacological Study; Drug:Tacrolimus; Drug:Vincristine Sulfate,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01251861,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01251861,False,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Drug:Akt Inhibitor MK2206; Drug:Bicalutamide; Other:Clinical Observation; Other:Laboratory Biomarker Analysis,[],"January 18, 2016",18,9223372036854775807,Male,False
NCT01229943,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01229943,False,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01198158,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01142388,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01142388,False,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],"June 2, 2015",18,9223372036854775807,Both,False
NCT01134614,National Cancer Institute (NCI),True,CO,https://ClinicalTrials.gov/show/NCT01134614,False,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Recurrent Melanoma; Stage III Melanoma; Stage IV Melanoma,Biological:ipilimumab; Biological:sargramostim,[],"March 23, 2015",18,9223372036854775807,Both,False
NCT01099449,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01099449,False,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT01097278,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT01091454,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT01091454,False,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Triple-negative Breast Cancer,Drug:brostallicin; Drug:cisplatin,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT01084083,Eastern Cooperative Oncology Group,True,CO,https://ClinicalTrials.gov/show/NCT01084083,False,Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer,Head and Neck Cancer; Precancerous Condition,Biological:cetuximab; Radiation:intensity-modulated radiation therapy (IMRT); Drug:Paclitaxel; Drug:Cisplatin,[],"September 22, 2015",18,9223372036854775807,Both,False
NCT01081262,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01081262,False,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer,Biological:Bevacizumab; Drug:Capecitabine; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Oxaliplatin; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 12, 2016",18,9223372036854775807,Female,False
NCT01078454,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01078454,False,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],"November 20, 2014",18,9223372036854775807,Both,False
NCT01078441,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01078441,False,"Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant",Refractory Multiple Myeloma,Drug:liposomal doxorubicin; Drug:bortezomib; Drug:dexamethasone; Drug:cyclophosphamide,[],"January 5, 2015",18,9223372036854775807,Both,False
NCT01012297,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT01012297,False,Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma,Recurrent Uterine Corpus Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Biological:Bevacizumab; Drug:Docetaxel; Biological:Filgrastim; Drug:Gemcitabine Hydrochloride; Biological:Pegfilgrastim; Other:Placebo,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT01011478,NSABP Foundation Inc,True,CO,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00954174,Gynecologic Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00954174,False,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00946712,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942331,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887536,NSABP Foundation Inc,False,CO,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00880191,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT00880191,False,Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy,"Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:dexamethasone; Drug:gabapentin; Other:placebo,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00874211,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00874211,False,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],"March 4, 2015",0,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,CO,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00860041,Alliance for Clinical Trials in Oncology,True,CO,https://ClinicalTrials.gov/show/NCT00860041,False,Acute Pain Caused by Paclitaxel in Patients With Cancer,"Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Behavioral:pain questionnaires,[],"July 7, 2015",18,9223372036854775807,Both,False
NCT00822120,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00822120,False,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],"May 8, 2015",18,60,Both,False
NCT00803062,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT00803062,False,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT00789958,Southwest Oncology Group,False,CO,https://ClinicalTrials.gov/show/NCT00789958,False,"S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct",Extrahepatic Bile Duct Cancer; Gallbladder Cancer,Drug:capecitabine; Drug:gemcitabine hydrochloride; Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy,[],"February 16, 2015",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00770809,National Cancer Institute (NCI),False,CO,https://ClinicalTrials.gov/show/NCT00770809,False,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT01691430,Yale University,False,CT,https://ClinicalTrials.gov/show/NCT01691430,False,A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents,Bacteriuria,Dietary Supplement:2 cranberry capsules; Dietary Supplement:Placebo,"[u'Branford Hills Health Care', u'Northbridge Health Care Center', u'Bridgeport Health Care Center', u'Bridgeport Manor', u'Riverside Health & Rehabilitation Center', u'Ludlowe Health Care Center', u'Glastonbury Health Care Center', u'The Nathaniel Witherell', u'Hamden Health Care Center', u'Arden House Care and Rehabilitation Center', u'Avery Heights', u'Wadsworth Glen Health Care and Rehabilitation Center', u""Water's Edge Center for Health & Rehabilitation"", u'Advanced Nursing & Rehab Center of New Haven', u'Mary Wade Home', u'Grimes Center', u'Shady Knoll Health Center', u'Lord Chamberlain Nursing & Rehabilitation Center', u'Village Green of Wallingford', u'Abbott Terrace Health Center', u'Hughes Health & Rehab Center']","October 22, 2015",65,9223372036854775807,Female,True
NCT00034879,AstraZeneca,False,CT,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT00625898,NSABP Foundation Inc,False,CT,https://ClinicalTrials.gov/show/NCT00625898,False,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,Breast Cancer,Drug:Docetaxel; Drug:Trastuzumab; Drug:Carboplatin; Drug:Bevacizumab; Drug:5-Fluorouracil; Drug:Epirubicin; Drug:Cyclophosphamide,[],"July 7, 2014",18,9223372036854775807,Female,False
NCT01033383,Yale University,True,CT,https://ClinicalTrials.gov/show/NCT01033383,False,Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents,Bacteriuria,Dietary Supplement:Placebo; Dietary Supplement:Cranberry Capsule,"[u'Northbridge Health Care Center', u'Sheriden Woods Health Care Center', u'The Carolton Chronic and Convalescent Hospital', u'Glastonbury Health Care Center', u'Middlesex Health Care Center', u'Wadsworth Glen Health Care and Rehabilitation Center', u'Beacon Brook Health Care Center', u'Laurel Ridge Health Care Center', u'Shady Knoll Health Center', u'Litchfield Woods Health Care Center', u'Maefair Health Care Center', u'Masonicare Health Center', u'Abbott Terracee Health Center', u'Saint Mary Home']","July 12, 2013",65,9223372036854775807,Female,True
NCT00667810,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT00667810,False,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,Alzheimer Disease,Drug:bapineuzumab; Drug:bapineuzumab; Drug:placebo,[],"December 4, 2015",50,89,Both,False
NCT00310180,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00324805,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00003906,NSABP Foundation Inc,True,CT,https://ClinicalTrials.gov/show/NCT00003906,False,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],"October 5, 2015",35,9223372036854775807,Female,False
NCT00382070,NSABP Foundation Inc,True,CT,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00080340,Telik,False,CT,https://ClinicalTrials.gov/show/NCT00080340,False,Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Non Small Cell Lung Carcinoma,Drug:TLK286 (Telcyta) HCl for Injection; Drug:gefitinib (Iressa),[],"January 10, 2008",18,9223372036854775807,Both,False
NCT00650039,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT00650039,False,"Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction",Pain,Drug:placebo; Drug:valdecoxib; Drug:valdecoxib,[],"June 3, 2008",18,75,Both,False
NCT00346216,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,CT,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00781391,Daiichi Sankyo Inc.,False,CT,https://ClinicalTrials.gov/show/NCT00781391,False,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke; Atrial Fibrillation; Embolism,Drug:warfarin tablets; Drug:Edoxaban tablets (high dose regimen-60mg); Drug:Edoxaban tablets (low dose regimen-30mg); Drug:placebo warfarin; Drug:placebo edoxaban,[],"March 12, 2015",21,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00111020,Bayer,False,CT,https://ClinicalTrials.gov/show/NCT00111020,False,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell","Drug:Sorafenib (Nexavar, BAY43-9006)",[],"August 5, 2014",15,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT02042443,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,CT,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01070836,Biogen,False,CT,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00217737,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00160173,ASCEND Therapeutics,False,CT,https://ClinicalTrials.gov/show/NCT00160173,False,Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy,Postmenopausal Symptoms,Drug:Estradiol,[],"July 11, 2013",45,65,Female,False
NCT01366183,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT00751946,University of Connecticut Health Center,True,CT,https://ClinicalTrials.gov/show/NCT00751946,False,Girls In Recovery From Life Stress (GIRLS) Study,Posttraumatic Stress Disorder; PTSD,Behavioral:Trauma Adaptive Recovery Group Education and Therapy; Behavioral:Enhanced Treatment As Usual,"[u'Polaris School', u'University of Connecticut Health Center', u'Gray Lodge Shelter for Women', u'Weaver High School', u'Bellizzi Middle School', u'Quirk Middle School', u'UCONN Health Partners']","September 24, 2010",13,17,Female,False
NCT00676143,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT00676143,False,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,Alzheimer Disease,Drug:bapineuzumab; Drug:placebo,[],"December 20, 2012",50,88,Both,False
NCT00450970,Agennix,False,CT,https://ClinicalTrials.gov/show/NCT00450970,False,Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC),Prostate Cancer,Drug:Oral Satraplatin,[],"August 9, 2012",18,9223372036854775807,Male,False
NCT00433511,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00373685,Pfizer,False,CT,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00262847,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00262847,False,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"August 18, 2015",18,9223372036854775807,Female,False
NCT00245739,"Tibotec Pharmaceuticals, Ireland",False,CT,https://ClinicalTrials.gov/show/NCT00245739,False,"TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.",HIV Infections,Drug:TMC-114,[],"April 10, 2014",18,9223372036854775807,Both,False
NCT00003594,Alliance for Clinical Trials in Oncology,True,CT,https://ClinicalTrials.gov/show/NCT00003594,False,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug:irinotecan; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT01620528,"AbbVie (prior sponsor, Abbott)",False,CT,https://ClinicalTrials.gov/show/NCT01620528,False,A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain,Endometriosis,Drug:Elagolix; Other:placebo,[],"November 13, 2015",18,49,Female,False
NCT01217697,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",False,CT,https://ClinicalTrials.gov/show/NCT01217697,False,Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer,"Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male",Drug:Abiraterone Acetate,[],"February 3, 2016",18,99,Both,False
NCT01101438,NCIC Clinical Trials Group,True,CT,https://ClinicalTrials.gov/show/NCT01101438,False,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],"May 5, 2015",18,74,Both,False
NCT01011478,NSABP Foundation Inc,True,CT,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00954174,Gynecologic Oncology Group,False,CT,https://ClinicalTrials.gov/show/NCT00954174,False,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00951496,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00937352,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT00937352,False,A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease,Alzheimer's Disease,Drug:Bapineuzumab,[],"November 26, 2013",51,9223372036854775807,Both,False
NCT00601900,National Cancer Institute (NCI),False,CT,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00575055,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT00575055,False,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),Alzheimer's Disease,Drug:Bapineuzumab 0.5 mg/kg; Drug:Placebo Control; Drug:Bapineuzumab 1.0 m/kg,[],"October 30, 2013",50,88,Both,False
NCT00574132,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",False,CT,https://ClinicalTrials.gov/show/NCT00574132,False,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),Alzheimer's Disease,Drug:Bapineuzumab 0.5 mg/kg; Drug:Placebo Control; Drug:Bapineuzumab 1.0 m/kg,[],"October 30, 2013",50,88,Both,False
NCT00454701,Astellas Pharma Inc,False,CT,https://ClinicalTrials.gov/show/NCT00454701,False,Assessment and Tracking of Long-term Alefacept Safety,Psoriasis,Drug:Alefacept exposure,[],"December 10, 2013",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00946712,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00588770,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02257528,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02257528,False,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02116530,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT02116530,False,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT02066181,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02066181,False,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01708954,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01708941,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01708941,False,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01648348,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01256398,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01256398,False,Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Alemtuzumab; Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Procedure:Autologous Hematopoietic Stem Cell Transplantation; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dasatinib; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide Phosphate; Biological:Filgrastim; Drug:Fludarabine Phosphate; Procedure:In Vitro-Treated Peripheral Blood Stem Cell Transplantation; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Melphalan; Drug:Mercaptopurine; Drug:Methotrexate; Biological:Pegfilgrastim; Other:Pharmacological Study; Drug:Tacrolimus; Drug:Vincristine Sulfate,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01366183,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT00956670,Gynecologic Oncology Group,False,DE,https://ClinicalTrials.gov/show/NCT00956670,False,"Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer",Lymphedema; Stage IA Cervical Cancer; Stage IA Uterine Corpus Cancer; Stage IA Vulvar Cancer; Stage IB Cervical Cancer; Stage IB Uterine Corpus Cancer; Stage IB Vulvar Cancer; Stage II Uterine Corpus Cancer; Stage II Vulvar Cancer; Stage IIA Cervical Cancer; Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVB Vulvar Cancer,Procedure:Therapeutic Lymphadenectomy; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Laparoscopic Surgery; Procedure:Study of High Risk Factors; Other:Questionnaire Administration; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01196390,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,DE,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT02224781,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02224781,False,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00640042,Pfizer,True,DE,https://ClinicalTrials.gov/show/NCT00640042,False,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],"June 6, 2012",21,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,DE,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01004640,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT01004640,False,Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial,Leukemia,Genetic:DNA analysis; Genetic:Southern blotting; Genetic:cytogenetic analysis; Genetic:polymerase chain reaction,[],"July 23, 2015",0,9223372036854775807,Both,False
NCT00072046,Alliance for Clinical Trials in Oncology,True,DE,https://ClinicalTrials.gov/show/NCT00072046,False,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00022087,Alliance for Clinical Trials in Oncology,True,DE,https://ClinicalTrials.gov/show/NCT00022087,False,"Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer",Breast Cancer; Osteoporosis,Dietary Supplement:calcium salts; Dietary Supplement:cholecalciferol; Drug:zoledronic acid,[],"September 26, 2013",40,9223372036854775807,Female,False
NCT02498600,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT02498600,False,"Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"January 11, 2016",18,9223372036854775807,Female,False
NCT01764633,Amgen,False,DE,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT01730534,AstraZeneca,False,DE,https://ClinicalTrials.gov/show/NCT01730534,False,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,"Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event",Drug:Dapagliflozin 10 mg; Drug:Placebo tablet,[],"December 10, 2015",40,130,Both,False
NCT01011478,NSABP Foundation Inc,True,DE,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00892177,Alliance for Clinical Trials in Oncology,False,DE,https://ClinicalTrials.gov/show/NCT00892177,False,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00805740,Pfizer,False,DE,https://ClinicalTrials.gov/show/NCT00805740,False,An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida,Candidiasis; Fungemia,Drug:Active anidulafungin; Drug:Active Caspofungin,"[u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site']","May 30, 2013",16,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00693992,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00496197,Pfizer,False,DE,https://ClinicalTrials.gov/show/NCT00496197,False,Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis,Candidiasis,Drug:Eraxis (anidulafungin); Drug:Diflucan (fluconazole); Drug:Vfend (voriconazole),[],"August 29, 2011",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00373685,Pfizer,False,DE,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00267748,Pfizer,False,DE,https://ClinicalTrials.gov/show/NCT00267748,False,Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC),"Carcinoma, Renal Cell",Drug:Sunitinib Malate Continuous Daily Dosing; Drug:Sunitinib Malate Schedule 4/2,[],"August 3, 2011",18,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,DE,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00262847,National Cancer Institute (NCI),False,DE,https://ClinicalTrials.gov/show/NCT00262847,False,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"August 18, 2015",18,9223372036854775807,Female,False
NCT00243503,Pfizer,False,DE,https://ClinicalTrials.gov/show/NCT00243503,False,Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer,Breast Neoplasms,Drug:SU011248/Trastuzumab,[],"July 20, 2011",18,9223372036854775807,Both,False
NCT02245568,TauRx Therapeutics Ltd,False,FL,https://ClinicalTrials.gov/show/NCT02245568,False,Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD),Alzheimer's Disease; Behavioral Variant Frontotemporal Dementia,Drug:TRx0237,[],"September 17, 2014",0,9223372036854775807,Both,False
NCT02139046,Takeda,False,FL,https://ClinicalTrials.gov/show/NCT02139046,False,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Drug:Febuxostat IR; Drug:Febuxostat XR; Drug:Febuxostat placebo; Drug:Colchicine; Drug:Naproxen; Drug:Lansoprazole,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT02122471,Synergy Pharmaceuticals Inc.,False,FL,https://ClinicalTrials.gov/show/NCT02122471,False,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 29, 2015",18,80,Both,False
NCT02030600,Novo Nordisk A/S,False,FL,https://ClinicalTrials.gov/show/NCT02030600,False,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes","Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT02008344,"MDVI, LLC",False,FL,https://ClinicalTrials.gov/show/NCT02008344,False,Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults,Influenza,Drug:favipiravir; Drug:placebo,[],"October 20, 2015",18,80,Both,False
NCT02004522,"Infinity Pharmaceuticals, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT02004522,False,A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO),Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Drug:IPI-145 (duvelisib); Drug:Ofatumumab,[],"November 17, 2015",18,9223372036854775807,Both,False
NCT01982240,Synergy Pharmaceuticals Inc.,False,FL,https://ClinicalTrials.gov/show/NCT01982240,False,12-Week Study of Plecanatide for CIC (The CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],"February 17, 2015",18,80,Both,False
NCT01959529,Novo Nordisk A/S,False,FL,https://ClinicalTrials.gov/show/NCT01959529,False,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],"January 8, 2016",50,9223372036854775807,Both,False
NCT01789957,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01789957,False,Extension Study for 2993-112,Type 2 Diabetes Mellitus,Drug:AC2993,[],"February 23, 2015",16,75,Both,False
NCT01764633,Amgen,False,FL,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT01732822,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01732822,False,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Peripheral Artery Disease,Drug:Ticagrelor; Drug:Clopidogrel,[],"December 21, 2015",50,130,Both,False
NCT01730534,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01730534,False,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,"Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event",Drug:Dapagliflozin 10 mg; Drug:Placebo tablet,[],"December 10, 2015",40,130,Both,False
NCT01715818,Hoffmann-La Roche,False,FL,https://ClinicalTrials.gov/show/NCT01715818,False,A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities,"Cardiovascular Disease, Diabetes Mellitus, Type 2",Drug:Placebo; Drug:aleglitazar,[],"February 1, 2016",40,9223372036854775807,Both,False
NCT01696643,Cubist Pharmaceuticals LLC,False,FL,https://ClinicalTrials.gov/show/NCT01696643,False,Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation,Opioid-Induced Constipation,Drug:CB-5945; Drug:Placebo,[],"January 5, 2016",18,80,Both,False
NCT01687998,Eli Lilly and Company,False,FL,https://ClinicalTrials.gov/show/NCT01687998,False,A Study of Evacetrapib in High-Risk Vascular Disease,Cardiovascular Diseases,Drug:Evacetrapib; Drug:Placebo,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01676220,Sanofi,True,FL,https://ClinicalTrials.gov/show/NCT01676220,False,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy,Type 2 Diabetes Mellitus,Drug:HOE901-U300 (new formulation of insulin glargine); Drug:Lantus (insulin glargine),[],"May 28, 2015",18,9223372036854775807,Both,False
NCT01674530,Dr. Reddy's Laboratories Limited,False,FL,https://ClinicalTrials.gov/show/NCT01674530,False,Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation,Chronic Idiopathic Constipation,Drug:Lubiprostone; Drug:Lubiprostone; Drug:Placebo,[],"April 2, 2014",18,9223372036854775807,Both,False
NCT01642914,Forest Laboratories,False,FL,https://ClinicalTrials.gov/show/NCT01642914,False,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Matching placebo,[],"September 30, 2013",18,9223372036854775807,Both,True
NCT01626742,Abbott Nutrition,False,FL,https://ClinicalTrials.gov/show/NCT01626742,False,A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study,Hospitalized Elderly,Other:Ready to Drink Flavored Beverage; Other:Ready to drink flavored beverage w/ AN 777,[],"April 24, 2015",65,9223372036854775807,Both,False
NCT01620255,Pfizer,False,FL,https://ClinicalTrials.gov/show/NCT01620255,False,A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis,Ulcerative Colitis,Drug:PF-00547659 SC Injection; Drug:PF-00547659 SC Injection; Drug:PF-00547659 SC Injection; Drug:PF-00547659 SC Injection; Drug:PF-00547659 SC Injection,[],"November 5, 2015",18,65,Both,False
NCT01609582,Takeda,False,FL,https://ClinicalTrials.gov/show/NCT01609582,False,Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease,Type 2 Diabetes; Cardiovascular Disease,Drug:TAK-875; Drug:TAK-875 Placebo,[],"October 15, 2015",18,9223372036854775807,Both,False
NCT01601704,Takeda,False,FL,https://ClinicalTrials.gov/show/NCT01601704,False,Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study),Obesity; Overweight,Drug:NB32; Drug:PBO; Behavioral:Weight Management Program,[],"February 26, 2015",45,9223372036854775807,Both,False
NCT01576718,Teva Pharmaceutical Industries,False,FL,https://ClinicalTrials.gov/show/NCT01576718,False,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications,Asthma,Drug:Fluticasone propionate DPI Dose 1; Drug:Fluticasone propionate DPI Dose 2; Drug:Fluticasone propionate DPI Dose 3; Drug:Fluticasone propionate DPI Dose 4; Other:Placebo DPI; Drug:Flovent Diskus 250 mcg,[],"March 19, 2015",12,9223372036854775807,Both,False
NCT01572792,Forest Laboratories,False,FL,https://ClinicalTrials.gov/show/NCT01572792,False,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:Placebo,[],"February 27, 2015",40,9223372036854775807,Both,False
NCT01553747,"Furiex Pharmaceuticals, Inc",False,FL,https://ClinicalTrials.gov/show/NCT01553747,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Other:Placebo Comparator,[],"April 26, 2015",18,80,Both,False
NCT01553591,"Furiex Pharmaceuticals, Inc",False,FL,https://ClinicalTrials.gov/show/NCT01553591,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"April 26, 2015",18,80,Both,False
NCT01543178,"Valeant Pharmaceuticals International, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT01543178,False,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01508026,Forest Laboratories,False,FL,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01507831,Sanofi,True,FL,https://ClinicalTrials.gov/show/NCT01507831,False,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),Hypercholesterolemia,Drug:Placebo (for alirocumab); Drug:Alirocumab; Drug:Lipid-Modifying Therapy (LMT),[],"November 18, 2015",18,9223372036854775807,Both,False
NCT01475721,GlaxoSmithKline,False,FL,https://ClinicalTrials.gov/show/NCT01475721,False,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],"December 10, 2015",12,9223372036854775807,Both,False
NCT01462344,GlaxoSmithKline,False,FL,https://ClinicalTrials.gov/show/NCT01462344,False,6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg,[],"October 1, 2015",4,11,Both,False
NCT01455857,Intarcia Therapeutics,False,FL,https://ClinicalTrials.gov/show/NCT01455857,False,A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes,Type 2 Diabetes,Drug:ITCA 650; Other:ITCA placebo,[],"July 28, 2015",18,80,Both,False
NCT01452529,Purdue Pharma LP,True,FL,https://ClinicalTrials.gov/show/NCT01452529,False,Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain,Chronic Low Back Pain,Drug:Hydrocodone bitartrate q24h film-coated tablets; Drug:Placebo to match hydrocodone bitartrate q24h tablets,[],"August 27, 2015",18,9223372036854775807,Both,False
NCT01444430,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01444430,False,A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents,Asthma,Drug:Symbicort pMDI; Drug:Symbicort pMDI; Drug:budesonide pMDI; Drug:budesonide pMDI,[],"November 12, 2015",12,130,Both,False
NCT01437397,Forest Laboratories,False,FL,https://ClinicalTrials.gov/show/NCT01437397,False,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:placebo,[],"April 5, 2013",40,9223372036854775807,Both,False
NCT01436175,Shire,False,FL,https://ClinicalTrials.gov/show/NCT01436175,False,SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study,Major Depressive Disorder,Drug:SPD489 (Lisdexamfetamine dimesylate) + Antidepressant,[],"February 5, 2015",18,65,Both,False
NCT01432444,"Otsuka Pharmaceutical Development & Commercialization, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT01432444,False,Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole,Schizophrenia,Drug:Aripiprazole (Abilify) IM Depot Injection,[],"April 20, 2015",18,65,Both,False
NCT01427283,Purdue Pharma LP,False,FL,https://ClinicalTrials.gov/show/NCT01427283,False,A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain,Low Back Pain,Drug:Oxycodone/Naloxone controlled-release; Drug:Oxycodone HCl controlled-release; Drug:Placebo,[],"February 11, 2015",18,9223372036854775807,Both,False
NCT01427270,Purdue Pharma LP,False,FL,https://ClinicalTrials.gov/show/NCT01427270,False,Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain,Low Back Pain,Drug:Oxycodone/Naloxone controlled-release; Drug:Oxycodone HCl controlled-release; Drug:Placebo,[],"November 6, 2014",18,9223372036854775807,Both,False
NCT01415505,Forest Laboratories,False,FL,https://ClinicalTrials.gov/show/NCT01415505,False,Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension,Hypertension,"Drug:Nebivolol, Valsartan and Hydrochlorothiazide",[],"May 31, 2013",18,9223372036854775807,Both,False
NCT01395524,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01395524,False,A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Drug:NKTR-118; Drug:NKTR-118; Drug:Placebo,[],"June 15, 2015",18,84,Both,False
NCT01391325,"Ardea Biosciences, Inc.",False,FL,https://ClinicalTrials.gov/show/NCT01391325,False,Allopurinol Outcome Study,Gout,Drug:Allopurinol,[],"May 16, 2014",18,85,Both,False
NCT01358526,Purdue Pharma LP,False,FL,https://ClinicalTrials.gov/show/NCT01358526,False,Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain,Low Back Pain,Drug:Oxycodone/Naloxone Controlled-release; Drug:Placebo,[],"October 14, 2015",18,9223372036854775807,Both,False
NCT01349322,Radiation Therapy Oncology Group,False,FL,https://ClinicalTrials.gov/show/NCT01349322,False,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01336205,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01336205,False,Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Drug:NKTR-118; Drug:Usual care,[],"October 13, 2014",18,84,Both,False
NCT01327846,Novartis Pharmaceuticals,False,FL,https://ClinicalTrials.gov/show/NCT01327846,False,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],"May 19, 2015",18,9223372036854775807,Both,False
NCT01313676,GlaxoSmithKline,False,FL,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01309841,AstraZeneca,False,FL,https://ClinicalTrials.gov/show/NCT01309841,False,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Opioid-Induced Constipation (OIC),Drug:NKTR-118; Drug:NKTR-118; Drug:Placebo,[],"May 29, 2015",18,84,Both,False
NCT01306890,Dendreon,False,GA,https://ClinicalTrials.gov/show/NCT01306890,False,A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer,Advanced Prostate Cancer; Prostatic Neoplasms,Biological:sipuleucel-T,[],"October 5, 2015",18,9223372036854775807,Male,False
NCT01275677,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00769379,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00433511,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,GA,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00373685,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00346216,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,GA,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,GA,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00072046,Alliance for Clinical Trials in Oncology,True,GA,https://ClinicalTrials.gov/show/NCT00072046,False,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00053898,NSABP Foundation Inc,True,GA,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT01360554,Pfizer,False,GA,https://ClinicalTrials.gov/show/NCT01360554,False,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer (NSCLC),Drug:Dacomitinib (PF-00299804); Drug:Active Comparator (erlotinib); Drug:Placebo erlotinib; Drug:Placebo PF00299804,[],"January 4, 2016",18,9223372036854775807,Both,False
NCT00209092,Emory University,True,GA,https://ClinicalTrials.gov/show/NCT00209092,False,Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer,Breast Cancer,Drug:Docetaxel; Drug:Capecitabine,"[u'Grady Memorial Hospital', u'Emory Crawford Long Hospital', u'Emory University Winship Cancer Institute', u'Augusta Oncology Associates, PC 1348 Walton Way, Ste. 4300', u'Augusta Oncology Associates, PC 3696 Wheeler Road', u'WellStar Health System-Northwest Georgia Oncology Center, PC', u'WellStar Health System-Georgia Cancer Specialists', u'WellStar Health System-Northwest Georgia Oncology Center, PC', u'John B. Amos Cancer Center', u'Suburban Hematology-Oncology Associates, PC', u'South Atlanta Hematology-Oncology Group', u'Suburban Hematology-Oncology Associates, PC', u'Central Georgia Cancer Care, PC', u'WellStar Health System-Georgia Cancer Specialists', u'WellStar Health System-Northwest Georgia Oncology Center, PC', u'South Atlanta Hematology-Oncology Group', u'Suburban Hematology-Oncology Associates, PC', u'South Atlanta Hematology-Oncology Group', u'Central Georgia Cancer Care, PC']","March 6, 2015",18,9223372036854775807,Female,False
NCT00803062,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00803062,False,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT00601900,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00588770,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00856492,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00856492,False,"S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer",Breast Cancer,Biological:bevacizumab; Biological:pegfilgrastim; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel albumin-stabilized nanoparticle formulation,[],"May 8, 2015",18,9223372036854775807,Female,False
NCT00079274,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00003641,Eastern Cooperative Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00003641,False,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Other:clinical observation,[],"July 11, 2012",18,9223372036854775807,Both,False
NCT01099449,Alliance for Clinical Trials in Oncology,False,GA,https://ClinicalTrials.gov/show/NCT01099449,False,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT00946712,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942331,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00920010,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00920010,False,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],"February 5, 2015",0,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00602641,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00602641,False,"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:melphalan; Drug:prednisone; Drug:thalidomide; Drug:lenalidomide,[],"June 9, 2015",18,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,GA,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT02311907,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT01011478,NSABP Foundation Inc,True,GA,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00874211,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00874211,False,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],"March 4, 2015",0,9223372036854775807,Both,False
NCT00658515,Hoffmann-La Roche,False,GA,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00450281,Southwest Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00450281,False,"S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",Lung Cancer,Genetic:chromogenic in situ hybridization; Genetic:gene expression analysis; Genetic:mutation analysis; Genetic:polymerase chain reaction; Genetic:polymorphism analysis; Other:fluorescent antibody technique; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis; Other:matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other:study of socioeconomic and demographic variables; Procedure:study of high risk factors,[],"October 23, 2015",18,120,Both,False
NCT00303628,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00303628,False,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],"May 20, 2014",18,9223372036854775807,Both,False
NCT00265941,Radiation Therapy Oncology Group,True,GA,https://ClinicalTrials.gov/show/NCT00265941,False,Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Drug:cisplatin,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00087178,NSABP Foundation Inc,False,GA,https://ClinicalTrials.gov/show/NCT00087178,False,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],"October 5, 2015",18,9223372036854775807,Female,False
NCT00063999,Gynecologic Oncology Group,False,GA,https://ClinicalTrials.gov/show/NCT00063999,False,"Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Endometrial Cancer,Biological:filgrastim; Drug:carboplatin; Drug:cisplatin; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"April 23, 2009",18,9223372036854775807,Female,False
NCT00034879,AstraZeneca,False,GA,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT01313676,GlaxoSmithKline,False,GA,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT00849056,GlaxoSmithKline,False,GA,https://ClinicalTrials.gov/show/NCT00849056,False,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00828139,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00828139,False,Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:ziv-aflibercept; Drug:topotecan hydrochloride,[],"April 9, 2014",18,9223372036854775807,Both,False
NCT00775645,Southwest Oncology Group,True,GA,https://ClinicalTrials.gov/show/NCT00775645,False,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy",Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity,Dietary Supplement:acetyl-L-carnitine hydrochloride; Other:placebo,[],"January 13, 2014",18,9223372036854775807,Female,False
NCT00770809,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00770809,False,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT00665561,ViiV Healthcare,False,GA,https://ClinicalTrials.gov/show/NCT00665561,False,Prospective Observational Epidemiologic Study of Maraviroc's Safety,Human Immunodeficiency Virus,Drug:Maraviroc along with an optimized background antiretroviral drug regimen; Drug:Optimized background antiretroviral drug regimen without maraviroc,[],"December 11, 2015",18,9223372036854775807,Both,False
NCT00617708,National Cancer Institute (NCI),False,GA,https://ClinicalTrials.gov/show/NCT00617708,False,S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,Stage IV Pancreatic Cancer,Biological:cixutumumab; Drug:erlotinib hydrochloride; Drug:gemcitabine hydrochloride,[],"July 25, 2014",18,9223372036854775807,Both,False
NCT00070564,Southwest Oncology Group,True,GA,https://ClinicalTrials.gov/show/NCT00070564,False,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",Breast Cancer,Biological:pegfilgrastim; Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"September 15, 2015",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02116530,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT02116530,False,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01229943,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01229943,False,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT00972478,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT00972478,False,"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",Stage II Contiguous Adult Diffuse Large Cell Lymphoma; Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate; Drug:Vorinostat,[],"December 30, 2015",18,9223372036854775807,Both,False
NCT00946712,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00892177,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT00892177,False,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00822120,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00822120,False,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],"May 8, 2015",18,60,Both,False
NCT00769379,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00324805,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,HI,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01515800,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01515800,False,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],"October 23, 2015",18,120,Female,False
NCT01309672,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01309672,False,S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy,Prostate Cancer,Drug:abiraterone acetate; Drug:degarelix; Drug:leuprolide acetate; Procedure:orchiectomy,[],"December 8, 2015",18,120,Male,False
NCT01198158,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01097278,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT00996047,Southwest Oncology Group,True,HI,https://ClinicalTrials.gov/show/NCT00996047,False,"S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Genetic:cytogenetic analysis; Genetic:fluorescence in situ hybridization,[],"March 5, 2015",0,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00919425,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00919425,False,"S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Other:biologic sample preservation procedure,[],"March 5, 2015",0,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00719563,Alliance for Clinical Trials in Oncology,True,HI,https://ClinicalTrials.gov/show/NCT00719563,False,American Ginseng in Treating Patients With Fatigue Caused by Cancer,"Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",Drug:American ginseng; Other:placebo,[],"July 14, 2014",18,9223372036854775807,Both,False
NCT00644228,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT00644228,False,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],"September 12, 2014",18,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,HI,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00070564,Southwest Oncology Group,True,HI,https://ClinicalTrials.gov/show/NCT00070564,False,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",Breast Cancer,Biological:pegfilgrastim; Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"September 15, 2015",18,9223372036854775807,Both,False
NCT02311907,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT01642251,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01466881,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01466881,False,Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma,Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Hepatosplenic T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT01439945,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01439945,False,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,Breast Cancer; Cancer Survivor; Hot Flashes,Drug:magnesium oxide; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Female,False
NCT01376349,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01376349,False,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],"September 24, 2015",18,9223372036854775807,Female,False
NCT01260701,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01260701,False,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],"December 14, 2015",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01120236,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01120236,False,Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer,Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer,Drug:Bicalutamide; Biological:Cixutumumab; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Drug:Leuprolide Acetate; Other:Pharmacological Study,[],"June 25, 2015",18,9223372036854775807,Male,False
NCT01099449,Alliance for Clinical Trials in Oncology,False,HI,https://ClinicalTrials.gov/show/NCT01099449,False,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT01078454,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01078454,False,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],"November 20, 2014",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00874211,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00874211,False,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],"March 4, 2015",0,9223372036854775807,Both,False
NCT00860041,Alliance for Clinical Trials in Oncology,True,HI,https://ClinicalTrials.gov/show/NCT00860041,False,Acute Pain Caused by Paclitaxel in Patients With Cancer,"Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Behavioral:pain questionnaires,[],"July 7, 2015",18,9223372036854775807,Both,False
NCT00856492,Southwest Oncology Group,False,HI,https://ClinicalTrials.gov/show/NCT00856492,False,"S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer",Breast Cancer,Biological:bevacizumab; Biological:pegfilgrastim; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel albumin-stabilized nanoparticle formulation,[],"May 8, 2015",18,9223372036854775807,Female,False
NCT00731731,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT00731731,False,"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Cognitive/Functional Effects,Radiation:3-dimensional conformal radiation therapy; Drug:temozolomide; Drug:vorinostat; Procedure:cognitive assessment; Other:laboratory biomarker analysis,[],"April 28, 2015",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02066181,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT02066181,False,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01653028,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01653028,False,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,HI,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02465060,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01547741,NSABP Foundation Inc,False,ID,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01385137,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01385137,False,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],"October 15, 2015",18,120,Female,False
NCT01309672,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01309672,False,S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy,Prostate Cancer,Drug:abiraterone acetate; Drug:degarelix; Drug:leuprolide acetate; Procedure:orchiectomy,[],"December 8, 2015",18,120,Male,False
NCT00874211,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT00874211,False,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],"March 4, 2015",0,9223372036854775807,Both,False
NCT00644293,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT00644293,False,"A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults",Pharyngitis; Tonsillitis,Drug:azithromycin (Zithromax); Drug:placebo; Drug:azithromycin SR; Drug:placebo,[],"June 3, 2011",13,9223372036854775807,Both,False
NCT00643227,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT00643227,False,"A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients",Pneumonia,Drug:clarithromycin extended release (ER); Drug:azithromycin SR,[],"March 19, 2008",16,9223372036854775807,Both,False
NCT00588770,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00346216,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02116530,Alliance for Clinical Trials in Oncology,False,ID,https://ClinicalTrials.gov/show/NCT02116530,False,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01004978,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01004978,False,Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,Hepatocellular Carcinoma; Non-Resectable Hepatocellular Carcinoma,Drug:Cisplatin; Drug:Doxorubicin Hydrochloride; Drug:Doxorubicin-Eluting Beads; Other:Laboratory Biomarker Analysis; Drug:Mitomycin; Other:Pharmacological Study; Other:Placebo; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00661193,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT00661193,False,S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:erlotinib hydrochloride; Drug:paclitaxel,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT00309985,Eastern Cooperative Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT00309985,False,Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer,Prostate Cancer,Drug:antiandrogen therapy; Drug:docetaxel,[],"May 15, 2015",18,9223372036854775807,Male,False
NCT00205777,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT00205777,False,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Osteoporosis,Drug:Bazedoxifene Acetate; Other:Placebo,[],"February 28, 2013",55,80,Female,False
NCT02257528,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02257528,False,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02224781,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02224781,False,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01764633,Amgen,False,ID,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT01508026,Forest Laboratories,False,ID,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01313676,GlaxoSmithKline,False,ID,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01198158,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01130272,"Furiex Pharmaceuticals, Inc",False,ID,https://ClinicalTrials.gov/show/NCT01130272,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"June 11, 2012",18,65,Both,False
NCT01126437,Boehringer Ingelheim,False,ID,https://ClinicalTrials.gov/show/NCT01126437,False,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],"May 20, 2014",40,9223372036854775807,Both,False
NCT01097278,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT00829166,Hoffmann-La Roche,False,ID,https://ClinicalTrials.gov/show/NCT00829166,False,An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Drug:Trastuzumab emtansine [Kadcyla]; Drug:Lapatinib; Drug:Capecitabine,[],"April 2, 2015",18,9223372036854775807,Both,False
NCT00678392,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT00678392,False,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,ID,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT02137837,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT02137837,False,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],"May 20, 2015",18,9223372036854775807,Female,False
NCT02042443,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01648348,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01543178,"Valeant Pharmaceuticals International, Inc.",False,ID,https://ClinicalTrials.gov/show/NCT01543178,False,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01331837,Hoffmann-La Roche,False,ID,https://ClinicalTrials.gov/show/NCT01331837,False,A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors,"Cardiovascular Disease, Rheumatoid Arthritis",Drug:Etanercept; Drug:Tocilizumab,[],"September 18, 2015",50,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,ID,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01070836,Biogen,False,ID,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT00946712,Southwest Oncology Group,False,ID,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00809354,Pfizer,False,ID,https://ClinicalTrials.gov/show/NCT00809354,False,Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip,Osteoarthritis; Arthritis,Drug:NSAID; Biological:tanezumab; Biological:tanezumab; Biological:tanezumab; Drug:NSAID; Biological:tanezumab; Drug:NSAID,[],"March 4, 2015",18,9223372036854775807,Both,False
NCT00685113,Duramed Research,False,ID,https://ClinicalTrials.gov/show/NCT00685113,False,A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder,Overactive Bladder,Drug:DR-3001; Drug:DR-3001; Drug:Placebo,[],"August 30, 2013",18,9223372036854775807,Female,True
NCT00560482,Active Biotech AB,True,ID,https://ClinicalTrials.gov/show/NCT00560482,False,Efficacy Study of ABR-215050 to Treat Prostate Cancer,Prostate Cancer,"Drug:ABR-215050, tasquinimod; Drug:Placebo",[],"October 2, 2015",18,9223372036854775807,Male,False
NCT00430248,Takeda,True,ID,https://ClinicalTrials.gov/show/NCT00430248,False,Efficacy and Safety of Oral Febuxostat in Participants With Gout,Gout,Drug:Febuxostat; Drug:Febuxostat; Drug:Allopurinol,[],"January 31, 2012",18,85,Both,False
NCT02500797,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02311907,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT02257528,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02257528,False,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02042443,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01708954,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01708941,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01708941,False,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01648348,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01642251,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01623869,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01623869,False,Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery,Adult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma,Other:Laboratory Biomarker Analysis; Biological:Trebananib,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT01609790,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01609790,False,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,IL,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01522976,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01522976,False,Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Adult Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts,Drug:Azacitidine; Drug:Lenalidomide; Drug:Vorinostat,[],"June 24, 2015",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01439945,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01439945,False,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,Breast Cancer; Cancer Survivor; Hot Flashes,Drug:magnesium oxide; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Female,False
NCT01412879,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01412879,False,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:cyclophosphamide; Drug:cytarabine; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:methotrexate; Drug:vincristine sulfate,[],"September 15, 2015",18,65,Both,False
NCT01376349,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01376349,False,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],"September 24, 2015",18,9223372036854775807,Female,False
NCT01286233,NSABP Foundation Inc,False,IL,https://ClinicalTrials.gov/show/NCT01286233,False,Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32,Breast Cancer; Depression; Fatigue; Sleep Disorders,Drug:Metformin; Drug:Placebo,[],"September 8, 2015",18,74,Female,False
NCT01275677,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01251861,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01251861,False,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Drug:Akt Inhibitor MK2206; Drug:Bicalutamide; Other:Clinical Observation; Other:Laboratory Biomarker Analysis,[],"January 18, 2016",18,9223372036854775807,Male,False
NCT01238211,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01238211,False,Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:Cytarabine; Drug:Dasatinib; Drug:Daunorubicin Hydrochloride; Other:Laboratory Biomarker Analysis,[],"December 25, 2015",18,9223372036854775807,Both,False
NCT01198158,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01190449,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01190449,False,"Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma",Lymphoma,Biological:ofatumumab,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT01189227,NSABP Foundation Inc,False,IL,https://ClinicalTrials.gov/show/NCT01189227,False,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,Colorectal Cancer; Metastatic Cancer,Procedure:Postoperative chemotherapy; Procedure:Perioperative chemotherapy,[],"May 8, 2013",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01145495,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01145495,False,"Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma",Stage II Grade 1 Contiguous Follicular Lymphoma; Stage II Grade 1 Non-Contiguous Follicular Lymphoma; Stage II Grade 2 Contiguous Follicular Lymphoma; Stage II Grade 2 Non-Contiguous Follicular Lymphoma; Stage II Grade 3 Contiguous Follicular Lymphoma; Stage II Grade 3 Non-Contiguous Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma,Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],"December 18, 2015",18,9223372036854775807,Both,False
NCT01142388,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01142388,False,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],"June 2, 2015",18,9223372036854775807,Both,False
NCT01134614,National Cancer Institute (NCI),True,IL,https://ClinicalTrials.gov/show/NCT01134614,False,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Recurrent Melanoma; Stage III Melanoma; Stage IV Melanoma,Biological:ipilimumab; Biological:sargramostim,[],"March 23, 2015",18,9223372036854775807,Both,False
NCT01105312,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01105312,False,Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer,Breast Cancer,Drug:letrozole; Drug:panobinostat; Genetic:RNA analysis; Genetic:microarray analysis; Genetic:reverse transcriptase-polymerase chain reaction; Other:enzyme-linked immunosorbent assay; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01099449,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01099449,False,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT01097278,Southwest Oncology Group,False,IL,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT01091454,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01091454,False,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Triple-negative Breast Cancer,Drug:brostallicin; Drug:cisplatin,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT01086605,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01086605,False,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],"August 4, 2015",18,9223372036854775807,Both,False
NCT01081262,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01081262,False,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer,Biological:Bevacizumab; Drug:Capecitabine; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Oxaliplatin; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 12, 2016",18,9223372036854775807,Female,False
NCT01078454,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01078454,False,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],"November 20, 2014",18,9223372036854775807,Both,False
NCT01070836,Biogen,False,IL,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,IL,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,IL,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01013961,ECOG-ACRIN Cancer Research Group,False,IL,https://ClinicalTrials.gov/show/NCT01013961,False,Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Biological:alemtuzumab; Biological:rituximab,[],"February 1, 2016",65,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,IL,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01642251,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,IN,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01167712,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT00954174,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00954174,False,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00942357,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00803062,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00803062,False,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT00785291,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00588770,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00378703,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00378703,False,"Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer",Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Sorafenib; Drug:temsirolimus; Biological:bevacizumab,[],"April 14, 2015",18,9223372036854775807,Both,False
NCT00346216,Pfizer,False,IN,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00264901,Novo Nordisk A/S,False,IN,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01708954,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01198158,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00946712,Southwest Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,IN,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00003641,Eastern Cooperative Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT00003641,False,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Other:clinical observation,[],"July 11, 2012",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01366183,Gynecologic Oncology Group,False,IN,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00951496,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00134056,Southwest Oncology Group,True,IN,https://ClinicalTrials.gov/show/NCT00134056,False,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],"May 6, 2015",18,9223372036854775807,Male,False
NCT02311907,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT01835158,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01648348,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01012297,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01012297,False,Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma,Recurrent Uterine Corpus Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Biological:Bevacizumab; Drug:Docetaxel; Biological:Filgrastim; Drug:Gemcitabine Hydrochloride; Biological:Pegfilgrastim; Other:Placebo,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00693992,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00684983,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00684983,False,"Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",HER2/Neu Positive; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Capecitabine; Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Other:Quality-of-Life Assessment,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT00313573,Indiana University Melvin and Bren Simon Cancer Center,True,IN,https://ClinicalTrials.gov/show/NCT00313573,False,Telemedicine or Standard Care in Treating Patients With Depression and/or Pain Caused By Cancer,"Depression; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:management of therapy complications; Procedure:pain therapy; Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,"[u'Community Cancer Center at Community Hospital of Anderson', u'Community Cancer Care at Bedford Oncology Specialty Clinic', u'Columbus Regional Hospital Cancer Center', u'Community Cancer Care at Putnam County Hospital', u'Community Cancer Care at Decatur County Hospital', u'Community Regional Cancer Care at Community Hospital East', u'Community Cancer Care', u'Veterans Affairs Medical Center - Indianapolis', u'William N. Wishard Memorial Hospital', u'Methodist Cancer Center at Methodist Hospital', u'Community Regional Cancer Care at Community Hospital North', u'Regenstrief Institute, Incorporated', u'Community Cancer Care at Howard Regional Health System', u""Community Cancer Care at King's Daughters' Hospital"", u'Schneck Medical Center', u'Community Cancer Care at Perry County Hospital', u'Community Cancer Care at Tipton County Memorial Hospital']","September 19, 2013",18,9223372036854775807,Both,False
NCT01081262,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT01081262,False,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer,Biological:Bevacizumab; Drug:Capecitabine; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Oxaliplatin; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 12, 2016",18,9223372036854775807,Female,False
NCT01011478,NSABP Foundation Inc,True,IN,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,IN,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00658515,Hoffmann-La Roche,False,IN,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00644228,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00644228,False,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],"September 12, 2014",18,9223372036854775807,Both,False
NCT00625898,NSABP Foundation Inc,False,IN,https://ClinicalTrials.gov/show/NCT00625898,False,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,Breast Cancer,Drug:Docetaxel; Drug:Trastuzumab; Drug:Carboplatin; Drug:Bevacizumab; Drug:5-Fluorouracil; Drug:Epirubicin; Drug:Cyclophosphamide,[],"July 7, 2014",18,9223372036854775807,Female,False
NCT00602459,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00602459,False,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT00601900,National Cancer Institute (NCI),False,IN,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01763216,University of Iowa,False,IA,https://ClinicalTrials.gov/show/NCT01763216,False,Improving Mood in Assisted Living Settings,Depressive Symptoms; Clinical Depression,Other:Road Tour; Other:Boatload of Crosswords,"[u'Lakeview Village Retirement', u'The Fountains Senior Community Living', u'Carlise Center for Assisted Living', u'Western Home Communities', u'Irving Point Affordable Assistant Living', u'Keystone Cedars', u'Meth-Wick Community', u'Prairie Hills at Cedar Rapids', u'Bickford of Clinton', u'Woodlands Creek Active Retirement Community', u'Petersen Commons Assisted Living Community of Marycrest', u'Ridgecrest Village', u'Silvercrest Garner Active Retirement Community', u'Senior Star at Elmore Place', u'Wesley Acres', u'Valley View Village', u'The Kensington Assisted Living Community', u'University of Iowa Colleges of Nursing and Public Health', u'Emerson Point', u'Melrose Meadows', u'Oaknoll Retirement Residence', u'Legacy Senior Living Community', u'Bishop Drumm--Martina Place', u'The Villages at Marion', u'Summit Pointe', u""Iowa Veteran's Home"", u'Lutheran Living Senior Campus', u'Manor Health Care Center', u'Prairie Hills Assisted Living', u'Friendship Village Retirement Community', u'Simpson Memorial Home, Inc.', u'Highland Ridge Senior Living Community']","November 11, 2015",55,9223372036854775807,Both,True
NCT01708954,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01653028,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01653028,False,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,IA,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01366183,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01198158,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,IA,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00946712,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00920010,Southwest Oncology Group,False,IA,https://ClinicalTrials.gov/show/NCT00920010,False,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],"February 5, 2015",0,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00693992,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00588770,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00513747,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT00513747,False,Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia,Leukemia,Biological:rituximab; Drug:fludarabine phosphate,[],"October 26, 2015",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,IA,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00326898,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00303628,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00303628,False,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],"May 20, 2014",18,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,IA,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00262847,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00262847,False,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"August 18, 2015",18,9223372036854775807,Female,False
NCT00217737,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00134056,Southwest Oncology Group,True,IA,https://ClinicalTrials.gov/show/NCT00134056,False,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],"May 6, 2015",18,9223372036854775807,Male,False
NCT00087399,Alliance for Clinical Trials in Oncology,True,IA,https://ClinicalTrials.gov/show/NCT00087399,False,Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy,Breast Cancer; Hot Flashes,Drug:gabapentin; Drug:antidepressant,[],"July 7, 2015",18,9223372036854775807,Female,False
NCT00087139,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00087139,False,Ixabepilone in Treating Patients With Metastatic Prostate Cancer,Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Drug:ixabepilone,[],"April 21, 2014",18,9223372036854775807,Male,False
NCT00079274,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00072046,Alliance for Clinical Trials in Oncology,True,IA,https://ClinicalTrials.gov/show/NCT00072046,False,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00054418,Alliance for Clinical Trials in Oncology,True,IA,https://ClinicalTrials.gov/show/NCT00054418,False,Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer,Breast Cancer; Osteoporosis,Dietary Supplement:calcium carbonate; Dietary Supplement:vitamin D; Drug:risedronate sodium; Other:placebo,[],"November 12, 2013",18,9223372036854775807,Female,False
NCT00053898,NSABP Foundation Inc,True,IA,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT00052910,Alliance for Clinical Trials in Oncology,True,IA,https://ClinicalTrials.gov/show/NCT00052910,False,Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer,Esophageal Cancer; Gastric Cancer,Drug:cisplatin; Drug:epirubicin hydrochloride; Drug:fluorouracil; Drug:leucovorin calcium; Radiation:radiation therapy,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00049127,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00049127,False,Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor,Adult Anaplastic Oligodendroglioma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor,Drug:imatinib mesylate; Other:laboratory biomarker analysis; Other:pharmacological study,[],"October 1, 2014",18,9223372036854775807,Both,False
NCT00045162,Southwest Oncology Group,True,IA,https://ClinicalTrials.gov/show/NCT00045162,False,S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:etoposide; Drug:irinotecan hydrochloride,[],"July 3, 2013",18,9223372036854775807,Both,False
NCT00040885,Alliance for Clinical Trials in Oncology,True,IA,https://ClinicalTrials.gov/show/NCT00040885,False,"Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)",Anorexia; Cachexia; Fatigue; Lung Cancer,Biological:infliximab; Drug:docetaxel; Other:placebo,[],"July 7, 2015",18,9223372036854775807,Both,False
NCT00039494,National Cancer Institute (NCI),False,IA,https://ClinicalTrials.gov/show/NCT00039494,False,Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,Drug:erlotinib hydrochloride; Radiation:3-dimensional conformal radiation therapy; Drug:temozolomide,[],"August 1, 2013",18,9223372036854775807,Both,False
NCT00016406,Southwest Oncology Group,True,IA,https://ClinicalTrials.gov/show/NCT00016406,False,"S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer",Breast Cancer,Biological:filgrastim; Drug:cyclophosphamide; Drug:doxorubicin; Drug:paclitaxel; Procedure:surgery,[],"January 23, 2013",18,9223372036854775807,Female,False
NCT00014534,Alliance for Clinical Trials in Oncology,False,IA,https://ClinicalTrials.gov/show/NCT00014534,False,Combination Chemotherapy in Treating Patients With Bladder Cancer,Bladder Cancer,Biological:filgrastim; Drug:cisplatin; Drug:doxorubicin hydrochloride; Drug:gemcitabine hydrochloride,[],"September 27, 2013",18,9223372036854775807,Both,False
NCT00003596,Radiation Therapy Oncology Group,True,IA,https://ClinicalTrials.gov/show/NCT00003596,False,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer,Anal Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:mitomycin C; Radiation:radiation therapy,[],"November 18, 2013",18,9223372036854775807,Both,False
NCT00003594,Alliance for Clinical Trials in Oncology,True,IA,https://ClinicalTrials.gov/show/NCT00003594,False,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug:irinotecan; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT00003389,Eastern Cooperative Oncology Group,True,IA,https://ClinicalTrials.gov/show/NCT00003389,False,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma,Lymphoma,Drug:Doxorubicin; Drug:Bleomycin; Drug:Vinblastine; Drug:Dacarbazine; Drug:Vincristine; Drug:Mechlorethamine; Drug:Etoposide; Drug:Prednisone; Drug:Cyclophosphamide; Radiation:Radiotherapy,[],"September 25, 2015",16,9223372036854775807,Both,False
NCT02311907,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT02224781,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02224781,False,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02196181,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02042443,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01716715,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01716715,False,"Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 12, 2016",18,9223372036854775807,Female,False
NCT01708954,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01708941,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01708941,False,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01688973,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01688973,False,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery,Childhood Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Tivantinib,[],"January 11, 2016",0,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01653028,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01653028,False,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01648348,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,KS,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01498289,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01466881,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01466881,False,Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma,Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Hepatosplenic T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT01412879,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01412879,False,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:cyclophosphamide; Drug:cytarabine; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:methotrexate; Drug:vincristine sulfate,[],"September 15, 2015",18,65,Both,False
NCT01385137,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01385137,False,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],"October 15, 2015",18,120,Female,False
NCT01376349,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01376349,False,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],"September 24, 2015",18,9223372036854775807,Female,False
NCT01366183,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01309672,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01309672,False,S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy,Prostate Cancer,Drug:abiraterone acetate; Drug:degarelix; Drug:leuprolide acetate; Procedure:orchiectomy,[],"December 8, 2015",18,120,Male,False
NCT01286233,NSABP Foundation Inc,False,KS,https://ClinicalTrials.gov/show/NCT01286233,False,Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32,Breast Cancer; Depression; Fatigue; Sleep Disorders,Drug:Metformin; Drug:Placebo,[],"September 8, 2015",18,74,Female,False
NCT01275677,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01260701,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01260701,False,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],"December 14, 2015",18,9223372036854775807,Both,False
NCT01256398,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01256398,False,Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Untreated Adult Acute Lymphoblastic Leukemia,Biological:Alemtuzumab; Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Procedure:Autologous Hematopoietic Stem Cell Transplantation; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dasatinib; Drug:Daunorubicin Hydrochloride; Drug:Dexamethasone; Drug:Etoposide Phosphate; Biological:Filgrastim; Drug:Fludarabine Phosphate; Procedure:In Vitro-Treated Peripheral Blood Stem Cell Transplantation; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Melphalan; Drug:Mercaptopurine; Drug:Methotrexate; Biological:Pegfilgrastim; Other:Pharmacological Study; Drug:Tacrolimus; Drug:Vincristine Sulfate,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01229943,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01229943,False,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01189227,NSABP Foundation Inc,False,KS,https://ClinicalTrials.gov/show/NCT01189227,False,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,Colorectal Cancer; Metastatic Cancer,Procedure:Postoperative chemotherapy; Procedure:Perioperative chemotherapy,[],"May 8, 2013",18,9223372036854775807,Both,False
NCT01142388,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01142388,False,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],"June 2, 2015",18,9223372036854775807,Both,False
NCT01120236,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01120236,False,Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer,Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer,Drug:Bicalutamide; Biological:Cixutumumab; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Drug:Leuprolide Acetate; Other:Pharmacological Study,[],"June 25, 2015",18,9223372036854775807,Male,False
NCT01099449,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01099449,False,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT01098630,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01098630,False,"Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer",Recurrent Cervical Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Uterine Corpus Cancer; Stage I Uterine Sarcoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage II Uterine Corpus Cancer; Stage II Uterine Sarcoma; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage III Uterine Corpus Cancer; Stage III Uterine Sarcoma; Stage IV Uterine Corpus Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Medical Chart Review; Other:Questionnaire Administration,[],"December 23, 2014",0,9223372036854775807,Female,False
NCT01097278,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT01093222,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01093222,False,"Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",Extrahepatic Bile Duct Adenocarcinoma; Gallbladder Adenocarcinoma; Gallbladder Adenocarcinoma With Squamous Metaplasia; Hilar Cholangiocarcinoma; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Undifferentiated Gallbladder Carcinoma; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma,Drug:Erlotinib Hydrochloride; Drug:Sorafenib Tosylate,[],"June 3, 2015",18,9223372036854775807,Both,False
NCT01080521,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01080521,False,"Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy",Cognitive Side Effects of Cancer Therapy; Malignant Ovarian Mixed Epithelial Tumor; Malignant Ovarian Surface Epithelial-Stromal Tumor; Ovarian Brenner Tumor; Ovarian Carcinosarcoma; Ovarian Choriocarcinoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Dysgerminoma; Ovarian Embryonal Carcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Germ Cell Tumor; Ovarian Mucinous Cystadenocarcinoma; Ovarian Polyembryoma; Ovarian Sarcoma; Ovarian Serous Cystadenocarcinoma; Ovarian Teratoma; Ovarian Yolk Sac Tumor; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Procedure:Cognitive Assessment; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01078441,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01078441,False,"Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant",Refractory Multiple Myeloma,Drug:liposomal doxorubicin; Drug:bortezomib; Drug:dexamethasone; Drug:cyclophosphamide,[],"January 5, 2015",18,9223372036854775807,Both,False
NCT01017601,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT01017601,False,Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Biological:Seneca Valley virus-001; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,KS,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT01000558,Southwest Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT01000558,False,SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma,Lymphoma,Other:biologic sample preservation procedure,[],"May 17, 2013",18,9223372036854775807,Both,False
NCT00996047,Southwest Oncology Group,True,KS,https://ClinicalTrials.gov/show/NCT00996047,False,"S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Genetic:cytogenetic analysis; Genetic:fluorescence in situ hybridization,[],"March 5, 2015",0,9223372036854775807,Both,False
NCT00993928,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT00993928,False,Home-Based Programs for Improving Sleep in Cancer Survivors,Cancer Survivor; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders,Behavioral:Home-based sleep intervention,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00977574,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT00977574,False,"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Biological:Bevacizumab; Drug:Carboplatin; Drug:Ixabepilone; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Temsirolimus,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00976573,Alliance for Clinical Trials in Oncology,False,KS,https://ClinicalTrials.gov/show/NCT00976573,False,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",Melanoma (Skin),Biological:bevacizumab; Drug:carboplatin; Drug:everolimus; Drug:paclitaxel,[],"September 18, 2015",18,9223372036854775807,Both,False
NCT00972478,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT00972478,False,"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",Stage II Contiguous Adult Diffuse Large Cell Lymphoma; Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate; Drug:Vorinostat,[],"December 30, 2015",18,9223372036854775807,Both,False
NCT00956670,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00956670,False,"Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer",Lymphedema; Stage IA Cervical Cancer; Stage IA Uterine Corpus Cancer; Stage IA Vulvar Cancer; Stage IB Cervical Cancer; Stage IB Uterine Corpus Cancer; Stage IB Vulvar Cancer; Stage II Uterine Corpus Cancer; Stage II Vulvar Cancer; Stage IIA Cervical Cancer; Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVB Vulvar Cancer,Procedure:Therapeutic Lymphadenectomy; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Laparoscopic Surgery; Procedure:Study of High Risk Factors; Other:Questionnaire Administration; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00955305,National Cancer Institute (NCI),False,KS,https://ClinicalTrials.gov/show/NCT00955305,False,"Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer",Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cixutumumab; Drug:Paclitaxel,[],"December 31, 2015",18,9223372036854775807,Both,False
NCT00954174,Gynecologic Oncology Group,False,KS,https://ClinicalTrials.gov/show/NCT00954174,False,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02054026,"Mathematica Policy Research, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT02054026,False,Impact Evaluation of the Reducing the Risk Program,Sexual Behavior,Behavioral:Reducing the Risk,"[u'Bardstown High School', u'Warren Central High School', u'Warren East High School', u'Greenwood High School', u'Central Hardin High School', u'Metcalfe County High School', u'Elizabethtown High School', u'Franklin-Simpson High School', u'LaRue High School', u'Marion County High School', u'North Hardin High School', u'Logan County High School', u'Russellville Junior/Senior High School']","September 21, 2015",0,9223372036854775807,Both,True
NCT00346216,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,KY,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT01411878,University of Louisville,False,KY,https://ClinicalTrials.gov/show/NCT01411878,False,Louisville Teen Pregnancy Prevention Project,Pregnancy; Sexually Transmitted Diseases,Behavioral:Reducing the Risk; Behavioral:Love Notes,"[u'Jewish Family and Career Services', u'House of Ruth', u'Presbyterian Community Center', u""The Steward's Staff"", u'Gate of Hope Ministries', u'St George Community Center', u'Neighborhood House', u'One Plus One Equals You', u'Americana Community Center', u'Canaan Community Development Corporation', u'Maryhurst', u'Department for Community Based Services: Jefferson County Region']","September 6, 2011",14,19,Both,True
NCT01802333,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT00588770,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01886872,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00942331,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00658515,Hoffmann-La Roche,False,KY,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT02498600,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02498600,False,"Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"January 11, 2016",18,9223372036854775807,Female,False
NCT02257528,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT02257528,False,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT01967394,University of Louisville,False,KY,https://ClinicalTrials.gov/show/NCT01967394,False,"Social Media, Teen Moms and PPD",Postpartum Depression,Other:Use of internet based social marketing intervention; Other:No use of social media,"[u'Three Rivers', u'Hands Program of Kenton County (Young Families of Children, Inc)', u'Lincoln Trail Health Department', u'St. Joseph Hospital', u'University of Louisville Hospital', u'Hands Program of Boone and Campbell Counties (Every Child Succeeds)', u'Three Rivers Health Department', u'Lake Cumberland Health Department']","December 25, 2015",13,21,Female,False
NCT00626327,Novartis Vaccines,False,KY,https://ClinicalTrials.gov/show/NCT00626327,False,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,Meningococcal Infections,Biological:MenACWY-CRM + MMRV; Biological:MMRV; Biological:MenACWY-CRM,[],"April 12, 2013",7,1,Both,True
NCT00373685,Pfizer,False,KY,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00053898,NSABP Foundation Inc,True,KY,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT00034879,AstraZeneca,False,KY,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT00003906,NSABP Foundation Inc,True,KY,https://ClinicalTrials.gov/show/NCT00003906,False,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],"October 5, 2015",35,9223372036854775807,Female,False
NCT01553591,"Furiex Pharmaceuticals, Inc",False,KY,https://ClinicalTrials.gov/show/NCT01553591,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"April 26, 2015",18,80,Both,False
NCT01543178,"Valeant Pharmaceuticals International, Inc.",False,KY,https://ClinicalTrials.gov/show/NCT01543178,False,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01313676,GlaxoSmithKline,False,KY,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT00942357,Gynecologic Oncology Group,False,KY,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00806195,Novartis,False,KY,https://ClinicalTrials.gov/show/NCT00806195,False,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis; Meningococcal Infection,"Biological:MenACWY-CRM197; Biological:DTaP (Diptheria, Tetanus, Pertussis) Vaccine; Biological:Hib (Haemophilus influenza b) Vaccine; Biological:IPV (Inactivated Polio Vaccine) Vaccine; Biological:Pneumococcal conjugate Vaccine; Biological:MMR (Measles, Mumps, and Rubella) Vaccine; Biological:Varicella Vaccine; Biological:Hepatitis A Virus",[],"May 13, 2013",55,89,Both,True
NCT00403767,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",False,KY,https://ClinicalTrials.gov/show/NCT00403767,False,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation; Stroke; Embolism,Drug:Rivaroxaban; Drug:Warfarin; Drug:Matching placebo for Rivaroxaban arm (Warfarin placebo); Drug:Matching placebo for Warfarin arm (Rivaroxaban placebo),[],"April 10, 2014",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,KY,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00310180,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00247416,Susanne Arnold,True,KY,https://ClinicalTrials.gov/show/NCT00247416,False,Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer,Stage IV Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,Drug:Gemcitabine; Drug:Dexamethasone; Drug:Carboplatin,"[u'Commonwealth Cancer Center', u'Markey Cancer Center', u'Brown Cancer Center', u'St. Claire Regional Medical Center', u'Montgomery Cancer Center', u'Owensboro Medical HealthCare System', u'West Kentucky Hematology & Oncology Group, PSC']","January 16, 2014",18,9223372036854775807,Both,False
NCT00053053,Radiation Therapy Oncology Group,True,KY,https://ClinicalTrials.gov/show/NCT00053053,False,Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer,"Cachexia; Lymphoma; Lymphoproliferative Disorder; Unspecified Adult Solid Tumor, Protocol Specific",Dietary Supplement:Juven; Dietary Supplement:Non-Juven Supplement,[],"October 8, 2013",17,9223372036854775807,Both,False
NCT00047125,European Organisation for Research and Treatment of Cancer - EORTC,False,KY,https://ClinicalTrials.gov/show/NCT00047125,False,Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor,Carcinoma of Unknown Primary,Radiation:radiation therapy,[],"June 19, 2012",18,9223372036854775807,Female,False
NCT00004917,Radiation Therapy Oncology Group,True,KY,https://ClinicalTrials.gov/show/NCT00004917,False,Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer,Anemia; Head and Neck Cancer,Biological:epoetin alfa; Drug:cisplatin; Radiation:radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT00003591,Radiation Therapy Oncology Group,True,KY,https://ClinicalTrials.gov/show/NCT00003591,False,"Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer",Pancreatic Cancer,Drug:paclitaxel; Radiation:radiation therapy,[],"November 11, 2013",18,9223372036854775807,Both,False
NCT00003312,Radiation Therapy Oncology Group,True,KY,https://ClinicalTrials.gov/show/NCT00003312,False,Brachytherapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:iodine I 125,[],"January 23, 2014",0,9223372036854775807,Male,False
NCT00003139,Radiation Therapy Oncology Group,True,KY,https://ClinicalTrials.gov/show/NCT00003139,False,Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer,Head and Neck Cancer; Oral Complications,Drug:pilocarpine hydrochloride; Other:Placebo,[],"November 14, 2015",18,120,Both,False
NCT00002873,Radiation Therapy Oncology Group,True,KY,https://ClinicalTrials.gov/show/NCT00002873,False,Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:brachytherapy,[],"July 17, 2013",0,9223372036854775807,Female,False
NCT00002791,Radiation Therapy Oncology Group,True,KY,https://ClinicalTrials.gov/show/NCT00002791,False,Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma,Sarcoma,Biological:filgrastim; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:ifosfamide; Drug:mesna; Procedure:conventional surgery; Radiation:brachytherapy; Radiation:intraoperative radiation therapy; Radiation:radioisotope therapy,[],"January 23, 2014",18,9223372036854775807,Both,False
NCT00002622,Alliance for Clinical Trials in Oncology,True,KY,https://ClinicalTrials.gov/show/NCT00002622,False,Talc in Treating Patients With Malignant Pleural Effusion,Metastatic Cancer,Drug:talc; Drug:Talc,[],"September 27, 2013",18,9223372036854775807,Both,False
NCT00002545,Radiation Therapy Oncology Group,True,KY,https://ClinicalTrials.gov/show/NCT00002545,False,Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme,Brain and Central Nervous System Tumors,Drug:carmustine; Radiation:low-LET photon therapy,[],"August 9, 2013",18,9223372036854775807,Both,False
NCT02139046,Takeda,False,KY,https://ClinicalTrials.gov/show/NCT02139046,False,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Drug:Febuxostat IR; Drug:Febuxostat XR; Drug:Febuxostat placebo; Drug:Colchicine; Drug:Naproxen; Drug:Lansoprazole,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01648348,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,KY,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01167712,National Cancer Institute (NCI),False,KY,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01100684,Tioga Pharmaceuticals,False,KY,https://ClinicalTrials.gov/show/NCT01100684,False,Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS),Diarrhea Predominant Irritable Bowel Syndrome,Drug:Asimadoline; Drug:Placebo,[],"December 17, 2013",18,79,Both,False
NCT02465060,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01327846,Novartis Pharmaceuticals,False,LA,https://ClinicalTrials.gov/show/NCT01327846,False,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],"May 19, 2015",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01015833,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,LA,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT01042769,Hoffmann-La Roche,False,LA,https://ClinicalTrials.gov/show/NCT01042769,False,A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Aleglitazar; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01658943,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT00373685,Pfizer,False,LA,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,LA,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01011478,NSABP Foundation Inc,True,LA,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00946712,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00569127,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00569127,False,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],"January 5, 2015",0,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00262600,Boehringer Ingelheim,False,LA,https://ClinicalTrials.gov/show/NCT00262600,False,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],"November 5, 2014",18,9223372036854775807,Both,False
NCT00003389,Eastern Cooperative Oncology Group,True,LA,https://ClinicalTrials.gov/show/NCT00003389,False,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma,Lymphoma,Drug:Doxorubicin; Drug:Bleomycin; Drug:Vinblastine; Drug:Dacarbazine; Drug:Vincristine; Drug:Mechlorethamine; Drug:Etoposide; Drug:Prednisone; Drug:Cyclophosphamide; Radiation:Radiotherapy,[],"September 25, 2015",16,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00658515,Hoffmann-La Roche,False,LA,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,LA,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00217737,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00056407,GlaxoSmithKline,True,LA,https://ClinicalTrials.gov/show/NCT00056407,False,"""REDUCE"" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk","Neoplasms, Prostate",Drug:Dutasteride; Drug:Placebo,[],"April 23, 2015",50,75,Male,False
NCT01886872,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT00693992,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00588770,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00412984,Bristol-Myers Squibb,False,LA,https://ClinicalTrials.gov/show/NCT00412984,False,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,Atrial Fibrillation; Atrial Flutter,Drug:warfarin; Drug:apixaban,[],"September 27, 2013",18,9223372036854775807,Both,False
NCT00070564,Southwest Oncology Group,True,LA,https://ClinicalTrials.gov/show/NCT00070564,False,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",Breast Cancer,Biological:pegfilgrastim; Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"September 15, 2015",18,9223372036854775807,Both,False
NCT00052910,Alliance for Clinical Trials in Oncology,True,LA,https://ClinicalTrials.gov/show/NCT00052910,False,Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer,Esophageal Cancer; Gastric Cancer,Drug:cisplatin; Drug:epirubicin hydrochloride; Drug:fluorouracil; Drug:leucovorin calcium; Radiation:radiation therapy,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00034879,AstraZeneca,False,LA,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT01968798,Minneapolis Medical Research Foundation,False,LA,https://ClinicalTrials.gov/show/NCT01968798,False,ASPREE Cancer Endpoints Study,Cancer,Drug:Aspirin; Drug:Placebo,[],"December 8, 2014",65,9223372036854775807,Both,True
NCT01764633,Amgen,False,LA,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT01553591,"Furiex Pharmaceuticals, Inc",False,LA,https://ClinicalTrials.gov/show/NCT01553591,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"April 26, 2015",18,80,Both,False
NCT01070836,Biogen,False,LA,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT01038583,Minneapolis Medical Research Foundation,False,LA,https://ClinicalTrials.gov/show/NCT01038583,False,Aspirin in Reducing Events in the Elderly,Functional Disability; Dementia; Heart Disease; Stroke; Cancer; Bleeding; Depression,Drug:100 mg enteric-coated aspirin; Drug:Placebo,[],"September 23, 2015",65,9223372036854775807,Both,True
NCT00822120,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT00822120,False,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],"May 8, 2015",18,60,Both,False
NCT00601900,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00580216,Sanofi,False,LA,https://ClinicalTrials.gov/show/NCT00580216,False,Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation,Atrial Fibrillation,Drug:Idrabiotaparinux; Drug:Warfarin; Drug:Placebo (for idrabiotaparinux); Drug:Placebo (for warfarin); Drug:Avidin; Drug:Placebo (for avidin),[],"February 26, 2014",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00303953,National Cancer Institute (NCI),False,LA,https://ClinicalTrials.gov/show/NCT00303953,False,PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma,Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma,Drug:belinostat,[],"April 23, 2014",18,9223372036854775807,Both,False
NCT00087178,NSABP Foundation Inc,False,LA,https://ClinicalTrials.gov/show/NCT00087178,False,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],"October 5, 2015",18,9223372036854775807,Female,False
NCT00075946,Eastern Cooperative Oncology Group,True,LA,https://ClinicalTrials.gov/show/NCT00075946,False,Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma,Lymphoma,Biological:rituximab,[],"June 3, 2015",18,9223372036854775807,Both,False
NCT00072046,Alliance for Clinical Trials in Oncology,True,LA,https://ClinicalTrials.gov/show/NCT00072046,False,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00049179,Southwest Oncology Group,False,LA,https://ClinicalTrials.gov/show/NCT00049179,False,S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia,Leukemia,Drug:cytarabine; Drug:gemtuzumab ozogamicin,[],"March 5, 2015",18,9223372036854775807,Both,False
NCT00041119,Alliance for Clinical Trials in Oncology,True,LA,https://ClinicalTrials.gov/show/NCT00041119,False,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"July 23, 2015",18,9223372036854775807,Female,False
NCT00310180,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT01275677,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02465060,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00878709,"Puma Biotechnology, Inc.",False,ME,https://ClinicalTrials.gov/show/NCT00878709,False,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],"August 20, 2015",18,9223372036854775807,Female,False
NCT00324805,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01942135,Pfizer,False,ME,https://ClinicalTrials.gov/show/NCT01942135,False,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Drug:Palbociclib; Drug:Fulvestrant; Drug:Placebo; Drug:Fulvestrant,[],"November 16, 2015",18,9223372036854775807,Female,False
NCT01886872,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,ME,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT00769379,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00658515,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00239681,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT00239681,False,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],"February 6, 2014",50,9223372036854775807,Both,False
NCT01764633,Amgen,False,ME,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT01730534,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT01730534,False,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,"Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event",Drug:Dapagliflozin 10 mg; Drug:Placebo tablet,[],"December 10, 2015",40,130,Both,False
NCT01642251,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01577381,Pfizer,False,ME,https://ClinicalTrials.gov/show/NCT01577381,False,"Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration",Age-Related Maculopathy,Biological:RN6G; Biological:Placebo,[],"November 6, 2015",60,90,Both,False
NCT01225562,AstraZeneca,True,ME,https://ClinicalTrials.gov/show/NCT01225562,False,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",Myocardial Infarction; Cardiovascular Death; Atherothrombosis; Stroke,Drug:Ticagrelor 90 mg; Drug:Ticagrelor 60 mg; Drug:Ticagrelor Placebo,[],"December 18, 2015",50,130,Both,False
NCT01154140,Pfizer,False,ME,https://ClinicalTrials.gov/show/NCT01154140,False,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,Non Squamous Lung Cancer,Drug:treatment; Drug:treatment,[],"November 30, 2015",18,9223372036854775807,Both,False
NCT01070836,Biogen,False,ME,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT00402363,GlaxoSmithKline,True,ME,https://ClinicalTrials.gov/show/NCT00402363,False,"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation","Fibrillation, Atrial; Atrial Fibrillation",Drug:omega-3-acid ethyl esters; Drug:Placebo,[],"February 7, 2013",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,ME,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00326898,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00245739,"Tibotec Pharmaceuticals, Ireland",False,ME,https://ClinicalTrials.gov/show/NCT00245739,False,"TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.",HIV Infections,Drug:TMC-114,[],"April 10, 2014",18,9223372036854775807,Both,False
NCT00134173,Pfizer,False,ME,https://ClinicalTrials.gov/show/NCT00134173,False,A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease,Coronary Disease; Coronary Arteriosclerosis; Hyperlipidemia,Drug:torcetrapib/atorvastatin; Drug:atorvastatin,[],"December 6, 2007",18,75,Both,False
NCT00034879,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT00024102,Alliance for Clinical Trials in Oncology,True,ME,https://ClinicalTrials.gov/show/NCT00024102,False,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,Breast Cancer,Drug:Standard Treatment; Drug:capecitabine,[],"June 23, 2015",65,9223372036854775807,Female,False
NCT02074488,University of Maine,False,ME,https://ClinicalTrials.gov/show/NCT02074488,False,Balancing Act: Impact on Falls in Older Adults With Vision Impairment,Postural Balance,Other:Balancing Act exercise curriculum; Other:Informational Brochure,"[u'University of New England', u'University of Maine', u'The Iris Network']","December 1, 2015",62,9223372036854775807,Both,False
NCT01954394,Sanofi,False,ME,https://ClinicalTrials.gov/show/NCT01954394,False,Open Label Study of Long Term Safety Evaluation of Alirocumab,Hypercholesterolemia,Drug:Alirocumab SAR236553 (REGN727),[],"August 21, 2015",18,9223372036854775807,Both,False
NCT01854918,Amgen,False,ME,https://ClinicalTrials.gov/show/NCT01854918,False,Open Label Study of Long Term Evaluation Against LDL-C Trial-2,Hyperlipidemia and Mixed Dyslipidemia,Biological:evolocumab (AMG 145) and standard of care; Other:Standard of care,[],"October 1, 2015",18,85,Both,False
NCT01835158,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01763866,Amgen,True,ME,https://ClinicalTrials.gov/show/NCT01763866,False,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Hyperlipidemia,Biological:Evolocumab; Drug:Ezetimibe; Drug:Placebo to Evolocumab; Drug:Placebo to Ezetimibe; Drug:Atorvastatin; Drug:Rosuvastatin; Drug:Simvastatin,[],"November 18, 2015",18,80,Both,False
NCT01648348,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01380730,Amgen,True,ME,https://ClinicalTrials.gov/show/NCT01380730,False,LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy,Hyperlipidemia,Biological:Evolocumab; Other:Placebo to Evolocumab,[],"September 1, 2015",18,80,Both,False
NCT01366183,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01313676,GlaxoSmithKline,False,ME,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01238172,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01238172,False,Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance,Prostate Cancer,Other:dietary education and counseling; Other:prostate cancer foundation booklet,[],"August 20, 2015",50,80,Male,False
NCT01126437,Boehringer Ingelheim,False,ME,https://ClinicalTrials.gov/show/NCT01126437,False,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],"May 20, 2014",40,9223372036854775807,Both,False
NCT01107886,AstraZeneca,False,ME,https://ClinicalTrials.gov/show/NCT01107886,False,Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications,Type 2 Diabetes Mellitus,Drug:Saxagliptin; Drug:Placebo,[],"July 9, 2014",40,9223372036854775807,Both,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,ME,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,ME,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT01000727,GlaxoSmithKline,False,ME,https://ClinicalTrials.gov/show/NCT01000727,False,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Drug:Darapladib 160 mg; Drug:Placebo; Other:Standard Therapy,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00990327,Forest Laboratories,False,ME,https://ClinicalTrials.gov/show/NCT00990327,False,Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI,Coronary Artery Disease,Drug:Apadenoson SPECT-MPI; Drug:Adenosine SPECT-MPI,[],"April 27, 2012",18,9223372036854775807,Both,False
NCT00951496,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00942357,Gynecologic Oncology Group,False,ME,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,ME,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00844649,Celgene Corporation,False,ME,https://ClinicalTrials.gov/show/NCT00844649,False,Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas,Metastatic Pancreatic Cancer,Drug:Albumin-bound paclitaxel (ABI-007); Drug:Gemcitabine,[],"October 19, 2015",18,79,Both,False
NCT00829166,Hoffmann-La Roche,False,ME,https://ClinicalTrials.gov/show/NCT00829166,False,An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer,Breast Cancer,Drug:Trastuzumab emtansine [Kadcyla]; Drug:Lapatinib; Drug:Capecitabine,[],"April 2, 2015",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00346216,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,MD,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00373685,Pfizer,False,MD,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00808808,MedImmune LLC,True,MD,https://ClinicalTrials.gov/show/NCT00808808,False,Assessing Choice in the Employer Setting (ACES) Study,Healthy,Biological:Choice of TIV or FluMist with baseline advertisement; Other:Choice of TIV or FluMist with enhanced advertisement and incentives; Biological:Control - Usual care offering TIV only with baseline advertisement,[],"October 28, 2013",18,9223372036854775807,Both,True
NCT01547741,NSABP Foundation Inc,False,MD,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT00262600,Boehringer Ingelheim,False,MD,https://ClinicalTrials.gov/show/NCT00262600,False,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],"November 5, 2014",18,9223372036854775807,Both,False
NCT00053898,NSABP Foundation Inc,True,MD,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT00808067,Boehringer Ingelheim,False,MD,https://ClinicalTrials.gov/show/NCT00808067,False,RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial,Atrial Fibrillation,Drug:dabigatran dose 1; Drug:dabigatran dose 2,[],"June 3, 2014",18,9223372036854775807,Both,False
NCT00658515,Hoffmann-La Roche,False,MD,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00625898,NSABP Foundation Inc,False,MD,https://ClinicalTrials.gov/show/NCT00625898,False,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,Breast Cancer,Drug:Docetaxel; Drug:Trastuzumab; Drug:Carboplatin; Drug:Bevacizumab; Drug:5-Fluorouracil; Drug:Epirubicin; Drug:Cyclophosphamide,[],"July 7, 2014",18,9223372036854775807,Female,False
NCT00433511,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00887536,NSABP Foundation Inc,False,MD,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00087178,NSABP Foundation Inc,False,MD,https://ClinicalTrials.gov/show/NCT00087178,False,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],"October 5, 2015",18,9223372036854775807,Female,False
NCT00327691,Pfizer,True,MD,https://ClinicalTrials.gov/show/NCT00327691,False,A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels,Cardiovascular Disease; Cerebrovascular Accident; Coronary Heart Disease,Drug:Atorvastatin,[],"May 1, 2007",35,75,Both,False
NCT00326898,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00262847,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00262847,False,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"August 18, 2015",18,9223372036854775807,Female,False
NCT01764633,Amgen,False,MD,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT00079274,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00067938,GlaxoSmithKline,False,MD,https://ClinicalTrials.gov/show/NCT00067938,False,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],"October 11, 2012",18,9223372036854775807,Both,False
NCT01313676,GlaxoSmithKline,False,MD,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01000727,GlaxoSmithKline,False,MD,https://ClinicalTrials.gov/show/NCT01000727,False,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Drug:Darapladib 160 mg; Drug:Placebo; Other:Standard Therapy,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00601900,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00412984,Bristol-Myers Squibb,False,MD,https://ClinicalTrials.gov/show/NCT00412984,False,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,Atrial Fibrillation; Atrial Flutter,Drug:warfarin; Drug:apixaban,[],"September 27, 2013",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,MD,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,MD,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00103181,NSABP Foundation Inc,True,MD,https://ClinicalTrials.gov/show/NCT00103181,False,Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:3-dimensional conformal accelerated partial breast irradiation; Radiation:brachytherapy; Radiation:whole breast irradiation; Radiation:MammoSite or other single-entry intracavitary device,[],"October 8, 2015",18,9223372036854775807,Female,False
NCT00067457,GlaxoSmithKline,False,MD,https://ClinicalTrials.gov/show/NCT00067457,False,Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy,Irritable Colon; Irritable Bowel Syndrome (IBS),Drug:alosetron,[],"April 15, 2015",18,9223372036854775807,Female,False
NCT00951496,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,MD,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00549796,Johns Hopkins University,False,MD,https://ClinicalTrials.gov/show/NCT00549796,False,Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery,Coronary Arteriosclerosis; Angina Pectoris,Other:Percutaneous coronary intervention (PCI),[],"September 10, 2014",18,9223372036854775807,Both,False
NCT00507416,"Millennium Pharmaceuticals, Inc.",False,MD,https://ClinicalTrials.gov/show/NCT00507416,False,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Multiple Myeloma,Drug:Bortezomib; Drug:Dexamethasone; Drug:Melphalan; Drug:Prednisone; Drug:Thalidomide,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT00505778,Warner Chilcott,False,MD,https://ClinicalTrials.gov/show/NCT00505778,False,A Comparison of Once a Day Dose Compared to 2 Doses/Day,Ulcerative Colitis,Drug:Mesalamine Once-Daily; Drug:Mesalamine Twice-Daily,[],"April 15, 2013",18,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,MD,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00079001,Alliance for Clinical Trials in Oncology,True,MD,https://ClinicalTrials.gov/show/NCT00079001,False,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer; Prostate Cancer,Drug:zoledronic acid; Other:placebo; Drug:androgen deprivation therapy; Drug:GnRH agonist; Dietary Supplement:Calcium supplement; Dietary Supplement:Vitamin D,[],"November 23, 2015",18,9223372036854775807,Male,False
NCT00042081,"Anesiva, Inc.",True,MD,https://ClinicalTrials.gov/show/NCT00042081,False,Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures,Coronary Artery Disease,Drug:CGT003 (E2F Duplex Decoy),[],"May 4, 2006",18,80,Both,False
NCT01886872,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01475721,GlaxoSmithKline,False,MD,https://ClinicalTrials.gov/show/NCT01475721,False,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],"December 10, 2015",12,9223372036854775807,Both,False
NCT01349322,Radiation Therapy Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT01349322,False,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01167712,National Cancer Institute (NCI),False,MD,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01011478,NSABP Foundation Inc,True,MD,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,MD,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00781391,Daiichi Sankyo Inc.,False,MD,https://ClinicalTrials.gov/show/NCT00781391,False,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke; Atrial Fibrillation; Embolism,Drug:warfarin tablets; Drug:Edoxaban tablets (high dose regimen-60mg); Drug:Edoxaban tablets (low dose regimen-30mg); Drug:placebo warfarin; Drug:placebo edoxaban,[],"March 12, 2015",21,9223372036854775807,Both,False
NCT01454947,University of Southern California,False,MA,https://ClinicalTrials.gov/show/NCT01454947,False,Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study),Acute Respiratory Infections (ARIs),Behavioral:Clinical Decision Support: Justification Alerts; Behavioral:Audit and Feedback: Social Norms; Behavioral:CDS Order Sets: Alternative Prescriptions,[],"November 2, 2011",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,MA,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00324805,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00079274,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00053898,NSABP Foundation Inc,True,MA,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00769379,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00034879,AstraZeneca,False,MA,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT01198886,Tufts University,False,MA,https://ClinicalTrials.gov/show/NCT01198886,False,"The Vitality, Independence, and Vigor in Elders Study I Clinical Trial",Functionally Limited; Sedentary,Other:Successful Aging Program; Other:Exercise-Nutrition Program,"[u'Drake Village', u'Nashoba Park', u'Compass on the Bay', u'Chestnut Park at Cleveland Circle', u'Neville Place at Fresh Pond', u'Youville House', u'Chelmsford Crossings', u'Putnam Farms at Danvers', u'Standish Village at Lower Mills', u'Youville Place', u'Methuen Village', u'Golda Meir House', u'Evans Park at Newton Center', u'Coleman House', u'The Falls at Cordingly Dam', u'Holland Street Center', u'Waltham Crossings']","May 11, 2015",65,9223372036854775807,Both,True
NCT01116882,Harvard Clinical Research Institute,False,MA,https://ClinicalTrials.gov/show/NCT01116882,False,Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings,Coronary Artery Diseases,Procedure:PCI,"[u'Beth Israel Deaconnes Medical Center', u'Massachusetts General Hospital', u'Boston University Medical Center', u""Brigham and Women's Hospital"", u'Tufts New England Medical Center', u""Caritas St. Elizabeth's Hospital"", u'Brockton Hospital', u'Caritas Good Samaritan Medical Center', u'Lahey Clinic', u'Metrowest Medical Center', u'Lawrence General Hospital', u'Saints Memorial Medical Center', u'Lowell General Hospital', u'Melrose Wakefield Hospital', u'Caritas Holy Family Hospital', u'Caritas Norwood Hospital', u'South Shore Hospital']","March 18, 2015",18,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,MA,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00087178,NSABP Foundation Inc,False,MA,https://ClinicalTrials.gov/show/NCT00087178,False,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],"October 5, 2015",18,9223372036854775807,Female,False
NCT00052910,Alliance for Clinical Trials in Oncology,True,MA,https://ClinicalTrials.gov/show/NCT00052910,False,Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer,Esophageal Cancer; Gastric Cancer,Drug:cisplatin; Drug:epirubicin hydrochloride; Drug:fluorouracil; Drug:leucovorin calcium; Radiation:radiation therapy,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00041119,Alliance for Clinical Trials in Oncology,True,MA,https://ClinicalTrials.gov/show/NCT00041119,False,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"July 23, 2015",18,9223372036854775807,Female,False
NCT01886872,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT00658515,Hoffmann-La Roche,False,MA,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00003906,NSABP Foundation Inc,True,MA,https://ClinicalTrials.gov/show/NCT00003906,False,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],"October 5, 2015",35,9223372036854775807,Female,False
NCT00003857,Radiation Therapy Oncology Group,True,MA,https://ClinicalTrials.gov/show/NCT00003857,False,Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ,Breast Cancer,Drug:tamoxifen citrate; Procedure:adjuvant therapy; Radiation:radiation therapy,[],"November 14, 2015",26,120,Female,False
NCT01547741,NSABP Foundation Inc,False,MA,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT00264901,Novo Nordisk A/S,False,MA,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00346216,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02378051,Massachusetts General Hospital,False,MA,https://ClinicalTrials.gov/show/NCT02378051,False,Staying Strong With Schools - A School-Based Resilience Support Intervention for Military-Connected Children,Staying Strong With Schools Intervention; Waitlist Control,Behavioral:Staying Strong with Schools Intervention,"[u'Community Charter School', u'East Falmouth Elementary School', u'North Falmouth Elementary School', u'Mullen-Hall School', u'Morse Pond School', u'Hyannis West Elementary School', u'Barnstable United Elementary School', u'West Villages Elementary School', u'Teaticket Elementary School', u'West Barnstable Elementary School']","February 26, 2015",6,9223372036854775807,Both,False
NCT02072421,Harvard Clinical Research Institute,False,MA,https://ClinicalTrials.gov/show/NCT02072421,False,The MASS COMM Post-Randomization Phase Cohort Study,Coronary Artery Disease,Procedure:PCI,"[u'Good Samaritan Medical Center', u'Brockton Hospital', u'Metrowest Medical Center', u'Lawrence General Hospital', u'Lowell General Hospital', u'Saints Memorial Medical Center', u'Melrose-Wakefield Hospital', u'Holy Family Hospital', u'Norwood Hospital', u'South Shore Hospital']","March 18, 2015",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01070836,Biogen,False,MA,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT00951496,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00785291,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00667810,Pfizer,False,MA,https://ClinicalTrials.gov/show/NCT00667810,False,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,Alzheimer Disease,Drug:bapineuzumab; Drug:bapineuzumab; Drug:placebo,[],"December 4, 2015",50,89,Both,False
NCT00574132,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",False,MA,https://ClinicalTrials.gov/show/NCT00574132,False,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),Alzheimer's Disease,Drug:Bapineuzumab 0.5 mg/kg; Drug:Placebo Control; Drug:Bapineuzumab 1.0 m/kg,[],"October 30, 2013",50,88,Both,False
NCT00326898,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00262600,Boehringer Ingelheim,False,MA,https://ClinicalTrials.gov/show/NCT00262600,False,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],"November 5, 2014",18,9223372036854775807,Both,False
NCT00239681,AstraZeneca,False,MA,https://ClinicalTrials.gov/show/NCT00239681,False,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],"February 6, 2014",50,9223372036854775807,Both,False
NCT00094302,New England Research Institutes,True,MA,https://ClinicalTrials.gov/show/NCT00094302,False,Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function,"Cardiovascular Diseases; Heart Diseases; Heart Failure, Congestive",Drug:Spironolactone; Drug:Placebo,[],"February 11, 2015",50,9223372036854775807,Both,False
NCT00056407,GlaxoSmithKline,True,MA,https://ClinicalTrials.gov/show/NCT00056407,False,"""REDUCE"" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk","Neoplasms, Prostate",Drug:Dutasteride; Drug:Placebo,[],"April 23, 2015",50,75,Male,False
NCT00024102,Alliance for Clinical Trials in Oncology,True,MA,https://ClinicalTrials.gov/show/NCT00024102,False,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,Breast Cancer,Drug:Standard Treatment; Drug:capecitabine,[],"June 23, 2015",65,9223372036854775807,Female,False
NCT01764633,Amgen,False,MA,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT01303458,Boston Medical Center,False,MA,https://ClinicalTrials.gov/show/NCT01303458,False,Addressing Low-Income Families' Basic Social Needs at Pediatric Visits,The Focus of This Study is to Address Low-income Families' Basic Social Needs at Pediatric Visits.,Behavioral:Basic Needs Surveillance (BNS) protocol,"[u'Arvin Garg', u'Codman Square Health Center', u'Dorchester House Multi-Service Center', u'Neponset Health Center', u""Upham's Corner Health Center"", u'Harvard Street Neighborhood Health Center', u'Greater Roslindale Medical and Dental Center', u'The Dimock Center', u'South Boston Community Health Center']","December 22, 2014",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT00770809,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00770809,False,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT00644228,National Cancer Institute (NCI),False,MA,https://ClinicalTrials.gov/show/NCT00644228,False,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],"September 12, 2014",18,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,MA,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00402857,Tufts Medical Center,False,MA,https://ClinicalTrials.gov/show/NCT00402857,False,Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders,Attention Deficit Disorder With Hyperactivity; Attention Deficit and Disruptive Behavior Disorders,Behavioral:Incredible Years Program,"[u'MGH Chelsea Healthcare Center', u'Codman Square Health Center', u'Martha Eliot Health Center', u'Medical Associates Pediatrics', u'Southboro Medical Group', u'Pediatrics West', u'Westwood-Mansfield Pediatric Associates', u'Wilmington Pediatrics', u'Woburn Pediatric Associates']","February 11, 2013",22,38,Both,True
NCT00003596,Radiation Therapy Oncology Group,True,MA,https://ClinicalTrials.gov/show/NCT00003596,False,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer,Anal Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:mitomycin C; Radiation:radiation therapy,[],"November 18, 2013",18,9223372036854775807,Both,False
NCT01546987,Radiation Therapy Oncology Group,False,MA,https://ClinicalTrials.gov/show/NCT01546987,False,"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer",Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:orteronel; Drug:triptorelin,[],"November 14, 2015",18,9223372036854775807,Male,False
NCT02465060,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02311907,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02137837,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT02137837,False,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],"May 20, 2015",18,9223372036854775807,Female,False
NCT02042443,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01708954,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01688973,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01688973,False,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery,Childhood Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Tivantinib,[],"January 11, 2016",0,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01648348,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,MI,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01515800,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01515800,False,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],"October 23, 2015",18,120,Female,False
NCT01498289,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01468909,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01468909,False,"Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"January 12, 2016",18,9223372036854775807,Female,False
NCT01439945,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01439945,False,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,Breast Cancer; Cancer Survivor; Hot Flashes,Drug:magnesium oxide; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Female,False
NCT01385137,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01385137,False,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],"October 15, 2015",18,120,Female,False
NCT01376349,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01376349,False,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],"September 24, 2015",18,9223372036854775807,Female,False
NCT01366183,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01349322,Radiation Therapy Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01349322,False,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01309672,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01309672,False,S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy,Prostate Cancer,Drug:abiraterone acetate; Drug:degarelix; Drug:leuprolide acetate; Procedure:orchiectomy,[],"December 8, 2015",18,120,Male,False
NCT01275677,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01260701,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01260701,False,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],"December 14, 2015",18,9223372036854775807,Both,False
NCT01251861,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01251861,False,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Drug:Akt Inhibitor MK2206; Drug:Bicalutamide; Other:Clinical Observation; Other:Laboratory Biomarker Analysis,[],"January 18, 2016",18,9223372036854775807,Male,False
NCT01238172,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01238172,False,Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance,Prostate Cancer,Other:dietary education and counseling; Other:prostate cancer foundation booklet,[],"August 20, 2015",50,80,Male,False
NCT01229943,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01229943,False,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01198158,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01196429,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01196429,False,"Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer",Ovarian Clear Cell Cystadenocarcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer,Drug:Carboplatin; Drug:Docetaxel; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Temsirolimus,[],"November 20, 2015",18,9223372036854775807,Female,False
NCT01196390,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01189227,NSABP Foundation Inc,False,MI,https://ClinicalTrials.gov/show/NCT01189227,False,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,Colorectal Cancer; Metastatic Cancer,Procedure:Postoperative chemotherapy; Procedure:Perioperative chemotherapy,[],"May 8, 2013",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01156142,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01156142,False,Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy,Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain,Drug:doxepin hydrochloride; Other:placebo,[],"July 30, 2015",18,9223372036854775807,Both,False
NCT01142388,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01142388,False,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],"June 2, 2015",18,9223372036854775807,Both,False
NCT01139957,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01139957,False,Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer,Breast Carcinoma; Fallopian Tube Carcinoma; Ovarian Neoplasm; Primary Peritoneal Carcinoma,Procedure:Evaluation of Cancer Risk Factors; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Procedure:Study of High Risk Factors,[],"June 3, 2015",30,9223372036854775807,Female,False
NCT01120275,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01120275,False,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Solar Radiation-related Skin Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other:laboratory biomarker analysis,[],"June 9, 2014",18,9223372036854775807,Both,False
NCT01120236,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01120236,False,Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer,Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer,Drug:Bicalutamide; Biological:Cixutumumab; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Drug:Leuprolide Acetate; Other:Pharmacological Study,[],"June 25, 2015",18,9223372036854775807,Male,False
NCT01099449,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01099449,False,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT01098630,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01098630,False,"Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer",Recurrent Cervical Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Uterine Corpus Cancer; Stage I Uterine Sarcoma; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage II Uterine Corpus Cancer; Stage II Uterine Sarcoma; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage III Uterine Corpus Cancer; Stage III Uterine Sarcoma; Stage IV Uterine Corpus Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Medical Chart Review; Other:Questionnaire Administration,[],"December 23, 2014",0,9223372036854775807,Female,False
NCT01097278,Southwest Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT01091454,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01091454,False,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Triple-negative Breast Cancer,Drug:brostallicin; Drug:cisplatin,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT01086605,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01086605,False,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],"August 4, 2015",18,9223372036854775807,Both,False
NCT01080521,Gynecologic Oncology Group,False,MI,https://ClinicalTrials.gov/show/NCT01080521,False,"Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy",Cognitive Side Effects of Cancer Therapy; Malignant Ovarian Mixed Epithelial Tumor; Malignant Ovarian Surface Epithelial-Stromal Tumor; Ovarian Brenner Tumor; Ovarian Carcinosarcoma; Ovarian Choriocarcinoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Dysgerminoma; Ovarian Embryonal Carcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Germ Cell Tumor; Ovarian Mucinous Cystadenocarcinoma; Ovarian Polyembryoma; Ovarian Sarcoma; Ovarian Serous Cystadenocarcinoma; Ovarian Teratoma; Ovarian Yolk Sac Tumor; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Procedure:Cognitive Assessment; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01017601,Alliance for Clinical Trials in Oncology,False,MI,https://ClinicalTrials.gov/show/NCT01017601,False,Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Biological:Seneca Valley virus-001; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,MI,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,MI,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT02500797,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02311907,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02066181,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT02066181,False,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01708954,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01708941,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01708941,False,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01688973,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01688973,False,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery,Childhood Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Tivantinib,[],"January 11, 2016",0,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01653028,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01653028,False,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01648348,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01642251,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,MN,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01540565,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01540565,False,"Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Veliparib,[],"January 5, 2016",18,9223372036854775807,Female,False
NCT01522976,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01522976,False,Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Adult Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts,Drug:Azacitidine; Drug:Lenalidomide; Drug:Vorinostat,[],"June 24, 2015",18,9223372036854775807,Both,False
NCT01466881,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01466881,False,Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma,Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Hepatosplenic T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT01439945,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01439945,False,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,Breast Cancer; Cancer Survivor; Hot Flashes,Drug:magnesium oxide; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Female,False
NCT01412879,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01412879,False,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:cyclophosphamide; Drug:cytarabine; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:methotrexate; Drug:vincristine sulfate,[],"September 15, 2015",18,65,Both,False
NCT01376349,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01376349,False,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],"September 24, 2015",18,9223372036854775807,Female,False
NCT01369849,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01369849,False,"Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia,Drug:Akt Inhibitor MK2206; Drug:Bendamustine Hydrochloride; Other:Laboratory Biomarker Analysis; Biological:Rituximab,[],"August 24, 2015",18,9223372036854775807,Both,False
NCT01366183,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01286233,NSABP Foundation Inc,False,MN,https://ClinicalTrials.gov/show/NCT01286233,False,Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32,Breast Cancer; Depression; Fatigue; Sleep Disorders,Drug:Metformin; Drug:Placebo,[],"September 8, 2015",18,74,Female,False
NCT01275677,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01251861,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01251861,False,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Drug:Akt Inhibitor MK2206; Drug:Bicalutamide; Other:Clinical Observation; Other:Laboratory Biomarker Analysis,[],"January 18, 2016",18,9223372036854775807,Male,False
NCT01229943,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01229943,False,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01198158,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01198145,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01198145,False,Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy,"Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific",Drug:sulfasalazine; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01189227,NSABP Foundation Inc,False,MN,https://ClinicalTrials.gov/show/NCT01189227,False,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,Colorectal Cancer; Metastatic Cancer,Procedure:Postoperative chemotherapy; Procedure:Perioperative chemotherapy,[],"May 8, 2013",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01156142,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01156142,False,Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy,Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain,Drug:doxepin hydrochloride; Other:placebo,[],"July 30, 2015",18,9223372036854775807,Both,False
NCT01142388,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01142388,False,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],"June 2, 2015",18,9223372036854775807,Both,False
NCT01139957,Gynecologic Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01139957,False,Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer,Breast Carcinoma; Fallopian Tube Carcinoma; Ovarian Neoplasm; Primary Peritoneal Carcinoma,Procedure:Evaluation of Cancer Risk Factors; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Procedure:Study of High Risk Factors,[],"June 3, 2015",30,9223372036854775807,Female,False
NCT01134614,National Cancer Institute (NCI),True,MN,https://ClinicalTrials.gov/show/NCT01134614,False,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Recurrent Melanoma; Stage III Melanoma; Stage IV Melanoma,Biological:ipilimumab; Biological:sargramostim,[],"March 23, 2015",18,9223372036854775807,Both,False
NCT01097278,Southwest Oncology Group,False,MN,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT01091454,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01091454,False,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Triple-negative Breast Cancer,Drug:brostallicin; Drug:cisplatin,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT01086605,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01086605,False,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],"August 4, 2015",18,9223372036854775807,Both,False
NCT01078454,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01078454,False,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],"November 20, 2014",18,9223372036854775807,Both,False
NCT01078441,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01078441,False,"Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant",Refractory Multiple Myeloma,Drug:liposomal doxorubicin; Drug:bortezomib; Drug:dexamethasone; Drug:cyclophosphamide,[],"January 5, 2015",18,9223372036854775807,Both,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01017601,Alliance for Clinical Trials in Oncology,False,MN,https://ClinicalTrials.gov/show/NCT01017601,False,Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Biological:Seneca Valley virus-001; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01012297,National Cancer Institute (NCI),False,MN,https://ClinicalTrials.gov/show/NCT01012297,False,Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma,Recurrent Uterine Corpus Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Biological:Bevacizumab; Drug:Docetaxel; Biological:Filgrastim; Drug:Gemcitabine Hydrochloride; Biological:Pegfilgrastim; Other:Placebo,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00264901,Novo Nordisk A/S,False,MS,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00373685,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00600821,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT00600821,False,A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.,Non-Small-Cell Lung Carcinoma; Adenocarcinoma,Drug:Bevacizumab; Drug:Carboplatin; Drug:Paclitaxel; Drug:AG-013736 (axitinib); Drug:Carboplatin; Drug:Paclitaxel,[],"October 16, 2013",18,9223372036854775807,Both,False
NCT00083889,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT00083889,False,SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma,"Carcinoma, Renal Cell",Drug:Interferon-alfa; Drug:SU011248,[],"January 19, 2010",18,9223372036854775807,Both,False
NCT00003906,NSABP Foundation Inc,True,MS,https://ClinicalTrials.gov/show/NCT00003906,False,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],"October 5, 2015",35,9223372036854775807,Female,False
NCT01284062,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT01284062,False,Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients,"Colitis, Ulcerative",Biological:Anrukinzumab; Biological:Anrukinzumab; Biological:Anrukinzumab; Other:placebo,[],"November 10, 2014",18,65,Both,False
NCT01275677,National Cancer Institute (NCI),False,MS,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00769379,National Cancer Institute (NCI),False,MS,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00596830,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT00596830,False,"Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology","Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung","Drug:CP-751,871 (Figitumumab); Drug:Carboplatin; Drug:Paclitaxel; Drug:Carboplatin; Drug:Paclitaxel",[],"December 11, 2013",18,9223372036854775807,Both,False
NCT00588770,National Cancer Institute (NCI),False,MS,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00467844,GTx,False,MS,https://ClinicalTrials.gov/show/NCT00467844,False,Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.,Cachexia,Drug:GTx-024; Drug:GTx-024; Drug:Placebo,[],"June 26, 2014",0,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,MS,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00240383,Bristol-Myers Squibb,False,MS,https://ClinicalTrials.gov/show/NCT00240383,False,"Dose Ranging Study With LT, Monotherapy, PPAR",Diabetes Mellitus II,Drug:Muraglitazar,[],"September 10, 2010",18,70,Both,False
NCT00239681,AstraZeneca,False,MS,https://ClinicalTrials.gov/show/NCT00239681,False,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],"February 6, 2014",50,9223372036854775807,Both,False
NCT02102204,Amgen,False,MS,https://ClinicalTrials.gov/show/NCT02102204,False,To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis,"Hyperparathyroidism, Secondary",Drug:AMG 416,[],"December 22, 2015",18,110,Both,False
NCT01785875,Amgen,False,MS,https://ClinicalTrials.gov/show/NCT01785875,False,20120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HD,"Hyperparathyroidism, Secondary",Drug:AMG 416,[],"December 19, 2015",18,100,Both,False
NCT01547741,NSABP Foundation Inc,False,MS,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01508026,Forest Laboratories,False,MS,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01356602,Novartis Pharmaceuticals,False,MS,https://ClinicalTrials.gov/show/NCT01356602,False,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Acute Gouty Arthritis,Drug:Canakinumab pre-filled syringe; Drug:Canakinumab lyophilized powder; Drug:Triamcinolone Acetonide; Drug:Placebo,[],"December 10, 2013",18,85,Both,False
NCT00891020,Hoffmann-La Roche,False,MS,https://ClinicalTrials.gov/show/NCT00891020,False,A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs),Rheumatoid Arthritis,Drug:tocilizumab [RoActemra/Actemra]; Drug:tocilizumab [RoActemra/Actemra]; Drug:Nonbiologic DMARDs of investigator's choice,[],"October 19, 2012",18,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,MS,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00658515,Hoffmann-La Roche,False,MS,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00471146,Pfizer,False,MS,https://ClinicalTrials.gov/show/NCT00471146,False,Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.,"Carcinoma, Pancreatic Ductal",Drug:AG-013736; Drug:Gemcitabine; Drug:Gemcitabine; Drug:placebo,[],"June 14, 2012",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,MS,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00057928,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT00057928,False,"S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer",Cervical Cancer,Drug:cisplatin; Drug:gemcitabine hydrochloride; Drug:paclitaxel,[],"June 11, 2012",0,9223372036854775807,Female,False
NCT00053833,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT00053833,False,"S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Drug:irinotecan,[],"November 7, 2013",0,9223372036854775807,Female,False
NCT00045617,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT00045617,False,"S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer",Lung Cancer,Biological:monoclonal antibody 11D10 anti-idiotype vaccine; Biological:monoclonal antibody GD2 anti-idiotype vaccine; Drug:cisplatin; Drug:etoposide; Radiation:radiation therapy,[],"June 11, 2012",18,9223372036854775807,Both,False
NCT00041119,Alliance for Clinical Trials in Oncology,True,MS,https://ClinicalTrials.gov/show/NCT00041119,False,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"July 23, 2015",18,9223372036854775807,Female,False
NCT00034879,AstraZeneca,False,MS,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT00032123,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00032123,False,Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer,Esophageal Cancer; Gastric Cancer,Drug:erlotinib hydrochloride,[],"June 21, 2013",0,9223372036854775807,Both,False
NCT00031772,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00031772,False,S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer,Breast Cancer; Psychosocial Effects of Cancer and Its Treatment,Procedure:psychosocial assessment and care,[],"February 12, 2013",18,9223372036854775807,Female,False
NCT00030433,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00030433,False,S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Drug:gemcitabine hydrochloride; Drug:irinotecan hydrochloride,[],"February 12, 2013",18,9223372036854775807,Both,False
NCT00026520,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00026520,False,Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Drug:thalidomide,[],"June 20, 2013",18,9223372036854775807,Both,False
NCT00026156,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00026156,False,S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:docetaxel; Drug:vinorelbine tartrate,[],"February 12, 2013",18,9223372036854775807,Both,False
NCT00023777,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00023777,False,S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia,Leukemia,Biological:filgrastim; Biological:sargramostim; Drug:cytarabine; Drug:daunorubicin hydrochloride,[],"March 5, 2015",56,9223372036854775807,Both,False
NCT00023751,Alliance for Clinical Trials in Oncology,False,MS,https://ClinicalTrials.gov/show/NCT00023751,False,Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer,Colorectal Cancer,Drug:fluorouracil; Drug:leucovorin calcium; Procedure:conventional surgery; Radiation:radiation therapy,[],"July 13, 2015",18,9223372036854775807,Both,False
NCT00016965,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00016965,False,BMS-247550 in Treating Patients With Advanced Pancreatic Cancer,Pancreatic Cancer,Drug:ixabepilone,[],"June 20, 2013",18,9223372036854775807,Both,False
NCT00016939,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00016939,False,Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer,Kidney Cancer,Drug:alvocidib,[],"June 20, 2013",0,9223372036854775807,Both,False
NCT00016419,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT00016419,False,S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome,Leukemia; Myelodysplastic Syndromes,Biological:anti-thymocyte globulin; Drug:cyclosporine,[],"March 5, 2015",15,9223372036854775807,Both,False
NCT00014196,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT00014196,False,S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:docetaxel; Radiation:radiation therapy,[],"February 12, 2013",18,9223372036854775807,Both,False
NCT00014144,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT00014144,False,"S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract",Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer,Drug:gefitinib,[],"October 5, 2012",0,9223372036854775807,Both,False
NCT00012363,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00012363,False,S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus,Esophageal Cancer; Gastric Cancer,Drug:gemcitabine hydrochloride; Drug:irinotecan hydrochloride,[],"June 12, 2012",18,9223372036854775807,Both,False
NCT00006708,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT00006708,False,S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,Lymphoma,Biological:filgrastim; Biological:rituximab; Drug:carboplatin; Drug:etoposide; Drug:ifosfamide,[],"April 8, 2013",18,9223372036854775807,Both,False
NCT00006487,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00006487,False,S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:etoposide; Drug:tirapazamine; Radiation:radiation therapy,[],"October 3, 2012",18,9223372036854775807,Both,False
NCT00006484,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00006484,False,Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:paclitaxel; Drug:tirapazamine,[],"June 20, 2013",18,9223372036854775807,Both,False
NCT00006248,Southwest Oncology Group,True,MS,https://ClinicalTrials.gov/show/NCT00006248,False,S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer,Head and Neck Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:paclitaxel,[],"April 8, 2013",18,9223372036854775807,Both,False
NCT00005834,Southwest Oncology Group,False,MS,https://ClinicalTrials.gov/show/NCT00005834,False,S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma,Multiple Myeloma,Biological:filgrastim; Drug:cisplatin; Drug:cyclophosphamide; Drug:dexamethasone; Drug:etoposide; Drug:thalidomide,[],"March 5, 2015",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02196181,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01658943,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,MO,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01498289,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01198158,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01097278,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT01015833,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00954174,Gynecologic Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00954174,False,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00946712,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00920010,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00920010,False,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],"February 5, 2015",0,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,MO,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00693992,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00640042,Pfizer,True,MO,https://ClinicalTrials.gov/show/NCT00640042,False,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],"June 6, 2012",21,9223372036854775807,Both,False
NCT00602459,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00602459,False,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT00588770,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00569127,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00569127,False,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],"January 5, 2015",0,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,MO,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00450281,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00450281,False,"S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",Lung Cancer,Genetic:chromogenic in situ hybridization; Genetic:gene expression analysis; Genetic:mutation analysis; Genetic:polymerase chain reaction; Genetic:polymorphism analysis; Other:fluorescent antibody technique; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis; Other:matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other:study of socioeconomic and demographic variables; Procedure:study of high risk factors,[],"October 23, 2015",18,120,Both,False
NCT00408408,NSABP Foundation Inc,True,MO,https://ClinicalTrials.gov/show/NCT00408408,False,"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery",Breast Cancer,Biological:bevacizumab; Drug:capecitabine; Drug:cyclophosphamide; Drug:docetaxel; Drug:doxorubicin hydrochloride (Adriamycin); Drug:gemcitabine hydrochloride,[],"February 9, 2015",18,9223372036854775807,Female,False
NCT00378703,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00378703,False,"Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer",Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Sorafenib; Drug:temsirolimus; Biological:bevacizumab,[],"April 14, 2015",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,MO,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,MO,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00262847,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00262847,False,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"August 18, 2015",18,9223372036854775807,Female,False
NCT00217737,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00134056,Southwest Oncology Group,True,MO,https://ClinicalTrials.gov/show/NCT00134056,False,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],"May 6, 2015",18,9223372036854775807,Male,False
NCT00087178,NSABP Foundation Inc,False,MO,https://ClinicalTrials.gov/show/NCT00087178,False,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],"October 5, 2015",18,9223372036854775807,Female,False
NCT00079274,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00075946,Eastern Cooperative Oncology Group,True,MO,https://ClinicalTrials.gov/show/NCT00075946,False,Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma,Lymphoma,Biological:rituximab,[],"June 3, 2015",18,9223372036854775807,Both,False
NCT00075764,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00075764,False,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],"May 8, 2014",18,9223372036854775807,Female,False
NCT00070564,Southwest Oncology Group,True,MO,https://ClinicalTrials.gov/show/NCT00070564,False,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",Breast Cancer,Biological:pegfilgrastim; Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"September 15, 2015",18,9223372036854775807,Both,False
NCT00063999,Gynecologic Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00063999,False,"Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Endometrial Cancer,Biological:filgrastim; Drug:carboplatin; Drug:cisplatin; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"April 23, 2009",18,9223372036854775807,Female,False
NCT00041119,Alliance for Clinical Trials in Oncology,True,MO,https://ClinicalTrials.gov/show/NCT00041119,False,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"July 23, 2015",18,9223372036854775807,Female,False
NCT00006721,Southwest Oncology Group,False,MO,https://ClinicalTrials.gov/show/NCT00006721,False,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma,Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Radiation:tositumomab and iodine I 131 tositumomab,[],"February 21, 2014",18,9223372036854775807,Both,False
NCT02042443,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,MO,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02311907,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT00951496,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00946712,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942331,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00920010,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00920010,False,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],"February 5, 2015",0,9223372036854775807,Both,False
NCT00828139,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00828139,False,Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:ziv-aflibercept; Drug:topotecan hydrochloride,[],"April 9, 2014",18,9223372036854775807,Both,False
NCT00803062,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00803062,False,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT00785291,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00776100,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT00776100,False,Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Other:clinical observation; Radiation:radiation therapy,[],"July 8, 2015",18,9223372036854775807,Both,False
NCT00770809,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00770809,False,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT00684983,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00684983,False,"Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",HER2/Neu Positive; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Capecitabine; Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Lapatinib Ditosylate; Other:Quality-of-Life Assessment,[],"December 23, 2015",18,9223372036854775807,Both,False
NCT00658814,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00658814,False,Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,Adult Acute Megakaryoblastic Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With Maturation; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Myeloid Leukemia Without Maturation; Adult Acute Myelomonocytic Leukemia; Adult Erythroleukemia; Adult Pure Erythroid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:Azacitidine; Drug:Gemtuzumab Ozogamicin,[],"February 4, 2016",60,9223372036854775807,Both,False
NCT00644228,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00644228,False,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],"September 12, 2014",18,9223372036854775807,Both,False
NCT00617708,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00617708,False,S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,Stage IV Pancreatic Cancer,Biological:cixutumumab; Drug:erlotinib hydrochloride; Drug:gemcitabine hydrochloride,[],"July 25, 2014",18,9223372036854775807,Both,False
NCT00602641,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00602641,False,"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:melphalan; Drug:prednisone; Drug:thalidomide; Drug:lenalidomide,[],"June 9, 2015",18,9223372036854775807,Both,False
NCT00601900,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00588770,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00569127,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00569127,False,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],"January 5, 2015",0,9223372036854775807,Both,False
NCT00520975,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00520975,False,First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU,HER2/Neu Positive; Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"December 17, 2015",18,9223372036854775807,Both,False
NCT00513747,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT00513747,False,Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia,Leukemia,Biological:rituximab; Drug:fludarabine phosphate,[],"October 26, 2015",18,9223372036854775807,Both,False
NCT00499369,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00499369,False,Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Biological:bevacizumab,[],"July 25, 2014",18,9223372036854775807,Both,False
NCT00454194,Alliance for Clinical Trials in Oncology,False,MT,https://ClinicalTrials.gov/show/NCT00454194,False,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Drug:pemetrexed disodium; Drug:sorafenib tosylate,[],"July 6, 2015",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00352365,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00352365,False,Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia,Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia,Drug:lenalidomide,[],"July 25, 2014",60,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00313586,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00313586,False,"Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia",Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA; Alkylating Agent-Related Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome; Untreated Adult Acute Myeloid Leukemia,Drug:Azacitidine; Drug:Entinostat; Other:Laboratory Biomarker Analysis,[],"December 17, 2015",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00303953,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00303953,False,PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma,Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma,Drug:belinostat,[],"April 23, 2014",18,9223372036854775807,Both,False
NCT00303628,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00303628,False,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],"May 20, 2014",18,9223372036854775807,Both,False
NCT00262847,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00262847,False,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"August 18, 2015",18,9223372036854775807,Female,False
NCT00217737,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00134056,Southwest Oncology Group,True,MT,https://ClinicalTrials.gov/show/NCT00134056,False,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],"May 6, 2015",18,9223372036854775807,Male,False
NCT00124618,Alliance for Clinical Trials in Oncology,True,MT,https://ClinicalTrials.gov/show/NCT00124618,False,Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,Lung Cancer,Biological:cetuximab; Radiation:radiation therapy,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00124579,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00124579,False,"S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",Multiple Myeloma,Drug:bortezomib; Drug:dexamethasone; Drug:thalidomide,[],"March 5, 2015",18,9223372036854775807,Both,False
NCT00109967,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00109967,False,CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,Recurrent Mantle Cell Lymphoma,Biological:rituximab; Drug:temsirolimus,[],"March 21, 2014",18,9223372036854775807,Both,False
NCT00109837,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00109837,False,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,Leukemia,Biological:filgrastim; Drug:cyclophosphamide; Drug:cytarabine; Drug:daunorubicin; Drug:dexamethasone; Drug:doxorubicin; Drug:leucovorin; Drug:mercaptopurine; Drug:methotrexate; Drug:mitoxantrone; Drug:Asparaginase; Drug:prednisone; Drug:thioguanine; Drug:vincristine; Radiation:radiation therapy; Drug:allopurinol; Drug:bactrim,[],"March 5, 2015",18,64,Both,False
NCT00107380,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00107380,False,"S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",Lymphoma,Biological:rituximab; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate; Radiation:tositumomab and iodine I 131 tositumomab,[],"September 28, 2015",18,120,Both,False
NCT00093470,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00093470,False,Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission,Adult Acute Myeloid Leukemia; Adult Acute Myeloid Leukemia in Remission,Procedure:Clinical Observation; Drug:Tipifarnib,[],"October 13, 2015",18,9223372036854775807,Both,False
NCT00090961,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00090961,False,"S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer",Lung Cancer; Pulmonary Complications,Other:educational intervention; Other:supervised exercise program,[],"October 31, 2012",0,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00070499,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00070499,False,Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia,"Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase of Disease",Drug:Dasatinib; Drug:Imatinib Mesylate; Other:Laboratory Biomarker Analysis,[],"January 6, 2016",18,9223372036854775807,Both,False
NCT00049179,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00049179,False,S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia,Leukemia,Drug:cytarabine; Drug:gemtuzumab ozogamicin,[],"March 5, 2015",18,9223372036854775807,Both,False
NCT00049127,National Cancer Institute (NCI),False,MT,https://ClinicalTrials.gov/show/NCT00049127,False,Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor,Adult Anaplastic Oligodendroglioma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor,Drug:imatinib mesylate; Other:laboratory biomarker analysis; Other:pharmacological study,[],"October 1, 2014",18,9223372036854775807,Both,False
NCT00045162,Southwest Oncology Group,True,MT,https://ClinicalTrials.gov/show/NCT00045162,False,S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:etoposide; Drug:irinotecan hydrochloride,[],"July 3, 2013",18,9223372036854775807,Both,False
NCT00040937,Southwest Oncology Group,True,MT,https://ClinicalTrials.gov/show/NCT00040937,False,"S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma",Multiple Myeloma,Biological:filgrastim; Biological:sargramostim; Drug:cyclophosphamide; Drug:dexamethasone; Drug:melphalan; Drug:prednisone; Drug:thalidomide; Procedure:peripheral blood stem cell transplantation,[],"March 5, 2015",18,65,Both,False
NCT00039377,National Cancer Institute (NCI),True,MT,https://ClinicalTrials.gov/show/NCT00039377,False,"Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",Adult Acute Lymphoblastic Leukemia in Remission,Drug:imatinib mesylate; Drug:methotrexate; Drug:vincristine sulfate; Drug:leucovorin calcium; Procedure:peripheral blood stem cell transplantation; Procedure:autologous hematopoietic stem cell transplantation; Procedure:allogeneic hematopoietic stem cell transplantation; Radiation:total-body irradiation; Drug:tacrolimus; Biological:filgrastim; Drug:etoposide; Drug:cyclophosphamide; Drug:cytarabine; Other:laboratory biomarker analysis,[],"November 13, 2014",15,59,Both,False
NCT00008385,Eastern Cooperative Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00008385,False,Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer,Lung Cancer,Dietary Supplement:selenium; Other:placebo,[],"May 15, 2015",18,9223372036854775807,Both,False
NCT00006237,Southwest Oncology Group,False,MT,https://ClinicalTrials.gov/show/NCT00006237,False,S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma,Melanoma (Skin),Biological:interleukin-2; Biological:filgrastim; Biological:interferon alfa; Drug:cisplatin; Drug:dacarbazine; Drug:vinblastine,[],"March 5, 2015",18,9223372036854775807,Both,False
NCT00003896,Southwest Oncology Group,True,MT,https://ClinicalTrials.gov/show/NCT00003896,False,"S9912 Combination Chemo in Stage III Ovarian Cancer,",Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer,Drug:cisplatin; Drug:liposomal doxorubicin; Drug:paclitaxel,[],"January 2, 2013",0,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00769379,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00588770,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00003594,Alliance for Clinical Trials in Oncology,True,NE,https://ClinicalTrials.gov/show/NCT00003594,False,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug:irinotecan; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT01642251,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00942331,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT02066181,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02066181,False,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00346216,Pfizer,False,NE,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,NE,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00072046,Alliance for Clinical Trials in Oncology,True,NE,https://ClinicalTrials.gov/show/NCT00072046,False,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00373685,Pfizer,False,NE,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02498600,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02498600,False,"Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"January 11, 2016",18,9223372036854775807,Female,False
NCT02315430,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT00892177,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT00892177,False,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00569127,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00569127,False,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],"January 5, 2015",0,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,NE,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00079001,Alliance for Clinical Trials in Oncology,True,NE,https://ClinicalTrials.gov/show/NCT00079001,False,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer; Prostate Cancer,Drug:zoledronic acid; Other:placebo; Drug:androgen deprivation therapy; Drug:GnRH agonist; Dietary Supplement:Calcium supplement; Dietary Supplement:Vitamin D,[],"November 23, 2015",18,9223372036854775807,Male,False
NCT00003596,Radiation Therapy Oncology Group,True,NE,https://ClinicalTrials.gov/show/NCT00003596,False,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer,Anal Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:mitomycin C; Radiation:radiation therapy,[],"November 18, 2013",18,9223372036854775807,Both,False
NCT02257528,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT02257528,False,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT01313676,GlaxoSmithKline,False,NE,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,NE,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00463567,Novartis,False,NE,https://ClinicalTrials.gov/show/NCT00463567,False,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive; COPD; Lung Diseases, Obstructive",Drug:Indacaterol; Drug:Formoterol (12 g b.i.d.); Drug:Tiotropium (18 g o.d.); Drug:Placebo to Indacaterol; Drug:Placebo to Formoterol,[],"July 22, 2011",40,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,NE,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00324805,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00041119,Alliance for Clinical Trials in Oncology,True,NE,https://ClinicalTrials.gov/show/NCT00041119,False,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"July 23, 2015",18,9223372036854775807,Female,False
NCT01167712,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT00567580,Radiation Therapy Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT00567580,False,Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:flutamide; Radiation:radiation therapy,[],"March 31, 2015",18,9223372036854775807,Male,False
NCT00217737,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00087399,Alliance for Clinical Trials in Oncology,True,NE,https://ClinicalTrials.gov/show/NCT00087399,False,Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy,Breast Cancer; Hot Flashes,Drug:gabapentin; Drug:antidepressant,[],"July 7, 2015",18,9223372036854775807,Female,False
NCT00057876,Eastern Cooperative Oncology Group,True,NE,https://ClinicalTrials.gov/show/NCT00057876,False,Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer,Pancreatic Cancer,Drug:Gemcitabine; Radiation:radiation therapy,[],"February 11, 2013",18,9223372036854775807,Both,False
NCT00043069,Alliance for Clinical Trials in Oncology,True,NE,https://ClinicalTrials.gov/show/NCT00043069,False,Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer,Osteoporosis; Prostate Cancer,Dietary Supplement:calcium carbonate; Dietary Supplement:cholecalciferol; Drug:Estrogen Antagonists; Drug:risedronate sodium; Other:placebo,[],"July 7, 2015",18,9223372036854775807,Male,False
NCT01572792,Forest Laboratories,False,NE,https://ClinicalTrials.gov/show/NCT01572792,False,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:Placebo,[],"February 27, 2015",40,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,NE,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01437397,Forest Laboratories,False,NE,https://ClinicalTrials.gov/show/NCT01437397,False,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide/Formoterol Fumarate; Drug:Aclidinium Bromide; Drug:Formoterol Fumarate; Drug:placebo,[],"April 5, 2013",40,9223372036854775807,Both,False
NCT01286233,NSABP Foundation Inc,False,NE,https://ClinicalTrials.gov/show/NCT01286233,False,Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32,Breast Cancer; Depression; Fatigue; Sleep Disorders,Drug:Metformin; Drug:Placebo,[],"September 8, 2015",18,74,Female,False
NCT00942357,Gynecologic Oncology Group,False,NE,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00693992,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00601900,National Cancer Institute (NCI),False,NE,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00490139,GlaxoSmithKline,False,NE,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT02500797,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02196181,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02097238,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02097238,False,Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma,Recurrent Osteosarcoma,Drug:Eribulin Mesylate; Other:Pharmacological Study,[],"December 18, 2015",12,49,Both,False
NCT02066181,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02066181,False,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,Desmoid-Type Fibromatosis,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate,[],"January 25, 2016",18,9223372036854775807,Both,False
NCT02042443,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01708954,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01196390,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00946712,Southwest Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00588770,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00346216,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00373256,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT00373256,False,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Drug:Sunitinib; Drug:paclitaxel; Drug:bevacizumab; Drug:paclitaxel,[],"September 5, 2012",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,NV,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT01508026,Forest Laboratories,False,NV,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT00887536,NSABP Foundation Inc,False,NV,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00625898,NSABP Foundation Inc,False,NV,https://ClinicalTrials.gov/show/NCT00625898,False,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,Breast Cancer,Drug:Docetaxel; Drug:Trastuzumab; Drug:Carboplatin; Drug:Bevacizumab; Drug:5-Fluorouracil; Drug:Epirubicin; Drug:Cyclophosphamide,[],"July 7, 2014",18,9223372036854775807,Female,False
NCT01942135,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT01942135,False,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Drug:Palbociclib; Drug:Fulvestrant; Drug:Placebo; Drug:Fulvestrant,[],"November 16, 2015",18,9223372036854775807,Female,False
NCT01937715,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT01937715,False,A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,Metastatic Colorectal Carcinoma,Drug:PF-05212384; Drug:FOLFIRI regimen; Biological:Bevacizumab; Drug:FOLFIRI,[],"December 15, 2015",18,9223372036854775807,Both,False
NCT01740427,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT01740427,False,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),Breast Neoplasms,Drug:PD-0332991; Drug:Letrozole; Drug:Placebo; Drug:Letrozole,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01441414,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT01441414,False,PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma,Metastatic Renal Cell Carcinoma,Biological:PF-04856884; Drug:Axitinib (AG-013736); Drug:Axitinib (AG-013736),"[u'Pinnacle Oncology Hematology', u'Arizona Oncology Associates, PC - HOPE', u'Arizona Oncology Associates, PC-HOPE', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Rocky Mountain Cancer Centers', u'Nebraska Methodist Hospital', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Regional Cancer Care-Durham', u'Investigational Products Center (IPC) (drug shipment only)', u'Texas Oncology-Tyler', u'Seattle Cancer Care Alliance', u'University of Washington Medical Center', u'Masarykuv onkologicky ustav']","December 11, 2015",18,9223372036854775807,Both,False
NCT01306890,Dendreon,False,NV,https://ClinicalTrials.gov/show/NCT01306890,False,A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer,Advanced Prostate Cancer; Prostatic Neoplasms,Biological:sipuleucel-T,[],"October 5, 2015",18,9223372036854775807,Male,False
NCT01298219,"Sucampo Pharmaceuticals, Inc.",False,NV,https://ClinicalTrials.gov/show/NCT01298219,False,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL),Opioid-induced Bowel Dysfunction,Drug:Lubiprostone; Drug:Placebo,[],"February 1, 2013",18,9223372036854775807,Both,False
NCT00968968,GlaxoSmithKline,False,NV,https://ClinicalTrials.gov/show/NCT00968968,False,Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,Cancer,Drug:Lapatinib; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00920816,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT00920816,False,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],"November 12, 2015",18,9223372036854775807,Both,False
NCT00721409,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT00721409,False,Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer,Breast Cancer,Drug:PD 0332991; Drug:letrozole; Drug:letrozole,[],"November 4, 2015",18,9223372036854775807,Female,False
NCT00616772,"AbbVie (prior sponsor, Abbott)",False,NV,https://ClinicalTrials.gov/show/NCT00616772,False,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia,Drug:ABT-335; Drug:Placebo; Other:Atorvastatin,[],"December 3, 2013",45,9223372036854775807,Both,False
NCT00257205,AstraZeneca,False,NV,https://ClinicalTrials.gov/show/NCT00257205,False,"CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy",Melanoma,"Drug:dacarbazine; Drug:CP-675,206; Drug:temozolomide",[],"June 25, 2012",18,9223372036854775807,Both,False
NCT00196989,GlaxoSmithKline,False,NV,https://ClinicalTrials.gov/show/NCT00196989,False,Study In People With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:Pioglitazone; Drug:GW677954,[],"June 17, 2015",18,70,Both,False
NCT01925274,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT01925274,False,A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug:PF-05212384; Drug:irinotecan; Drug:Cetuximab; Drug:Irinotecan,"[u'CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center', u'UCLA West Medical Pharmacy', u'Drug Management Only: UCLA West Medical Pharmacy, Att: Steven L Wong, Pharm D', u'TRIO_US', u'TRIO-US Central Administration (Regulatory Management only)', u'TRIO-US Central Administration', u'UCLA West Medical Pharmacy', u'West Valley Hematology/Oncology Group', u'Siteman Cancer Center - West County', u'Drug Shipping Address: Washington University Infusion Center Pharmacy', u'Siteman Cancer Center - South County', u'Barnes Jewish Hospital', u'Washington University School of Medicine', u'Siteman Cancer Center - St Peters', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada - Sunset Rd.', u'Comprehensive Cancer Centers of Nevada', u'Comprehensive Cancer Centers of Nevada', u'Roswell Park Cancer Institute', u'Kadlec Medical Center', u'Outpatient Imaging Center', u'Medical Oncology Associates, PS', u'Spokane Valley Cancer Center', u'Aichi cancer center central hospital', u'National Cancer Center Hospital East', u'National Cancer Center', u'Seoul National University Hospital / Department of Internal Medicine', u'Samsung Medical Center', u'Asan Medical Center', u'Hospital General Universitario Gregorio Mara\xf1\xf3n']","January 11, 2016",18,9223372036854775807,Both,False
NCT01767194,National Cancer Institute (NCI),False,NV,https://ClinicalTrials.gov/show/NCT01767194,False,Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,Ganglioneuroblastoma; Recurrent Neuroblastoma,Biological:Dinutuximab; Drug:Irinotecan Hydrochloride; Other:Laboratory Biomarker Analysis; Biological:Sargramostim; Drug:Temozolomide; Drug:Temsirolimus,[],"October 27, 2015",0,9223372036854775807,Both,False
NCT01244191,Daiichi Sankyo Inc.,False,NV,https://ClinicalTrials.gov/show/NCT01244191,False,"ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer","Non Squamous, Non-small-cell Lung Cancer",Drug:Tivantinib (ARQ 197) plus erlotinib; Drug:ARQ 197 placebo plus erlotinib,[],"October 22, 2015",18,9223372036854775807,Both,False
NCT01195662,AstraZeneca,False,NV,https://ClinicalTrials.gov/show/NCT01195662,False,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,Type 2 Diabetes,Drug:Dapagliflozin; Drug:Placebo matching Dapagliflozin,[],"December 2, 2015",18,89,Both,False
NCT01137474,Bristol-Myers Squibb,False,NV,https://ClinicalTrials.gov/show/NCT01137474,False,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,Type 2 Diabetes,Drug:Dapagliflozin; Drug:Placebo-matching dapagliflozin; Drug:Oral antidiabetic agent; Drug:Angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB); Drug:With or without insulin,[],"April 1, 2014",18,89,Both,False
NCT00900250,Children's Oncology Group,False,NV,https://ClinicalTrials.gov/show/NCT00900250,False,Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma,Refractory Childhood Hodgkin Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma,Other:Cytology Specimen Collection Procedure,[],"May 12, 2015",0,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,NV,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00839527,GlaxoSmithKline,False,NV,https://ClinicalTrials.gov/show/NCT00839527,False,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00838916,GlaxoSmithKline,False,NV,https://ClinicalTrials.gov/show/NCT00838916,False,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:insulin glargine,[],"May 22, 2014",18,9223372036854775807,Both,False
NCT00838903,GlaxoSmithKline,False,NV,https://ClinicalTrials.gov/show/NCT00838903,False,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],"August 11, 2014",18,9223372036854775807,Both,False
NCT00683137,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT00683137,False,Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery,Pain; Hallux Valgus,Drug:valdecoxib; Drug:valdecoxib; Drug:valdecoxib/placebo,[],"May 22, 2008",18,9223372036854775807,Both,False
NCT00678392,Pfizer,False,NV,https://ClinicalTrials.gov/show/NCT00678392,False,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT02515981,Dartmouth-Hitchcock Medical Center,False,NH,https://ClinicalTrials.gov/show/NCT02515981,False,New Hampshire Medicaid Wellness Incentive Program,Tobacco Dependence; Obesity; Mental Illness,Behavioral:NH Medicaid Incentives Program,"[u'New Hampshire Hospital', u'Riverbend Community Mental Health Center', u'Center for Life Management', u'Community Partners', u'Mondadnock Family Services', u'West Central Behavioral Health Care', u'Northern Human Services', u'The Mental Health Center of Greater Manchester', u'Greater Nashua Mental Health Center at Community Council', u'Harbor Homes', u'Genesis Behavioral Heatlh', u'Seacoast Mental Health Center']","January 21, 2016",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00310180,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT01886872,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00068328,Alliance for Clinical Trials in Oncology,True,NH,https://ClinicalTrials.gov/show/NCT00068328,False,Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer,Breast Cancer; Psychosocial Effects of Cancer and Its Treatment,Procedure:psychosocial assessment and care; Procedure:quality-of-life assessment,[],"July 23, 2015",65,9223372036854775807,Female,False
NCT00785291,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,NH,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,NH,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00041119,Alliance for Clinical Trials in Oncology,True,NH,https://ClinicalTrials.gov/show/NCT00041119,False,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"July 23, 2015",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01004640,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT01004640,False,Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial,Leukemia,Genetic:DNA analysis; Genetic:Southern blotting; Genetic:cytogenetic analysis; Genetic:polymerase chain reaction,[],"July 23, 2015",0,9223372036854775807,Both,False
NCT00892177,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT00892177,False,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00770809,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00770809,False,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT00655876,Radiation Therapy Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT00655876,False,"Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer",Esophageal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:paclitaxel; Radiation:radiation therapy,[],"March 31, 2015",18,74,Both,False
NCT00601900,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00489411,Alliance for Clinical Trials in Oncology,True,NH,https://ClinicalTrials.gov/show/NCT00489411,False,Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,"Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific",Drug:duloxetine hydrochloride; Other:placebo,[],"July 6, 2015",25,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,NH,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00316836,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT00316836,False,"Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole",Breast Cancer,Procedure:mammography,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00288080,Radiation Therapy Oncology Group,True,NH,https://ClinicalTrials.gov/show/NCT00288080,False,Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:docetaxel; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:prednisone; Drug:triptorelin; Radiation:radiation therapy,[],"March 20, 2015",18,9223372036854775807,Male,False
NCT00053898,NSABP Foundation Inc,True,NH,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT01547741,NSABP Foundation Inc,False,NH,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01101438,NCIC Clinical Trials Group,True,NH,https://ClinicalTrials.gov/show/NCT01101438,False,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],"May 5, 2015",18,74,Both,False
NCT01099449,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT01099449,False,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT00942331,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00899223,Alliance for Clinical Trials in Oncology,True,NH,https://ClinicalTrials.gov/show/NCT00899223,False,"Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes",Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Other:biologic sample preservation procedure,[],"July 11, 2013",0,9223372036854775807,Both,False
NCT00602459,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00602459,False,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT00573287,Dartmouth-Hitchcock Medical Center,False,NH,https://ClinicalTrials.gov/show/NCT00573287,False,First Episode Schizophrenia and Cannabis-Related Disorder Study,Cannabis-Related Disorder; Substance-Related Disorders; Schizophrenia; Psychotic Disorders,Drug:clozapine; Drug:risperidone,"[u'New Hampshire Hospital', u'Dartmouth Hitchcock Medical Center', u'West Central Behavioral Health', u'Mental Health Center of Greater Manchester', u'Center for Psychiatric Advancement & Community Council of Nashua']","March 1, 2013",17,45,Both,False
NCT00417040,Alliance for Clinical Trials in Oncology,False,NH,https://ClinicalTrials.gov/show/NCT00417040,False,Using the Internet to Collect Symptoms and the Ability to Carry Out Daily Activities From Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy,Prostate Cancer,Other:internet-based intervention; Procedure:assessment of therapy complications; Other:Questionnaire Administration,[],"July 23, 2015",18,9223372036854775807,Male,False
NCT00217737,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00117975,Alliance for Clinical Trials in Oncology,True,NH,https://ClinicalTrials.gov/show/NCT00117975,False,"Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",Lymphoma,Biological:galiximab; Biological:rituximab,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00103181,NSABP Foundation Inc,True,NH,https://ClinicalTrials.gov/show/NCT00103181,False,Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:3-dimensional conformal accelerated partial breast irradiation; Radiation:brachytherapy; Radiation:whole breast irradiation; Radiation:MammoSite or other single-entry intracavitary device,[],"October 8, 2015",18,9223372036854775807,Female,False
NCT00079001,Alliance for Clinical Trials in Oncology,True,NH,https://ClinicalTrials.gov/show/NCT00079001,False,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer; Prostate Cancer,Drug:zoledronic acid; Other:placebo; Drug:androgen deprivation therapy; Drug:GnRH agonist; Dietary Supplement:Calcium supplement; Dietary Supplement:Vitamin D,[],"November 23, 2015",18,9223372036854775807,Male,False
NCT00075764,Southwest Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT00075764,False,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],"May 8, 2014",18,9223372036854775807,Female,False
NCT00066690,International Breast Cancer Study Group,True,NH,https://ClinicalTrials.gov/show/NCT00066690,False,Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer,Breast Cancer,Drug:exemestane; Drug:tamoxifen citrate; Drug:triptorelin; Procedure:oophorectomy; Radiation:radiation therapy,[],"November 6, 2013",0,9223372036854775807,Female,False
NCT00008385,Eastern Cooperative Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT00008385,False,Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer,Lung Cancer,Dietary Supplement:selenium; Other:placebo,[],"May 15, 2015",18,9223372036854775807,Both,False
NCT00004124,Southwest Oncology Group,True,NH,https://ClinicalTrials.gov/show/NCT00004124,False,"S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer",Prostate Cancer,Drug:bicalutamide; Drug:goserelin; Drug:mitoxantrone hydrochloride; Drug:prednisone,[],"October 3, 2012",18,9223372036854775807,Male,False
NCT00003389,Eastern Cooperative Oncology Group,True,NH,https://ClinicalTrials.gov/show/NCT00003389,False,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma,Lymphoma,Drug:Doxorubicin; Drug:Bleomycin; Drug:Vinblastine; Drug:Dacarbazine; Drug:Vincristine; Drug:Mechlorethamine; Drug:Etoposide; Drug:Prednisone; Drug:Cyclophosphamide; Radiation:Radiotherapy,[],"September 25, 2015",16,9223372036854775807,Both,False
NCT02334280,Dartmouth-Hitchcock Medical Center,False,NH,https://ClinicalTrials.gov/show/NCT02334280,False,Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI,Schizophrenia; Bipolar Disorder; Schizoaffective Disorder,Behavioral:In SHAPE,"[u'West Central Behavioral Health', u'Mental Health Center of Greater Manchester', u'Greater Nashua Mental Health Center at Community Council', u'Center for Life Management']","January 7, 2015",21,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01648348,National Cancer Institute (NCI),False,NH,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01546987,Radiation Therapy Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT01546987,False,"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer",Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:orteronel; Drug:triptorelin,[],"November 14, 2015",18,9223372036854775807,Male,False
NCT01302834,Radiation Therapy Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT01302834,False,Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer,Head and Neck Cancer; Precancerous Condition,Biological:cetuximab; Drug:cisplatin,[],"November 14, 2015",18,120,Both,False
NCT01262560,Radiation Therapy Oncology Group,False,NH,https://ClinicalTrials.gov/show/NCT01262560,False,Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer,Dysphagia; Lung Cancer; Pain; Esophagitis,Drug:Manuka honey; Drug:Viscous lidocaine and magnesium aluminum oxide (Maalox); Liquid or solid oxycodone,[],"March 17, 2015",18,9223372036854775807,Both,False
NCT01245621,Dartmouth-Hitchcock Medical Center,True,NH,https://ClinicalTrials.gov/show/NCT01245621,False,Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III),Advanced Cancer,Behavioral:Later entry group; Behavioral:Early palliative care intervention,"[u'Dartmouth-Hitchcock Medical Center - Lebanon', u'Dartmouth-Hitchcock Clinic - Manchester', u'St. Joseph Hospital', u'Dartmouth-Hitchcock NCCC Nashua', u'Providence VA Medical Center', u'Mountainview Medical', u""Veteran's Administration Hospital""]","January 2, 2014",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00658515,Hoffmann-La Roche,False,NJ,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00640042,Pfizer,True,NJ,https://ClinicalTrials.gov/show/NCT00640042,False,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],"June 6, 2012",21,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,NJ,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00373685,Pfizer,False,NJ,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00264901,Novo Nordisk A/S,False,NJ,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00053898,NSABP Foundation Inc,True,NJ,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT00034879,AstraZeneca,False,NJ,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00878709,"Puma Biotechnology, Inc.",False,NJ,https://ClinicalTrials.gov/show/NCT00878709,False,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],"August 20, 2015",18,9223372036854775807,Female,False
NCT00346216,Pfizer,False,NJ,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01732822,AstraZeneca,False,NJ,https://ClinicalTrials.gov/show/NCT01732822,False,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Peripheral Artery Disease,Drug:Ticagrelor; Drug:Clopidogrel,[],"December 21, 2015",50,130,Both,False
NCT00003906,NSABP Foundation Inc,True,NJ,https://ClinicalTrials.gov/show/NCT00003906,False,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],"October 5, 2015",35,9223372036854775807,Female,False
NCT00501059,Bayer,False,NJ,https://ClinicalTrials.gov/show/NCT00501059,False,A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease,Moderate Risk of CVD,"Drug:Aspirin (Acetylsalicylic acid, BAYE4465); Drug:Placebo",[],"December 14, 2015",55,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,NJ,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00005044,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00005044,False,Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:flutamide; Drug:releasing hormone agonist therapy; Procedure:neoadjuvant therapy; Radiation:radiation therapy,[],"November 14, 2015",18,120,Male,False
NCT00003162,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00003162,False,Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer,Breast Cancer; Metastatic Cancer; Pain; Prostate Cancer,Procedure:pain therapy; Radiation:radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT00002874,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00002874,False,"Radiation Therapy With or Without Bicalutamide in Treating Patients With Stage II, Stage III, or Recurrent Prostate Cancer",Prostate Cancer,Drug:bicalutamide; Radiation:low-LET cobalt-60 gamma ray therapy; Radiation:low-LET photon therapy,[],"March 26, 2015",0,9223372036854775807,Male,False
NCT00245739,"Tibotec Pharmaceuticals, Ireland",False,NJ,https://ClinicalTrials.gov/show/NCT00245739,False,"TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.",HIV Infections,Drug:TMC-114,[],"April 10, 2014",18,9223372036854775807,Both,False
NCT00003313,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00003313,False,Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer,Drug/Agent Toxicity by Tissue/Organ; Lung Cancer; Oral Complications; Radiation Toxicity,Biological:filgrastim; Drug:amifostine trihydrate; Drug:carboplatin; Drug:paclitaxel; Radiation:radiation therapy,[],"November 19, 2014",18,9223372036854775807,Both,False
NCT00781391,Daiichi Sankyo Inc.,False,NJ,https://ClinicalTrials.gov/show/NCT00781391,False,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke; Atrial Fibrillation; Embolism,Drug:warfarin tablets; Drug:Edoxaban tablets (high dose regimen-60mg); Drug:Edoxaban tablets (low dose regimen-30mg); Drug:placebo warfarin; Drug:placebo edoxaban,[],"March 12, 2015",21,9223372036854775807,Both,False
NCT00549796,Johns Hopkins University,False,NJ,https://ClinicalTrials.gov/show/NCT00549796,False,Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery,Coronary Arteriosclerosis; Angina Pectoris,Other:Percutaneous coronary intervention (PCI),[],"September 10, 2014",18,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,NJ,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00262847,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00262847,False,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"August 18, 2015",18,9223372036854775807,Female,False
NCT00004917,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00004917,False,Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer,Anemia; Head and Neck Cancer,Biological:epoetin alfa; Drug:cisplatin; Radiation:radiation therapy,[],"November 14, 2015",18,9223372036854775807,Both,False
NCT00004011,Southwest Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00004011,False,S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:paclitaxel; Procedure:conventional surgery,[],"January 30, 2013",18,9223372036854775807,Both,False
NCT00003930,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00003930,False,Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer,Bladder Cancer,Drug:cisplatin; Drug:gemcitabine hydrochloride; Drug:paclitaxel; Procedure:conventional surgery; Radiation:radiation therapy,[],"October 13, 2015",18,9223372036854775807,Both,False
NCT00002597,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00002597,False,Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer,Prostate Cancer,Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Radiation:radiation therapy,[],"November 14, 2015",0,9223372036854775807,Male,False
NCT01547741,NSABP Foundation Inc,False,NJ,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01070836,Biogen,False,NJ,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,NJ,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00303628,National Cancer Institute (NCI),False,NJ,https://ClinicalTrials.gov/show/NCT00303628,False,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],"May 20, 2014",18,9223372036854775807,Both,False
NCT00257608,"Genentech, Inc.",False,NJ,https://ClinicalTrials.gov/show/NCT00257608,False,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),Non-Small Cell Lung Cancer,Drug:bevacizumab; Drug:placebo; Drug:erlotinib HCl,[],"September 30, 2015",18,9223372036854775807,Both,False
NCT00118131,University of Medicine and Dentistry of New Jersey,False,NJ,https://ClinicalTrials.gov/show/NCT00118131,False,Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:docetaxel,"[u'Central Jersey Oncology Center, PA - East Brunswick', u'JFK Medical Center in Edison', u'CentraState Medical Center', u'Cancer Institute of New Jersey at Hamilton', u'Monmouth Medical Center', u'Mountainside Hospital Cancer Center', u'Jersey Shore University Medical Center', u'Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School', u""Saint Peter's University Hospital"", u'UMDNJ - University Hospital', u'Raritan Bay Medical Center', u'Somerset Medical Center', u'Overlook Hospital']","September 19, 2013",18,9223372036854775807,Both,False
NCT00053053,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00053053,False,Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer,"Cachexia; Lymphoma; Lymphoproliferative Disorder; Unspecified Adult Solid Tumor, Protocol Specific",Dietary Supplement:Juven; Dietary Supplement:Non-Juven Supplement,[],"October 8, 2013",17,9223372036854775807,Both,False
NCT00047125,European Organisation for Research and Treatment of Cancer - EORTC,False,NJ,https://ClinicalTrials.gov/show/NCT00047125,False,Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor,Carcinoma of Unknown Primary,Radiation:radiation therapy,[],"June 19, 2012",18,9223372036854775807,Female,False
NCT00031967,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00031967,False,Melatonin and Radiation Therapy in Treating Patients With Brain Metastases,"Metastatic Cancer; Radiation Toxicity; Unspecified Adult Solid Tumor, Protocol Specific",Drug:therapeutic melatonin; Radiation:radiation therapy,[],"November 18, 2013",0,9223372036854775807,Both,False
NCT00023738,Radiation Therapy Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT00023738,False,"Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma",Sarcoma,Biological:filgrastim; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:ifosfamide; Drug:semaxanib; Procedure:conventional surgery; Radiation:radiation therapy,[],"June 20, 2013",18,9223372036854775807,Both,False
NCT00023725,Radiation Therapy Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT00023725,False,Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma,Sarcoma,Drug:semaxanib; Procedure:conventional surgery; Radiation:radiation therapy,[],"June 20, 2013",18,9223372036854775807,Both,False
NCT00017160,Radiation Therapy Oncology Group,False,NJ,https://ClinicalTrials.gov/show/NCT00017160,False,"Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma",Stage III Adult Soft Tissue Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage IVA Adult Soft Tissue Sarcoma; Stage IIB Adult Soft Tissue Sarcoma; Stage IIC Adult Soft Tissue Sarcoma,Drug:doxorubicin; Drug:filgrastim; Drug:ifosfamide; Procedure:biological response modifier therapy; Procedure:brachytherapy; Procedure:chemotherapy; Procedure:colony-stimulating factor therapy; Procedure:conventional surgery; Procedure:cytokine therapy; Procedure:intraoperative radiotherapy; Procedure:radiation therapy; Procedure:surgery,[],"June 25, 2013",0,9223372036854775807,Both,False
NCT00011999,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00011999,False,Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer,Head and Neck Cancer,Drug:cisplatin; Drug:paclitaxel; Procedure:conventional surgery; Radiation:radiation therapy,[],"November 14, 2015",21,9223372036854775807,Both,False
NCT00008398,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00008398,False,Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer,Head and Neck Cancer; Oral Complications; Radiation Toxicity,Biological:sargramostim; Procedure:quality-of-life assessment; Radiation:radiation therapy,[],"November 18, 2013",0,9223372036854775807,Both,False
NCT00006481,Radiation Therapy Oncology Group,True,NJ,https://ClinicalTrials.gov/show/NCT00006481,False,Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer,Head and Neck Cancer; Skin Reactions Secondary to Radiation Therapy,Drug:Biafine cream; Procedure:quality-of-life assessment; Radiation:radiation therapy,[],"November 18, 2013",0,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,NM,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,NM,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01374425,"Genentech, Inc.",False,NM,https://ClinicalTrials.gov/show/NCT01374425,False,Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer,Colorectal Cancer,Drug:5-fluorouracil; Drug:Bevacizumab; Drug:Irinotecan; Drug:Leucovorin; Drug:Oxaliplatin,[],"January 8, 2016",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00075764,Southwest Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT00075764,False,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],"May 8, 2014",18,9223372036854775807,Female,False
NCT01515800,Southwest Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT01515800,False,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],"October 23, 2015",18,120,Female,False
NCT01275677,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00871169,New Mexico Cancer Care Alliance,False,NM,https://ClinicalTrials.gov/show/NCT00871169,False,"Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",Pancreatic Cancer,"Drug:Irinotecan, oxaliplatin, and cetuximab","[u'University of New Mexico Cancer Center @ Lovelace Medical Center', u'Hematology Oncology Associates', u'Cancer Center at Presbyterian Hospital', u'University of New Mexico Cancer Center', u'Memorial Medical Center- Cancer Center']","January 15, 2016",18,9223372036854775807,Both,False
NCT00659269,New Mexico Cancer Care Alliance,False,NM,https://ClinicalTrials.gov/show/NCT00659269,False,A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients,Cancer,Dietary Supplement:Multivitamin (MV); Dietary Supplement:Multivitamin + Vitamin B12 + Vitamin B6; Drug:Chemotherapy,"[u'University of New Mexico Cancer Center @ Lovelace Medical Center', u'Hematology Oncology Associates', u'Cancer Center at Presbyterian Hospital', u'University of New Mexico Cancer Center', u'New Mexico Cancer Care Associates']","December 16, 2015",18,9223372036854775807,Both,False
NCT00391586,New Mexico Cancer Care Alliance,False,NM,https://ClinicalTrials.gov/show/NCT00391586,False,"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","Carcinoma, Non-Small-Cell Lung",Drug:Erlotinib; Drug:Platinum-based chemotherapy,"[u'Lovelace Medical Group', u'Hematology Oncology Associates NM', u'Presbyterian Medical Group', u'University of New Mexico Cancer Center', u'New Mexico Cancer Care Associates']","August 14, 2015",18,80,Both,False
NCT00382018,Southwest Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT00382018,False,S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy,Breast Cancer,Drug:chemotherapy,[],"September 15, 2015",18,9223372036854775807,Female,False
NCT00326898,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00288080,Radiation Therapy Oncology Group,True,NM,https://ClinicalTrials.gov/show/NCT00288080,False,Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:docetaxel; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:prednisone; Drug:triptorelin; Radiation:radiation therapy,[],"March 20, 2015",18,9223372036854775807,Male,False
NCT00072046,Alliance for Clinical Trials in Oncology,True,NM,https://ClinicalTrials.gov/show/NCT00072046,False,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00069745,Agennix,False,NM,https://ClinicalTrials.gov/show/NCT00069745,False,Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen,Prostate Cancer; Hormone Refractory Prostate Cancer,Drug:Satraplatin; Drug:Prednisone,[],"August 1, 2012",18,9223372036854775807,Male,False
NCT00053898,NSABP Foundation Inc,True,NM,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT00034879,AstraZeneca,False,NM,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT00003906,NSABP Foundation Inc,True,NM,https://ClinicalTrials.gov/show/NCT00003906,False,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],"October 5, 2015",35,9223372036854775807,Female,False
NCT02224781,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT02224781,False,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01376349,Alliance for Clinical Trials in Oncology,False,NM,https://ClinicalTrials.gov/show/NCT01376349,False,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],"September 24, 2015",18,9223372036854775807,Female,False
NCT01357291,Pepperdine University,False,NM,https://ClinicalTrials.gov/show/NCT01357291,False,Evaluating New Mexico's Recidivism Reduction Program,Behavior,Behavioral:Recidivism Reduction Program; Behavioral:Business-as-usual,"[u'Western New Mexico Correctional Facility (WNMCF)', u'Central New Mexico Correctional Facility (CNMCF)', u'Penitentiary of New Mexico (PNM)', u'Springer Correctional Facility (SCF)']","May 19, 2011",18,9223372036854775807,Male,False
NCT01169922,University of New Mexico,False,NM,https://ClinicalTrials.gov/show/NCT01169922,False,HIV Prevention With Adolescents: Neurocognitive Deficits and Treatment Response,Risk Reduction Behavior; Sexual Behavior; Health Behavior; Drinking Behavior; Adolescent Behavior,Behavioral:SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION; Behavioral:INFORMATION-ONLY SEXUAL RISK REDUCTION,"[u'Diversion Meetings (Youth Services Center)', u'Youth Reporting Center (Youth Services Center)', u'Albuquerque Academy', u'Sandia Preparatory School']","August 5, 2011",14,18,Both,True
NCT01086605,Alliance for Clinical Trials in Oncology,False,NM,https://ClinicalTrials.gov/show/NCT01086605,False,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],"August 4, 2015",18,9223372036854775807,Both,False
NCT01012297,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT01012297,False,Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma,Recurrent Uterine Corpus Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma,Biological:Bevacizumab; Drug:Docetaxel; Biological:Filgrastim; Drug:Gemcitabine Hydrochloride; Biological:Pegfilgrastim; Other:Placebo,[],"November 11, 2015",18,9223372036854775807,Female,False
NCT00775645,Southwest Oncology Group,True,NM,https://ClinicalTrials.gov/show/NCT00775645,False,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy",Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity,Dietary Supplement:acetyl-L-carnitine hydrochloride; Other:placebo,[],"January 13, 2014",18,9223372036854775807,Female,False
NCT00741429,Mannkind Corporation,False,NM,https://ClinicalTrials.gov/show/NCT00741429,False,A 2-Month Safety Follow-Up Trial,Type 1 Diabetes; Type 2 Diabetes,Drug:Technosphere Insulin Inhalation Powder; Drug:Comparator,[],"December 1, 2014",18,70,Both,False
NCT00644228,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00644228,False,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],"September 12, 2014",18,9223372036854775807,Both,False
NCT00637247,AmpliMed Corporation,True,NM,https://ClinicalTrials.gov/show/NCT00637247,False,A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer,Pancreatic Neoplasms,Drug:imexon in combination with gemcitabine; Drug:imexon placebo + gemcitabine,[],"November 30, 2010",18,9223372036854775807,Both,False
NCT00588770,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,NM,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00337129,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00337129,False,S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer,Head and Neck Cancer,Drug:eribulin mesylate,[],"August 11, 2015",18,9223372036854775807,Both,False
NCT00331760,Radiation Therapy Oncology Group,True,NM,https://ClinicalTrials.gov/show/NCT00331760,False,Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery,Cervical Cancer; Endometrial Cancer,Drug:cisplatin; Radiation:intensity-modulated radiation therapy,[],"October 13, 2015",18,9223372036854775807,Female,False
NCT00303628,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT00303628,False,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],"May 20, 2014",18,9223372036854775807,Both,False
NCT00276055,New Mexico Cancer Care Alliance,False,NM,https://ClinicalTrials.gov/show/NCT00276055,False,"Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma",Sarcoma,"Drug:Gemcitabine, Docetaxel and Bevacizumab","[u'Hematology Oncology Associates', u'University of New Mexico', u'St. Vincent Regional Medical Center', u'New Mexico Cancer Care Associates']","June 17, 2015",18,9223372036854775807,Both,False
NCT00263588,GlaxoSmithKline,True,NM,https://ClinicalTrials.gov/show/NCT00263588,False,Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer,"Neoplasms, Breast",Drug:lapatinib,[],"January 28, 2016",18,9223372036854775807,Both,False
NCT00250822,New Mexico Cancer Care Alliance,False,NM,https://ClinicalTrials.gov/show/NCT00250822,False,"Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter",Liver Cancer,Drug:Gemcitabine and Oxaliplatin,"[u'Hematology Oncology Associates', u'Lovelace Sandia Health Systems Dept of Hematology', u'University of New Mexico', u'St. Vincent Regional Medical Center']","September 23, 2011",18,9223372036854775807,Both,False
NCT00250029,New Mexico Cancer Care Alliance,False,NM,https://ClinicalTrials.gov/show/NCT00250029,False,Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen,Colonic Diseases; Cancer,Drug:Oxaliplatin,"[u'Hematology Oncology Associates', u'Lovelace Sandia Health Systems Dept of Hematology', u'University of New Mexico Cancer Center', u'New Mexico Veterans Administration Health Care System']","September 23, 2011",18,9223372036854775807,Both,False
NCT00127933,Hoffmann-La Roche,False,NM,https://ClinicalTrials.gov/show/NCT00127933,False,XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer,Breast Cancer,Drug:capecitabine [Xeloda]; Drug:Taxotere; Drug:Herceptin (HER2-neu positive patients only); Drug:capecitabine [Xeloda]; Drug:Taxotere,[],"July 13, 2011",18,9223372036854775807,Female,False
NCT00108745,Gynecologic Oncology Group,False,NM,https://ClinicalTrials.gov/show/NCT00108745,False,Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer,Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Drug:Paclitaxel Poliglumex; Other:Clinical Observation; Drug:Paclitaxel,[],"December 23, 2014",0,9223372036854775807,Female,False
NCT00087178,NSABP Foundation Inc,False,NM,https://ClinicalTrials.gov/show/NCT00087178,False,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],"October 5, 2015",18,9223372036854775807,Female,False
NCT00070564,Southwest Oncology Group,True,NM,https://ClinicalTrials.gov/show/NCT00070564,False,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",Breast Cancer,Biological:pegfilgrastim; Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"September 15, 2015",18,9223372036854775807,Both,False
NCT00041067,Southwest Oncology Group,True,NM,https://ClinicalTrials.gov/show/NCT00041067,False,"S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer",Breast Cancer,Biological:filgrastim; Biological:trastuzumab; Drug:docetaxel; Drug:vinorelbine,[],"May 20, 2013",18,9223372036854775807,Female,False
NCT01942668,TherapeuticsMD,False,NM,https://ClinicalTrials.gov/show/NCT01942668,False,A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms,Menopause,Drug:Estradiol; Drug:Progesterone; Drug:Placebo,[],"October 13, 2015",40,65,Female,False
NCT01886872,National Cancer Institute (NCI),False,NM,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01666444,VentiRx Pharmaceuticals Inc.,False,NM,https://ClinicalTrials.gov/show/NCT01666444,False,"VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer,Drug:pegylated liposomal doxorubicin (PLD); Drug:VTX-2337; Drug:Placebo,[],"January 5, 2016",18,9223372036854775807,Female,False
NCT01835158,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,NY,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01349322,Radiation Therapy Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT01349322,False,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01313676,GlaxoSmithKline,False,NY,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01275677,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01101438,NCIC Clinical Trials Group,True,NY,https://ClinicalTrials.gov/show/NCT01101438,False,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],"May 5, 2015",18,74,Both,False
NCT01070836,Biogen,False,NY,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,NY,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00658515,Hoffmann-La Roche,False,NY,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,NY,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00454701,Astellas Pharma Inc,False,NY,https://ClinicalTrials.gov/show/NCT00454701,False,Assessment and Tracking of Long-term Alefacept Safety,Psoriasis,Drug:Alefacept exposure,[],"December 10, 2013",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00426660,ViiV Healthcare,False,NY,https://ClinicalTrials.gov/show/NCT00426660,False,Expanded Access Program for Maraviroc At Multiple Centers,Advanced HIV Infection,Drug:maraviroc,[],"September 12, 2011",16,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,NY,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00373685,Pfizer,False,NY,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00346216,Pfizer,False,NY,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00264901,Novo Nordisk A/S,False,NY,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00262600,Boehringer Ingelheim,False,NY,https://ClinicalTrials.gov/show/NCT00262600,False,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],"November 5, 2014",18,9223372036854775807,Both,False
NCT00239681,AstraZeneca,False,NY,https://ClinicalTrials.gov/show/NCT00239681,False,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],"February 6, 2014",50,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00111020,Bayer,False,NY,https://ClinicalTrials.gov/show/NCT00111020,False,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell","Drug:Sorafenib (Nexavar, BAY43-9006)",[],"August 5, 2014",15,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00053898,NSABP Foundation Inc,True,NY,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT00034879,AstraZeneca,False,NY,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT00003906,NSABP Foundation Inc,True,NY,https://ClinicalTrials.gov/show/NCT00003906,False,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],"October 5, 2015",35,9223372036854775807,Female,False
NCT00002378,Hoffmann-La Roche,False,NY,https://ClinicalTrials.gov/show/NCT00002378,False,A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients,HIV Infections,Drug:Ritonavir; Drug:Nelfinavir mesylate; Drug:Saquinavir; Drug:Delavirdine mesylate; Drug:Lamivudine; Drug:Stavudine; Drug:Zidovudine,[],"June 23, 2005",16,9223372036854775807,Both,False
NCT00000814,National Institute of Allergy and Infectious Diseases (NIAID),True,NY,https://ClinicalTrials.gov/show/NCT00000814,False,A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease,HIV Infections,Drug:Nevirapine; Drug:Zidovudine; Drug:Didanosine,[],"March 30, 2012",6,20,Both,False
NCT00000781,National Institute of Allergy and Infectious Diseases (NIAID),True,NY,https://ClinicalTrials.gov/show/NCT00000781,False,"A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)",HIV Infections,Drug:Nevirapine; Drug:Zidovudine; Drug:Zalcitabine; Drug:Didanosine,[],"March 30, 2012",13,9223372036854775807,Both,False
NCT00000638,National Institute of Allergy and Infectious Diseases (NIAID),True,NY,https://ClinicalTrials.gov/show/NCT00000638,False,Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection,HIV Infections; Tuberculosis,Drug:Isoniazid; Drug:Pyrazinamide; Drug:Pyridoxine hydrochloride; Drug:Rifampin,[],"March 29, 2012",13,9223372036854775807,Both,False
NCT00000637,National Institute of Allergy and Infectious Diseases (NIAID),True,NY,https://ClinicalTrials.gov/show/NCT00000637,False,"A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children",HIV Infections,Drug:Zidovudine; Drug:Didanosine,[],"March 29, 2012",3,17,Both,False
NCT00000811,National Institute of Allergy and Infectious Diseases (NIAID),True,NY,https://ClinicalTrials.gov/show/NCT00000811,False,A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children,"Bacterial Infections; Pneumonia, Pneumocystis Carinii; HIV Infections",Drug:Azithromycin; Drug:Atovaquone; Drug:Sulfamethoxazole-Trimethoprim,[],"April 2, 2012",3,18,Both,False
NCT00000796,National Institute of Allergy and Infectious Diseases (NIAID),True,NY,https://ClinicalTrials.gov/show/NCT00000796,False,A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.,HIV Infections; Tuberculosis,Drug:Cycloserine; Drug:Ethionamide; Drug:Capreomycin sulfate; Drug:Aminosalicylic acid; Drug:Streptomycin sulfate; Drug:Ethambutol hydrochloride; Drug:Amikacin sulfate; Drug:Isoniazid; Drug:Pyrazinamide; Drug:Pyridoxine hydrochloride; Drug:Levofloxacin; Drug:Rifampin; Drug:Clofazimine,"[u'Cook County Hosp', u'Henry Ford Hosp', u'Samaritan Village Inc / Bronx Municipal Hosp', u'Bronx Municipal Hosp Ctr/Jacobi Med Ctr', u'Comprehensive Health Care Ctr / Bronx Municipal Hosp', u'Montefiore Drug Treatment Ctr / Bronx Municipal Hosp', u'Montefiore Family Health Ctr / Bronx Municipal Hosp', u'Bronx Lebanon Hosp Ctr', u'Jack Weiler Hosp / Bronx Municipal Hosp', u'Montefiore Med Ctr / Bronx Municipal Hosp', u'North Central Bronx Hosp / Bronx Municipal Hosp', u'Interfaith Med Ctr', u'SUNY / Health Sciences Ctr at Brooklyn', u'Beth Israel Med Ctr', u'Harlem AIDS Treatment Group / Harlem Hosp Ctr', u'Bellevue Hosp / New York Univ Med Ctr', u""Saint Clare's Hosp and Health Ctr"", u'Cornell Univ Med Ctr', u'Mount Sinai Med Ctr', u'Columbia Presbyterian Med Ctr', u'Clinical Directors Network of Region II']","March 30, 2012",13,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,NY,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00803062,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00803062,False,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT00557921,Cogentus Pharmaceuticals,False,NY,https://ClinicalTrials.gov/show/NCT00557921,False,Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1),Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease; Percutaneous Coronary Intervention,Drug:CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Drug:Plavix (clopidogrel 75 mg) and aspirin,[],"January 27, 2009",21,9223372036854775807,Both,False
NCT00303628,National Cancer Institute (NCI),False,NY,https://ClinicalTrials.gov/show/NCT00303628,False,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],"May 20, 2014",18,9223372036854775807,Both,False
NCT00103181,NSABP Foundation Inc,True,NY,https://ClinicalTrials.gov/show/NCT00103181,False,Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:3-dimensional conformal accelerated partial breast irradiation; Radiation:brachytherapy; Radiation:whole breast irradiation; Radiation:MammoSite or other single-entry intracavitary device,[],"October 8, 2015",18,9223372036854775807,Female,False
NCT00001083,National Institute of Allergy and Infectious Diseases (NIAID),True,NY,https://ClinicalTrials.gov/show/NCT00001083,False,Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs,HIV Infections,Drug:Indinavir sulfate; Drug:Ritonavir; Drug:Nevirapine; Drug:Lamivudine; Drug:Stavudine; Drug:Zidovudine,[],"February 14, 2012",2,17,Both,False
NCT00001066,National Institute of Allergy and Infectious Diseases (NIAID),True,NY,https://ClinicalTrials.gov/show/NCT00001066,False,A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children,HIV Infections,Drug:Lamivudine; Drug:Zidovudine; Drug:Didanosine,[],"March 1, 2011",3,15,Both,False
NCT00000841,National Institute of Allergy and Infectious Diseases (NIAID),True,NY,https://ClinicalTrials.gov/show/NCT00000841,False,A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months,HIV Infections,Drug:Indinavir sulfate; Drug:Lamivudine; Drug:Stavudine; Drug:Zidovudine,[],"July 26, 2013",18,9223372036854775807,Both,False
NCT01764633,Amgen,False,NY,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT02465060,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02196181,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,NC,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01508026,Forest Laboratories,False,NC,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01313676,GlaxoSmithKline,False,NC,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01275677,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01130272,"Furiex Pharmaceuticals, Inc",False,NC,https://ClinicalTrials.gov/show/NCT01130272,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"June 11, 2012",18,65,Both,False
NCT01070836,Biogen,False,NC,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00942331,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00433511,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,NC,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00373685,Pfizer,False,NC,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00346216,Pfizer,False,NC,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,NC,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,NC,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00262847,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00262847,False,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"August 18, 2015",18,9223372036854775807,Female,False
NCT00217737,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00041119,Alliance for Clinical Trials in Oncology,True,NC,https://ClinicalTrials.gov/show/NCT00041119,False,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"July 23, 2015",18,9223372036854775807,Female,False
NCT00053898,NSABP Foundation Inc,True,NC,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT00034879,AstraZeneca,False,NC,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT01764633,Amgen,False,NC,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT00067938,GlaxoSmithKline,False,NC,https://ClinicalTrials.gov/show/NCT00067938,False,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],"October 11, 2012",18,9223372036854775807,Both,False
NCT00003906,NSABP Foundation Inc,True,NC,https://ClinicalTrials.gov/show/NCT00003906,False,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],"October 5, 2015",35,9223372036854775807,Female,False
NCT01642914,Forest Laboratories,False,NC,https://ClinicalTrials.gov/show/NCT01642914,False,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Chronic Constipation,Drug:Linaclotide 290 micrograms; Drug:Linaclotide 145 micrograms; Drug:Matching placebo,[],"September 30, 2013",18,9223372036854775807,Both,True
NCT00072046,Alliance for Clinical Trials in Oncology,True,NC,https://ClinicalTrials.gov/show/NCT00072046,False,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,NC,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01126437,Boehringer Ingelheim,False,NC,https://ClinicalTrials.gov/show/NCT01126437,False,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],"May 20, 2014",40,9223372036854775807,Both,False
NCT00887536,NSABP Foundation Inc,False,NC,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT01835158,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01642251,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01000727,GlaxoSmithKline,False,NC,https://ClinicalTrials.gov/show/NCT01000727,False,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Drug:Darapladib 160 mg; Drug:Placebo; Other:Standard Therapy,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00838903,GlaxoSmithKline,False,NC,https://ClinicalTrials.gov/show/NCT00838903,False,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],"August 11, 2014",18,9223372036854775807,Both,False
NCT00693992,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00658515,Hoffmann-La Roche,False,NC,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00639418,MedImmune LLC,True,NC,https://ClinicalTrials.gov/show/NCT00639418,False,A Study to Describe Pediatric Influenza Vaccine Coverage,Healthy,Biological:Influenza vaccination,[],"September 12, 2014",6,9223372036854775807,Both,True
NCT00588770,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00373256,Pfizer,False,NC,https://ClinicalTrials.gov/show/NCT00373256,False,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Drug:Sunitinib; Drug:paclitaxel; Drug:bevacizumab; Drug:paclitaxel,[],"September 5, 2012",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT01959529,Novo Nordisk A/S,False,NC,https://ClinicalTrials.gov/show/NCT01959529,False,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],"January 8, 2016",50,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,NC,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01553591,"Furiex Pharmaceuticals, Inc",False,NC,https://ClinicalTrials.gov/show/NCT01553591,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"April 26, 2015",18,80,Both,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT00892177,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT00892177,False,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,ND,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00205777,Pfizer,False,ND,https://ClinicalTrials.gov/show/NCT00205777,False,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Osteoporosis,Drug:Bazedoxifene Acetate; Other:Placebo,[],"February 28, 2013",55,80,Female,False
NCT00053898,NSABP Foundation Inc,True,ND,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT00946712,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00433511,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,ND,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00324805,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00134056,Southwest Oncology Group,True,ND,https://ClinicalTrials.gov/show/NCT00134056,False,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],"May 6, 2015",18,9223372036854775807,Male,False
NCT00075946,Eastern Cooperative Oncology Group,True,ND,https://ClinicalTrials.gov/show/NCT00075946,False,Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma,Lymphoma,Biological:rituximab,[],"June 3, 2015",18,9223372036854775807,Both,False
NCT00075764,Southwest Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT00075764,False,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],"May 8, 2014",18,9223372036854775807,Female,False
NCT00041119,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00041119,False,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"July 23, 2015",18,9223372036854775807,Female,False
NCT00003596,Radiation Therapy Oncology Group,True,ND,https://ClinicalTrials.gov/show/NCT00003596,False,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer,Anal Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:mitomycin C; Radiation:radiation therapy,[],"November 18, 2013",18,9223372036854775807,Both,False
NCT00003594,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00003594,False,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug:irinotecan; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01366183,Gynecologic Oncology Group,False,ND,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01004887,North Central Cancer Treatment Group,False,ND,https://ClinicalTrials.gov/show/NCT01004887,False,Study of Tissue and Blood Samples From Patients With High-Grade Glioma,Brain and Central Nervous System Tumors,Genetic:DNA ploidy analysis; Genetic:fluorescence in situ hybridization; Genetic:microsatellite instability analysis; Genetic:mutation analysis; Genetic:polymerase chain reaction; Other:diagnostic laboratory biomarker analysis; Other:flow cytometry; Other:immunohistochemistry staining method,[],"June 27, 2013",0,9223372036854775807,Both,False
NCT00880191,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT00880191,False,Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy,"Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:dexamethasone; Drug:gabapentin; Other:placebo,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00860041,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00860041,False,Acute Pain Caused by Paclitaxel in Patients With Cancer,"Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Behavioral:pain questionnaires,[],"July 7, 2015",18,9223372036854775807,Both,False
NCT00826540,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT00826540,False,Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer,Drug:sorafenib tosylate; Biological:bevacizumab,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT00776100,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT00776100,False,Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Other:clinical observation; Radiation:radiation therapy,[],"July 8, 2015",18,9223372036854775807,Both,False
NCT00719563,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00719563,False,American Ginseng in Treating Patients With Fatigue Caused by Cancer,"Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",Drug:American ginseng; Other:placebo,[],"July 14, 2014",18,9223372036854775807,Both,False
NCT00641706,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00641706,False,"Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme",Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,Drug:vorinostat; Procedure:therapeutic conventional surgery; Drug:bortezomib,[],"April 28, 2014",18,9223372036854775807,Both,False
NCT00626405,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00626405,False,Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery,Melanoma (Skin),Biological:bevacizumab; Drug:carboplatin; Drug:paclitaxel albumin-stabilized nanoparticle formulation; Drug:temozolomide,[],"July 8, 2015",18,9223372036854775807,Both,False
NCT00550836,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT00550836,False,Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer,Pancreatic Cancer,Biological:panitumumab; Drug:erlotinib hydrochloride; Drug:gemcitabine hydrochloride,[],"July 8, 2015",18,9223372036854775807,Both,False
NCT00521001,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00521001,False,Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,Melanoma (Skin),Drug:everolimus; Drug:temozolomide,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT00516503,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00516503,False,Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Drug:baclofen/amitriptyline/ketamine gel; Other:placebo,[],"July 3, 2015",18,9223372036854775807,Both,False
NCT00489411,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00489411,False,Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,"Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific",Drug:duloxetine hydrochloride; Other:placebo,[],"July 6, 2015",25,9223372036854775807,Both,False
NCT00460109,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00460109,False,Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma,Lymphoma,Biological:denileukin diftitox; Biological:rituximab,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT00454194,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT00454194,False,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Drug:pemetrexed disodium; Drug:sorafenib tosylate,[],"July 6, 2015",18,9223372036854775807,Both,False
NCT00376675,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00376675,False,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,"Fatigue; Unspecified Adult Solid Tumor, Protocol Specific",Drug:methylphenidate hydrochloride; Other:placebo,[],"September 14, 2015",18,9223372036854775807,Both,False
NCT00329719,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00329719,False,Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,Drug:sorafenib tosylate; Drug:temsirolimus; Procedure:conventional surgery,[],"May 29, 2015",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00326599,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00326599,False,Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:cediranib maleate; Drug:gemcitabine hydrochloride,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT00316836,Alliance for Clinical Trials in Oncology,False,ND,https://ClinicalTrials.gov/show/NCT00316836,False,"Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole",Breast Cancer,Procedure:mammography,[],"July 13, 2015",18,9223372036854775807,Female,False
NCT00310180,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00303628,National Cancer Institute (NCI),False,ND,https://ClinicalTrials.gov/show/NCT00303628,False,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],"May 20, 2014",18,9223372036854775807,Both,False
NCT00296036,North Central Cancer Treatment Group,True,ND,https://ClinicalTrials.gov/show/NCT00296036,False,Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer,"Breast Cancer; Drug/Agent Toxicity by Tissue/Organ; Unspecified Adult Solid Tumor, Protocol Specific",Dietary Supplement:pyridoxine hydrochloride; Drug:urea/lactic acid-based topical cream; Other:placebo,[],"November 17, 2010",18,9223372036854775807,Both,False
NCT00268489,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00268489,False,Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,Lung Cancer,Biological:bevacizumab; Drug:pemetrexed disodium,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT00227565,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00227565,False,Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:pemetrexed disodium; Radiation:radiation,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT00112528,Alliance for Clinical Trials in Oncology,True,ND,https://ClinicalTrials.gov/show/NCT00112528,False,"Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer",Pancreatic Cancer,Biological:bevacizumab; Drug:gemcitabine hydrochloride; Drug:oxaliplatin,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02311907,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02137837,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT02137837,False,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],"May 20, 2015",18,9223372036854775807,Female,False
NCT02042443,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01716715,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01716715,False,"Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 12, 2016",18,9223372036854775807,Female,False
NCT01708954,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01708941,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01708941,False,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01688973,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01688973,False,Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery,Childhood Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma,Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Tivantinib,[],"January 11, 2016",0,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01653028,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01653028,False,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01648348,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01642251,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01609790,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01609790,False,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,OH,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01522976,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01522976,False,Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Adult Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts,Drug:Azacitidine; Drug:Lenalidomide; Drug:Vorinostat,[],"June 24, 2015",18,9223372036854775807,Both,False
NCT01515800,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01515800,False,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],"October 23, 2015",18,120,Female,False
NCT01508026,Forest Laboratories,False,OH,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01439945,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01439945,False,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,Breast Cancer; Cancer Survivor; Hot Flashes,Drug:magnesium oxide; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Female,False
NCT01412879,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01412879,False,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:cyclophosphamide; Drug:cytarabine; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:methotrexate; Drug:vincristine sulfate,[],"September 15, 2015",18,65,Both,False
NCT01385137,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01385137,False,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],"October 15, 2015",18,120,Female,False
NCT01376349,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01376349,False,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],"September 24, 2015",18,9223372036854775807,Female,False
NCT01366183,Gynecologic Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01349322,Radiation Therapy Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01349322,False,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01313676,GlaxoSmithKline,False,OH,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01275677,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01260701,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01260701,False,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],"December 14, 2015",18,9223372036854775807,Both,False
NCT01251861,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01251861,False,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Drug:Akt Inhibitor MK2206; Drug:Bicalutamide; Other:Clinical Observation; Other:Laboratory Biomarker Analysis,[],"January 18, 2016",18,9223372036854775807,Male,False
NCT01229943,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01229943,False,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01198158,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01198145,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01198145,False,Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy,"Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific",Drug:sulfasalazine; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01189227,NSABP Foundation Inc,False,OH,https://ClinicalTrials.gov/show/NCT01189227,False,Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery,Colorectal Cancer; Metastatic Cancer,Procedure:Postoperative chemotherapy; Procedure:Perioperative chemotherapy,[],"May 8, 2013",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01142388,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01142388,False,Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Recurrent Esophageal Carcinoma; Stage IV Esophageal Cancer,Biological:Cixutumumab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study,[],"June 2, 2015",18,9223372036854775807,Both,False
NCT01120275,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01120275,False,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Solar Radiation-related Skin Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other:laboratory biomarker analysis,[],"June 9, 2014",18,9223372036854775807,Both,False
NCT01099449,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01099449,False,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT01097278,Southwest Oncology Group,False,OH,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT01093222,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01093222,False,"Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",Extrahepatic Bile Duct Adenocarcinoma; Gallbladder Adenocarcinoma; Gallbladder Adenocarcinoma With Squamous Metaplasia; Hilar Cholangiocarcinoma; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Undifferentiated Gallbladder Carcinoma; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma,Drug:Erlotinib Hydrochloride; Drug:Sorafenib Tosylate,[],"June 3, 2015",18,9223372036854775807,Both,False
NCT01091454,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01091454,False,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Triple-negative Breast Cancer,Drug:brostallicin; Drug:cisplatin,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT01086605,Alliance for Clinical Trials in Oncology,False,OH,https://ClinicalTrials.gov/show/NCT01086605,False,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],"August 4, 2015",18,9223372036854775807,Both,False
NCT01081262,National Cancer Institute (NCI),False,OH,https://ClinicalTrials.gov/show/NCT01081262,False,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer,Biological:Bevacizumab; Drug:Capecitabine; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Oxaliplatin; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 12, 2016",18,9223372036854775807,Female,False
NCT00769379,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00264901,Novo Nordisk A/S,False,OK,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00036270,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT00036270,False,Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane,Breast Neoplasms,Drug:exemestane (Aromasin); Drug:tamoxifen + exemestane,[],"October 6, 2015",50,9223372036854775807,Female,False
NCT01287897,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT01287897,False,A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy,Crohn's Disease,Drug:PF-04236921 SC injection; Drug:PF-04236921 SC injection; Drug:PF-04236921 SC injection,[],"December 14, 2015",18,75,Both,False
NCT00946712,Southwest Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00857220,Sunovion,False,OK,https://ClinicalTrials.gov/show/NCT00857220,False,Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia,Insomnia; Attention Deficit Hyperactivity Disorder,Drug:eszopiclone; Drug:eszopiclone,[],"June 18, 2013",6,17,Both,False
NCT00412984,Bristol-Myers Squibb,False,OK,https://ClinicalTrials.gov/show/NCT00412984,False,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,Atrial Fibrillation; Atrial Flutter,Drug:warfarin; Drug:apixaban,[],"September 27, 2013",18,9223372036854775807,Both,False
NCT00267748,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT00267748,False,Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC),"Carcinoma, Renal Cell",Drug:Sunitinib Malate Continuous Daily Dosing; Drug:Sunitinib Malate Schedule 4/2,[],"August 3, 2011",18,9223372036854775807,Both,False
NCT00080340,Telik,False,OK,https://ClinicalTrials.gov/show/NCT00080340,False,Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Non Small Cell Lung Carcinoma,Drug:TLK286 (Telcyta) HCl for Injection; Drug:gefitinib (Iressa),[],"January 10, 2008",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT00942331,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00809354,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT00809354,False,Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip,Osteoarthritis; Arthritis,Drug:NSAID; Biological:tanezumab; Biological:tanezumab; Biological:tanezumab; Drug:NSAID; Biological:tanezumab; Drug:NSAID,[],"March 4, 2015",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00673049,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT00673049,False,"Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer","Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Adenosquamous Cell","Drug:CP 751,871 (Figitumumab); Drug:Erlotinib; Drug:Erlotinib",[],"July 22, 2013",18,9223372036854775807,Both,False
NCT00609622,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT00609622,False,Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer,Colorectal Neoplasms,Drug:sunitinib; Drug:mFOLFOX6; Drug:bevacizumab; Drug:mFOLFOX6,[],"September 10, 2012",18,9223372036854775807,Both,False
NCT00457392,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT00457392,False,A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone,"Carcinoma, Non-Small Cell Lung",Drug:erlotinib; Drug:sunitinib; Drug:erlotinib; Drug:placebo,[],"September 24, 2013",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00373685,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00346216,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00130897,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT00130897,False,Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma,"Carcinoma, Renal Cell",Drug:Sutent,[],"March 8, 2012",18,9223372036854775807,Both,False
NCT00003906,NSABP Foundation Inc,True,OK,https://ClinicalTrials.gov/show/NCT00003906,False,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],"October 5, 2015",35,9223372036854775807,Female,False
NCT01366183,Gynecologic Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01035255,Novartis Pharmaceuticals,False,OK,https://ClinicalTrials.gov/show/NCT01035255,False,This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure,Heart Failure With Reduced Ejection Fraction,Drug:LCZ696 200 mg BID; Drug:Enalapril 10 mg BID,[],"September 9, 2015",18,9223372036854775807,Both,False
NCT00856973,Sunovion,False,OK,https://ClinicalTrials.gov/show/NCT00856973,False,Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia,Insomnia; Attention Deficit Hyperactivity Disorder,Drug:eszopiclone; Drug:eszopiclone; Drug:Placebo,[],"June 7, 2013",6,17,Both,False
NCT00658515,Hoffmann-La Roche,False,OK,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00217737,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00205777,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT00205777,False,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Osteoporosis,Drug:Bazedoxifene Acetate; Other:Placebo,[],"February 28, 2013",55,80,Female,False
NCT00067938,GlaxoSmithKline,False,OK,https://ClinicalTrials.gov/show/NCT00067938,False,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],"October 11, 2012",18,9223372036854775807,Both,False
NCT00034879,AstraZeneca,False,OK,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT02045732,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT02045732,False,A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS),Multiple Sclerosis,Biological:PF-06342674 0.25 mg/kg; Biological:Placebo; Biological:PF-06342674 1.5 mg/kg; Biological:PF-06342674 6.0 mg/kg,"[u'Albany Advanced Imaging', u'Fallon Wellness Pharmacy', u'Northeast Eye Center', u'The MS Center of Northeastern New York', u'Cleveland Clinic', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Retina Vitreous Center', u'Lynn Health Science Institute', u'Pfizer Investigational Site', u'Radiology Associates (X-ray facility only)']","January 12, 2016",18,55,Both,False
NCT02031640,"Teva Branded Pharmaceutical Products, R&D Inc.",False,OK,https://ClinicalTrials.gov/show/NCT02031640,False,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,Asthma,Drug:Beclomethasone dipropionate; Drug:Placebo; Drug:Albuterol/salbutamol,[],"May 21, 2015",12,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01855789,Hoffmann-La Roche,False,OK,https://ClinicalTrials.gov/show/NCT01855789,False,A Study on the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous RoActemra/Actemra (Tocilizumab) With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:methotrexate; Drug:placebo; Drug:tocilizumab [RoActemra/Actemra],[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01789957,AstraZeneca,False,OK,https://ClinicalTrials.gov/show/NCT01789957,False,Extension Study for 2993-112,Type 2 Diabetes Mellitus,Drug:AC2993,[],"February 23, 2015",16,75,Both,False
NCT01658943,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01609790,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01609790,False,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,OK,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01543178,"Valeant Pharmaceuticals International, Inc.",False,OK,https://ClinicalTrials.gov/show/NCT01543178,False,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01508026,Forest Laboratories,False,OK,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01345318,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT01345318,False,B0151005 Open-Label Extension Study,Crohn's Disease,Biological:PF-04236921; Biological:PF-04236921,[],"January 19, 2016",18,75,Both,False
NCT01262677,Pfizer,False,OK,https://ClinicalTrials.gov/show/NCT01262677,False,Once-A-Day Pregabalin For Partial Seizures,"Partial Seizures; Epilepsies, Partial",Drug:pregabalin; Drug:pregabalin; Drug:pregabalin; Drug:pregabalin; Drug:pregabalin; Drug:pregabalin; Drug:placebo,[],"September 13, 2013",18,9223372036854775807,Both,False
NCT01198158,National Cancer Institute (NCI),False,OK,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01130272,"Furiex Pharmaceuticals, Inc",False,OK,https://ClinicalTrials.gov/show/NCT01130272,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"June 11, 2012",18,65,Both,False
NCT01100684,Tioga Pharmaceuticals,False,OK,https://ClinicalTrials.gov/show/NCT01100684,False,Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS),Diarrhea Predominant Irritable Bowel Syndrome,Drug:Asimadoline; Drug:Placebo,[],"December 17, 2013",18,79,Both,False
NCT01076764,Sanofi,False,OK,https://ClinicalTrials.gov/show/NCT01076764,False,Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy,Acute Coronary Syndrome,Drug:Otamixaban (XRP0673); Drug:Otamixaban matching placebo; Drug:Unfractionated Heparin; Drug:Unfractionated Heparin matching placebo; Drug:Eptifibatide; Drug:Eptifibatide matching placebo,[],"May 16, 2013",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,OK,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00769379,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00324805,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00433511,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00878709,"Puma Biotechnology, Inc.",False,OR,https://ClinicalTrials.gov/show/NCT00878709,False,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],"August 20, 2015",18,9223372036854775807,Female,False
NCT00382070,NSABP Foundation Inc,True,OR,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00326898,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,OR,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00785291,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT01198158,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01000558,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01000558,False,SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma,Lymphoma,Other:biologic sample preservation procedure,[],"May 17, 2013",18,9223372036854775807,Both,False
NCT00946712,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00103181,NSABP Foundation Inc,True,OR,https://ClinicalTrials.gov/show/NCT00103181,False,Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:3-dimensional conformal accelerated partial breast irradiation; Radiation:brachytherapy; Radiation:whole breast irradiation; Radiation:MammoSite or other single-entry intracavitary device,[],"October 8, 2015",18,9223372036854775807,Female,False
NCT00075764,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00075764,False,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],"May 8, 2014",18,9223372036854775807,Female,False
NCT00874211,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00874211,False,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],"March 4, 2015",0,9223372036854775807,Both,False
NCT00775645,Southwest Oncology Group,True,OR,https://ClinicalTrials.gov/show/NCT00775645,False,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy",Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity,Dietary Supplement:acetyl-L-carnitine hydrochloride; Other:placebo,[],"January 13, 2014",18,9223372036854775807,Female,False
NCT00644228,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00644228,False,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],"September 12, 2014",18,9223372036854775807,Both,False
NCT00265941,Radiation Therapy Oncology Group,True,OR,https://ClinicalTrials.gov/show/NCT00265941,False,Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer,Head and Neck Cancer,Biological:cetuximab; Drug:cisplatin,[],"November 11, 2015",18,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT01385137,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01385137,False,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],"October 15, 2015",18,120,Female,False
NCT00920010,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00920010,False,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],"February 5, 2015",0,9223372036854775807,Both,False
NCT00919425,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00919425,False,"S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Other:biologic sample preservation procedure,[],"March 5, 2015",0,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,OR,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00041119,Alliance for Clinical Trials in Oncology,True,OR,https://ClinicalTrials.gov/show/NCT00041119,False,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"July 23, 2015",18,9223372036854775807,Female,False
NCT01886872,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,OR,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00382018,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00382018,False,S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy,Breast Cancer,Drug:chemotherapy,[],"September 15, 2015",18,9223372036854775807,Female,False
NCT00053898,NSABP Foundation Inc,True,OR,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT00003857,Radiation Therapy Oncology Group,True,OR,https://ClinicalTrials.gov/show/NCT00003857,False,Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ,Breast Cancer,Drug:tamoxifen citrate; Procedure:adjuvant therapy; Radiation:radiation therapy,[],"November 14, 2015",26,120,Female,False
NCT01802333,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01097278,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT00822120,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00822120,False,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],"May 8, 2015",18,60,Both,False
NCT00337129,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00337129,False,S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer,Head and Neck Cancer,Drug:eribulin mesylate,[],"August 11, 2015",18,9223372036854775807,Both,False
NCT00304031,Radiation Therapy Oncology Group,True,OR,https://ClinicalTrials.gov/show/NCT00304031,False,Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,Brain and Central Nervous System Tumors,Drug:Concurrent temozolomide; Radiation:Concurrent radiation therapy; Drug:100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle; Drug:75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle,[],"October 13, 2015",18,120,Both,False
NCT00109850,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00109850,False,"S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer",Esophageal Cancer,Biological:cetuximab; Drug:cisplatin; Drug:irinotecan hydrochloride; Radiation:radiation therapy,[],"November 16, 2015",18,9223372036854775807,Both,False
NCT00057746,Radiation Therapy Oncology Group,True,OR,https://ClinicalTrials.gov/show/NCT00057746,False,Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer,Lung Cancer,Radiation:Prophylactic Cranial Irradiation (PCI),[],"January 15, 2014",0,9223372036854775807,Both,False
NCT00003641,Eastern Cooperative Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00003641,False,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Other:clinical observation,[],"July 11, 2012",18,9223372036854775807,Both,False
NCT00003596,Radiation Therapy Oncology Group,True,OR,https://ClinicalTrials.gov/show/NCT00003596,False,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer,Anal Cancer,Drug:cisplatin; Drug:fluorouracil; Drug:mitomycin C; Radiation:radiation therapy,[],"November 18, 2013",18,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,OR,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00919139,Southwest Oncology Group,False,OR,https://ClinicalTrials.gov/show/NCT00919139,False,"S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.",Multiple Myeloma; Smoldering Myeloma; Waldenstrom's Macroglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Amyloidosis,Other:biologic sample preservation procedure,[],"April 1, 2015",0,9223372036854775807,Both,False
NCT00887536,NSABP Foundation Inc,False,OR,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00828139,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00828139,False,Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:ziv-aflibercept; Drug:topotecan hydrochloride,[],"April 9, 2014",18,9223372036854775807,Both,False
NCT00693992,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00640042,Pfizer,True,OR,https://ClinicalTrials.gov/show/NCT00640042,False,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],"June 6, 2012",21,9223372036854775807,Both,False
NCT00601900,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00569127,National Cancer Institute (NCI),False,OR,https://ClinicalTrials.gov/show/NCT00569127,False,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],"January 5, 2015",0,9223372036854775807,Both,False
NCT00346216,Pfizer,False,OR,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,OR,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01642251,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01609790,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01609790,False,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,PA,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01475721,GlaxoSmithKline,False,PA,https://ClinicalTrials.gov/show/NCT01475721,False,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],"December 10, 2015",12,9223372036854775807,Both,False
NCT01349322,Radiation Therapy Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT01349322,False,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01313676,GlaxoSmithKline,False,PA,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01275677,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01198158,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01070836,Biogen,False,PA,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT01042704,"Robert Redner, MD",True,PA,https://ClinicalTrials.gov/show/NCT01042704,False,Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma,Myeloma,Drug:Bendamustine; Drug:Lenalidomide; Drug:Dexamethasone; Drug:Aspirin; Drug:Prophylaxis; Drug:Antibiotic; Other:Biweekly Follow Up; Other:Cyclical Follow Up; Other:Restaging; Other:Post-Treatment Follow Up,"[u'Karmanos Cancer Institute', u'UPMC Cancer Centers - Teramana Cancer Center', u'UPMC Cancer Centers - Beaver', u'UPMC Cancer Centers - Jefferson', u'UPMC Cancer Centers - Arnold Palmer at Mountain View', u'UPMC Cancer Centers - Arnold Palmer at Oakbrook', u'UPMC Cancer Centers - Indiana', u'UPMC Cancer Centers - Johnstown', u'Hematology-Oncology Associates of UPCI', u'Hematology/Oncology - Private Practice', u'UPMC Cancer Centers - Monroeville', u'UPMC Cancer Centers - Arnold Palmer at Mt. Pleasant', u'UPMC Cancer Centers - New Castle', u""UPMC Cancer Centers - St. Margaret's"", u'UPMC Cancer Centers - Hillman Cancer Center', u'UPMC Cancer Centers - Drake', u'VA Healthcare System - 646', u'UPMC Cancer Centers - Passavant', u'UPMC Cancer Centers - Uniontown', u'UPMC Cancer Centers - Washington', u'UPMC Cancer Centers - North Hills', u'UPMC Cancer Centers - Windber']","January 13, 2016",18,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,PA,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT01000727,GlaxoSmithKline,False,PA,https://ClinicalTrials.gov/show/NCT01000727,False,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Drug:Darapladib 160 mg; Drug:Placebo; Other:Standard Therapy,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00984217,University of Pittsburgh,False,PA,https://ClinicalTrials.gov/show/NCT00984217,False,Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies,"Adenoma, Pleomorphic; Mixed Salivary Gland Tumor; Salivary Gland Tumor, Mixed; Syringoma, Chondroid",Radiation:Radiation; Drug:Panitumumab,"[u'UPMC Cancer Center - Teramana Cancer Center - Steubenville', u'UPMC Cancer Center - Beaver', u'UPMC Cancer Center - Clairton', u'UPMC Cancer Center -Arnold Palmer Pavilion', u'UPMC Cancer Center - Oakbrook Commons - Greensburg', u'UPMC Cancer Center - Oakbrook Commons', u'UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg', u'UPMC Cancer Center - Indiana', u'UPMC Cancer Center - John P. Murtha Pavilion - Johnstown', u'UPMC Cancer Center - McKeesport', u'UPMC Cancer Center - Monroeville', u'UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group', u'UPMC Cancer Center -Mt. Pleasant', u'UPMC Cancer Center - New Castle', u'UPMC Cancer Centers', u""UPMC Cancer Center - St. Margaret's"", u'UPMC Cancer Center -Delafield Rd.', u'Hillman Cancer Center: University of Pittsburgh Cancer Institute / UPMC Department of Radiology', u'UPMC Cancer Center -UPMC Shadyside', u'UPMC Cancer Center - Passavant', u'UPMC Cancer Center - Upper St. Clair', u'UPMC Cancer Center -Drake', u'UPMC Presbyterian -Radiation Oncology', u'UPMC Cancer Center -UPMC Northwest', u'UPMC Cancer Center - Uniontown', u'UPMC Cancer Center - Washington', u'UPMC Cancer Center - North Hills']","January 6, 2016",18,9223372036854775807,Both,False
NCT00954174,Gynecologic Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT00954174,False,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00946712,Southwest Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00887159,National Cancer Institute (NCI),True,PA,https://ClinicalTrials.gov/show/NCT00887159,False,Cisplatin and Etoposide With or Without Vismodegib or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:cixutumumab; Drug:vismodegib; Drug:cisplatin; Drug:etoposide,[],"July 1, 2015",18,9223372036854775807,Both,False
NCT00884741,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00884741,False,Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Cognitive Side Effects of Cancer Therapy,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Procedure:Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Procedure:Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Temozolomide,[],"July 29, 2015",18,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,PA,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00781391,Daiichi Sankyo Inc.,False,PA,https://ClinicalTrials.gov/show/NCT00781391,False,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Stroke; Atrial Fibrillation; Embolism,Drug:warfarin tablets; Drug:Edoxaban tablets (high dose regimen-60mg); Drug:Edoxaban tablets (low dose regimen-30mg); Drug:placebo warfarin; Drug:placebo edoxaban,[],"March 12, 2015",21,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00658515,Hoffmann-La Roche,False,PA,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00640042,Pfizer,True,PA,https://ClinicalTrials.gov/show/NCT00640042,False,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],"June 6, 2012",21,9223372036854775807,Both,False
NCT00625898,NSABP Foundation Inc,False,PA,https://ClinicalTrials.gov/show/NCT00625898,False,BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab,Breast Cancer,Drug:Docetaxel; Drug:Trastuzumab; Drug:Carboplatin; Drug:Bevacizumab; Drug:5-Fluorouracil; Drug:Epirubicin; Drug:Cyclophosphamide,[],"July 7, 2014",18,9223372036854775807,Female,False
NCT00588770,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00581360,University of Pittsburgh,False,PA,https://ClinicalTrials.gov/show/NCT00581360,False,Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck,Adenoid Cystic Carcinoma,Drug:doxorubicin and bortezomib,"[u'UPMC Cancer Center - Teramana Cancer Center - Steubenville', u'UPMC Cancer Center - Beaver', u'UPMC Cancer Center - Clairton', u'UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg', u'UPMC Cancer Center - Oakbrook Commons - Greensburg', u'UPMC Cancer Center - Indiana', u'UPMC Cancer Center - John P. Murtha Pavilion - Johnstown', u'UPMC Cancer Center - McKeesport', u'UPMC Cancer Center -Haymaker Rd.', u'UPMC Cancer Center -Mosside Blvd.', u'UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group', u'UPMC Cancer Center -Mt. Pleasant', u'UPMC Cancer Center -New Castle', u'UPMC Cancer Center - Mercy', u'University of Pittsburgh Cancer Institute-Hillman Cancer Center', u'UPMC Cancer Center - Passavant', u'UPMC Cancer Center -Drake', u'UPMC Cancer Center -Delafield Rd.', u'UPMC Cancer Center - Uniontown', u'UPMC Cancer Center - Washington', u'UPMC Cancer Center -Wexford']","January 9, 2014",18,9223372036854775807,Both,False
NCT00567580,Radiation Therapy Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT00567580,False,Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:flutamide; Radiation:radiation therapy,[],"March 31, 2015",18,9223372036854775807,Male,False
NCT00566852,Radiation Therapy Oncology Group,False,PA,https://ClinicalTrials.gov/show/NCT00566852,False,Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors,"Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific",Drug:memantine hydrochloride; Other:placebo; Radiation:radiation therapy,[],"March 26, 2015",18,9223372036854775807,Both,False
NCT00557921,Cogentus Pharmaceuticals,False,PA,https://ClinicalTrials.gov/show/NCT00557921,False,Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1),Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease; Percutaneous Coronary Intervention,Drug:CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Drug:Plavix (clopidogrel 75 mg) and aspirin,[],"January 27, 2009",21,9223372036854775807,Both,False
NCT00492206,University of Pittsburgh,False,PA,https://ClinicalTrials.gov/show/NCT00492206,False,Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC,Non Small Cell Lung Cancer (NSCLC),Drug:Cetuximab,"[u'Sylvester Comprehensive Cancer Center, University of Miami', u'Emory Winship Cancer Institute', u'Sidney Kimmel Comprehensive Cancer Center at John Hopkins', u'UPMC Cancer Center -Teramana Cancer Center', u'UPMC Cancer Center -Beaver', u'UPMC Cancer Center - Clairton', u'UPMC Cancer Center - Oakbrook Commons', u'UPMC Cancer Center -Arnold Palmer Pavilion', u'Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center', u'UPMC Cancer Center -Indiana', u'UPMC Cancer Center -John P. Murtha Pavilion', u'UPMC Cancer Center -McKeesport', u'UPMC Cancer Center -Haymaker Rd.', u'UPMC Cancer Center -Mosside Blvd.', u'UPMC Cancer Center -Sewickley Medical Center', u'UPMC Cancer Center -Mt. Pleasant', u'UPMC Cancer Center -Jameson', u'UPMC Cancer Center -New Castle', u'UPMC Cancer Center -St. Clair', u'UPMC Cancer Center -Delafield Rd.', u'UPMC Cancer Center -St. Margaret', u'Universtity of Pittsburgh Cancer Institute -Hillman Cancer Center', u'UPMC Presbyterian -Radiation Oncology', u'UPMC Cancer Center -Passavant', u'UPMC Cancer Center -Drake', u'UPMC Cancer Center -UPMC Shadyside', u'UPMC Cancer Center -UPMC Northwest', u'UPMC Cancer Center -Robert Eberly Pavilion', u'UPMC Cancer Center -Uniontown', u'UPMC Cancer Center -Washington', u'UPMC Cancer Center -Wexford']","January 16, 2013",18,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,PA,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00408694,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00408694,False,"Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer",Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx,Radiation:3-dimensional conformal radiation therapy; Radiation:intensity-modulated radiation therapy; Biological:bevacizumab; Drug:cisplatin; Drug:fluorouracil,[],"April 21, 2014",18,9223372036854775807,Both,False
NCT00403767,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",False,PA,https://ClinicalTrials.gov/show/NCT00403767,False,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation; Stroke; Embolism,Drug:Rivaroxaban; Drug:Warfarin; Drug:Matching placebo for Rivaroxaban arm (Warfarin placebo); Drug:Matching placebo for Warfarin arm (Rivaroxaban placebo),[],"April 10, 2014",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,PA,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00373685,Pfizer,False,PA,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00365105,Radiation Therapy Oncology Group,True,PA,https://ClinicalTrials.gov/show/NCT00365105,False,"Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer",Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer,Dietary Supplement:Calcium; Dietary Supplement:Vitamin D; Drug:zoledronic acid; Drug:Sm-153; Radiation:Sr-89,[],"March 20, 2015",18,9223372036854775807,Both,False
NCT00346216,Pfizer,False,PA,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00304031,Radiation Therapy Oncology Group,True,PA,https://ClinicalTrials.gov/show/NCT00304031,False,Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,Brain and Central Nervous System Tumors,Drug:Concurrent temozolomide; Radiation:Concurrent radiation therapy; Drug:100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle; Drug:75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle,[],"October 13, 2015",18,120,Both,False
NCT00303628,National Cancer Institute (NCI),False,PA,https://ClinicalTrials.gov/show/NCT00303628,False,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],"May 20, 2014",18,9223372036854775807,Both,False
NCT00288080,Radiation Therapy Oncology Group,True,PA,https://ClinicalTrials.gov/show/NCT00288080,False,Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:buserelin; Drug:docetaxel; Drug:flutamide; Drug:goserelin acetate; Drug:leuprolide acetate; Drug:prednisone; Drug:triptorelin; Radiation:radiation therapy,[],"March 20, 2015",18,9223372036854775807,Male,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,PA,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00346216,Pfizer,False,RI,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00053898,NSABP Foundation Inc,True,RI,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT02465060,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01827761,Brown University,False,RI,https://ClinicalTrials.gov/show/NCT01827761,False,Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258,Cancer,Behavioral:Questionnaire,"[u'Memorial Hospital', u'Rhode Island Hospital (including Newport)', u'The Miriam Hospital', u'Roger Williams Medical Center']","May 9, 2014",18,9223372036854775807,Both,False
NCT01764633,Amgen,False,RI,https://ClinicalTrials.gov/show/NCT01764633,False,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Dyslipidemia,Biological:Evolocumab (AMG 145); Other:Placebo; Drug:Effective statin therapy,[],"January 20, 2016",40,85,Both,False
NCT01547741,NSABP Foundation Inc,False,RI,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00862368,The Miriam Hospital,True,RI,https://ClinicalTrials.gov/show/NCT00862368,False,Sustaining Smoking Cessation in Smokers With Kids With Asthma,Asthma; Smoking Cessation,Behavioral:PAM; Behavioral:PAM-Enhanced/Asthma Counseling Phone Calls; Behavioral:Follow-Up Phone Calls - Child Wellness Topic,"[u""St. Anne's Hospital"", u'Memorial Hospital of RI', u""Hasbro Children's Hospital"", u'The Miriam Hospital', u'Kent County Hospital']","April 24, 2012",18,9223372036854775807,Both,True
NCT00861705,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00705406,BioCryst Pharmaceuticals,False,RI,https://ClinicalTrials.gov/show/NCT00705406,False,"A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza","Acute, Uncomplicated Human Influenza",Drug:Peramivir; Drug:Placebo,[],"February 12, 2015",18,9223372036854775807,Both,False
NCT00607256,Pfizer,False,RI,https://ClinicalTrials.gov/show/NCT00607256,False,"Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia",Fibromyalgia,"Drug:[S,S]-reboxetine",[],"February 15, 2011",18,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,RI,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00373685,Pfizer,False,RI,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,RI,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00240383,Bristol-Myers Squibb,False,RI,https://ClinicalTrials.gov/show/NCT00240383,False,"Dose Ranging Study With LT, Monotherapy, PPAR",Diabetes Mellitus II,Drug:Muraglitazar,[],"September 10, 2010",18,70,Both,False
NCT00239681,AstraZeneca,False,RI,https://ClinicalTrials.gov/show/NCT00239681,False,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],"February 6, 2014",50,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00041119,Alliance for Clinical Trials in Oncology,True,RI,https://ClinicalTrials.gov/show/NCT00041119,False,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,Breast Cancer,Drug:AC regimen; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"July 23, 2015",18,9223372036854775807,Female,False
NCT00034879,AstraZeneca,False,RI,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT00003797,Brown University,False,RI,https://ClinicalTrials.gov/show/NCT00003797,False,Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas,Pancreatic Cancer,Biological:trastuzumab; Drug:gemcitabine hydrochloride,"[u""Rush-Presbyterian-St. Luke's Medical Center"", u'New England Medical Center Hospital', u""St. Elizabeth's Medical Center"", u'Cancer Institute of New Jersey', u'Memorial Sloan-Kettering Cancer Center', u'Mount Sinai Medical Center, NY', u'University of Pittsburgh Cancer Institute', u'Memorial Hospital of Rhode Island', u'Rhode Island Hospital', u'Roger Williams Medical Center/BUSM', u'Brown University Oncology Group', u'University of Texas - MD Anderson Cancer Center']","December 18, 2013",18,9223372036854775807,Both,False
NCT01900665,Eli Lilly and Company,False,RI,https://ClinicalTrials.gov/show/NCT01900665,False,Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo,Alzheimer's Disease,Drug:Solanezumab; Drug:Placebo,[],"April 29, 2015",55,90,Both,False
NCT01757925,UnitedHealth Group,False,RI,https://ClinicalTrials.gov/show/NCT01757925,False,Evaluation of a Commercial Gaming Impact in a Childhood Obesity Intervention,Childhood Obesity,Behavioral:weight managment program; Other:Active Gaming,"[u'YMCA Andvore', u'YMCA Lawrence', u'YMCA Merrimack Valley of MAss', u'YMCA Boroughs', u'Barrinton YMCA', u'Newman YMCA', u'YMCA Kent', u'Jones Elementary', u'Barabara Jordan Elementary', u'Oyster Creek Elementary', u'Townwest Elementary']","December 28, 2012",6,12,Both,True
NCT01744353,Brown University,False,RI,https://ClinicalTrials.gov/show/NCT01744353,False,BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study,Metastatic Pancreatic Cancer,Drug:FOLFOX-A,"[u'Memorial Hospital', u'Rhode Island Hospital (including Newport and East Greenwich locations)', u'The Miriam Hospital']","April 3, 2015",18,9223372036854775807,Both,False
NCT01744340,howard safran,False,RI,https://ClinicalTrials.gov/show/NCT01744340,False,A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer,Head and Neck Cancer; Colon Cancer,Drug:Head and neck; Drug:Colon- Closed as of May 2014,"[u'Montefiore', u'Memorial Hospital', u'Rhode Island Hospital', u'The Miriam Hospital']","March 27, 2015",18,9223372036854775807,Both,False
NCT01507545,Morphotek,False,RI,https://ClinicalTrials.gov/show/NCT01507545,False,Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO),Metastatic Colorectal Cancer; Colorectal Cancer,Drug:MORAb-004; Drug:Placebo,[],"September 4, 2015",18,9223372036854775807,Both,False
NCT01479621,Teva Pharmaceutical Industries,False,RI,https://ClinicalTrials.gov/show/NCT01479621,False,A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids,Asthma,Drug:Placebo; Drug:Flovent Diskus; Drug:Fluticasone propionate DPI Dose 1; Drug:Fluticasone propionate DPI Dose 2; Drug:Fluticasone propionate DPI Dose 3; Drug:Fluticasone propionate DPI Dose 4,[],"March 19, 2015",12,9223372036854775807,Both,False
NCT01475721,GlaxoSmithKline,False,RI,https://ClinicalTrials.gov/show/NCT01475721,False,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],"December 10, 2015",12,9223372036854775807,Both,False
NCT01365130,howard safran,False,RI,https://ClinicalTrials.gov/show/NCT01365130,False,Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen,Esophageal; Gastrooesophageal Cancer; Gastric Cancer,Drug:jevtana,"[u'Memorial Hospital', u'Brown University Oncology Research Group', u'Roger Williams']","June 12, 2014",18,9223372036854775807,Both,False
NCT01363843,William Sikov,False,RI,https://ClinicalTrials.gov/show/NCT01363843,False,Complete Neoadjuvant Treatment for REctal Cancer (CONTRE),Colon Cancer; Rectal Cancer,Drug:FOLFOX6; Radiation:RT with concurrent chemotherapy; Procedure:Surgery,"[u'Memorial Hospital', u'The Miriam Hospital', u'Rhode Island Hospital']","July 25, 2014",18,9223372036854775807,Both,False
NCT01351389,Brown University,False,RI,https://ClinicalTrials.gov/show/NCT01351389,False,Brief Interventions in the Emergency Department for Alcohol and HIV/Sexual Risk,Alcohol Consumption; Unsafe Sex,Behavioral:Brief Motivational Intervention (BMI); Behavioral:Brief Advice,"[u'Memorial Hospital of Rhode Island', u'Brown University Center for Alcohol and Addiction Studies', u'Kent Hospital']","September 12, 2014",18,65,Both,False
NCT01327846,Novartis Pharmaceuticals,False,RI,https://ClinicalTrials.gov/show/NCT01327846,False,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],"May 19, 2015",18,9223372036854775807,Both,False
NCT01313676,GlaxoSmithKline,False,RI,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01302067,Pfizer,False,RI,https://ClinicalTrials.gov/show/NCT01302067,False,A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine,Overactive Bladder,Drug:Fesoterodine 8mg; Drug:Fesoterodine 4mg; Drug:Placebo,[],"February 25, 2014",18,9223372036854775807,Both,False
NCT01302054,Pfizer,False,RI,https://ClinicalTrials.gov/show/NCT01302054,False,"A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.","Urinary Bladder, Overactive",Drug:Fesoterodine 8 mg; Drug:Placebo,[],"March 22, 2013",18,9223372036854775807,Both,False
NCT01276509,Pfizer,False,RI,https://ClinicalTrials.gov/show/NCT01276509,False,Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease,Crohn's Disease,Drug:PF-00547659 SC injection; Drug:PF-00547659 SC injection; Drug:PF-00547659 SC injection; Drug:PF-00547659 SC injection,[],"December 7, 2015",18,75,Both,False
NCT01224795,BioCryst Pharmaceuticals,False,RI,https://ClinicalTrials.gov/show/NCT01224795,False,A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.,Influenza,Drug:Peramivir; Drug:Placebo Comparator,[],"December 15, 2014",12,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,RI,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01175226,Biota Scientific Management Pty Ltd,False,RI,https://ClinicalTrials.gov/show/NCT01175226,False,A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection,Rhinovirus,Drug:BTA798; Drug:Placebo,[],"September 12, 2013",18,70,Both,False
NCT01130272,"Furiex Pharmaceuticals, Inc",False,RI,https://ClinicalTrials.gov/show/NCT01130272,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"June 11, 2012",18,65,Both,False
NCT01101438,NCIC Clinical Trials Group,True,RI,https://ClinicalTrials.gov/show/NCT01101438,False,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],"May 5, 2015",18,74,Both,False
NCT01057693,Pfizer,False,RI,https://ClinicalTrials.gov/show/NCT01057693,False,Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy,"Diabetic Neuropathy, Painful",Drug:pregabalin (Lyrica); Drug:Placebo,[],"January 18, 2013",18,9223372036854775807,Both,False
NCT01042769,Hoffmann-La Roche,False,RI,https://ClinicalTrials.gov/show/NCT01042769,False,A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Aleglitazar; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT00937352,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",False,RI,https://ClinicalTrials.gov/show/NCT00937352,False,A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease,Alzheimer's Disease,Drug:Bapineuzumab,[],"November 26, 2013",51,9223372036854775807,Both,False
NCT00911937,Pfizer,False,RI,https://ClinicalTrials.gov/show/NCT00911937,False,A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency,Overactive Bladder,Drug:Fesoterodine; Drug:Placebo,[],"July 9, 2012",18,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,RI,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01097278,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT00942331,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00373685,Pfizer,False,SC,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00346216,Pfizer,False,SC,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,SC,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00946712,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00803062,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00803062,False,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT02042443,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,SC,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01313676,GlaxoSmithKline,False,SC,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01015833,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00954174,Gynecologic Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT00954174,False,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00324805,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01099449,Alliance for Clinical Trials in Oncology,False,SC,https://ClinicalTrials.gov/show/NCT01099449,False,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT00874211,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT00874211,False,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],"March 4, 2015",0,9223372036854775807,Both,False
NCT00499369,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00499369,False,Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy,Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer,Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Biological:bevacizumab,[],"July 25, 2014",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT00951496,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00450281,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT00450281,False,"S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",Lung Cancer,Genetic:chromogenic in situ hybridization; Genetic:gene expression analysis; Genetic:mutation analysis; Genetic:polymerase chain reaction; Genetic:polymorphism analysis; Other:fluorescent antibody technique; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis; Other:matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other:study of socioeconomic and demographic variables; Procedure:study of high risk factors,[],"October 23, 2015",18,120,Both,False
NCT01385137,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT01385137,False,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],"October 15, 2015",18,120,Female,False
NCT01011478,NSABP Foundation Inc,True,SC,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00792701,Southwest Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT00792701,False,S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:gemcitabine hydrochloride; Other:active surveillance,[],"February 5, 2015",18,9223372036854775807,Both,False
NCT02276222,Sunovion Respiratory Development Inc.,False,SC,https://ClinicalTrials.gov/show/NCT02276222,False,A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD,Chronic Obstructive Pulmonary Disease (COPD),Drug:Glycopyrrolate (SUN-101 ); Drug:tiotropium (Spiriva),[],"August 25, 2015",40,9223372036854775807,Both,False
NCT01642251,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01508026,Forest Laboratories,False,SC,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00775645,Southwest Oncology Group,True,SC,https://ClinicalTrials.gov/show/NCT00775645,False,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy",Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity,Dietary Supplement:acetyl-L-carnitine hydrochloride; Other:placebo,[],"January 13, 2014",18,9223372036854775807,Female,False
NCT00602459,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00602459,False,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT00569127,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00569127,False,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],"January 5, 2015",0,9223372036854775807,Both,False
NCT00567580,Radiation Therapy Oncology Group,False,SC,https://ClinicalTrials.gov/show/NCT00567580,False,Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer,Prostate Cancer,Drug:bicalutamide; Drug:flutamide; Radiation:radiation therapy,[],"March 31, 2015",18,9223372036854775807,Male,False
NCT02500797,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02311907,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT01712516,Novartis Pharmaceuticals,False,SC,https://ClinicalTrials.gov/show/NCT01712516,False,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Chronic Obstructive Pulmonary Disease (COPD),Drug:QVA149; Drug:QAB149; Drug:NVA237; Drug:Placebo,[],"July 13, 2015",40,9223372036854775807,Both,False
NCT01709864,Novartis Pharmaceuticals,False,SC,https://ClinicalTrials.gov/show/NCT01709864,False,NVA237 Versus Placebo 12-week Efficacy Study,Chronic Obstructive Pulmonary Disease,Drug:NVA237; Drug:Placebo,[],"February 12, 2015",40,9223372036854775807,Both,False
NCT01126437,Boehringer Ingelheim,False,SC,https://ClinicalTrials.gov/show/NCT01126437,False,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],"May 20, 2014",40,9223372036854775807,Both,False
NCT01004640,Alliance for Clinical Trials in Oncology,False,SC,https://ClinicalTrials.gov/show/NCT01004640,False,Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial,Leukemia,Genetic:DNA analysis; Genetic:Southern blotting; Genetic:cytogenetic analysis; Genetic:polymerase chain reaction,[],"July 23, 2015",0,9223372036854775807,Both,False
NCT00937937,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00937937,False,Dinaciclib in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Mucosal Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:dinaciclib,[],"June 9, 2014",18,9223372036854775807,Both,False
NCT00892177,Alliance for Clinical Trials in Oncology,False,SC,https://ClinicalTrials.gov/show/NCT00892177,False,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00887536,NSABP Foundation Inc,False,SC,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00770809,National Cancer Institute (NCI),False,SC,https://ClinicalTrials.gov/show/NCT00770809,False,Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,HER2/Neu Positive; Male Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Drug:Lapatinib Ditosylate; Biological:Trastuzumab; Drug:Paclitaxel; Other:Laboratory Biomarker Analysis,[],"May 7, 2015",18,9223372036854775807,Both,False
NCT00601900,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00433511,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00769379,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00326898,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,SD,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT00946712,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00887159,National Cancer Institute (NCI),True,SD,https://ClinicalTrials.gov/show/NCT00887159,False,Cisplatin and Etoposide With or Without Vismodegib or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:cixutumumab; Drug:vismodegib; Drug:cisplatin; Drug:etoposide,[],"July 1, 2015",18,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00803062,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00803062,False,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT00785291,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00588770,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00569127,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00569127,False,"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor",Neuroendocrine Carcinoma,Biological:Recombinant Interferon Alfa-2b; Drug:Octreotide Acetate; Biological:Bevacizumab,[],"January 5, 2015",0,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,SD,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00134056,Southwest Oncology Group,True,SD,https://ClinicalTrials.gov/show/NCT00134056,False,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],"May 6, 2015",18,9223372036854775807,Male,False
NCT00087178,NSABP Foundation Inc,False,SD,https://ClinicalTrials.gov/show/NCT00087178,False,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],"October 5, 2015",18,9223372036854775807,Female,False
NCT00075946,Eastern Cooperative Oncology Group,True,SD,https://ClinicalTrials.gov/show/NCT00075946,False,Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma,Lymphoma,Biological:rituximab,[],"June 3, 2015",18,9223372036854775807,Both,False
NCT00003594,Alliance for Clinical Trials in Oncology,True,SD,https://ClinicalTrials.gov/show/NCT00003594,False,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug:irinotecan; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT02311907,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT01886872,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01720173,Gynecologic Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT01720173,False,"Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Biological:Dalantercept; Other:Laboratory Biomarker Analysis,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT01498289,Southwest Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01011478,NSABP Foundation Inc,True,SD,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00954174,Gynecologic Oncology Group,False,SD,https://ClinicalTrials.gov/show/NCT00954174,False,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00951496,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00892177,Alliance for Clinical Trials in Oncology,False,SD,https://ClinicalTrials.gov/show/NCT00892177,False,Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme,Glioblastoma Multiforme,Biological:bevacizumab; Drug:dasatinib; Other:placebo,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00891878,Alliance for Clinical Trials in Oncology,False,SD,https://ClinicalTrials.gov/show/NCT00891878,False,Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction,Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer,Drug:capecitabine; Drug:sunitinib malate,[],"July 8, 2015",18,9223372036854775807,Both,False
NCT00808132,Pfizer,False,SD,https://ClinicalTrials.gov/show/NCT00808132,False,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Menopause; Osteoporosis,Drug:bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; Drug:bazedoxifene 20 mg/ conjugated estrogens 0.625 mg; Drug:bazedoxifene 20 mg; Drug:conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg; Drug:Placebo,[],"March 10, 2014",40,64,Female,False
NCT00798603,Alliance for Clinical Trials in Oncology,False,SD,https://ClinicalTrials.gov/show/NCT00798603,False,"Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",Lung Cancer,Biological:bevacizumab; Drug:carboplatin; Drug:pemetrexed disodium,[],"July 3, 2015",70,9223372036854775807,Both,False
NCT00702949,Alliance for Clinical Trials in Oncology,True,SD,https://ClinicalTrials.gov/show/NCT00702949,False,Pregabalin in Treating Women With Hot Flashes,Breast Cancer; Hot Flashes,Drug:pregabalin; Other:placebo,[],"November 23, 2015",18,9223372036854775807,Female,True
NCT00693992,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00644228,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00644228,False,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],"September 12, 2014",18,9223372036854775807,Both,False
NCT00602641,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00602641,False,"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:melphalan; Drug:prednisone; Drug:thalidomide; Drug:lenalidomide,[],"June 9, 2015",18,9223372036854775807,Both,False
NCT00531817,Hoffmann-La Roche,False,SD,https://ClinicalTrials.gov/show/NCT00531817,False,A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug:Tocilizumab; Drug:Placebo; Drug:Permitted DMARDs,[],"August 13, 2012",18,9223372036854775807,Both,False
NCT00521001,Alliance for Clinical Trials in Oncology,True,SD,https://ClinicalTrials.gov/show/NCT00521001,False,Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,Melanoma (Skin),Drug:everolimus; Drug:temozolomide,[],"July 9, 2015",18,9223372036854775807,Both,False
NCT00516698,Alliance for Clinical Trials in Oncology,False,SD,https://ClinicalTrials.gov/show/NCT00516698,False,Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer,Breast Cancer,Genetic:polymorphism analysis; Other:high performance liquid chromatography; Other:laboratory biomarker analysis; Procedure:radiomammography,[],"July 5, 2015",18,9223372036854775807,Female,False
NCT00516503,Alliance for Clinical Trials in Oncology,True,SD,https://ClinicalTrials.gov/show/NCT00516503,False,Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer,"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific",Drug:baclofen/amitriptyline/ketamine gel; Other:placebo,[],"July 3, 2015",18,9223372036854775807,Both,False
NCT00438659,North Central Cancer Treatment Group,True,SD,https://ClinicalTrials.gov/show/NCT00438659,False,Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ,Breast Cancer; Dermatologic Complications; Radiation Toxicity; Skin Reactions Secondary to Radiation Therapy,Drug:mometasone furoate; Other:placebo,[],"February 11, 2015",18,9223372036854775807,Both,False
NCT00404235,Alliance for Clinical Trials in Oncology,True,SD,https://ClinicalTrials.gov/show/NCT00404235,False,Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,Melanoma (Skin),Drug:carboplatin; Drug:paclitaxel albumin-stabilized nanoparticle formulation,[],"July 7, 2015",18,9223372036854775807,Both,False
NCT00382070,NSABP Foundation Inc,True,SD,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT00378703,National Cancer Institute (NCI),False,SD,https://ClinicalTrials.gov/show/NCT00378703,False,"Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer",Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Sorafenib; Drug:temsirolimus; Biological:bevacizumab,[],"April 14, 2015",18,9223372036854775807,Both,False
NCT00376675,Alliance for Clinical Trials in Oncology,True,SD,https://ClinicalTrials.gov/show/NCT00376675,False,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,"Fatigue; Unspecified Adult Solid Tumor, Protocol Specific",Drug:methylphenidate hydrochloride; Other:placebo,[],"September 14, 2015",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00264901,Novo Nordisk A/S,False,TN,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT00080340,Telik,False,TN,https://ClinicalTrials.gov/show/NCT00080340,False,Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Non Small Cell Lung Carcinoma,Drug:TLK286 (Telcyta) HCl for Injection; Drug:gefitinib (Iressa),[],"January 10, 2008",18,9223372036854775807,Both,False
NCT01740427,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT01740427,False,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),Breast Neoplasms,Drug:PD-0332991; Drug:Letrozole; Drug:Placebo; Drug:Letrozole,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00678392,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00678392,False,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT00615056,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00615056,False,A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen,Colorectal Neoplasms,"Drug:Bevacizumab (avastin); Drug:FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]); Drug:AG-013736 (axitinib); Drug:FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]); Drug:AG-013736 (axitinib); Drug:FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]); Drug:Bevacizumab (avastin); Drug:FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])",[],"April 12, 2013",18,9223372036854775807,Both,False
NCT00057720,Telik,False,TN,https://ClinicalTrials.gov/show/NCT00057720,False,TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer,Ovarian Neoplasms,Drug:TLK286 HCl for injection; Drug:topotecan hydrochloride for injection; Drug:doxorubicin HCl liposome injection,[],"July 21, 2011",18,9223372036854775807,Female,False
NCT00932451,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00932451,False,"An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","Carcinoma, Non-Small-Cell Lung",Drug:PF-02341066,[],"November 23, 2015",18,9223372036854775807,Both,False
NCT00887536,NSABP Foundation Inc,False,TN,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00373685,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00346216,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01154140,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT01154140,False,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,Non Squamous Lung Cancer,Drug:treatment; Drug:treatment,[],"November 30, 2015",18,9223372036854775807,Both,False
NCT00932893,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00932893,False,"An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","Carcinoma, Non-Small-Cell Lung",Drug:PF-02341066; Drug:Pemetrexed; Drug:Docetaxel,[],"December 3, 2015",18,9223372036854775807,Both,False
NCT00640042,Pfizer,True,TN,https://ClinicalTrials.gov/show/NCT00640042,False,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",Pain,Drug:morphine sulfate extended release capsules,[],"June 6, 2012",21,9223372036854775807,Both,False
NCT00968708,Takeda,False,TN,https://ClinicalTrials.gov/show/NCT00968708,False,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"Diabetes Mellitus, Type 2; Acute Coronary Syndrome",Drug:Alogliptin; Drug:Placebo,[],"April 15, 2014",18,9223372036854775807,Both,False
NCT00878709,"Puma Biotechnology, Inc.",False,TN,https://ClinicalTrials.gov/show/NCT00878709,False,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],"August 20, 2015",18,9223372036854775807,Female,False
NCT00137436,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00137436,False,Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer,Prostatic Neoplasms,Drug:Docetaxel; Drug:Prednisone; Drug:SU011248,"[u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site', u'Pfizer Investigational Site']","August 25, 2011",18,9223372036854775807,Male,False
NCT00849056,GlaxoSmithKline,False,TN,https://ClinicalTrials.gov/show/NCT00849056,False,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00798889,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00798889,False,Rollover Protocol for Prior SU011248 Protocols,Solid Tumors,Drug:Sunitinib,[],"December 13, 2012",18,9223372036854775807,Both,False
NCT00699374,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00699374,False,Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer,"Carcinoma, Hepatocellular",Drug:sunitinib malate; Drug:sorafenib,[],"December 7, 2012",18,9223372036854775807,Both,False
NCT00839527,GlaxoSmithKline,False,TN,https://ClinicalTrials.gov/show/NCT00839527,False,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00838903,GlaxoSmithKline,False,TN,https://ClinicalTrials.gov/show/NCT00838903,False,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],"August 11, 2014",18,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,TN,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00435409,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00435409,False,A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer,Breast Neoplasms,Drug:Sunitinib + Capecitabine; Drug:Capecitabine,[],"June 15, 2012",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00403767,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",False,TN,https://ClinicalTrials.gov/show/NCT00403767,False,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation; Stroke; Embolism,Drug:Rivaroxaban; Drug:Warfarin; Drug:Matching placebo for Rivaroxaban arm (Warfarin placebo); Drug:Matching placebo for Warfarin arm (Rivaroxaban placebo),[],"April 10, 2014",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00239681,AstraZeneca,False,TN,https://ClinicalTrials.gov/show/NCT00239681,False,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],"February 6, 2014",50,9223372036854775807,Both,False
NCT00113516,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00113516,False,A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer,Drug:carboplatin; Drug:paclitaxel; Drug:sunitinib,[],"May 14, 2010",18,9223372036854775807,Both,False
NCT00072852,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00072852,False,"Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine",Breast Neoplasms,Drug:Irinotecan,[],"October 15, 2008",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01136967,Eisai Inc.,False,TN,https://ClinicalTrials.gov/show/NCT01136967,False,"An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma",Unresectable Stage III; Stage IV Melanoma,Drug:E7080; Drug:E7080,[],"April 1, 2014",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00471276,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00471276,False,Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer,Breast Neoplasms,Drug:sunitinib,[],"July 21, 2011",18,9223372036854775807,Female,False
NCT00460603,Pfizer,False,TN,https://ClinicalTrials.gov/show/NCT00460603,False,Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer,Colorectal Neoplasms,Drug:bevacizumab; Drug:AG-013726; Drug:AG-013736 (axitinib),[],"November 7, 2013",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00088556,Telik,False,TN,https://ClinicalTrials.gov/show/NCT00088556,False,"Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung",Drug:TLK286; Drug:carboplatin; Drug:paclitaxel,[],"May 30, 2012",18,9223372036854775807,Both,False
NCT00067938,GlaxoSmithKline,False,TN,https://ClinicalTrials.gov/show/NCT00067938,False,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],"October 11, 2012",18,9223372036854775807,Both,False
NCT00006104,Vanderbilt-Ingram Cancer Center,False,TN,https://ClinicalTrials.gov/show/NCT00006104,False,Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer,Breast Cancer,Biological:trastuzumab; Drug:docetaxel,"[u'Providence Hospital', u'Robert H. Lurie Comprehensive Cancer Center, Northwestern University', u'Evanston Hospital', u'Owensboro Medical Health System', u'Fox Chase Cancer Center', u'Erlanger Health Systems', u'Memorial Health Care System', u'Williamson Medical Center', u'Jackson-Madison County Hospital', u'Methodist/Thompson Oncology Research', u'Tennessee Cancer Specialists', u'Boston Baskin Cancer Group', u'St. Thomas Health Services', u'Vanderbilt-Ingram Cancer Center', u'Methodist Medical Center of Oak Ridge']","August 10, 2012",18,9223372036854775807,Female,False
NCT01959529,Novo Nordisk A/S,False,TN,https://ClinicalTrials.gov/show/NCT01959529,False,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],"January 8, 2016",50,9223372036854775807,Both,False
NCT01508026,Forest Laboratories,False,TN,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01130272,"Furiex Pharmaceuticals, Inc",False,TN,https://ClinicalTrials.gov/show/NCT01130272,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"June 11, 2012",18,65,Both,False
NCT01100684,Tioga Pharmaceuticals,False,TN,https://ClinicalTrials.gov/show/NCT01100684,False,Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS),Diarrhea Predominant Irritable Bowel Syndrome,Drug:Asimadoline; Drug:Placebo,[],"December 17, 2013",18,79,Both,False
NCT01070836,Biogen,False,TN,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT00838916,GlaxoSmithKline,False,TN,https://ClinicalTrials.gov/show/NCT00838916,False,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:insulin glargine,[],"May 22, 2014",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,TN,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00699998,Eli Lilly and Company,False,TN,https://ClinicalTrials.gov/show/NCT00699998,False,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,Drug:Clopidogrel; Drug:Prasugrel; Drug:Commercially-available Aspirin,[],"March 21, 2013",18,9223372036854775807,Both,False
NCT00666211,Vanderbilt-Ingram Cancer Center,False,TN,https://ClinicalTrials.gov/show/NCT00666211,False,Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain,"Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Pain; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",Other:educational intervention; Other:Titrated pain management; Other:questionnaire administration,"[u'Jennie Stuart Medical Center', u'Mitchell Memorial Cancer Center at Owensboro Medical Health System', u'Erlanger Health System', u'Tennessee Plateau Oncology', u'Center for Biomedical Research', u'The Jones Clinic', u'Vanderbilt-Ingram Cancer Center - Cool Springs', u'Vanderbilt-Ingram Cancer Center at Franklin', u'Meharry Medical College', u'Veterans Affairs Medical Center - Nashville', u'Vanderbilt-Ingram Cancer Center']","August 4, 2012",21,9223372036854775807,Both,False
NCT02122471,Synergy Pharmaceuticals Inc.,False,TX,https://ClinicalTrials.gov/show/NCT02122471,False,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Chronic Idiopathic Constipation,Drug:Plecanatide; Drug:Placebo,[],"January 29, 2015",18,80,Both,False
NCT02030600,Novo Nordisk A/S,False,TX,https://ClinicalTrials.gov/show/NCT02030600,False,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes","Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],"December 8, 2015",18,9223372036854775807,Both,False
NCT01959529,Novo Nordisk A/S,False,TX,https://ClinicalTrials.gov/show/NCT01959529,False,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin degludec; Drug:insulin glargine,[],"January 8, 2016",50,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,TX,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01543178,"Valeant Pharmaceuticals International, Inc.",False,TX,https://ClinicalTrials.gov/show/NCT01543178,False,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Irritable Bowel Syndrome With Diarrhea,Drug:open-label rifaximin; Drug:double-blind placebo; Drug:double-blind rifaximin,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01508026,Forest Laboratories,False,TX,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01475721,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT01475721,False,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],"December 10, 2015",12,9223372036854775807,Both,False
NCT01462344,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT01462344,False,6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg,[],"October 1, 2015",4,11,Both,False
NCT01458275,Sunovion,False,TX,https://ClinicalTrials.gov/show/NCT01458275,False,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR),Seasonal Allergic Rhinitis,Drug:Ciclesonide nasal aerosol 37 mcg; Drug:ciclesonide nasal aerosol 74 mcg; Drug:Placebo,[],"April 16, 2014",6,11,Both,False
NCT01427270,Purdue Pharma LP,False,TX,https://ClinicalTrials.gov/show/NCT01427270,False,Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain,Low Back Pain,Drug:Oxycodone/Naloxone controlled-release; Drug:Oxycodone HCl controlled-release; Drug:Placebo,[],"November 6, 2014",18,9223372036854775807,Both,False
NCT01349322,Radiation Therapy Oncology Group,False,TX,https://ClinicalTrials.gov/show/NCT01349322,False,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01327846,Novartis Pharmaceuticals,False,TX,https://ClinicalTrials.gov/show/NCT01327846,False,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,Drug:Canakinumab; Drug:Placebo,[],"May 19, 2015",18,9223372036854775807,Both,False
NCT01313676,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01306890,Dendreon,False,TX,https://ClinicalTrials.gov/show/NCT01306890,False,A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer,Advanced Prostate Cancer; Prostatic Neoplasms,Biological:sipuleucel-T,[],"October 5, 2015",18,9223372036854775807,Male,False
NCT01275677,National Cancer Institute (NCI),False,TX,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01195662,AstraZeneca,False,TX,https://ClinicalTrials.gov/show/NCT01195662,False,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,Type 2 Diabetes,Drug:Dapagliflozin; Drug:Placebo matching Dapagliflozin,[],"December 2, 2015",18,89,Both,False
NCT01183780,Eli Lilly and Company,False,TX,https://ClinicalTrials.gov/show/NCT01183780,False,A Study in Second Line Metastatic Colorectal Cancer,Colorectal Cancer,Biological:Ramucirumab; Biological:Placebo; Drug:Irinotecan; Drug:Folinic Acid; Drug:5-Fluorouracil,[],"September 14, 2015",18,9223372036854775807,Both,False
NCT01168973,Eli Lilly and Company,False,TX,https://ClinicalTrials.gov/show/NCT01168973,False,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,Non-Small Cell Lung Cancer,Biological:Ramucirumab; Drug:Placebo (for Ramucirumab); Drug:Docetaxel,[],"August 20, 2015",18,9223372036854775807,Both,False
NCT01130272,"Furiex Pharmaceuticals, Inc",False,TX,https://ClinicalTrials.gov/show/NCT01130272,False,"Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea",Irritable Bowel Syndrome,Drug:JNJ-27018966; Drug:Placebo,[],"June 11, 2012",18,65,Both,False
NCT01107886,AstraZeneca,False,TX,https://ClinicalTrials.gov/show/NCT01107886,False,Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications,Type 2 Diabetes Mellitus,Drug:Saxagliptin; Drug:Placebo,[],"July 9, 2014",40,9223372036854775807,Both,False
NCT01098539,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT01098539,False,A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin,[],"July 24, 2014",18,9223372036854775807,Both,False
NCT01075100,US Oncology Research,False,TX,https://ClinicalTrials.gov/show/NCT01075100,False,Ixabepilone + Carboplatin Metastatic Breast Cancer,Metastatic Breast Cancer,Drug:Ixabepilone; Drug:Carboplatin,[],"May 19, 2014",18,9223372036854775807,Both,False
NCT01068912,"MDVI, LLC",False,TX,https://ClinicalTrials.gov/show/NCT01068912,False,Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza,Influenza,Drug:Favipiravir; Drug:Favipiravir; Drug:Placebo comparator,[],"October 20, 2015",20,80,Both,False
NCT01042769,Hoffmann-La Roche,False,TX,https://ClinicalTrials.gov/show/NCT01042769,False,A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug:Aleglitazar; Drug:Placebo,[],"February 1, 2016",18,9223372036854775807,Both,False
NCT01035255,Novartis Pharmaceuticals,False,TX,https://ClinicalTrials.gov/show/NCT01035255,False,This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure,Heart Failure With Reduced Ejection Fraction,Drug:LCZ696 200 mg BID; Drug:Enalapril 10 mg BID,[],"September 9, 2015",18,9223372036854775807,Both,False
NCT01000727,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT01000727,False,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,Drug:Darapladib 160 mg; Drug:Placebo; Other:Standard Therapy,[],"September 3, 2015",18,9223372036854775807,Both,False
NCT00976391,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT00976391,False,A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine,"Diabetes Mellitus, Type 2",Biological:albiglutide + insulin glargine; Drug:insulin glargine + preprandial lispro insulin,[],"July 31, 2014",18,75,Both,False
NCT00946712,Southwest Oncology Group,False,TX,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00887536,NSABP Foundation Inc,False,TX,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00878709,"Puma Biotechnology, Inc.",False,TX,https://ClinicalTrials.gov/show/NCT00878709,False,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,Breast Cancer,Drug:neratinib; Other:placebo,[],"August 20, 2015",18,9223372036854775807,Female,False
NCT00849056,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT00849056,False,Safety and Efficacy of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:placebo,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00849017,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT00849017,False,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Biological:albiglutide uptitration; Biological:placebo,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00839527,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT00839527,False,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug:placebo to match albiglutide; Biological:albiglutide; Drug:metformin; Drug:glimepiride; Drug:pioglitazone; Drug:placebo to match pioglitazone,[],"May 29, 2014",18,9223372036854775807,Both,False
NCT00838916,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT00838916,False,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:insulin glargine,[],"May 22, 2014",18,9223372036854775807,Both,False
NCT00838903,GlaxoSmithKline,False,TX,https://ClinicalTrials.gov/show/NCT00838903,False,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Biological:albiglutide; Drug:sitagliptin; Drug:glimepiride; Drug:metformin; Biological:placebo albiglutide; Drug:placebo sitagliptin; Drug:placebo glimepiride,[],"August 11, 2014",18,9223372036854775807,Both,False
NCT00821327,US Oncology Research,False,TX,https://ClinicalTrials.gov/show/NCT00821327,False,"Gemzar, Cisp, Sunitinib Urothelial Ca",Urothelial Cancer,"Drug:Gemcitabine, Cisplatin, Sunitinib",[],"May 20, 2014",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,TX,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00678392,Pfizer,False,TX,https://ClinicalTrials.gov/show/NCT00678392,False,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT00658515,Hoffmann-La Roche,False,TX,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00642603,Hoffmann-La Roche,False,TX,https://ClinicalTrials.gov/show/NCT00642603,False,A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Drug:capecitabine [Xeloda]; Drug:capecitabine [Xeloda]; Drug:bevacizumab [Avastin]; Drug:oxaliplatin; Drug:irinotecan,[],"May 31, 2011",18,9223372036854775807,Both,False
NCT00616772,"AbbVie (prior sponsor, Abbott)",False,TX,https://ClinicalTrials.gov/show/NCT00616772,False,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia,Drug:ABT-335; Drug:Placebo; Other:Atorvastatin,[],"December 3, 2013",45,9223372036854775807,Both,False
NCT00599313,US Oncology Research,False,TX,https://ClinicalTrials.gov/show/NCT00599313,False,Phase II Sunitinib Prog Met AIPC,Metastatic Prostate Cancer,Drug:Sunitinib,[],"May 21, 2014",18,9223372036854775807,Male,False
NCT00593827,Bristol-Myers Squibb,False,TX,https://ClinicalTrials.gov/show/NCT00593827,False,Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer,Metastatic Breast Cancer,Drug:Ixabepilone; Drug:Ixabepilone,[],"April 25, 2012",18,9223372036854775807,Female,False
NCT00557921,Cogentus Pharmaceuticals,False,TX,https://ClinicalTrials.gov/show/NCT00557921,False,Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1),Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease; Percutaneous Coronary Intervention,Drug:CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Drug:Plavix (clopidogrel 75 mg) and aspirin,[],"January 27, 2009",21,9223372036854775807,Both,False
NCT00527111,US Oncology Research,False,TX,https://ClinicalTrials.gov/show/NCT00527111,False,Pre-op Rectal ChemoRad +/- Cetuximab,Rectal Cancer,Drug:Cetuximab; Drug:5-fluorouracil; Radiation:Pelvic irradiation,[],"November 7, 2015",18,9223372036854775807,Both,False
NCT00518115,GlaxoSmithKline,True,TX,https://ClinicalTrials.gov/show/NCT00518115,False,Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only,"Diabetes Mellitus, Type 2",Drug:Albiglutide (GSK716155) or exenatide,[],"June 19, 2014",18,75,Both,False
NCT00517829,US Oncology Research,False,TX,https://ClinicalTrials.gov/show/NCT00517829,False,Docetaxel+Oxali+/-Cetux Met Gastric/GEJ,Gastric Cancer Adenocarcinoma Metastatic,Drug:Docetaxel + oxaliplatin; Drug:Docetaxel + oxaliplatin + cetuximab,[],"May 19, 2014",18,9223372036854775807,Both,False
NCT00507416,"Millennium Pharmaceuticals, Inc.",False,TX,https://ClinicalTrials.gov/show/NCT00507416,False,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Multiple Myeloma,Drug:Bortezomib; Drug:Dexamethasone; Drug:Melphalan; Drug:Prednisone; Drug:Thalidomide,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT01546844,HealthInsight,False,UT,https://ClinicalTrials.gov/show/NCT01546844,False,Mobile Health Technology as an Intervention for Diabetes Self-Management,Type II Diabetes Mellitus,Other:Participation in Care4Life,"[u'Coalville Health Center', u'Pioneer Comprehensive Medical', u'Holladay Family Practice', u'Olympus Clinic', u'Exodus Healthcare - Main Office - Magna', u'Community Health Centers Inc. - 72nd Street Clinic', u'Park City Healthcare, Inc.', u'Riverton Family Health Center', u'Granger Medical-Riverton', u'Stephen D. Ratcliffe Community Health Center', u'Alpine Internal Medicine', u'HealthInsight', u'Central City Community Health Center Health First Family Medicine', u'Evolutionary Healthcare, Llc', u'Health Clinic Of Utah - SLC', u'Wasatch Internal Medicine', u'Jordan Ridge Family Medicine', u""Utah Healthcare Institute - St. Mark's Family Medicine"", u'Wasatch Homeless Health Care - 4th Street Clinic', u""Utah Physicians Care Centers - St Mark's Internal Medicine"", u'Barbara E. Rizzardi, M.D.', u'Copperview Medical Center, Llc', u'Community Health Centers Inc. - Oquirrh View', u'Valley Family Medicine', u'Advanced Practice Medical Clinic', u'Granger Medical - Jordan Medical Arts', u'Jordan Meadows Medical Center', u'West Valley Family And Preventive Medicine', u'Granger Medical Clinic Inc. - Main Office', u'Kathryn Allen, MD']","September 4, 2012",18,9223372036854775807,Both,False
NCT02199691,"Sanofi Pasteur, a Sanofi Company",False,UT,https://ClinicalTrials.gov/show/NCT02199691,False,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents,Meningitis; Meningococcal Meningitis; Meningococcal Infections,"Biological:Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine; Biological:Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197Conjugate Vaccine; Biological:Adacel: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Biological:GARDASIL: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant; Biological:Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine; Biological:Adacel: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Biological:GARDASIL: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant",[],"November 5, 2015",10,17,Both,True
NCT01508026,Forest Laboratories,False,UT,https://ClinicalTrials.gov/show/NCT01508026,False,"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",Stage 1 Hypertension; Stage 2 Hypertension,Drug:Nebivolol and Valsartan 1; Drug:Nebivolol and Valsartan 2; Drug:Nebivolol and Valsartan 3; Drug:Nebivolol 1; Drug:Nebivolol 2; Drug:Valsartan 1; Drug:Valsartan 2; Drug:Placebo,[],"March 28, 2014",18,9223372036854775807,Both,False
NCT00806195,Novartis,False,UT,https://ClinicalTrials.gov/show/NCT00806195,False,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Meningitis; Meningococcal Infection,"Biological:MenACWY-CRM197; Biological:DTaP (Diptheria, Tetanus, Pertussis) Vaccine; Biological:Hib (Haemophilus influenza b) Vaccine; Biological:IPV (Inactivated Polio Vaccine) Vaccine; Biological:Pneumococcal conjugate Vaccine; Biological:MMR (Measles, Mumps, and Rubella) Vaccine; Biological:Varicella Vaccine; Biological:Hepatitis A Virus",[],"May 13, 2013",55,89,Both,True
NCT00423735,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00423735,False,Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Neoplasm,Drug:Dasatinib; Other:Pharmacological Study,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT00390455,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00390455,False,Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive,Estrogen Receptor Positive; HER2 Positive Breast Carcinoma; HER2/Neu Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer,Drug:Lapatinib Ditosylate; Drug:Fulvestrant; Other:Placebo; Other:Laboratory Biomarker Analysis,[],"June 1, 2015",18,9223372036854775807,Female,False
NCT00369122,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00369122,False,"Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer,Radiation:external beam radiation therapy; Radiation:brachytherapy; Biological:bevacizumab; Drug:cisplatin,[],"September 22, 2014",0,9223372036854775807,Female,False
NCT00326898,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00303628,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00303628,False,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009),Adenocarcinoma of the Rectum; Stage II Rectal Cancer; Stage III Rectal Cancer,Drug:oxaliplatin; Drug:fluorouracil; Drug:leucovorin calcium; Drug:bevacizumab; Procedure:laboratory biomarker analysis,[],"May 20, 2014",18,9223372036854775807,Both,False
NCT00262847,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00262847,False,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"August 18, 2015",18,9223372036854775807,Female,False
NCT00217737,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02184572,GlaxoSmithKline,False,UT,https://ClinicalTrials.gov/show/NCT02184572,False,"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",Measles; Mumps; Rubella,"Biological:GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762); Biological:Merck & Co., Inc.'s M-M-RII (also called M-M-R Vax Pro), combined measles-mumps-rubella virus vaccine; Biological:Varivax (Merck & Co., Inc.); Biological:Havrix; Biological:Prevnar 13 (Pfizer Inc.)",[],"February 4, 2016",12,15,Both,True
NCT01167712,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT00803062,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00803062,False,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT00310180,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00303953,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00303953,False,PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma,Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma,Drug:belinostat,[],"April 23, 2014",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02196181,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01547741,NSABP Foundation Inc,False,UT,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00942357,Gynecologic Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00920010,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00920010,False,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],"February 5, 2015",0,9223372036854775807,Both,False
NCT00874211,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00874211,False,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],"March 4, 2015",0,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00792948,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00792948,False,Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia,Adult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Adult L1 Acute Lymphoblastic Leukemia; Adult L2 Acute Lymphoblastic Leukemia; Adult T Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dasatinib; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Biological:Filgrastim; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Methotrexate; Drug:Methylprednisolone; Procedure:Peripheral Blood Stem Cell Transplantation; Drug:Prednisone; Drug:Sirolimus; Drug:Tacrolimus; Radiation:Total-Body Irradiation; Drug:Vincristine Sulfate,[],"January 12, 2016",18,60,Both,False
NCT00683137,Pfizer,False,UT,https://ClinicalTrials.gov/show/NCT00683137,False,Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery,Pain; Hallux Valgus,Drug:valdecoxib; Drug:valdecoxib; Drug:valdecoxib/placebo,[],"May 22, 2008",18,9223372036854775807,Both,False
NCT00617708,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00617708,False,S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,Stage IV Pancreatic Cancer,Biological:cixutumumab; Drug:erlotinib hydrochloride; Drug:gemcitabine hydrochloride,[],"July 25, 2014",18,9223372036854775807,Both,False
NCT00450281,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00450281,False,"S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",Lung Cancer,Genetic:chromogenic in situ hybridization; Genetic:gene expression analysis; Genetic:mutation analysis; Genetic:polymerase chain reaction; Genetic:polymorphism analysis; Other:fluorescent antibody technique; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis; Other:matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other:study of socioeconomic and demographic variables; Procedure:study of high risk factors,[],"October 23, 2015",18,120,Both,False
NCT00433381,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00433381,False,Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma,Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor,Drug:irinotecan hydrochloride; Biological:bevacizumab; Drug:temozolomide,[],"May 7, 2014",18,9223372036854775807,Both,False
NCT00376961,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00376961,False,"S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",Lymphoma,Biological:rituximab; Drug:bortezomib; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:prednisone; Drug:vincristine sulfate,[],"May 8, 2015",18,9223372036854775807,Both,False
NCT00337129,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00337129,False,S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer,Head and Neck Cancer,Drug:eribulin mesylate,[],"August 11, 2015",18,9223372036854775807,Both,False
NCT00305864,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT00305864,False,"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,Radiation:3-dimensional conformal radiation therapy; Drug:temozolomide; Drug:motexafin gadolinium,[],"April 29, 2014",18,9223372036854775807,Both,False
NCT00134056,Southwest Oncology Group,True,UT,https://ClinicalTrials.gov/show/NCT00134056,False,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],"May 6, 2015",18,9223372036854775807,Male,False
NCT00124579,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00124579,False,"S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",Multiple Myeloma,Drug:bortezomib; Drug:dexamethasone; Drug:thalidomide,[],"March 5, 2015",18,9223372036854775807,Both,False
NCT00107276,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00107276,False,S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer,Breast Cancer,Drug:capecitabine; Drug:cyclophosphamide,[],"July 3, 2013",18,9223372036854775807,Female,False
NCT00089323,NSABP Foundation Inc,False,UT,https://ClinicalTrials.gov/show/NCT00089323,False,"Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer",Breast Cancer,Procedure:Bone Marrow Aspiration,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT00079001,Alliance for Clinical Trials in Oncology,True,UT,https://ClinicalTrials.gov/show/NCT00079001,False,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Metastatic Cancer; Prostate Cancer,Drug:zoledronic acid; Other:placebo; Drug:androgen deprivation therapy; Drug:GnRH agonist; Dietary Supplement:Calcium supplement; Dietary Supplement:Vitamin D,[],"November 23, 2015",18,9223372036854775807,Male,False
NCT00075764,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00075764,False,S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer,Breast Cancer,Drug:anastrozole; Drug:fulvestrant,[],"May 8, 2014",18,9223372036854775807,Female,False
NCT00062439,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00062439,False,S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors,Lung Cancer,Drug:cisplatin; Drug:docetaxel; Drug:etoposide; Procedure:conventional surgery; Radiation:radiation therapy,[],"October 30, 2013",0,9223372036854775807,Both,False
NCT00003641,Eastern Cooperative Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT00003641,False,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Other:clinical observation,[],"July 11, 2012",18,9223372036854775807,Both,False
NCT01964989,Novartis Vaccines,False,UT,https://ClinicalTrials.gov/show/NCT01964989,False,"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.",Influenza Virus,Biological:Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV); Biological:Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV),[],"December 7, 2015",6,72,Both,True
NCT01841736,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01609790,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01609790,False,Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors,Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Placebo; Biological:Trebananib,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01385137,Southwest Oncology Group,False,UT,https://ClinicalTrials.gov/show/NCT01385137,False,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],"October 15, 2015",18,120,Female,False
NCT01240746,"Sanofi Pasteur, a Sanofi Company",True,UT,https://ClinicalTrials.gov/show/NCT01240746,False,Study of Quadrivalent Influenza Vaccine Among Children,Influenza,"Biological:Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative; Biological:Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative; Biological:Quadrivalent Influenza Vaccine, No Preservative",[],"June 16, 2015",6,8,Both,True
NCT01196390,National Cancer Institute (NCI),False,UT,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01143259,"Intermountain Health Care, Inc.",False,UT,https://ClinicalTrials.gov/show/NCT01143259,False,Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use,Ileus,Drug:Alvimopam; Drug:300 mg Polyethylene,"[u'American Fork Hospital', u'Valley View Hospital', u'Logan Regional Hospital', u'Intermoutain Medical Center', u'McKay-Dee Hospital', u'Utah Valley', u'LDS Hospital', u'Alta View Hospital', u'Dixie Regional']","August 25, 2014",18,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,UT,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT01004640,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT01004640,False,Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial,Leukemia,Genetic:DNA analysis; Genetic:Southern blotting; Genetic:cytogenetic analysis; Genetic:polymerase chain reaction,[],"July 23, 2015",0,9223372036854775807,Both,False
NCT00372996,Pfizer,False,VT,https://ClinicalTrials.gov/show/NCT00372996,False,"Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer",Breast Neoplasms,"Drug:CP-751,871; Drug:exemestane; Drug:exemestane; Drug:Fulvestrant",[],"October 6, 2015",18,9223372036854775807,Female,False
NCT00053898,NSABP Foundation Inc,True,VT,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00003906,NSABP Foundation Inc,True,VT,https://ClinicalTrials.gov/show/NCT00003906,False,Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,Breast Cancer,Drug:Raloxifene; Drug:Tamoxifen,[],"October 5, 2015",35,9223372036854775807,Female,False
NCT00003389,Eastern Cooperative Oncology Group,True,VT,https://ClinicalTrials.gov/show/NCT00003389,False,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma,Lymphoma,Drug:Doxorubicin; Drug:Bleomycin; Drug:Vinblastine; Drug:Dacarbazine; Drug:Vincristine; Drug:Mechlorethamine; Drug:Etoposide; Drug:Prednisone; Drug:Cyclophosphamide; Radiation:Radiotherapy,[],"September 25, 2015",16,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01457391,Dartmouth-Hitchcock Medical Center,False,VT,https://ClinicalTrials.gov/show/NCT01457391,False,Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment,"Stress Disorders, Post-Traumatic; Substance-Related Disorders",Behavioral:Cognitive Behavioral Therapy; Behavioral:Individual Addiction Counseling; Behavioral:Treatment-as-usual,"[u'Central Vermont Substance Abuse Services', u'Brattleboro Retreat', u'Howard Center', u'Evergreen - Rutland Mental Health']","February 12, 2015",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00310180,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00023751,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT00023751,False,Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer,Colorectal Cancer,Drug:fluorouracil; Drug:leucovorin calcium; Procedure:conventional surgery; Radiation:radiation therapy,[],"July 13, 2015",18,9223372036854775807,Both,False
NCT00022087,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00022087,False,"Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer",Breast Cancer; Osteoporosis,Dietary Supplement:calcium salts; Dietary Supplement:cholecalciferol; Drug:zoledronic acid,[],"September 26, 2013",40,9223372036854775807,Female,False
NCT00003312,Radiation Therapy Oncology Group,True,VT,https://ClinicalTrials.gov/show/NCT00003312,False,Brachytherapy in Treating Patients With Prostate Cancer,Prostate Cancer,Radiation:iodine I 125,[],"January 23, 2014",0,9223372036854775807,Male,False
NCT00002596,Memorial Sloan Kettering Cancer Center,True,VT,https://ClinicalTrials.gov/show/NCT00002596,False,Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors,Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Testicular Germ Cell Tumor,Biological:bleomycin sulfate; Biological:filgrastim; Drug:carboplatin; Drug:cisplatin; Drug:cyclophosphamide; Drug:etoposide; Procedure:autologous bone marrow transplantation; Procedure:bone marrow ablation with stem cell support; Procedure:conventional surgery; Procedure:peripheral blood stem cell transplantation; Radiation:radiation therapy,[],"June 25, 2013",12,9223372036854775807,Male,False
NCT00002545,Radiation Therapy Oncology Group,True,VT,https://ClinicalTrials.gov/show/NCT00002545,False,Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme,Brain and Central Nervous System Tumors,Drug:carmustine; Radiation:low-LET photon therapy,[],"August 9, 2013",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,VT,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01198158,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00942331,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00693992,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00602459,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT00602459,False,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,VT,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00423735,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT00423735,False,Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Neoplasm,Drug:Dasatinib; Other:Pharmacological Study,[],"January 5, 2016",18,9223372036854775807,Both,False
NCT00331773,Radiation Therapy Oncology Group,True,VT,https://ClinicalTrials.gov/show/NCT00331773,False,Radiation Therapy in Treating Patients With Stage II Prostate Cancer,Prostate Cancer,Radiation:3-dimensional conformal radiation therapy (3D-CRT); Radiation:hypofractionated radiation therapy; Radiation:Intensity-modulated radiation therapy (IMRT),[],"March 20, 2015",18,9223372036854775807,Male,False
NCT00326898,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00257608,"Genentech, Inc.",False,VT,https://ClinicalTrials.gov/show/NCT00257608,False,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),Non-Small Cell Lung Cancer,Drug:bevacizumab; Drug:placebo; Drug:erlotinib HCl,[],"September 30, 2015",18,9223372036854775807,Both,False
NCT00099125,Radiation Therapy Oncology Group,True,VT,https://ClinicalTrials.gov/show/NCT00099125,False,"Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Brain and Central Nervous System Tumors,Drug:irinotecan hydrochloride; Drug:temozolomide; Procedure:adjuvant therapy; Radiation:radiation therapy,[],"January 23, 2014",18,9223372036854775807,Both,False
NCT00052845,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00052845,False,"Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",Prostate Cancer,Drug:docetaxel; Drug:estramustine phosphate sodium; Drug:exisulind,[],"September 27, 2013",18,9223372036854775807,Male,False
NCT00048971,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT00048971,False,Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy,Colorectal Cancer; Diarrhea; Neutropenia,Genetic:mutation analysis; Genetic:polymorphic microsatellite marker analysis,[],"July 14, 2015",18,9223372036854775807,Both,False
NCT00042965,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00042965,False,Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer,Kidney Cancer,Drug:capecitabine; Drug:gemcitabine hydrochloride,[],"July 7, 2015",18,9223372036854775807,Both,False
NCT00041054,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00041054,False,Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:etoposide; Drug:exisulind,[],"July 13, 2015",18,9223372036854775807,Both,False
NCT00033696,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00033696,False,Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer,Lung Cancer,Biological:filgrastim; Drug:carboplatin; Drug:etoposide; Drug:paclitaxel; Drug:topotecan hydrochloride; Radiation:radiation therapy,[],"September 25, 2013",18,9223372036854775807,Both,False
NCT00032084,Southwest Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT00032084,False,S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery,Lung Cancer,Behavioral:smoking cessation intervention; Drug:bupropion hydrochloride; Drug:nicotine; Procedure:psychosocial assessment and care,[],"March 8, 2013",18,9223372036854775807,Both,False
NCT00026195,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT00026195,False,Irinotecan in Treating Aging Patients With Solid Tumors,"Unspecified Adult Solid Tumor, Protocol Specific",Drug:irinotecan hydrochloride,[],"July 13, 2015",18,9223372036854775807,Both,False
NCT00012220,Cancer and Leukemia Group B,True,VT,https://ClinicalTrials.gov/show/NCT00012220,False,Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas,Pancreatic Cancer,Drug:cisplatin; Drug:docetaxel; Drug:gemcitabine hydrochloride; Drug:irinotecan hydrochloride,[],"October 8, 2013",18,9223372036854775807,Both,False
NCT00010218,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00010218,False,Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer,Lung Cancer,Drug:karenitecin,[],"September 25, 2013",18,9223372036854775807,Both,False
NCT00009906,National Cancer Institute (NCI),False,VT,https://ClinicalTrials.gov/show/NCT00009906,False,Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor,Gastrointestinal Stromal Tumor,Drug:Imatinib Mesylate,[],"December 19, 2014",15,9223372036854775807,Both,False
NCT00006265,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00006265,False,Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,Leukemia,Drug:ara-C; Biological:gemtuzumab ozogamicin,[],"September 27, 2013",17,9223372036854775807,Both,False
NCT00006223,Eastern Cooperative Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT00006223,False,flt3L in Treating Patients With Acute Myeloid Leukemia,Leukemia,Biological:recombinant flt3 ligand,[],"June 20, 2013",18,9223372036854775807,Both,False
NCT00006125,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00006125,False,Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma,Lymphoma,Drug:doxorubicin hydrochloride; Drug:topotecan hydrochloride,[],"July 7, 2015",0,9223372036854775807,Both,False
NCT00006029,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00006029,False,Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma,Lymphoma,Drug:gemcitabine hydrochloride; Drug:pegylated liposomal doxorubicin hydrochloride; Drug:vinorelbine tartrate,[],"July 7, 2015",0,9223372036854775807,Both,False
NCT00006015,National Cancer Institute (NCI),True,VT,https://ClinicalTrials.gov/show/NCT00006015,False,"Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer",Colorectal Cancer,Biological:trastuzumab; Drug:fluorouracil; Drug:leucovorin calcium; Drug:oxaliplatin,[],"May 1, 2013",18,9223372036854775807,Both,False
NCT00005972,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00005972,False,Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer,Lung Cancer,Drug:gemcitabine hydrochloride; Drug:irinotecan hydrochloride,[],"September 27, 2013",18,9223372036854775807,Both,False
NCT00005964,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT00005964,False,"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",Lymphoma,Biological:filgrastim; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:vincristine sulfate,[],"July 6, 2015",0,9223372036854775807,Both,False
NCT00005820,Alliance for Clinical Trials in Oncology,True,VT,https://ClinicalTrials.gov/show/NCT00005820,False,Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy,Prostate Cancer,Drug:nitrocamptothecin,[],"July 7, 2015",0,9223372036854775807,Male,False
NCT00005090,Southwest Oncology Group,False,VT,https://ClinicalTrials.gov/show/NCT00005090,False,S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease,Lymphoma,Biological:bleomycin sulfate; Drug:carmustine; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:vinblastine; Procedure:peripheral blood stem cell transplantation,[],"January 22, 2013",15,65,Both,False
NCT00005022,Radiation Therapy Oncology Group,True,VT,https://ClinicalTrials.gov/show/NCT00005022,False,Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer,Lung Cancer,Drug:cisplatin; Drug:etoposide; Radiation:radiation therapy,[],"October 31, 2013",18,80,Both,False
NCT00004933,Alliance for Clinical Trials in Oncology,False,VT,https://ClinicalTrials.gov/show/NCT00004933,False,Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa,Leukemia,Drug:hydroxyurea; Drug:Homoharringtonine,[],"June 23, 2015",16,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,VA,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00887536,NSABP Foundation Inc,False,VA,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00769379,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00658515,Hoffmann-La Roche,False,VA,https://ClinicalTrials.gov/show/NCT00658515,False,A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome,Coronary Heart Disease,Drug:Evidence-based medical care for Acute Coronary Syndrome; Drug:Placebo; Drug:dalcetrapib,[],"February 1, 2016",45,9223372036854775807,Both,False
NCT00346216,Pfizer,False,VA,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00264901,Novo Nordisk A/S,False,VA,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT01070836,Biogen,False,VA,https://ClinicalTrials.gov/show/NCT01070836,False,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Relapsing Multiple Sclerosis,Drug:natalizumab,[],"January 14, 2016",0,9223372036854775807,Both,False
NCT00034879,AstraZeneca,False,VA,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT00310180,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT01663727,Hoffmann-La Roche,False,VA,https://ClinicalTrials.gov/show/NCT01663727,False,"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",Metastatic Breast Cancer,Drug:Bevacizumab [Avastin]; Drug:Paclitaxel; Drug:Placebo,[],"November 2, 2015",18,9223372036854775807,Both,False
NCT00239681,AstraZeneca,False,VA,https://ClinicalTrials.gov/show/NCT00239681,False,JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events,Elevated High-sensitivity C-Reactive Protein (hsCRP),Drug:Rosuvastatin; Other:Placebo,[],"February 6, 2014",50,9223372036854775807,Both,False
NCT00067938,GlaxoSmithKline,False,VA,https://ClinicalTrials.gov/show/NCT00067938,False,Bipolar Study in Adults at Least 18 Years of Age,Bipolar Disorder,Drug:lamotrigine,[],"October 11, 2012",18,9223372036854775807,Both,False
NCT00373685,Pfizer,False,VA,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00053898,NSABP Foundation Inc,True,VA,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT01313676,GlaxoSmithKline,False,VA,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT00036270,Pfizer,False,VA,https://ClinicalTrials.gov/show/NCT00036270,False,Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane,Breast Neoplasms,Drug:exemestane (Aromasin); Drug:tamoxifen + exemestane,[],"October 6, 2015",50,9223372036854775807,Female,False
NCT00262600,Boehringer Ingelheim,False,VA,https://ClinicalTrials.gov/show/NCT00262600,False,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],"November 5, 2014",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01475721,GlaxoSmithKline,False,VA,https://ClinicalTrials.gov/show/NCT01475721,False,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,Asthma,Drug:ADVAIR 100/50mcg; Drug:ADVAIR 250/50mcg; Drug:ADVAIR 500/50mcg; Drug:FLOVENT 100mcg; Drug:FLOVENT 250mcg; Drug:FLOVENT 500mcg,[],"December 10, 2015",12,9223372036854775807,Both,False
NCT01349322,Radiation Therapy Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT01349322,False,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT00324805,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01104155,Eisai Inc.,False,VA,https://ClinicalTrials.gov/show/NCT01104155,False,"Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer",Non-small Cell Lung Cancer,Drug:eribulin mesylate + erlotinib; Drug:eribulin mesylate + erlotinib,[],"September 17, 2014",18,9223372036854775807,Both,False
NCT00041925,"Anesiva, Inc.",False,VA,https://ClinicalTrials.gov/show/NCT00041925,False,Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures,"Peripheral Vascular Diseases; Arterial Occlusive Diseases; Ischemia; Graft Occlusion, Vascular; Hyperplasia",Drug:CGT003 (E2F Duplex Decoy),[],"July 14, 2005",18,9223372036854775807,Both,False
NCT00785291,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00134056,Southwest Oncology Group,True,VA,https://ClinicalTrials.gov/show/NCT00134056,False,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],"May 6, 2015",18,9223372036854775807,Male,False
NCT00111020,Bayer,False,VA,https://ClinicalTrials.gov/show/NCT00111020,False,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell","Drug:Sorafenib (Nexavar, BAY43-9006)",[],"August 5, 2014",15,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,VA,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00433511,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00079274,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00968968,GlaxoSmithKline,False,VA,https://ClinicalTrials.gov/show/NCT00968968,False,Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,Cancer,Drug:Lapatinib; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02139046,Takeda,False,VA,https://ClinicalTrials.gov/show/NCT02139046,False,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Gout,Drug:Febuxostat IR; Drug:Febuxostat XR; Drug:Febuxostat placebo; Drug:Colchicine; Drug:Naproxen; Drug:Lansoprazole,[],"November 13, 2015",18,9223372036854775807,Both,False
NCT01740427,Pfizer,False,VA,https://ClinicalTrials.gov/show/NCT01740427,False,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),Breast Neoplasms,Drug:PD-0332991; Drug:Letrozole; Drug:Placebo; Drug:Letrozole,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00373256,Pfizer,False,VA,https://ClinicalTrials.gov/show/NCT00373256,False,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Breast Neoplasms,Drug:Sunitinib; Drug:paclitaxel; Drug:bevacizumab; Drug:paclitaxel,[],"September 5, 2012",18,9223372036854775807,Both,False
NCT00693992,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00087178,NSABP Foundation Inc,False,VA,https://ClinicalTrials.gov/show/NCT00087178,False,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],"October 5, 2015",18,9223372036854775807,Female,False
NCT00382070,NSABP Foundation Inc,True,VA,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT01167712,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01126437,Boehringer Ingelheim,False,VA,https://ClinicalTrials.gov/show/NCT01126437,False,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:tiotropium 18 mcg; Drug:tiotropium 1.25 mcg (2 actuations/day); Drug:tiotropium 2.5 mcg (2 actuations/day),[],"May 20, 2014",40,9223372036854775807,Both,False
NCT00968708,Takeda,False,VA,https://ClinicalTrials.gov/show/NCT00968708,False,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"Diabetes Mellitus, Type 2; Acute Coronary Syndrome",Drug:Alogliptin; Drug:Placebo,[],"April 15, 2014",18,9223372036854775807,Both,False
NCT00678392,Pfizer,False,VA,https://ClinicalTrials.gov/show/NCT00678392,False,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Kidney Neoplasms,Drug:Axitinib (AG-013736); Drug:Sorafenib,[],"December 10, 2015",18,9223372036854775807,Both,False
NCT00596830,Pfizer,False,VA,https://ClinicalTrials.gov/show/NCT00596830,False,"Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology","Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung","Drug:CP-751,871 (Figitumumab); Drug:Carboplatin; Drug:Paclitaxel; Drug:Carboplatin; Drug:Paclitaxel",[],"December 11, 2013",18,9223372036854775807,Both,False
NCT00403767,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",False,VA,https://ClinicalTrials.gov/show/NCT00403767,False,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Atrial Fibrillation; Stroke; Embolism,Drug:Rivaroxaban; Drug:Warfarin; Drug:Matching placebo for Rivaroxaban arm (Warfarin placebo); Drug:Matching placebo for Warfarin arm (Rivaroxaban placebo),[],"April 10, 2014",18,9223372036854775807,Both,False
NCT00262847,National Cancer Institute (NCI),False,VA,https://ClinicalTrials.gov/show/NCT00262847,False,"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"August 18, 2015",18,9223372036854775807,Female,False
NCT00063999,Gynecologic Oncology Group,False,VA,https://ClinicalTrials.gov/show/NCT00063999,False,"Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Endometrial Cancer,Biological:filgrastim; Drug:carboplatin; Drug:cisplatin; Drug:doxorubicin hydrochloride; Drug:paclitaxel,[],"April 23, 2009",18,9223372036854775807,Female,False
NCT02465060,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02257528,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02257528,False,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Other:Laboratory Biomarker Analysis; Biological:Nivolumab,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT02196181,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02137837,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT02137837,False,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],"May 20, 2015",18,9223372036854775807,Female,False
NCT01886872,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01716715,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01716715,False,"Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"January 12, 2016",18,9223372036854775807,Female,False
NCT01658943,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,WA,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01540565,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01540565,False,"Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Veliparib,[],"January 5, 2016",18,9223372036854775807,Female,False
NCT01515800,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01515800,False,S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer,Breast Cancer,Behavioral:Text message reminder,[],"October 23, 2015",18,120,Female,False
NCT01498289,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01468909,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01468909,False,"Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Pazopanib Hydrochloride; Other:Placebo,[],"January 12, 2016",18,9223372036854775807,Female,False
NCT01412879,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01412879,False,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,Lymphoma,Biological:rituximab; Drug:bendamustine hydrochloride; Drug:cyclophosphamide; Drug:cytarabine; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:methotrexate; Drug:vincristine sulfate,[],"September 15, 2015",18,65,Both,False
NCT01385137,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01385137,False,"S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy",Arthralgia; Breast Cancer; Pain,Dietary Supplement:omega-3 fatty acid; Other:placebo,[],"October 15, 2015",18,120,Female,False
NCT01275677,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01266447,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01266447,False,"Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Small Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage III Cervical Cancer; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer,Biological:Filgrastim; Other:Laboratory Biomarker Analysis; Biological:Pegfilgrastim; Drug:Topotecan Hydrochloride; Drug:Veliparib,[],"January 5, 2016",18,9223372036854775807,Female,False
NCT01260701,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01260701,False,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],"December 14, 2015",18,9223372036854775807,Both,False
NCT01229943,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01229943,False,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01196429,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01196429,False,"Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer",Ovarian Clear Cell Cystadenocarcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer,Drug:Carboplatin; Drug:Docetaxel; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Temsirolimus,[],"November 20, 2015",18,9223372036854775807,Female,False
NCT01196390,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01189266,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01189266,False,Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma,Childhood Glioblastoma; Untreated Childhood Anaplastic Astrocytoma; Untreated Childhood Anaplastic Oligoastrocytoma; Untreated Childhood Brain Stem Glioma; Untreated Childhood Giant Cell Glioblastoma; Untreated Childhood Gliosarcoma,Radiation:3-Dimensional Conformal Radiation Therapy; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 11, 2016",37,21,Both,False
NCT01167712,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01132820,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01132820,False,Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer,Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma,Drug:Cediranib Maleate; Other:Laboratory Biomarker Analysis,[],"January 5, 2016",18,9223372036854775807,Female,False
NCT01120275,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01120275,False,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Solar Radiation-related Skin Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other:laboratory biomarker analysis,[],"June 9, 2014",18,9223372036854775807,Both,False
NCT01120236,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01120236,False,Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer,Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer,Drug:Bicalutamide; Biological:Cixutumumab; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Drug:Leuprolide Acetate; Other:Pharmacological Study,[],"June 25, 2015",18,9223372036854775807,Male,False
NCT01078454,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01078454,False,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],"November 20, 2014",18,9223372036854775807,Both,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,WA,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01015833,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT01015833,False,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma,Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,WA,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT01000558,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT01000558,False,SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma,Lymphoma,Other:biologic sample preservation procedure,[],"May 17, 2013",18,9223372036854775807,Both,False
NCT00996047,Southwest Oncology Group,True,WA,https://ClinicalTrials.gov/show/NCT00996047,False,"S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Genetic:cytogenetic analysis; Genetic:fluorescence in situ hybridization,[],"March 5, 2015",0,9223372036854775807,Both,False
NCT00977574,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT00977574,False,"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer,Biological:Bevacizumab; Drug:Carboplatin; Drug:Ixabepilone; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Temsirolimus,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00972478,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT00972478,False,"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",Stage II Contiguous Adult Diffuse Large Cell Lymphoma; Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate; Drug:Vorinostat,[],"December 30, 2015",18,9223372036854775807,Both,False
NCT00951496,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00946712,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00920010,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00920010,False,S9925: Collecting and Storing Samples From Patients With Lung Cancer,Lung Cancer,Other:biologic sample preservation procedure,[],"February 5, 2015",0,9223372036854775807,Both,False
NCT00919425,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00919425,False,"S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer",Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms,Other:biologic sample preservation procedure,[],"March 5, 2015",0,9223372036854775807,Both,False
NCT00919139,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00919139,False,"S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.",Multiple Myeloma; Smoldering Myeloma; Waldenstrom's Macroglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Amyloidosis,Other:biologic sample preservation procedure,[],"April 1, 2015",0,9223372036854775807,Both,False
NCT00900484,Southwest Oncology Group,True,WA,https://ClinicalTrials.gov/show/NCT00900484,False,"SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma",Lymphoma,Other:biologic sample preservation procedure; Other:immunohistochemistry staining method; Other:laboratory biomarker analysis,[],"May 17, 2013",16,9223372036854775807,Both,False
NCT00874211,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00874211,False,S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases,"Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Procedure:assessment of therapy complications,[],"March 4, 2015",0,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00856492,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00856492,False,"S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer",Breast Cancer,Biological:bevacizumab; Biological:pegfilgrastim; Drug:cyclophosphamide; Drug:doxorubicin hydrochloride; Drug:paclitaxel albumin-stabilized nanoparticle formulation,[],"May 8, 2015",18,9223372036854775807,Female,False
NCT00828139,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT00828139,False,Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer,Biological:ziv-aflibercept; Drug:topotecan hydrochloride,[],"April 9, 2014",18,9223372036854775807,Both,False
NCT00822120,Southwest Oncology Group,False,WA,https://ClinicalTrials.gov/show/NCT00822120,False,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],"May 8, 2015",18,60,Both,False
NCT00792948,National Cancer Institute (NCI),False,WA,https://ClinicalTrials.gov/show/NCT00792948,False,Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia,Adult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Adult L1 Acute Lymphoblastic Leukemia; Adult L2 Acute Lymphoblastic Leukemia; Adult T Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cyclophosphamide; Drug:Cytarabine; Drug:Dasatinib; Drug:Dexamethasone; Drug:Doxorubicin Hydrochloride; Drug:Etoposide; Biological:Filgrastim; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Methotrexate; Drug:Methylprednisolone; Procedure:Peripheral Blood Stem Cell Transplantation; Drug:Prednisone; Drug:Sirolimus; Drug:Tacrolimus; Radiation:Total-Body Irradiation; Drug:Vincristine Sulfate,[],"January 12, 2016",18,60,Both,False
NCT00264901,Novo Nordisk A/S,False,WV,https://ClinicalTrials.gov/show/NCT00264901,False,Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes,"Diabetes; Diabetes Mellitus, Type 2",Drug:insulin detemir,[],"November 25, 2014",18,9223372036854775807,Both,False
NCT01961037,West Virginia University,False,WV,https://ClinicalTrials.gov/show/NCT01961037,False,Translation of an Evidence-Based Fall-Prevention Program Into Rural West Virginia Churches,Accidental Falls,Other:Tai Chi: Moving for Better Balance,"[u'Hughes River Presbyterian Church', u'Wesley United Methodist Church', u'Harper Memorial Church', u'First Baptist Church', u'First Assembly of God', u'Cisco Community Church', u'First Baptist Church', u'Memorial United Methodist Church', u'Spencer Presbyterian Church']","December 22, 2015",55,9223372036854775807,Both,True
NCT01275677,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00769379,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00382070,NSABP Foundation Inc,True,WV,https://ClinicalTrials.gov/show/NCT00382070,False,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,Breast Cancer,Drug:Letrozole; Other:Placebo,[],"November 4, 2014",18,9223372036854775807,Female,False
NCT02465060,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,WV,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT00310180,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00310180,False,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast Cancer,Drug:Anastrozole; Drug:Exemestane; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Drug:Tamoxifen Citrate,[],"February 4, 2016",18,75,Female,False
NCT00887536,NSABP Foundation Inc,False,WV,https://ClinicalTrials.gov/show/NCT00887536,False,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",Breast Cancer,Drug:bevacizumab; Drug:docetaxel; Drug:doxorubicin; Drug:cyclophosphamide; Drug:pegfilgrastim,[],"June 24, 2015",18,70,Female,False
NCT00433511,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00433511,False,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer,Biological:Bevacizumab; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00346216,Pfizer,False,WV,https://ClinicalTrials.gov/show/NCT00346216,False,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"Arthritis, Rheumatoid",Drug:celecoxib; Drug:Ibuprofen; Drug:Naproxen,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT00326898,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00326898,False,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sorafenib Tosylate; Drug:Sunitinib Malate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00217737,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00217737,False,"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer; Stage IIB Colon Cancer; Stage IIC Colon Cancer,Biological:Bevacizumab; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Oxaliplatin,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00087178,NSABP Foundation Inc,False,WV,https://ClinicalTrials.gov/show/NCT00087178,False,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,Breast Cancer,Drug:cyclophosphamide; Drug:adriamycin; Drug:epirubicin; Drug:fluorouracil,[],"October 5, 2015",18,9223372036854775807,Female,False
NCT00079274,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00079274,False,Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer,Adenocarcinoma of the Colon; Stage III Colon Cancer,Drug:irinotecan hydrochloride; Drug:oxaliplatin; Drug:leucovorin calcium; Drug:fluorouracil; Biological:cetuximab; Drug:Locally Directed Therapy,[],"January 23, 2015",18,9223372036854775807,Both,False
NCT00053898,NSABP Foundation Inc,True,WV,https://ClinicalTrials.gov/show/NCT00053898,False,Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy,Breast Cancer,Drug:anastrozole; Drug:tamoxifen citrate; Radiation:Radiation Therapy,[],"March 9, 2015",0,9223372036854775807,Female,False
NCT00034879,AstraZeneca,False,WV,https://ClinicalTrials.gov/show/NCT00034879,False,Iressa Expanded Access Program (EAP),Carcinoma; Non-small-cell Lung; Metastases; Neoplasm,Drug:ZD1839 (Gefitinib),[],"January 3, 2013",18,9223372036854775807,Both,False
NCT00003641,Eastern Cooperative Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT00003641,False,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,Melanoma (Skin),Biological:recombinant interferon alfa; Other:clinical observation,[],"July 11, 2012",18,9223372036854775807,Both,False
NCT01302067,Pfizer,False,WV,https://ClinicalTrials.gov/show/NCT01302067,False,A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine,Overactive Bladder,Drug:Fesoterodine 8mg; Drug:Fesoterodine 4mg; Drug:Placebo,[],"February 25, 2014",18,9223372036854775807,Both,False
NCT00588770,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00324805,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00324805,False,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer,Biological:Bevacizumab; Drug:Cisplatin; Drug:Docetaxel; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Pemetrexed Disodium; Other:Questionnaire Administration; Drug:Vinorelbine Tartrate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00265850,Alliance for Clinical Trials in Oncology,True,WV,https://ClinicalTrials.gov/show/NCT00265850,False,Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer,Colorectal Cancer,Biological:bevacizumab; Biological:cetuximab; Drug:FOLFOX or; Drug:FOLFIRI,[],"October 16, 2014",18,9223372036854775807,Both,False
NCT00110019,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00110019,False,Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,Mucosal Melanoma; Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Pharmacological Study; Other:Placebo; Drug:Sorafenib Tosylate,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00072046,Alliance for Clinical Trials in Oncology,True,WV,https://ClinicalTrials.gov/show/NCT00072046,False,Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer),Kidney Cancer,Biological:bevacizumab; Biological:recombinant interferon alfa,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT00052910,Alliance for Clinical Trials in Oncology,True,WV,https://ClinicalTrials.gov/show/NCT00052910,False,Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer,Esophageal Cancer; Gastric Cancer,Drug:cisplatin; Drug:epirubicin hydrochloride; Drug:fluorouracil; Drug:leucovorin calcium; Radiation:radiation therapy,[],"June 23, 2015",18,9223372036854775807,Both,False
NCT01708954,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01349322,Radiation Therapy Oncology Group,False,WV,https://ClinicalTrials.gov/show/NCT01349322,False,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01313676,GlaxoSmithKline,False,WV,https://ClinicalTrials.gov/show/NCT01313676,False,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug:fluticasone furoate/vilanterol; Drug:fluticasone furoate; Drug:vilanterol; Other:Placebo,[],"January 14, 2016",40,80,Both,False
NCT01101438,NCIC Clinical Trials Group,True,WV,https://ClinicalTrials.gov/show/NCT01101438,False,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,Breast Cancer,Drug:metformin hydrochloride; Other:placebo,[],"May 5, 2015",18,74,Both,False
NCT01011478,NSABP Foundation Inc,True,WV,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00693992,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00602641,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00602641,False,"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:melphalan; Drug:prednisone; Drug:thalidomide; Drug:lenalidomide,[],"June 9, 2015",18,9223372036854775807,Both,False
NCT00601900,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00520975,National Cancer Institute (NCI),False,WV,https://ClinicalTrials.gov/show/NCT00520975,False,First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU,HER2/Neu Positive; Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer,Biological:Bevacizumab; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"December 17, 2015",18,9223372036854775807,Both,False
NCT00490139,GlaxoSmithKline,False,WV,https://ClinicalTrials.gov/show/NCT00490139,False,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,"Neoplasms, Breast",Drug:Lapatinib; Biological:Trastuzumab,[],"November 5, 2015",18,9223372036854775807,Both,False
NCT00486668,NSABP Foundation Inc,True,WV,https://ClinicalTrials.gov/show/NCT00486668,False,A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer,Invasive Breast Cancer,Drug:doxorubicin; Drug:cyclophosphamide; Drug:paclitaxel; Drug:trastuzumab; Drug:lapatinib,[],"August 11, 2015",18,9223372036854775807,Female,False
NCT00408408,NSABP Foundation Inc,True,WV,https://ClinicalTrials.gov/show/NCT00408408,False,"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery",Breast Cancer,Biological:bevacizumab; Drug:capecitabine; Drug:cyclophosphamide; Drug:docetaxel; Drug:doxorubicin hydrochloride (Adriamycin); Drug:gemcitabine hydrochloride,[],"February 9, 2015",18,9223372036854775807,Female,False
NCT00373685,Pfizer,False,WV,https://ClinicalTrials.gov/show/NCT00373685,False,GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS),Osteoarthritis,Drug:Celecoxib; Drug:Any commercially available NSAID with the indication for osteoarthritis,[],"February 2, 2012",55,9223372036854775807,Both,False
NCT00262600,Boehringer Ingelheim,False,WV,https://ClinicalTrials.gov/show/NCT00262600,False,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Atrial Fibrillation; Stroke,Drug:warfarin; Drug:Dabigatran dose 1; Drug:Dabigatran dose 2,[],"November 5, 2014",18,9223372036854775807,Both,False
NCT00238264,Children's Oncology Group,True,WV,https://ClinicalTrials.gov/show/NCT00238264,False,Radiation Therapy in Treating Young Patients With Gliomas,Brain Tumor; Central Nervous System Tumor,Radiation:radiation therapy,[],"March 4, 2015",3,20,Both,False
NCT00134056,Southwest Oncology Group,True,WV,https://ClinicalTrials.gov/show/NCT00134056,False,"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",Metastatic Cancer; Prostate Cancer,Drug:atrasentan hydrochloride; Drug:docetaxel; Drug:prednisone; Other:placebo,[],"May 6, 2015",18,9223372036854775807,Male,False
NCT00111020,Bayer,False,WV,https://ClinicalTrials.gov/show/NCT00111020,False,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell","Drug:Sorafenib (Nexavar, BAY43-9006)",[],"August 5, 2014",15,9223372036854775807,Both,False
NCT00103181,NSABP Foundation Inc,True,WV,https://ClinicalTrials.gov/show/NCT00103181,False,Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer,Breast Cancer,Radiation:3-dimensional conformal accelerated partial breast irradiation; Radiation:brachytherapy; Radiation:whole breast irradiation; Radiation:MammoSite or other single-entry intracavitary device,[],"October 8, 2015",18,9223372036854775807,Female,False
NCT00089323,NSABP Foundation Inc,False,WV,https://ClinicalTrials.gov/show/NCT00089323,False,"Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer",Breast Cancer,Procedure:Bone Marrow Aspiration,[],"January 19, 2016",18,9223372036854775807,Both,False
NCT00075725,Children's Oncology Group,True,WV,https://ClinicalTrials.gov/show/NCT00075725,False,Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,Leukemia,Drug:cyclophosphamide; Drug:cytarabine; Drug:daunorubicin hydrochloride; Drug:dexamethasone; Drug:doxorubicin hydrochloride; Drug:leucovorin calcium; Drug:mercaptopurine; Drug:methotrexate; Drug:pegaspargase; Drug:prednisone; Drug:thioguanine; Drug:vincristine sulfate; Radiation:radiation therapy,[],"July 10, 2015",1,30,Both,False
NCT02465060,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT02311907,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT02116530,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT02116530,False,Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy,"Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific",Drug:Olanzapine; Drug:Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug:Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other:Placebo,[],"June 15, 2015",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01841736,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01708954,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01708954,False,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,Drug:Cabozantinib S-malate; Drug:Erlotinib Hydrochloride; Other:Laboratory Biomarker Analysis,[],"October 23, 2015",18,9223372036854775807,Both,False
NCT01708941,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01708941,False,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Recombinant Interferon Alfa-2b,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01642251,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,WI,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01522976,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01522976,False,Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Adult Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts,Drug:Azacitidine; Drug:Lenalidomide; Drug:Vorinostat,[],"June 24, 2015",18,9223372036854775807,Both,False
NCT01498289,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01366183,Gynecologic Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01349322,Radiation Therapy Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT01349322,False,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,Breast Cancer,Radiation:Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy; Radiation:Higher per daily radiation therapy; Radiation:Concurrent boost radiotherapy; Radiation:Standard per daily radiation therapy; Radiation:Sequential boost radiotherapy,[],"November 14, 2015",18,9223372036854775807,Female,False
NCT01275677,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01198158,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01198145,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT01198145,False,Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy,"Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific",Drug:sulfasalazine; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01134614,National Cancer Institute (NCI),True,WI,https://ClinicalTrials.gov/show/NCT01134614,False,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,Recurrent Melanoma; Stage III Melanoma; Stage IV Melanoma,Biological:ipilimumab; Biological:sargramostim,[],"March 23, 2015",18,9223372036854775807,Both,False
NCT01099449,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT01099449,False,Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy,Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity,Drug:calcium gluconate; Drug:magnesium sulfate; Other:placebo; Drug:oxaliplatin,[],"July 4, 2015",18,9223372036854775807,Both,False
NCT01078454,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT01078454,False,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],"November 20, 2014",18,9223372036854775807,Both,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01011478,NSABP Foundation Inc,True,WI,https://ClinicalTrials.gov/show/NCT01011478,False,Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery,Colorectal Cancer; Precancerous Condition,Drug:rosuvastatin; Other:placebo,[],"March 9, 2015",18,9223372036854775807,Both,False
NCT00986674,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00986674,False,Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,Biological:cixutumumab; Drug:carboplatin; Drug:paclitaxel; Biological:cetuximab,[],"September 19, 2014",18,9223372036854775807,Both,False
NCT00976573,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT00976573,False,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",Melanoma (Skin),Biological:bevacizumab; Drug:carboplatin; Drug:everolimus; Drug:paclitaxel,[],"September 18, 2015",18,9223372036854775807,Both,False
NCT00951496,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00946712,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00884741,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00884741,False,Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Cognitive Side Effects of Cancer Therapy,Radiation:3-Dimensional Conformal Radiation Therapy; Biological:Bevacizumab; Procedure:Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Procedure:Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging; Radiation:Intensity-Modulated Radiation Therapy; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Temozolomide,[],"July 29, 2015",18,9223372036854775807,Both,False
NCT00869206,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT00869206,False,"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement",Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary Complications,Drug:zoledronic acid,[],"July 23, 2015",18,9223372036854775807,Both,False
NCT00861705,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00861705,False,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Triple-Negative Breast Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 28, 2015",18,9223372036854775807,Both,False
NCT00822120,Southwest Oncology Group,False,WI,https://ClinicalTrials.gov/show/NCT00822120,False,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,Lymphoma; Nonneoplastic Condition,Biological:bleomycin sulfate; Biological:filgrastim; Drug:ABVD regimen; Drug:BEACOPP regimen; Drug:cyclophosphamide; Drug:dacarbazine; Drug:doxorubicin hydrochloride; Drug:etoposide; Drug:prednisone; Drug:procarbazine hydrochloride; Drug:vinblastine sulfate; Drug:vincristine sulfate,[],"May 8, 2015",18,60,Both,False
NCT00803062,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00803062,False,"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer,Biological:Bevacizumab; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Topotecan Hydrochloride,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT00785291,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00785291,False,"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Male Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer,Drug:Paclitaxel; Drug:Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug:Ixabepilone; Biological:Bevacizumab; Other:Questionnaire Administration; Other:Laboratory Biomarker Analysis,[],"June 5, 2015",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00719563,Alliance for Clinical Trials in Oncology,True,WI,https://ClinicalTrials.gov/show/NCT00719563,False,American Ginseng in Treating Patients With Fatigue Caused by Cancer,"Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific",Drug:American ginseng; Other:placebo,[],"July 14, 2014",18,9223372036854775807,Both,False
NCT00693992,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00693992,False,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Drug:Sunitinib Malate,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT00651261,Alliance for Clinical Trials in Oncology,True,WI,https://ClinicalTrials.gov/show/NCT00651261,False,"Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",Leukemia,Drug:cytarabine; Drug:daunorubicin; Drug:midostaurin; Other:placebo; Drug:dexamethasone acetate,[],"September 15, 2015",18,59,Both,False
NCT00644228,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00644228,False,Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:dexamethasone; Drug:lenalidomide; Drug:bortezomib; Other:laboratory biomarker analysis,[],"September 12, 2014",18,9223372036854775807,Both,False
NCT00602641,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00602641,False,"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,Drug:melphalan; Drug:prednisone; Drug:thalidomide; Drug:lenalidomide,[],"June 9, 2015",18,9223372036854775807,Both,False
NCT00602459,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00602459,False,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Cyclophosphamide; Drug:Fludarabine Phosphate; Other:Laboratory Biomarker Analysis; Drug:Lenalidomide; Biological:Rituximab,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT00601900,National Cancer Institute (NCI),False,WI,https://ClinicalTrials.gov/show/NCT00601900,False,Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer,Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IV Breast Cancer,Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Drug:Letrozole; Other:Questionnaire Administration; Drug:Tamoxifen Citrate,[],"April 23, 2015",18,9223372036854775807,Female,False
NCT00601627,Alliance for Clinical Trials in Oncology,False,WI,https://ClinicalTrials.gov/show/NCT00601627,False,"Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery",Pancreatic Cancer,Biological:panitumumab; Drug:capecitabine; Drug:fluorouracil; Drug:gemcitabine hydrochloride; Radiation:radiation therapy,[],"July 1, 2015",18,9223372036854775807,Both,False
NCT01886872,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01886872,False,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia,Drug:Bendamustine Hydrochloride; Drug:Ibrutinib; Other:Laboratory Biomarker Analysis; Other:Quality-of-Life Assessment; Biological:Rituximab,[],"February 4, 2016",65,9223372036854775807,Both,False
NCT01835158,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01835158,False,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis; Drug:Sunitinib Malate,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT02500797,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02500797,False,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Bone Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IVA Bone Sarcoma; Stage IVB Bone Sarcoma,Biological:Ipilimumab; Other:Laboratory Biomarker Analysis; Biological:Nivolumab; Other:Quality-of-Life Assessment,[],"January 11, 2016",18,9223372036854775807,Both,False
NCT02465060,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02465060,False,NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,Advanced Malignant Neoplasm; Lymphoma; Refractory Malignant Neoplasm; Solid Neoplasm,Drug:Afatinib; Drug:Crizotinib; Other:Cytology Specimen Collection Procedure; Drug:Dabrafenib; Drug:Defactinib; Other:Laboratory Biomarker Analysis; Drug:Osimertinib; Drug:Sunitinib Malate; Drug:Trametinib; Biological:Trastuzumab Emtansine,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02196181,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02196181,False,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma,Drug:Dabrafenib; Other:Laboratory Biomarker Analysis; Drug:Trametinib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02042443,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02042443,False,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma,Drug:Capecitabine; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis; Drug:Leucovorin Calcium; Drug:Trametinib,[],"February 3, 2016",0,9223372036854775807,Both,False
NCT01824823,Eastern Cooperative Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01824823,False,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer,Drug:afatinib; Other:placebo; Other:laboratory biomarker analysis,[],"September 11, 2015",18,9223372036854775807,Both,False
NCT01802333,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01802333,False,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Procedure:Allogeneic Hematopoietic Stem Cell Transplantation; Drug:Cytarabine; Drug:Daunorubicin Hydrochloride; Drug:Idarubicin; Other:Laboratory Biomarker Analysis; Drug:Vorinostat,[],"January 29, 2016",18,60,Both,False
NCT01648348,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01648348,False,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Neoplasm,Biological:Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Biological:Bevacizumab; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study; Other:Quality-of-Life Assessment,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02315430,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02315430,False,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Drug:Cabozantinib S-malate; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT01642251,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01642251,False,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,Carcinoma of Unknown Primary Origin; Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Newly Diagnosed Carcinoma of Unknown Primary Origin; Stage IV Non-Small Cell Lung Cancer,Drug:Cisplatin; Drug:Etoposide; Other:Laboratory Biomarker Analysis; Other:Placebo; Other:Quality-of-Life Assessment; Other:Questionnaire Administration; Drug:Veliparib,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01275677,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01275677,False,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer,Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00942331,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT00942331,False,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter Carcinoma,Biological:Bevacizumab; Drug:Cisplatin; Drug:Gemcitabine Hydrochloride; Other:Laboratory Biomarker Analysis; Other:Placebo,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT00769379,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT00769379,False,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,Ductal Breast Carcinoma In Situ; HER2/Neu Positive,Other:Laboratory Biomarker Analysis; Biological:Trastuzumab; Radiation:Whole Breast Irradiation,[],"February 4, 2016",18,9223372036854775807,Female,False
NCT00588770,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT00588770,False,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma; Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary,Biological:Bevacizumab; Drug:Carboplatin; Drug:Cisplatin; Other:Cytology Specimen Collection Procedure; Drug:Docetaxel; Drug:Fluorouracil; Other:Laboratory Biomarker Analysis,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT02311907,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT02311907,False,"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer",Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Drug:Carboplatin; Drug:Glutathione; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Placebo; Other:Quality-of-Life Assessment,[],"May 22, 2015",18,9223372036854775807,Female,False
NCT02137837,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT02137837,False,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",Breast Cancer,Drug:Fulvestrant; Drug:Anastrozole; Drug:Everolimus; Drug:Placebo - Anastrozole; Drug:Placebo - Everolimus,[],"May 20, 2015",18,9223372036854775807,Female,False
NCT01841736,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01841736,False,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Atypical Carcinoid Tumor; Foregut Carcinoid Tumor; Hindgut Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Carcinoid Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1,Other:Laboratory Biomarker Analysis; Drug:Pazopanib Hydrochloride; Other:Placebo; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Both,False
NCT01658943,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01658943,False,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer,Drug:Akt Inhibitor MK2206; Drug:Fluorouracil; Drug:Oxaliplatin; Drug:Selumetinib,[],"November 20, 2015",18,9223372036854775807,Both,False
NCT01653028,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01653028,False,Alisertib in Treating Patients With Advanced or Metastatic Sarcoma,Myxofibrosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Leiomyosarcoma; Recurrent Liposarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Soft Tissue Sarcoma; Stage IV Soft Tissue Sarcoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis,[],"February 2, 2016",18,9223372036854775807,Both,False
NCT01547741,NSABP Foundation Inc,False,WY,https://ClinicalTrials.gov/show/NCT01547741,False,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,Breast Cancer,Drug:Doxorubicin; Drug:Cyclophosphamide; Drug:Docetaxel; Drug:Paclitaxel,[],"October 21, 2015",18,9223372036854775807,Female,False
NCT01498289,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01498289,False,"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer,Drug:FOLFOX regimen; Drug:docetaxel; Drug:fluorouracil; Drug:irinotecan hydrochloride; Drug:leucovorin calcium; Drug:oxaliplatin,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01466881,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01466881,False,Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma,Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Hepatosplenic T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma,Drug:Alisertib; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"June 26, 2015",18,9223372036854775807,Both,False
NCT01376349,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01376349,False,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,Breast Cancer; Gynecologic Cancer,Drug:prasterone; Other:placebo,[],"September 24, 2015",18,9223372036854775807,Female,False
NCT01366183,Gynecologic Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01366183,False,"Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IB Fallopian Tube Cancer; Stage IC Fallopian Tube Cancer; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIB Fallopian Tube Cancer; Stage IIC Fallopian Tube Cancer; Stage III Ovarian Cancer; Stage III Primary Peritoneal Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIC Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer,Other:Pharmacological Study; Other:Questionnaire Administration; Procedure:Assessment of Therapy Complications; Other:Quality-of-Life Assessment; Drug:Carboplatin; Drug:Paclitaxel; Biological:Filgrastim,[],"December 23, 2014",75,9223372036854775807,Both,False
NCT01260701,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01260701,False,Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer,Adenocarcinoma of the Gastroesophageal Junction; Diffuse Gastric Adenocarcinoma; Gastric Intestinal Type Adenocarcinoma; Gastric Mixed Adenocarcinoma; Recurrent Gastric Carcinoma,Drug:Akt Inhibitor MK2206,[],"December 14, 2015",18,9223372036854775807,Both,False
NCT01238172,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01238172,False,Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance,Prostate Cancer,Other:dietary education and counseling; Other:prostate cancer foundation booklet,[],"August 20, 2015",50,80,Male,False
NCT01229943,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01229943,False,Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery,Gastrin-Producing Neuroendocrine Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer,Biological:Bevacizumab; Drug:Everolimus; Drug:Octreotide Acetate,[],"April 22, 2015",18,9223372036854775807,Both,False
NCT01198158,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01198158,False,Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy,Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biological:Bevacizumab; Drug:Everolimus; Other:Laboratory Biomarker Analysis; Other:Pharmacological Study,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01196390,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01196390,False,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer,Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Other:Quality-of-Life Assessment; Radiation:Radiation Therapy; Procedure:Therapeutic Conventional Surgery; Biological:Trastuzumab,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01167712,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01167712,False,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Procedure:Computed Tomography; Drug:Paclitaxel; Procedure:Therapeutic Conventional Surgery,[],"December 21, 2015",18,9223372036854775807,Female,False
NCT01120275,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01120275,False,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Solar Radiation-related Skin Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other:laboratory biomarker analysis,[],"June 9, 2014",18,9223372036854775807,Both,False
NCT01120236,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01120236,False,Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer,Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer,Drug:Bicalutamide; Biological:Cixutumumab; Drug:Goserelin Acetate; Other:Laboratory Biomarker Analysis; Drug:Leuprolide Acetate; Other:Pharmacological Study,[],"June 25, 2015",18,9223372036854775807,Male,False
NCT01097278,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01097278,False,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer,Dietary Supplement:cholecalciferol; Other:placebo,[],"January 7, 2015",18,50,Female,False
NCT01093222,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01093222,False,"Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",Extrahepatic Bile Duct Adenocarcinoma; Gallbladder Adenocarcinoma; Gallbladder Adenocarcinoma With Squamous Metaplasia; Hilar Cholangiocarcinoma; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Undifferentiated Gallbladder Carcinoma; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma,Drug:Erlotinib Hydrochloride; Drug:Sorafenib Tosylate,[],"June 3, 2015",18,9223372036854775807,Both,False
NCT01086605,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01086605,False,Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer,Breast Cancer,Drug:pixantrone dimaleate,[],"August 4, 2015",18,9223372036854775807,Both,False
NCT01081262,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01081262,False,Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer,Borderline Ovarian Mucinous Tumor; Ovarian Mucinous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer,Biological:Bevacizumab; Drug:Capecitabine; Drug:Carboplatin; Other:Laboratory Biomarker Analysis; Drug:Oxaliplatin; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"January 12, 2016",18,9223372036854775807,Female,False
NCT01078454,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01078454,False,Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis,Light Chain Deposition Disease; Primary Systemic Amyloidosis,Drug:melphalan; Drug:dexamethasone; Drug:bortezomib,[],"November 20, 2014",18,9223372036854775807,Both,False
NCT01041781,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01041781,False,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug:carboplatin; Drug:celecoxib; Drug:gemcitabine hydrochloride; Drug:pemetrexed disodium; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01017601,Alliance for Clinical Trials in Oncology,False,WY,https://ClinicalTrials.gov/show/NCT01017601,False,Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,Biological:Seneca Valley virus-001; Other:placebo,[],"July 31, 2015",18,9223372036854775807,Both,False
NCT01004978,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT01004978,False,Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,Hepatocellular Carcinoma; Non-Resectable Hepatocellular Carcinoma,Drug:Cisplatin; Drug:Doxorubicin Hydrochloride; Drug:Doxorubicin-Eluting Beads; Other:Laboratory Biomarker Analysis; Drug:Mitomycin; Other:Pharmacological Study; Other:Placebo; Drug:Sorafenib Tosylate,[],"February 4, 2016",18,9223372036854775807,Both,False
NCT01000558,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT01000558,False,SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma,Lymphoma,Other:biologic sample preservation procedure,[],"May 17, 2013",18,9223372036854775807,Both,False
NCT00972478,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT00972478,False,"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",Stage II Contiguous Adult Diffuse Large Cell Lymphoma; Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma,Drug:Cyclophosphamide; Drug:Doxorubicin Hydrochloride; Other:Laboratory Biomarker Analysis; Drug:Prednisone; Biological:Rituximab; Drug:Vincristine Sulfate; Drug:Vorinostat,[],"December 30, 2015",18,9223372036854775807,Both,False
NCT00956670,Gynecologic Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT00956670,False,"Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer",Lymphedema; Stage IA Cervical Cancer; Stage IA Uterine Corpus Cancer; Stage IA Vulvar Cancer; Stage IB Cervical Cancer; Stage IB Uterine Corpus Cancer; Stage IB Vulvar Cancer; Stage II Uterine Corpus Cancer; Stage II Vulvar Cancer; Stage IIA Cervical Cancer; Stage IIIA Vulvar Cancer; Stage IIIB Vulvar Cancer; Stage IIIC Vulvar Cancer; Stage IVB Vulvar Cancer,Procedure:Therapeutic Lymphadenectomy; Procedure:Therapeutic Conventional Surgery; Procedure:Therapeutic Laparoscopic Surgery; Procedure:Study of High Risk Factors; Other:Questionnaire Administration; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00954174,Gynecologic Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT00954174,False,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer",Ovarian Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Sarcoma; Stage I Ovarian Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Sarcoma; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Sarcoma; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIA Uterine Sarcoma; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIB Uterine Sarcoma; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma,Drug:Paclitaxel; Drug:Carboplatin; Drug:Ifosfamide; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00951496,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT00951496,False,"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Drug:Carboplatin; Drug:Cisplatin; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel; Drug:Paclitaxel; Other:Quality-of-Life Assessment,[],"February 3, 2016",18,9223372036854775807,Female,False
NCT00946712,Southwest Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT00946712,False,Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma; Stage IV Large Cell Lung Carcinoma; Stage IV Lung Adenocarcinoma; Stage IV Squamous Cell Lung Carcinoma,Biological:Bevacizumab; Drug:Carboplatin; Biological:Cetuximab; Other:Laboratory Biomarker Analysis; Drug:Paclitaxel,[],"September 1, 2015",18,9223372036854775807,Both,False
NCT00942357,Gynecologic Oncology Group,False,WY,https://ClinicalTrials.gov/show/NCT00942357,False,"Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer",Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer,Drug:Cisplatin; Radiation:Radiation Therapy; Radiation:Internal Radiation Therapy; Drug:Paclitaxel; Drug:Carboplatin; Other:Quality-of-Life Assessment,[],"December 23, 2014",18,9223372036854775807,Female,False
NCT00937937,National Cancer Institute (NCI),False,WY,https://ClinicalTrials.gov/show/NCT00937937,False,Dinaciclib in Treating Patients With Stage IV Melanoma,Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Mucosal Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Stage IV Melanoma; Superficial Spreading Malignant Melanoma,Drug:dinaciclib,[],"June 9, 2014",18,9223372036854775807,Both,False
